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Abstract 
This thesis describes the development of a fragment library in order to identify 
the value of shape-diverse molecules in their ability to target novel areas of shape-space. 
Chapter 1 introduces known approaches to ligand discovery as well as the concept 
of chemical space and molecular shape diversity.  Chapter 2 describes the computational 
tools and protocols used to identify fragments of interest from both commercial and Leeds 
libraries, that fulfil the criteria of maximum coverage of reference shapes as well as high 
shape-diversity. The synthesis of fragments based on Leeds chemistry is described in 
Chapter 3, focusing on four key chemistries established within the Nelson group, as well 
as the reselection of molecules to overcome synthetic challenges.  Chapter 4 describes the 
screen of the library of fragments using high-throughput X-ray crystallography, as well as 
the development of a novel fragment hit against Aurora A kinase.  Overall my fragment 
library was successful in its ability to investigate unexplored shape-space and presented 
valuable hits against a useful target.
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Abbreviations 
δ  chemical shift 
ATR  attenuated total reflectance 
Boc  tert-butyl oxy carbonyl 
Bu  butyl 
CAN  ceric ammonium nitrate 
CDI  carbonyldiimidazole 
conc.  concentrated 
COSY  correlation spectroscopy 
DCE  dichloroethane 
DCM  dichloromethane 
DDQ  2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD  diethyl azodicarboxylate 
DEPT  distortionless enhancement by polarisation transfer 
DIAD  diisopropyl azodicarboxylate 
DIBAL-H diisobutylaluminium hydride 
DIPEA  N,N-diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMS  dimethyl sulfide 
DMSO  dimethyl sulfoxide 
ES  electrospray 
Et  ethyl 
ether  diethyl ether 
HMBC  heteronuclear multiple bond correlation 
HMQC  heteronuclear multiple quantum coherence 
HRMS  high resolution mass spectroscopy 
FT-IR  fourier transform infra-red 
J  coupling constant 
LCMS  liquid chromatography mass spectroscopy 
m/z  mass to charge ratio 
Me  methyl 
m.p  melting point 
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NMR  nuclear magnetic resonance  
NOE  nuclear Overhauser effect 
petrol  petroleum spirit (b.p. 40-60 °C) 
PMB  para-methoxybenzyl 
RCM  ring-closing metathesis 
sat.  saturated 
TBDPS  tert-butyldiphenylsilyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
THP  tetrahydropyran 
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1 Introduction 
Our ability to address the issues which determine drug success or failure is reliant 
on possessing synthetic chemistry methodology to make the right molecules quickly and 
predictably.  A chemical lead is a molecule with good potency in biological assays, and 
reflects the targeted mechanism.  The absorption, distribution and metabolism profile 
(ADME) of a chemical lead could be determined; a drug must achieve high and sustained 
plasma concentrations after oral dosing to exert the desired effect.1   
Initial starting points (i.e. “hits” or “leads”) are often found by screening of 
compounds from chemical libraries which are usually reliant on robust chemical 
methodology for their production.  Such methodology includes reductive aminations, 
acylations, Pd-mediated cross-couplings and SNAr reactions.2  Once initial hits have been 
identified, the lead optimisation process aims to improve their drug-like profile and 
activity through the synthesis of many designed analogues.  Once a single clinical 
candidate molecule has been identified, scale-up and process chemistry then devises cost-
effective and efficient syntheses to deliver the final compound on multi-kilogram scales.3  
The drug discovery process is summarised in Figure 1. 
 
Figure 1 An overview of the drug discovery process highlighting the role of organic synthesis and the ideal 
properties of molecules at each stage.  MW = molecular weight in Da, logP = log(partition coefficient in n-
octanol/water).  Adapted from 3 
Oral drugs usually obey the Lipinski rule of fivei (MW <500 Da, logP <5, no. of 
hydrogen bond donors ≤5) in order to be easily absorbed.4  More recent studies have 
shown however, that compounds close to the limits defined by Lipinski actually have a 
                                                             
i Lipinski states that it is possible to fail one of the guidelines and still produce a successful drug. 
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lower probability of success in development, with significantly lower MW and logP values 
favoured in successful medicines.  These observations have led to several revised 
guidelines suggesting, for example, that molecules with logP <3 and polar surface 
area >75 will show greater safety in pre-clinical studies or that molecules with MW <400 
and logP <4 appear to be more successful in a range of assays of drug-like character.3  The 
drug optimization process is illustrated in Figure 2. 
 
The strategy of increasing lipophilicity to gain better binding to a drug target is 
often used to increase apparent drug potency but can also result in a greater probability 
of binding to other, undesired, drug targets.3  Controlling the lipophilicity of drug 
substances is thus pivotal to the drug discovery process and logP values in the range 1 to 
3 are now thought to give the best balance of properties for most oral drugs.  Other factors 
to take into consideration include the number of aromatic rings and the fraction of sp3-
hybridised carbons.5,6  
Though the degree of aromaticity may also be related to the logP of molecules, 
excessive levels of aromaticity are usually associated with undesirable outcomes.  This 
leads to suggestions that aromatic rings on lead-like molecules should be limited to a 
maximum of three, and a lower proportion of sp2-hybridised carbon atoms should be 
incorporated than typical historically.  Many functional groups are undesirable due to 
chemical stability issues (e.g. acid chlorides, many Michael acceptors, most 
organometallics), as well as the potential for toxicity, unwanted interactions with 
biological systems or general instability.3 
 
Figure 2 Optimal oral drug-like 
space can be defined by the 
central red oval.  As optimization 
tends to progress by addition of 
complexity and lipophilicity 
(arrow), starting points should 
be in lead-like (or fragment-like) 
areas of property space for the 
progression to end in drug-like 
space.  Adapted from 3 
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1.1  Approaches to Ligand Discovery 
Chemical technologies that have impacted drug discovery in previous decades 
include computational methods such as quantitative structure-activity relationships and 
combinatorial chemistry.1  Different approaches that are currently used to obtain 
chemical leads include from an existing lead or drug, from a natural product, and high 
throughput screening (HTS, described in Figure 3).  The preclinical drug-discovery 
cascade, starting from HTS and moving into the launched drug phase requires the 
screening of the order of one million compounds to find a suitable lead for one ultimately 
successful outcome.7  Fragment-based drug discovery (FBDD) is a new approach, 
increasingly used in the pharmaceutical industry, for reducing attrition and providing 
leads for challenging biological targets.8   
 
1.1.1 Traditional Approaches 
There are several traditional approaches to the discovery of drug molecules.  The 
most widespread traditional methods include the use of combinatorial libraries and HTS.  
The combinatorial chemistry approach is pursued in the hope to gain quick access to 
novel pharmaceuticals, through the rapid generation and screening of vast collections of 
molecules.9  A wide variety of high-speed and parallel synthetic techniques are applied 
such as solid-phase synthesis, and separation techniques in order to effect an easy 
purification of intermediates and final products.10  Combinatorial libraries consist of static 
populations of discrete molecules, derived from a set of units connected in various 
sequences by the repetitive application of specific chemical reactions, with the aim of 
producing as high a structural diversity as possible.11  The rapid increase in the 
availability of compound libraries drove the development of methods for faster and more 
efficient screening of lead molecules.  HTS is based on robotic handling of small amounts 
Figure 3 A typical drug discovery cascade using HTS, 
showing the number of compounds assessed at each stage 
(for illustrative purposes only).  A 40% false positive rate is 
assumed in evaluating HTS hits, and one in two to five leads 
are assumed to progress from lead identification to drug 
candidate.  The risk of failure increases as a molecule 
becomes a drug candidate because of high costs in clinical 
trials.  Adapted from 7  
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of materials, and equivalent advances in the detection of relevant signals and 
interpretation of the data.12 
The reality of drug-receptor interactions, at the molecular level, is too complex to 
provide a fail-safe in silico technology for drug discovery.  Beyond ligand-receptor 
interactions, there is the complexity of multiple binding modes, accessible conformational 
states (whether static or dynamic) for both ligand and receptor, affinity vs. selectivity, 
plasma protein binding, metabolic stability, ADME, as well as in vivo vs. in vitro properties 
of model compounds.   
In the combinatorial chemistry field, differences in the reactivity of similar, yet 
diverse reagents, often leads to impurity, or failure to synthesise the compounds at all.  In 
combination with inadequate or missing synthetic blocks, this has resulted in moderately 
successful lead-finding combinatorial libraries focused more on forming carbon-
heteroatom bonds and less on forming carbon-carbon bonds.13  In comparison, mixtures 
of compounds per well in HTS do not generally yield reliable results compared to one 
compound per well, and screening potentially reactive species is often a cause of false 
hits.14  Furthermore, single dose/single test procedures require repeat experiments in 
order to eliminate the false positives and to confirm the structure and biological activity 
of the HTS hits.  The stability of the compounds in solid form, or in solution, coupled with 
the compounds’ availability for future HTS, add further challenges.  
Permeability and solubility are properties increasingly being screened for with 
computational and experimental methods, prior to choosing candidate leads for further 
optimisation.  Virtual screening has emerged as an adaptive response to HTS, as Lipinski’s 
rule4 implemented early on in drug discovery could potentially increase the chance of 
success in drug discovery projects.  Compound filtering according to Lipinski rule of five 
can save time in the process of synthesis planning, and opens up the possibility of 
exploring large numbers of reagents - since post-enumeration property estimation is 
usually much more time-consuming.  
Filtering also avoids large numbers of reactive halogens in the products, the 
presence of highly flexible unsubstituted, unbranched alkyl chains, the formation of 
compounds that exceed the maximum accepted number of rings, or ionisable groups, in 
the product library.  More importantly, molecules that are reactive toward protein targets 
can also be removed, such as Michael acceptors, ketones and aldehydes.  Such compounds 
would not yield leads or hits, but would likely turn out to be false HTS positives.13  Finally, 
if changes that influence binding affinity and ADME properties were simultaneously 
monitored, there would be much more reduced chance of prediction errors and the 
approach is likely to converge on interesting compounds more rapidly.15  This could be a 
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less resource-demanding strategy and is especially useful in the absence of experimental 
hits from already existing drugs.  
It is notable that most drugs found in compiled databases were classically 
discovered and developed using biological assays, selective cytotoxicity assays and 
animal models of disease, not using biochemical (e.g. HTS) assays.  Today, there is a risk 
that high-throughput experiments reduce the opportunity for innovative and iterative 
thinking, as millions of molecules are screened simultaneously without the possibility of 
interpretation and analysis between the traditional rounds of experiments for this 
number of data points.7 
1.1.2 Fragment-Based Drug Discovery 
Fragment-based drug discovery identifies low MW ligands (typically 150-300 Da) 
that bind to biologically important macromolecules.1  A recent analysis16 suggests that 
projects involving fragment screening generate smaller, less lipophilic hits and leads than 
those identified through the use of other hit discovery techniques, such as HTS.  Compared 
with HTS, the fragment approach requires fewer compounds to be screened due to better 
coverage of chemical space, i.e. the space spanned by all possible chemical compounds in 
all possible topology isomers.17  As a result, fragment screening offers more efficient and 
successful optimization campaigns, despite the lower initial potency of the screening 
hits.1  Furthermore, reducing the numbers of molecules screened in the individual steps 
is desirable for academic groups or start-up companies that do not have the same 
screening capacities as large pharmaceutical companies.8 
The first and second fragment-based drugs, Zelboraf and Venclexta can be seen in 
Figure 4.  Zelboraf18 functions as a B-Raf enzyme inhibitor and is used to treat metastatic 
melanoma.  Zelboraf was discovered at Plexxikon and developed in partnership with 
Roche; the drug was approved in August 2011 and reached market in just six years.  
Venclexta19 functions as a Bcl-2 PPI inhibitor and is used to treat chronic lymphocytic 
leukaemia; the drug was co-developed by AbbVie and Genentech and approved in April 
2016. 
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Figure 4 The first and second drugs discovered using FBDD, Zelboraf and Venclexta. 
In FBDD, the optimization process starts from a small and efficiently binding 
fragment in which each atom in the molecule is involved in the desired binding 
interactions.  Thus, the size, complexity and physical properties of the molecule can be 
more easily controlled than when starting from a higher-affinity HTS hit that contains 
groups not essential to the desired binding.  If the “weak” fragment forms part of a potent 
drug, and still forms the same interactions with the protein, then the fragment in fact 
contributes over half1 the favourable binding energy despite being tens of thousands of 
times weaker in affinity.   
Ligand efficiency (LE = ΔG° ÷ N, the binding energy per heavy atom of a ligand to 
its binding partner) of a fragment can be maintained during a fragment-to-lead chemistry 
campaign, provided structural information about binding interactions is available.20  This 
can be achieved by growing the fragment synthetically to a proximal binding site, or by 
linking two fragments together.  An example of a fragment to drug campaign can be 
described in the discovery of AT7519, an inhibitor of cyclin-dependent kinases (CDK)21 
(Scheme 1).  The clogP (calculated logP) changes of the compound at each different stage 
of development is shown (Figure 5).  Binding energy is proportional to log(IC50), thus it 
can be shown that as binding energy of the compound increased (became more negative), 
LE against CDK was maintained, represented by the exponential relationship between IC50 
and number of heavy atoms (Figure 6).  This is generally the case for high LE fragments.1  
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Scheme 1 The discovery of AT7519.  Fragment 1 was identified from an X‑ray screen as binding to the hinge 
region of the kinase, and this interaction was consolidated with the amide in 2.  Growing into a proximal 
binding pocket and using di-ortho substitution to induce a twist in the second phenyl ring led to structure 3, 
the lead molecule.  To improve cell-based activity and in vivo efficacy, a piperidine solubilizing group was 
incorporated into the final candidate structure, AT7519.21  
  
Figure 5 Relationship between clogP and MW as the fragment is developed into a higher MW lead compound, 
before polar groups are incorporated into the final drug in order to optimise ADME (Scheme 1).  
  
Figure 6 Relationship between IC50 and number of heavy atoms as the fragment is developed into a higher 
MW lead and drug compound (Scheme 1).  Since log(IC50) is proportional to the binding energy of the ligand 
to its binding partner, the logarithmic trend observed between IC50 and number of heavy atoms indicates 
unchanged LE throughout this process i.e. the gradient is constant. 
In most cases, a co-crystal structure is necessary in order to fix the binding mode 
of the fragment before growing it.  This often reduces fragment screens to targets that 
have a soakable crystallography system established.  Unfortunately, the fragment or 
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analogues of the fragment may not be amenable to synthesis.  There is frequently a need 
for chemical synthesis to access a compound with potency similar to a compound that 
might be identified through other means such as HTS.  Secondly, it is hard to imagine 
certain types of chemotypes ever being obtained through FBDD, for example, a complex 
natural product with a few fused rings or a macrocyclic compound.8 
Due to their weaker affinity, specialized techniques are required to screen for 
fragments.  Biophysical methods such as X-ray diffraction, NMR spectroscopy, surface 
plasmon resonance (SPR), isothermal calorimetry and mass spectrometry have been 
exploited.22  There also continues to be a key role for more traditional biochemical 
screening formats such as fluorescence anisotropy or time-resolved fluorescence energy 
transfer, though the preferred configuration of such assays for fragment screening may 
need to be different from the format used in, for example, HTS.23   
These techniques usually require specialized equipment, personnel with specific 
expertise, supporting informatics infrastructure, and access to large amounts of purified 
protein (>10 mg).  The fragments also need to be soluble at the high concentrations used 
for screening, and this may be an advantage in the subsequent lead optimization stage.1  
Thus, in fragment screening, tolerance to large amounts of organic material is often 
necessary whereas in HTS the emphasis is on miniaturisation and cost reduction.23  
Previous difficult experiences in optimizing μM HTS hits created the assumption that it 
would be harder to start from a lower potency.  In practice, the high LE and the high 
quality interactions of fragments to the target protein make them much more 
optimisable.1 
1.2 Biophysical Methods for Fragment Screening 
Key structural methods such as X-ray crystallography or NMR spectroscopy can 
be used to rationalise fragment binding and direct synthetic modifications to the chemical 
scaffolds, allowing a rapid increase in affinity towards the target.  This also enables other 
properties, such as selectivity, to be explored at an early stage.24  Surface plasmon 
resonance (SPR) is another primary biophysical method for the screening of low 
molecular weight fragment libraries.  SPR biosensor technology is used to identify the 
binding of compounds to protein targets, as well as provide accurate information on the 
affinity and kinetics of molecular interactions.25  Other fragment screening methods 
include techniques such as isothermal titration calorimetry26 and mass spectrometry.22 
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1.2.1 Fragment Screening by Surface Plasmon Resonance 
SPR is a label-free technology used to monitor biomolecular interactions.27  This 
technique is highly sensitive and capable of detecting fragments with molecular weights 
as low as 100 Da bound to biomolecular targets.28  SPR is very attractive due to its low 
protein consumption,29 rapid assay development and kinetic and thermodynamic 
validation of hits.28  The protein is first immobilized onto a chip surface, which enables as 
many as thousands of molecules to be sequentially screened using the same surface 
before the protein needs to be renewed.29  In an SPR experiment, the change in the surface 
plasmon resonance angle upon interaction of the fragment with the immobilized protein 
creates the detected response.  The response in SPR is proportional to the fraction of 
bound protein.30  
It is important to note that protein–fragment interactions can be only be detected 
when working at fragment concentrations comparable to the dissociation rate constant 
of the fragment.  This is crucial when screening targets for which the fragments do not 
have a large binding efficiency index, such as some inhibitors of protein–protein 
interactions.29  Nevertheless, SPR allows the analysis of binding kinetics, thus providing 
the association and dissociation rate constant of the interactions.31  In addition, SPR-based 
fragment screening has potential to eliminate all nonspecific binders, and another 
advantage is the availability of multiple biosensor channels, meaning multiple proteins 
can be screened in parallel.28 
1.2.2 Fragment Screening by NMR 
NMR-based fragment screening offers a large dynamic range and is capable of 
capturing very weak interactions.29  Detection of binding by NMR may be achieved using 
techniques such as chemical shift perturbation, differential line broadening, transfer NOE, 
and diffusion-based methods. These methods can be distinguished by those that monitor 
NMR signals from the protein, and those that monitor signals from the ligands.32  The 
relatively low sensitivity of NMR detection can be partially offset by the high compound 
concentrations used when studying weak protein-fragment interactions,33 and this is the 
case even when the compounds are used at concentrations orders of magnitude lower 
than their dissociation binding constants.  Screening by NMR offers the benefit of 
identification of hits that are insoluble at the concentrations required for detection by 
other biophysical techniques.29  In addition, the ability for NMR to detect changes in the 
concentrations and aggregation states of the fragments significantly reduces the number 
of false positives compared to biochemical assays.33  Nevertheless, it is ideal for 
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complementary screening techniques to be applied for supporting evidence.29 
1.2.3 Fragment Screening by X-Ray Crystallography  
In order to use X-ray crystallography as a method for fragment screening, it is 
necessary to prepare and analyse large numbers of crystalline complexes.33   This is done 
by exposing the protein to the fragments, and solving the crystal structures of the 
resulting complexes.  One technique involves growing crystals of the target protein and 
then soaking them in solutions of the fragments; a soakable system is thus essential. This 
could be done either for single compounds or as cocktails of compounds.34  Screening by 
X-ray crystallography requires the production of diffraction quality crystals, which need 
be generated reproducibly and to a similar size and quality on a large scale. Thus, 
optimisation of the processes from protein production to crystallisation is necessary.  
Systems for efficient collection of X-ray diffraction data is key for rapid 
progression in the screening process.  A principal step in solving structures of protein–
ligand complexes is the placement of the ligand into the experimentally observed electron 
density,33 and final binding evidence is provided by the  X-ray structure of the fragment 
bound to the receptor.  In addition, this delivers the relevant structural information 
toward any fragment optimization in a medicinal chemistry campaign.  However, it can 
be difficult to observe electron density of fragment hits bound to their receptor due to 
various experimental causes.29 
1.3 Chemical Space 
Compared with higher MW molecules used in methods such as HTS or lead-
oriented synthesis, the fragment approach requires fewer compounds to be screened.  
This is because smaller, less complex molecules sample chemical space more efficiently 
and have a greater chance of fitting a given drug binding site.  It has been estimated35 that 
for every extra heavy atom added to an organic molecule, the number of potential 
structures increase by around a factor of 10 i.e. there are approximately 107 more 
molecules with MW 400 relative to those with MW 300.  Thus, by screening sets of lower 
MW compounds, a relatively greater proportion of accessible chemical space can be 
sampled thereby increasing the chance of finding hit molecules.  By analogy to the Lipinski 
Rule of five,4 fragments are often described using a modified Rule of three (MW <300 Da, 
logP <3, no. of hydrogen bonds ≤3).3,36 
Knowledge of active fragments can be used in data-mining analyses of the output 
from an HTS screen, and the ready availability of significant numbers of analogues in an 
HTS screening collection can provide rapid structure-activity relationships around 
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fragment hits.23  Molecular complexity is discussed in detail in this section, and its 
relevance to fragment screening.  Examples of library synthesis methods which allow the 
optimal coverage of chemical space include combinatorial variation of scaffolds used in 
lead and diversity-oriented synthesis, and chemistry and biology-based expansion in 
fragment screening. 
1.3.1 Molecular Complexity  
The molecular complexity model is based around the theory that a ligand binds to 
a receptor if there is an exact match between all of their interaction features (Figure 7).  
It was found that the probability of binding decreases rapidly as the complexity of the 
ligand increases, since there are many fewer ways of obtaining a match than a mismatch.  
In addition, the probability of finding a unique binding event, i.e. where the ligand matches 
the receptor in one way only, passes through a maximum, as very simple ligands can find 
multiple binding modes (Figure 8).23 
 
Figure 7 The complexity model where ligands are represented as linear strings of circles and squares and 
their receptor is represented as a combination of circular and square clefts.  A match corresponds to exactly 
complementing features of ligand and receptor.  Some ligands can match more than one way (modes 1, 2), 
and other ligands only show a unique mode.  
Figure 8  Data for 
random receptors of 
length 12.  This model 
shows that the 
probability of a ligand 
binding to a receptor in at 
least one mode decreases 
rapidly with ligand 
length (blue).  The 
probability of matching 
in one way only goes 
through a maximum (red, at ligand length 3).  Combined with the probability of physically detecting a binding 
event (green, the longer the ligand the more easily it is detected), gives the overall probability of a “useful 
event” (purple, where the ligand binds in a single binding mode and can be detected).  Reproduced from 23 
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Moreover, the physicochemical properties of larger, more complex molecules 
mean they are not compatible with good medicinal chemistry starting points due to the 
tendency for these properties to increase further during lead optimisation.  Key 
limitations to the model include the restriction to a binary interaction type (charge, shape, 
desolvation, polarisation, etc.), the one-dimensional nature of the representation and the 
requirement for all features to match.  
Ligand promiscuity can be calculated by determining the number of targets to 
which a given ligand binds.  Compounds with higher MW exhibit on average higher 
promiscuity, alongside increased lipophilicity.  A way of incorporating promiscuity into 
the model is to require only a threshold number of matches between ligand and receptor, 
ignoring any additional mismatches.  Under this approach it is found that the probability 
of a ligand interacting with a receptor increases with the size of the ligand, because there 
is a higher likelihood of finding suitable matching substrings in a longer ligand, although 
with lower potency (using the number of matches as a surrogate for potency).  In drug 
discovery the emphasis is on optimising the activity of a lead series against the primary 
target of interest whilst minimising activity at other targets; and since such compounds 
will tend to concentrate in lipid bilayers which are home to many key signalling systems, 
the likelihood of off-target interactions and ultimately toxicities will also be increased.23 
1.3.2 Lead-Oriented Synthesis 
In general, lead-like molecules have logP values in the range –1 to 3 and MW in the 
ideal range 200 to 350 g mol-1 (approximately 14 to 26 non-hydrogen atoms).3 Lead-
oriented synthesis must be able to deliver molecules with specific molecular properties, 
while also maintaining the synthetic efficiency to allow their cost-effective utilization.  It 
does this by focusing on the physicochemical and functional group properties of the target 
molecules.3  The concept and methods related to lead-likeness are very intuitive and fit 
with the current experience of what typically happens in lead optimization.7   
Unprotected polar functionality is often poorly compatible with many reagents 
due to high reactivity, insolubility in non-polar solvents, or coordination to a catalyst.37  
The pharmaceutical industry seeks to identify molecules able to efficiently interact with 
biological systems, frequently through polar or hydrogen bonding interactions; 
unfortunately, these polar interactions rely on functional groups such as weakly acidic OH 
and NH bonds or Lewis base/hydrogen bond acceptors.  Lead-oriented syntheses should 
ideally be able to mediate novel transformations in the presence of such biologically 
relevant functional groups.  But whilst these reactive groups can introduce further 
functionality or diversification, they also leave undesired structural features.  Similarly, 
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protecting groups often remain in reaction products requiring extra chemical steps for 
their removal which may severely limit the practical application in arrays.  Lead-oriented 
syntheses which do not leave residual undesired reactive centres or protecting groups are 
therefore of particular value.3 
In contrast, diversity-oriented synthesis targets scaffold diversity mainly in drug-
like space, by using cascades which produce large numbers of molecular scaffolds using a 
small set of transformations.3,38,39  Unlike lead-oriented synthesis, diversity-oriented 
synthesis shows little consideration towards molecular properties.  Other methods 
include target-oriented synthesis, which targets just one compound, and combinatorial 
chemistry, which targets large numbers of compounds.  Early combinatorial synthesis 
libraries relied on diverse capping groups for their overall diversity, but the addition of 
multiple points of diversity in order to build a large library often meant the molecules lie 
outside of lead-like space on grounds of size and lipophilicity.3  Examples of generic 
structures considered for a reduced complexity screening set is shown in Figure 9. 
 
 
1.3.2.1 Examples of Lead-Oriented Synthesis 
Methodology that allows the connectivity of building blocks to be varied whilst 
maintaining a common approach are particularly valuable e.g. an Iridium catalysed allylic 
amination reaction (Scheme 2).  Synthetic approaches to diverse lead-like molecular 
scaffolds are more powerful if more bonds are formed to individual building blocks, or if 
more building blocks are used.40  It should also be possible to vary all of the building 
blocks independently.  Finally, the value of specific synthetic approaches depends on the 
accessibility of the starting materials, the increased molecular complexity of the product 
scaffolds, the structural diversity of the product scaffolds, and the molecular properties 
of the derivatives.5  Further examples of advantageous synthetic approaches include 
scaffolds formed using Mitsunobu reactions, amino acid chemistry, and Ugi reactions 
(Scheme 3). 
Figure 9 Examples of generic 
structures considered for a reduced 
complexity screening set.  X and Y 
indicate possible heteroatoms.  
Synthetic handles are shown in bold.7 
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Scheme 2 Synthesis of example lead molecules using iridium-catalysed allylic amination reactions.  a) 2 mol% 
[Ir(dbcot)Cl]2, 4 mol% ligand 21, 4 mol% nBuNH2, DMSO, 55 °C.  dbcot = dibenzo[a,e]cyclooctatetraene.41 
 
Scheme 3 Synthesis of example lead molecules using key reactions including a) Mitsunobu chemistry42, 
b) amino acid chemistry43 and c) Ugi chemistry44.  
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1.3.3 Fragment Development 
Evaluation of several fragment libraries shows that they are predominantly 
populated with (hetero)aromatic-derived chemotypes, which might bias their success for 
certain targets.16  By combining fragment-based screening with virtual fragment linking 
and HTS fingerprints, another effective strategy has been developed not only to expand 
from low-affinity hits to potent compounds but also to hop in chemical space to 
substantially novel chemotypes.   
One approach8 (Scheme 4) involved information about desirable substructures 
being firstly extracted from a fragment screen, and this information is used to select larger 
compounds containing these substructures (chemistry-based expansion).  In the next step, 
the larger compounds are tested for activity, and information regarding the biological and 
biochemical activity enriched in the active compounds is used to select a subsequent set 
of small molecules for evaluation (biology-based expansion).  It was found that in the 
chemistry-based expansion the desirable linking of the fragment substructures is 
revealed.  Furthermore, in the second step, the biological fingerprints of the active hits 
were able to be uncovered, and by expanding on the basis of these fingerprints, active 
compounds were identified that contain chemotypes not covered by the original fragment 
library. 
 
Scheme 4  Fragment-hit expansion strategies, virtual fragment linking and HTS fingerprinting, use a 
combination of chemistry and biology-based expansion to select small molecules for testing.  In the first step, 
chemical features (highlighted in red and in blue) are extracted from the active and inactive fragment pool 
and used to generate conditions applied to the screening collection.  The top-ranked molecules are screened 
and then divided into an active and inactive sets to build a second classifier according to bioactivity profiles.  
Adapted from 8  
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Compounds that are identified from biological expansion often contain 
substructures that had been enriched in fragment hits in the hot-spot region, while 
exploring other parts of the binding pocket with substructures that fragment-based 
screening identified as unfavourable for the hotspot.  Although it might be by chance that 
these unfavourable substructures are present in the biological expansion hits, it is notable 
because the presence of the unfavourable substructures would preclude them from being 
identified earlier during the chemical expansion. 
Chemistry-based expansion of fragment hits was able to identify only active 
compounds concentrated in a very narrow area of chemical space.  However, as non-
structural descriptors, HTS-fingerprinting in biology-based expansion was able to reach 
out to active compounds further away in chemical space.  These observations show that 
it is the combination of orthogonal views on molecular similarity (chemical and biological) 
in the two hit-expansion steps that is crucial for a successful follow-up on fragment hits.  
Since random compound selection in the first step led to the identification of rather 
structurally diverse active molecules, the subsequent chemistry-based expansion was not 
biased toward a particular region but was able to retrieve active molecules scattered over 
large parts of chemical space.8  
1.4  Scaffold Diversity 
Assessing chemical diversity requires each structure to be characterized by one 
or more descriptors.  These can be molecular descriptors such as physicochemical 
properties or topological indexes.  Larger substructures such as ring systems can also be 
used; an advantage of using large features like rings is that structures having such features 
in common often belong to the same chemical family.  The framework is obtained by 
removing all side-chain atoms, i.e. non-ring atoms not on a direct path between two ring 
systems.  As a result, the framework of a structure is described by all of the ring systems 
and all the linkers.  Typically, the framework describes only molecular topology, i.e. 
contains no three-dimensional (3D) or stereochemical information.  Part of the reason 
this concept is useful in medicinal chemistry is that it describes the arrangement of rings 
in a structure, and rings are key building blocks in the design of drugs.45  
In order to identify the framework of each structure in a compound set, an 
iterative algorithm proceeds by flagging all terminal atoms, then every atom adjacent to 
a flagged atom unless it is adjacent to more than one unflagged atom; the process is 
repeated until no more atoms can be flagged.  When finished, the unflagged atoms and the 
bonds between them constitute the framework.  The graph level has connectivity 
information but ignores element and bond types, the graph/node level has connectivity 
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and element information but ignores bond types, and finally, the graph/node/bond level 
has connectivity, element, and bond type information (Figure 10).  Next, a procedure 
looks for a match between each new framework and all previously found frameworks; 
this procedure builds a portfolio of frameworks each of which is assigned a unique 
identifier.  Acyclic substances are ignored here because the framework definition is not 
applicable to these compounds.   
    
If many compounds derived from a framework have already been synthesised, 
these derivatives can serve as potential starting materials for further syntheses.  This 
suggests there is considerable overlap between the most common shapes of drugs and 
organic compounds in general, and contributing factors include chemical stability and 
synthetic accessibility.46  A method to assess the diversity of a screening collection uses 
the NC50C descriptor, which has been derived from a plot describing the density 
(percentage of classified compounds) of each class or framework, which was then 
transformed into a cumulative plot allowing interpolation of the percentage of 
frameworks required to describe 50% of classified compounds, or PC50C.  Since this 
metric is independent of the size of a library, it can be used to compare collections of 
different sizes.47    
The use of frameworks as the basis for diversity analysis has certain limitations 
in that it excludes acyclic compounds and the part of the structural diversity associated 
with acyclic side chains attached to the framework.  Nevertheless, this is a conceptually 
simple way to assess diversity for a large structure database.  A lack of structural diversity 
among test compounds is a potential drawback in the drug discovery process.48 
1.5  Shape Diversity 
Molecular 3D shape can be defined using their lowest-energy 3D conformer, 
which can then be used to calculate the proportion of “rod-like”, “disc-like” and “sphere-
like” characteristics belonging to the molecule, otherwise known as their principal 
Figure 10 The frameworks shown for three 
different compounds at the graph level, the 
graph/node level, and the graph/node/bond 
level.  All three compounds are identical at 
the graph level and two of the three 
compounds are identical at the graph/node 
level.  Adapted from 46 
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moment of inertia (PMI).  Some believe49 that these shape characteristics of a molecule 
together with its size constitutes the first, most basic level in a hierarchy of molecular 
descriptors.  On top of that, an abundance of secondary descriptors are necessary to refine 
the information with a more spatial view to the potential for interactions, such as polar 
surface area, hydrogen-bonding surface potential, surface charge distribution, or 
presence and location of specific pharmacophoric elements.   
The shape space coverage has been found to originate mainly from the nature and 
the 3D geometry (but not the size) of the central scaffold, while the number and nature of 
the peripheral substituents and conformational aspects were shown to be of minor 
importance.  It could also be argued that molecular shape is related to the scaffold only in 
the limit that the scaffold is large with respect to the entire molecule, meaning that the 
influence of the scaffold on the overall shape will disappear with decreasing size.  
Surprisingly, results indicate that even very small scaffolds exert a highly distinctive effect 
on the molecular shape distribution of the respective libraries.50  On the other hand, shape 
complementarity is necessary, but alone not sufficient for a compound to productively 
interact with a target, suggesting that molecules with similar shapes will not necessarily 
produce similar biological activities.  A second layer of complexity is added by the fact that 
many biological targets contain several different sites prone to interaction with small 
molecules. 
Another way of analysing chemical shape is based on comparing molecular shapes 
with a set of reference shapes.51  This relationship can be captured in the form of a binary 
string, or a fingerprint.ii  If there is similarity between the molecule and the reference 
shape above a predefined threshold, then the corresponding bit is switched on in the 
binary string.  The generated fingerprints can be used to identify similarities between two 
compounds by extracting common bits within their fingerprint.  Essentially, it is the 
number of reference shapes used which determines the number of bits set in a 
fingerprint.52   
1.5.1 Principal Moment of Inertia (PMI) 
Chemists often reason that compounds with greater 3D characteristics will be 
more complex as a result of higher numbers of sp3 centres, stereochemical relations etc., 
and will have lower hit rates in fragment screens.16  However, a recent analysis53 showed 
that addition of a methyl group can produce significant improvements in potency (and 
                                                             
ii This is different to biological fingerprints (Section 1.3.3). 
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ligand efficiency), primarily through conformational changes, generating more shape 
analogues.  
In order to calculate the proportion of “rod-like”, “disc-like” and “sphere-like” 
characteristics, normalized ratios of PMI50 are plotted into two-dimensional triangular 
graphs, where the vertices (1,1), (0.5, 0.5), (0,1) correspond to the “envelope” shapes of 
spheres, disks, and rods, respectively (Figure 11).  The plot is then used to compare the 
shape space covered by different compound sets, such as combinatorial libraries of 
varying size and composition.   
 
Molecular descriptors or properties need to be correlated with, and predictive for, 
biological activity, (back-)translatable into chemical structure terms, and fast to calculate.  
3D molecular shape intuitively meets the above criterion.  This is simply because a 
compound will only modulate the activity of a biological target, if its 3D shape can match 
the appropriate cavities, clefts, or bulges presented by the biological counterpart.  3D 
shapes are generated based on standard bond lengths, bond angles, and ring 
conformations, taking into account atom type, hybridization state, and bond order.50  PMIs 
on their own derived either computationally or experimentally from IR or microwave 
spectra, have previously been used to assess molecular properties such as shape, 
geometry, and conformational parameters.54 
It can be seen from Figure 11 that some areas of the triangle remain entirely 
unpopulated, such as the region around the right-hand corner, indicating the absence of 
fragments with 3D shapes.  However, the pharmaceutical track record of discoid 
molecules is undisputed, as evaluation of several fragment libraries show that they are 
predominantly populated with (hetero)aromatic-derived chemotypes.16  Results may 
have been distorted by restricting the shape analysis to only one conformation per 
Figure 11 PMI of a 3D fragment 
consortium members’ library 
(approximately 1000 fragments), 
which is representative of 
commercial fragment space.  
Reproduced from 16 
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compound, considering that the 3D structure determined from crystals of the small-
molecule alone is not necessarily congruent with that adopted in a complex with the 
biological target.50  Nevertheless, molecular flexibility can be fairly represented when a 
large library has been used. 
Fundamentally, it is beneficial for primary screening collections to strive for 
maximum shape diversity, because it is highly desirable to identify several distinct 
chemical series active on a given target, to predict potential downstream issues often 
encountered with one chemical family, such as toxicity or poor pharmacokinetics.  The 
envelope shape analysis offers a rapid way to assess and compare compound collections 
for their biological diversity, despite limitations such as the fact that it appears to 
disregard any information related to the situation on the inside of the molecular envelope.  
However, further studies50 have since shown that such “degenerate” situations are 
extremely rare and restricted only to highly symmetrical, unsubstituted molecules.  
1.5.2 Comparison of Shape Similarity 
3D similarity methods use geometric constraints and are valued for their ability 
to find compounds belonging to diverse chemical families.55  ROCS performs rapid 
overlays of 3D chemical structures using atom-centered Gaussians to compute geometric 
overlap.56  Shape similarity can be determined by similarity scores calculated using the 
Tanimoto equation. 
   
Figure 12 The rectangle and oval shapes represent two different shaped molecules A and B respectively, 
placed in positions of maximum overlap.  OAB is the volume overlap between conformer A and conformer B, 
OA is conformer A volume, and OB is conformer B volume.  A Tanimoto score of 1 indicates complete overlap.57 
Figure 12 shows a rectangle and oval which represent two different shaped 
molecules A and B, placed in positions of maximum overlap.  Here, OAB is the volume 
overlap between conformer A and conformer B, OA is conformer A volume, and OB is 
conformer B volume.  A Tanimoto score of 1 indicates complete overlap.  These shapes 
can then be used to identify a small set of diverse reference shapes representative of the 
entire library, and a binary fingerprint can be generated for each molecule in the library 
ABBA
AB
OOO
O

Tanimoto  
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in the form of bit strings.  Within every bit string, each bit corresponds to a computed 
similarity above a predefined threshold between the fragment and the reference shape.58  
Table 1 shows molecular fingerprints for two hypothetical molecules A and B, generated 
using ten reference shapes (1-10).  The ten reference shapes give rise to the 10 bits shown, 
where 1 indicates a correlation between the molecule and the reference shape, and 0 
indicates a lack of correlation.  This process is described in detail in Section 2.5. 
Reference 
Shape 
1 2 3 4 5 6 7 8 9 10 
Molecule A 1 0 0 1 0 0 0 1 0 0 
Molecule B 1 0 1 0 0 0 0 0 0 0 
Table 1 Molecular fingerprints for two hypothetical molecules A and B, generated using ten reference shapes 
(1-10).  The ten reference shapes give rise to the 10 bits shown, with each bit corresponding to a computed 
similarity between the molecule and the reference shape.  Here, 1 indicates a correlation between the 
molecule and the reference shape, and 0 indicates a lack of correlation.
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1.6  Project Aims 
My project aims to use novel methodology to design a fragment library in which 
the molecules will not only have distinct shapes, they will also be highly three-
dimensional.  Synthesis of the fragments will be completed and screened using 
biophysical methods in combination with a representative library of commercial 
fragments.  By covering under-explored areas of chemical space, I hope to identify high-
quality novel hits towards biologically relevant targets without the need to synthesise a 
large number of molecules, where the high shape-diversity of the library is key in order 
to reduce attrition rates in drug discovery. 
1.6.1 To design a virtual fragment library (Chapter 2) 
A range of scaffolds synthesised using chemistry validated in Leeds will be 
identified; based on these scaffolds, a virtual library of novel structures will be 
enumerated using established chemical routes.  A heavy atom range will be selected 
which allows the most diverse range of fragments to be included.  The library will next be 
combined with 100,000 randomly selected commercial molecules from the ZINC library59 
(which will also be filtered for the same heavy atom range) and a set of reference shapes 
will be identified by ROCS to represent the library.  These reference shapes will then be 
filtered for fragment-like properties using clogP values of –1 to 3.   
A simulated annealing protocol will be used to perform set comparison, allowing 
the most effective selection of 80 shape-diverse fragments based on different weightings 
of composition of virtual compounds, coverage of reference shapes, and diversity of 
fragments.  It will be decided here what proportion of the compounds would be virtual 
and what proportion of the compounds would be bought commercially.  Three-
dimensionality of the final library will be investigated using a PMI plot, an example of 
which can be seen in Figure 13 (following page).  It is hoped that the virtual compounds 
will exhibit higher 3D characteristics compared to commercial compounds.   
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1.6.2 To synthesise a set of shape-diverse fragments (Chapter 3) 
A retrosynthetic analysis of different virtual sets will allow selection of a set of 
molecules with the most established chemistry for synthesis; the key chemistries which 
will be investigated include iridium-catalysed allylic amination, amino acid chemistry, 
Mitsunobu chemistry and Ugi chemistry.  Synthetic challenges will be overcome by 
generating alternative libraries of 80 compounds without compromising on the coverage 
of reference shapes, and diversity of fragments 
1.6.3 To assess the biological properties of the library of fragments (Chapter 4) 
All 80 molecules will be screened against a number of established targets in a 
biophysical evaluation of their viability as fragments.  High-throughput X-ray 
crystallography will be used to observe binding interactions and indicate whether more 
3D Leeds fragments exhibit better binding compared to flatter commercial molecules.  
The project is summarised in Figure 14. 
 
Figure 14 Summary of each step of the project.
Figure 13 Example PMI plot where blue 
represents virtual compounds and grey 
represents commercial compounds.   
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2 Design of a Shape-Diverse Fragment Library 
This Chapter discusses the enumeration of a virtual library using scaffolds closely 
related to those previously synthesised by the group.  By varying the building blocks, 
virtual scaffolds could be identified, as well as undergo derivatisation to maximise their 
shape diversity.  Next, taking fragment-like properties into consideration, a heavy atom 
filter was selected.  ROCS was used to identify a range of reference shape molecules for 
the combined libraries of ZINC (commercial, 100,000 selected at random) and compounds 
based on Leeds chemistry.  Next, a selection protocol allowed a library of 80 compounds 
to be identified, of which 20 were virtual; the properties which were considered in the 
selection process included composition of virtual compounds, coverage of reference 
shapes, and diversity of fragments.  Finally, retrosynthetic analysis of fragments allowed 
the selection of the 20 compounds with the best-established chemistry for synthesis.  
2.1  Use of the Terms “Building block,” “Scaffold,” and “Fragment” 
Below are examples of the chemistries which will be discussed, shown via the 
retrosynthesis of target fragments which may later play a role in drug discovery.  First, 
the scaffold from which fragments are derivatised can be seen, followed by the building 
blocks of the reaction.  The underpinning chemistries which have been selected include 
iridium-catalysed allylic amination41, amino acid chemistry43, the Ugi reaction44 and the 
Mitsunobu reaction42 (Scheme 5). 
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Scheme 5 Retrosynthesis of exemplified fragments. 
2.2  Enumeration of the Compounds 
This section discusses the generation of virtual scaffolds using previously 
prepared scaffolds by the Nelson group, by changing building blocks as well as converting 
less desirable functional groups into those which are more versatile.  Derivatising the 
virtual scaffolds resulted in a virtual fragment library with high shape diversity. 
2.2.1 Identification of Scaffolds Previously Prepared 
Successful reactions previously completed by members of the Nelson group were 
summarised in order to gather a selection of reliable methodologies.  These involved 
cyclisation reactions such as aminoarylation, ring-closing metathesis, gold-mediated 
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hydroamination and the Heck, Ugi and Mitsunobu reactions.  Connective reactions 
preceding cyclisation involved transformations such as N-allylation, allylic and reductive 
amination, using building blocks such as allylic carbonates, amino acids and cyclic 
sulfamidates.  Scaffolds synthesised from each different starting material were grouped 
and tabulated for ease of reference.  These scaffolds were formed in reasonable yields 
with a well-adapted selection of methodologies; some examples can be seen in Scheme 6, 
and a full range can be found in the Appendix (Table 31). 
 
Scheme 6 Methodologies for formation, and yields of exemplified scaffolds.  
2.2.2 Identification of Virtual Scaffolds Potentially Synthesisable Using Previously 
Established Methods 
A range of small groups was chosen to replace interchangeable aryl and alkyl 
groups within the scaffolds with the intention of reducing the number of rotatable bonds.  
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This could be accomplished for example by using an alternative electron-deficient aryl 
bromide for the aminoarylation reaction or by changing the substituent on an amino acid 
building block.  By making only small alterations to the building blocks, it is presumed 
that the virtual scaffolds would largely remain synthetically accessible based on the 
precedent provided by the exemplified scaffolds.  Furthermore, less versatile groups such 
as alkenes were converted into more useful functionalities such as aldehydes and 
carboxylic acids - which practically would require a simple one step conversion.  Working 
retrosynthetically, it was important to ensure that the new desired building blocks were 
commercially available for synthetic practicality.  Some example conversions can be seen 
in Scheme 7 and a full range of building blocks and functional group interconversions can 
be found in the Appendix (Table 32).   
  
Each virtual scaffold was enumerated using Pipeline Pilot (PLP); Figure 15 shows 
an example protocol used to enumerate a range of virtual scaffolds based on amino acid 
chemistry.  Setting the reactant property allowed the enumerated compounds to be 
labelled according to the numeric identifier for each exemplified scaffold, and thus it was 
Scheme 7 Examples of exemplified and 
virtual scaffolds generated by 
a) changing substituents on building 
blocks and b) converting undesirable 
functional groups into more useful ones 
for derivatisation.  The original and 
changed substitutions are shown in red. 
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possible to see which exemplified scaffold gave the largest number of virtual scaffolds.  
These transformations involved changing alkene functionalities into more useful ketone, 
diol, aldehyde, acid or alcohol groups, whilst various substituents were diversified 
according to changes in the building block i.e. changing the nucleophile, isocyanate and 
initial amino acid.  By placing the components one after the other, it ensured that more 
than one enumeration could be done in parallel, generating a diverse range of compounds.   
 
Figure 15 Example Pipeline Pilot (PLP) protocol used to enumerate exemplified scaffolds to give virtual 
scaffolds, by using alternative starting materials (nucleophiles, isocyanates and amino acids) as well as 
converting undesirable functional groups (alkenes) into those which provide a better synthetic handle for 
novel derivatisation. 
The 2D co-ordinates component allowed the compounds to be easily visualised on 
an HTML viewer and the SD (structure-data) writer allowed the compounds to be stored 
as an SD file and later combined with other scaffolds.  Connecting the unchanged scaffolds 
directly to the SD writer meant that the exemplified scaffolds were not lost in the final list 
of compounds, whilst the canonical smiles component allowed the originator compound 
to be traced and appear as a 2D reference structure.  In addition, slight modifications were 
made to the exemplified scaffolds in order to prevent undesirable functional groups being 
fed into the resulting compounds.  Modifications included hydrolysis of unstable ester 
groups, removal of the trifluoroacetamide capping groups used in Mitsunobu chemistry 
as well as removal of reactive azide and iodide functional groups. 
2.2.3 Derivatisation of Virtual Scaffolds 
The SD files for all virtual scaffolds were next fed into a new protocol via the SD 
reader, which allowed derivatisation to occur using a range of small capping groups.  
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These decoration reactions included amide formation, reductive amination, sulfonamide 
formation, as well as N- and O- alkylation/arylation.  As seen in the protocol in Section 2.3, 
Figure 17, the first-row component simply deprotected the scaffolds allowing the 
undecorated compounds to be captured in the library.  The second-row derivatisation 
component allowed O-alkylation to occur as well as decorations involving a primary 
amine as the capping group i.e. amide coupling to a carboxylic acid functionality in the 
scaffold, and reductive amination of an aldehyde or ketone functionality in the scaffold.   
In contrast, the third-row derivatisation component allowed decoration of 
secondary amine functionalities already present within the scaffold, i.e. amide coupling to 
a small acid chloride, reductive amination using a small ketone/aldehyde, sulfonamide 
formation and finally, N-alkylation.  The complete range of virtual derivatisations can be 
found in the Appendix (Table 33), selected at random from the eMolecules online 
database using the lowest heavy atom filter available that still generated a reasonable 
number of capping molecules.  Some example fragments can be seen in Scheme 8. 
 
Scheme 8 Examples of virtual 
fragments generated by 
a) deprotecting and b) derivatising 
scaffolds.  The parts of the virtual 
scaffold shown in red highlight 
substituents which have been 
changed from the exemplified 
scaffold, and the parts of the virtual 
fragment shown in red highlight 
substituents which have been 
changed from the exemplified scaffold 
as well as the virtual scaffold. 
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The deprotection steps are split between N- and O-deprotection in the third row 
of the PLP protocol due to the special case of some nitrogens in the scaffold requiring 
deprotection to undergo decoration.  In addition, unlike individual diversification 
components for different sets of chemistries e.g. amino acid chemistry, derivatisation for 
the entire virtual scaffold library can be combined into a single component, since only one 
decoration is allowed per compound.  This allowed shape diversity to be added whilst 
minimising extra molecular weight.  The stereoisomers component enumerated all 
possible stereoisomers for those which are undefined - this is especially common within 
the amino acid building blocks, where the products are racemic.  Finally, undesired 
functionalities such as any untransformed alkenes and unreacted aldehydes were 
removed as well as any duplicate molecules, thus forming the final library of 66,814 
compounds.  Plots showing lipophilicity vs. number of heavy atoms of the final virtual 
library as well as 100,000 randomly selected ZINC compounds show that virtual 
compounds tend to be less lipophilic (Figure 16).  The mean value for AlogP iii  (the 
generated value for lipophilicity offered by PLP) of commercial compounds lies at 2.9446 
whereas the mean AlogP of virtual compounds lies at 0.91321.  
  
Figure 16 Lipophilicity vs. number of heavy atoms of a) 100,000 ZINC compounds (grey) and b) the final 
virtual library (blue).  It can be seen from the mean and standard deviation of the libraries here that virtual 
compounds tend to be less lipophilic. 
2.2.4 Summary of Route for Fragment Design 
Seen in Scheme 9 is a summary of conversion from the exemplified scaffold to a 
virtual fragment.  The benzyl group in the exemplified scaffold is interchangeable by 
changing the amino acid building block substituent to an ethyl group.  The undesirable 
alkene functionality is oxidised to a ketone and the undesirable ester functionality is 
                                                             
iii AlogP is similar to clogP but atomic-based as opposed to fragment-based. 
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hydrolysed to give the virtual scaffold.  Next, the still reactive secondary amine functional 
group is capped by acetyl chloride, while the carboxylic acid group is capped by 
cyclopropylamine and the ketone group is subjected to reductive amination with 
isopropylamine to give the virtual fragment. 
 
Scheme 9 Summary of route used to form a virtual fragment from an exemplified scaffold.  Here, the novel 
substituents and functionalities are highlighted in red in the virtual scaffold, as well as their predecessor, in 
the exemplified scaffold; a) The benzyl group in the exemplified scaffold 75 is interchangeable by changing 
the amino acid building block.  The undesirable alkene functionality is oxidised to a ketone and the 
undesirable ester functionality is hydrolysed to give the virtual scaffold 76; b) The still reactive secondary 
amine group is capped by a range of acid chlorides, and the carboxylic acid and ketone groups can react with 
a range of primary amine capping groups to undergo both amide formation and reductive amination to give 
virtual fragment 77 (final derivatisations are also shown in red). 
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2.3  Identification of a Suitable Heavy Atom Filter 
 
Following the design of the virtual fragment library, molecules are filtered via 
desirable fragment properties; here, the focus is on number of heavy atoms.  Each filter 
component (circled) allows the highest and lowest value threshold to be selected before 
the results are saved as an SD file.  The PLP protocol summarising this procedure can be 
seen in Figure 17. 
 
 
 
Figure 17 PLP protocol deprotecting and adding virtual derivatisation (N- and O-alkylation, and use of 
primary amine capping groups, Section 2.2.3) onto scaffolds before filtering fragments via number of heavy 
atoms (components circled). 
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Fragment-like molecules usually lie within the region of 16-24 heavy atoms, 
leaving a total of 22,975 molecules in the virtual library which fit within the criteria.  It 
was important to select a more restricted heavy atom range, i.e. 16-20, 18-22 or 20-24 to 
allow shape diversity analysis.  In order to identify which range covered the greatest 
number of scaffolds and thus maximised scaffold diversity, the following analysis was 
carried out evaluating the number of scaffolds available with heavy atom counts in the 
ranges 16-20, 18-22 and 20-24 heavy atoms.  In order to do this, the scaffolds which were 
not covered at all (shown as 0% of fragments covered per scaffold) have been highlighted 
in the Appendix for each heavy atom range (Table 34, along with the complete range of 
scaffolds).   
It is clear that although not the most prolific, the most shape-diverse set of 
fragments (containing the highest number of scaffolds) appear under the heavy atom 
range 18-22, with 12,715 molecules, some examples of which can be seen in Table 2.  It is 
key to note here that for individual scaffolds, the percentage total of generated fragments 
covered by each heavy atom range is not important as long as it is more than 0%.  Only 
one scaffold has not been covered by the heavy atom range 18-22, with three scaffolds 
excluded by the heavy atom range 16-20, and seven scaffolds excluded by the heavy atom 
range 20-24.  Comparing frequency plots of lipophilicity vs. number of heavy atoms of the 
ZINC commercial library against the virtual library, both of which contain only 
compounds with 18-22 heavy atoms, it could be observed that again, virtual compounds 
tend to be less lipophilic (Figure 18).  This is because the majority of virtual compounds 
reside in the AlogP ranges of −3 to 0 and 0 to 3 whereas in the case of the ZINC commercial 
library the majority of compounds tend to reside in the AlogP ranges of 0 to 3 and 3 to 6. 
 36 
 
a    
b  
Figure 18 Lipophilicity vs. number of heavy atoms of a) the ZINC commercial library and b) the virtual library, 
after both have been filtered for compounds with 18-22 heavy atoms.  The compounds have been binned into 
five AlogP ranges with frequency plotted against each.  It can be seen here that the majority of virtual 
compounds reside in the AlogP ranges of −3 to 0 and 0 to 3 whereas the majority of commercial compounds 
tend to reside in the AlogP ranges of 0 to 3 and 3 to 6. 
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Key chemistry 
for formation 
Example scaffold 
No. fragments 
based on 
scaffold 
16-20 
HA 
Percentage of 
total 
fragments 
18-22 
HA 
Percentage of 
total 
fragments 
20-24 
HA 
Percentage of 
total 
fragments 
Amino acid 
chemistry 
 
128 6 4.7% 50 39.1% 122 95.3% 
Iridium-
catalysed allylic 
amination 
reaction 
 
106 4 3.8% 22 20.8% 105 99.1% 
Mitsunobu 
reaction 
 
1315 783 59.5% 751 57.1% 660 50.2% 
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Ugi reaction 
 
334 13 3.9% 71 21.3% 329 98.5% 
 
Table 2 Percentage of molecules belonging to each HA (heavy atom) range, of the total number of fragments derivatised from example scaffolds.  It was on this basis that the heavy 
atom range 18-22 was chosen in order to incorporate the most diverse range of fragments.  
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2.4  Principal Moment of Inertia (PMI) Analysis 
Principal moment of inertia is directional, and its values in the x, y, and z directions 
can be determined for the lowest energy 3D conformer of each molecule.  The smallest 
and second smallest of these three values are normalised, where 
𝑠𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑃𝑀𝐼
𝑏𝑖𝑔𝑔𝑒𝑠𝑡 𝑃𝑀𝐼
= 𝐼1  and 
𝑠𝑒𝑐𝑜𝑛𝑑 𝑠𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑃𝑀𝐼
𝑏𝑖𝑔𝑔𝑒𝑠𝑡 𝑃𝑀𝐼
= 𝐼2 .  This eliminates the dependence of the representation of the 
library on the size of the molecules in question, which eases the need for decorrelation 
procedures when used in combination with other descriptors such as molecular weight, 
volume, or surface area.50  I2 can then be plotted against I1 generating a 2D scatter chart 
(Figure 19), where corners of the triangular distribution contain the reference shapes rod 
(0, 1), disc (0.5, 0.5) and sphere (1, 1).  It could be seen from the mean values of the 
libraries that the majority of molecules lie towards rod/disc-like shape space, and that in 
comparison to commercial compounds (grey), virtual compounds (blue) are moving away 
from rod/disc-like shape space and stretching towards more 3D shape space. 
 
Figure 19 PMI plots showing the distribution of a) commercial and b) virtual compounds in shape space, 
where 
𝒔𝒎𝒂𝒍𝒍𝒆𝒔𝒕 𝑷𝑴𝑰
𝒃𝒊𝒈𝒈𝒆𝒔𝒕 𝑷𝑴𝑰
= 𝑰𝟏 and 
𝒔𝒆𝒄𝒐𝒏𝒅 𝒔𝒎𝒂𝒍𝒍𝒆𝒔𝒕 𝑷𝑴𝑰
𝒃𝒊𝒈𝒈𝒆𝒔𝒕 𝑷𝑴𝑰
= 𝑰𝟐.  Commercial compounds are shown in grey and virtual 
compounds are shown in blue, with mean values and standard deviations of the libraries clearly indicated.  It 
can be seen here that virtual compounds are moving away from the rod/disc edge, where most commercial 
compounds reside, and into more 3D shape space. 
2.5  Identification of Reference Shapes for the Library and Generation of 
Shape Fingerprints 
In order to identify which fragment shapes are novel and suitable to target, 
reference shapes were generated from a combined library including virtual fragments 
and commercial fragments from the ZINC library.  ZINC fragments were filtered for 18-22 
heavy atoms, with duplicate molecules as well as salts being removed; around 100,000 of 
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these molecules were then randomly selected.  The 3D shapes of the combined library 
were generated using the CORINA 3D structure generator60 and the reference shapes 
were generated by ROCS. 
The process of reference shape selection is illustrated in Figure 20, where the axes 
are arbitrary molecular shape descriptors and the library of molecules (black dots) fills 
the entire graph.  In order to generate reference shapes, one fragment (1) is selected at 
random, with fragments which map within 0.8 Tanimoto similarity of itself removed (area 
shaded grey and black dots hollowed out).  Here, Tanimoto is a measure of shape overlap 
and a score of 0-1 is calculated, where a score of 0 indicated no shape match and a score 
of 1 indicates exact shape match (Section 1.5.2).  The value 0.8 Tanimoto was chosen as 
an arbitrary indication of similarity which allowed a reasonable number of reference 
shapes to be generated as a result.  Next, a second fragment (2) is selected which is least 
similar in shape to fragment 1, and fragments which map within 0.8 Tanimoto of (2) are 
again removed.  This action is repeated until all available shape space has been covered - 
by a total of 2477 reference shapes (only eight shown here, 1-8, highlighted as blue 
circles).   
 
 
Figure 20 Tanimoto plots to show how reference shapes are generated.  The axes are arbitrary molecular 
shape descriptors, black dots are fragments, blue circles are reference shapes (1-8) and grey circles cover 
fragments within 0.8 Tanimoto of the reference shape.  a) One fragment (1) is selected at random, with 
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fragments which map within 0.8 Tanimoto similarity of itself removed (area shaded grey and black dots 
hollowed out).  b) A second fragment (2) is selected which is least similar in shape to fragment 1, with 
fragments which map within 0.8 Tanimoto of itself removed.  c) A third fragment (3) is selected which is least 
similar in shape to fragment 2, with fragments which map within 0.8 Tanimoto of itself removed.  d) This 
action is repeated until all available shape space has been covered (reference shape fragments 1-8).  It can be 
seen here that although reference shapes are far apart from one another, some fragments map onto several 
reference shapes, making them less shape-diverse than those which map onto a singular reference shape 
(Section 2.6.1). 
The aim of the project is to synthesise a small and manageable library of molecules, 
which, in combination with those available commercially, are able to cover the vast 
majority of shape space.  It is possible to select this smaller library by using ROCS to 
perform full shape comparison of molecules from the rest of the combined library; 
however, this is computationally demanding and instead, ROCS is used to generate a 
fingerprint for each molecule as an alternative representation.  Fingerprint scoring is then 
performed by PLP to compare the rest of the combined library against one another and 
this can be done much more rapidly than full shape comparison (see simulated annealing 
in Section 2.6.1).  Generation of fingerprints by mapping molecules in the combined 
library onto reference shapes is shown using Tanimoto plots in Figure 21.  Here, the axes 
are arbitrary molecular shape descriptors, dark blue circles are reference shapes (1-8) 
and pale blue circles cover fragments within 0.7 Tanimoto of the reference shape.  The 
value 0.7 Tanimoto was chosen since it was smaller than but close to the 0.8 Tanimoto 
used to generate reference shapes.  One fragment (A) is selected at random, with 
reference shapes which map within 0.7 Tanimoto similarity of itself identified (area 
shaded pale blue and blue dots hollowed out).  A different fragment (B) is selected at 
random, with reference shapes which map within 0.7 Tanimoto similarity of itself 
identified (area shaded pale blue and blue dots hollowed out).   
 
Figure 21 Tanimoto plots to show how fingerprints are generated using reference shapes.  The axes are 
arbitrary molecular shape descriptors; dark blue circles are reference shapes (1-8) and pale blue circles cover 
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fragments within 0.7 Tanimoto of the reference shape.  a) One fragment (A) is selected at random, with 
reference shapes which map within 0.7 Tanimoto similarity of itself identified (area shaded pale blue and blue 
dots hollowed out).  b) A different fragment (B) is selected at random, with reference shapes which map 
within 0.7 Tanimoto similarity of itself identified (area shaded pale blue and blue dots hollowed out).   
The fingerprint generation for fragments A and B (Figure 21) can be seen in Table 
3, with each set bit in the bit string corresponding to 0.7 Tanimoto similarity or higher 
between the fragment and the reference shape.58  Here, fragment A covers reference 
shapes 2, 3, and 5, and fragment B covers reference shapes 4 and 7.  “1” as part of the bit 
string indicates the fragment’s correlation with the specific reference shape and “0” 
indicates a lack of correlation.  It is clear that even when only eight reference shapes are 
used, two fragments still give rise to very different fingerprints.  
Reference 
Shape 
1 2 3 4 5 6 7 8 
Fragment A 0 1 1 0 1 0 0 0 
Fragment B 0 0 0 1 0 0 1 0 
Table 3 Fingerprint generation of fragments A and B (Figure 21), with each set bit corresponding to 0.7 
Tanimoto similarity or higher between the fragment and the reference shape (8 reference shapes, i.e. 8 bits).  
Here, fragment A covers reference shapes 2, 3, and 5, and fragment B covers reference shapes 4 and 7.  “1” as 
part of the bit string indicates the fragment’s correlation with the specific reference shape and “0” indicates a 
lack of correlation.   
2.6  Identification of a Library of Synthetic Targets 
A target number of 80 compounds was decided upon for my fragment library, 
which will ideally represent all the shape space covered by the 2477 reference shapes, as 
well as being highly diverse.  Within these compounds, there will be a fraction of which 
will be based on chemistry validated in Leeds, and the rest will be commercially available.  
In order to ensure the most appropriate and unbiased selection of compounds, a 
simulated annealing protocol, which effectively compares sets of compounds against one 
another, was applied using PLP.   
Before identifying the best conditions for selection, the library of molecules was 
filtered by AlogP, using the fragment-like range of –1 to 3, giving 73,031 molecules for the 
input file.  Plots of lipophilicity vs. number of heavy atoms of the ZINC commercial library 
as well as the virtual library, each containing only compounds with 18 to 22 heavy atoms 
and AlogP –1 to 3 have been produced, to show frequency of fragments in each category  
Figure 22).  This indicated that overall the libraries skew towards containing more heavy 
 43 
 
atoms.  In addition, virtual compounds are less lipophilic as the majority reside in the 
AlogP of 0 to 1 category whereas the majority of commercial compounds reside in the 
AlogP of 2 to 3 category. 
a  
b  
 Figure 22 Lipophilicity vs. number of heavy atoms of a) the ZINC commercial library and b) the virtual library 
after filtering for compounds with heavy atoms 18-22 and AlogP –1-3.  The compounds have been binned into 
four AlogP ranges and in addition, plotted against frequency.  It can be seen here that the majority of virtual 
compounds reside in the AlogP range of 0 to 1 whereas the majority of commercial compounds reside in the 
AlogP range of 2 to 3.  In the case of both libraries, fragments skew towards containing a higher number of 
heavy atoms. 
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2.6.1 Optimising Conditions for Compound Selection 
In order to identify the best conditions for the protocol to be run, trial runs were 
completed for different weightings of composition, coverage and diversity. The scores of 
each trial run were then compared.  The optimal conditions (ideal weightings of 
composition, coverage and diversity) were then applied to the 73,031 filtered molecules 
(represented as bit strings for rapid computational analysis) in order to source the ideal 
library of 80 compounds.  Here, composition score is an indication of whether the ideal 
percentage of virtual compounds have been matched, coverage score indicates the 
fraction of reference shapes hit by the chosen set (where the more shapes hit the better), 
and diversity score indicates the shape diversity of the set i.e. it would be better to hit 
more reference shapes with the same number of fragments. 
In practical terms, composition score is calculated as the magnitude deviation of 
the set from the ideal percentage of virtual compounds hence a value of 0 indicates that 
the target value is matched.  Coverage score is calculated as 1 minus the fraction of bits 
which are switched on in the whole set hence a value of 0.1 implies 90% of the bits are 
covered by the set, i.e. the set contains molecules which would match with 90% of the 
reference set.  The diversity score is the average overlap of fingerprints considering all 
pairwise combinations within the set, normalised to the size of the set, whereby lower 
values equal less overlap.   
The final score is a result of a coefficient multiplied by a score for composition, 
coverage and diversity, where the lower the score in each section the better the result.  
The coefficients weight each part of the score in the final score.  Each run is optimised 
using a maximum of 5000 iterations with a cooling rate of 0.98, where 20 attempts are 
taken per temperature.  Cooling rate defines the speed of convergence of the process to 
minimum scores, where the higher the number the slower the cooling.  20 attempts will 
be taken per temperature in order to find a better set (with lower scores) before cooling 
is applied.  Here, temperature determines the percentage of compounds altered from the 
previous set when a new set of compounds is selected, and as it cools, that percentage 
decreases.  The initial temperature is set to alter a maximum of 30% of compounds in the 
initial set, and approaches 0 as the run converges to the optimum set.   
The process of set comparison begins with a comparison of the final score for two 
initial sets of compounds, sets 1 and 2.  The lower score is desirable so if the score of set 
2 is lower than set 1, set 2 becomes the new chosen set.  If, however, this is not the case, 
the probably of set 2 becoming the new chosen set is determined by the switch probability.   
𝑆𝑤𝑖𝑡𝑐ℎ 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  𝑒
−1×(𝑠𝑒𝑡 2−𝑠𝑒𝑡 1)
𝑡𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒     
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Once switch probability is calculated, it is then compared to a generated random 
number between 0 and 1.  If the switch probability is higher than the random number, set 
2 becomes the new chosen set.  Switch probability is calculated based on pseudo 
thermodynamics, where the smaller the difference between sets 1 and 2, and the higher 
the temperature, the more likely that set 2, despite having a higher score, will become the 
new chosen set.  The reason this protocol is in place is in order to avoid a local minimum 
early in the run, which would prevent a better set with a lower score to be identified.  This 
is illustrated later in Figure 24. 
The simulated annealing scoring process uses fingerprint comparison, which is 
much less computationally demanding than 3D shape matching using ROCS.  For 
illustration purposes, this can be explained using Tanimoto graphs (Figure 23).  Here, the 
axes are arbitrary molecular shape descriptors and the library of molecules (black dots) 
including the generated reference shapes (blue dots, 1-8) fill the entire graph.  Four 
fragments are selected at random (A-D), with reference shapes which map within 0.7 
Tanimoto similarity of each identified (area shaded pale blue and blue dots hollowed out).  
In plot a, only seven out of the eight reference shapes have been covered (reference shape 
6 has been left out), therefore the generated fragments exhibit low coverage.  In plot b, all 
eight reference shapes have been covered by the new set of fragments A, C, D, E, but 
reference shapes 2, 4 and 5 have been covered by more than one fragment.  Therefore, 
the generated fragments exhibit maximum coverage but low diversity.  In plot c, all eight 
reference shapes have been covered by the new set of fragments D, F, G, H, and each 
reference shape is only covered by one fragment.  Therefore, the generated fragments in 
plot c exhibit maximum coverage and high diversity, making it the most desirable set of 
four compounds. 
 46 
 
 
 
The chosen fragments from the libraries shown in Figure 23, plot a-c (libraries 1-
3, respectively) is next converted into fingerprints in Table 4, with each set bit 
corresponding to a similarity of 0.7 Tanimoto or higher between the fragment and the 
reference shape.  Here, 1 indicates the fragment’s correlation with the specific reference 
shape and 0 indicates a lack of correlation.  The coverage of each reference shape is then 
summarised for the library by indicating if they hit at least one fragment (where 1 
indicates yes and 0 indicates no). 
 
Figure 23 Tanimoto plots showing how the 
library of 80 fragments are selected (example 
shows library of four only).  The axes are 
arbitrary molecular shape descriptors, black 
dots are fragments, dark blue circles are 
reference shapes (1-8) and pale blue circles 
cover fragments within 0.7 Tanimoto of the 
reference shape.  a) Four fragments (A-D) are 
selected at random, with reference shapes 
which map within 0.7 Tanimoto similarity of 
each identified (area shaded pale blue and 
blue dots hollowed out).  Only seven out of 
eight reference shapes have been covered 
(reference shape 6 left out); the generated 
fragments exhibit low coverage.  b) All eight 
reference shapes have been covered by the 
new set of fragments A, C, D, E, but reference 
shapes 2, 4 and 5 have been covered by more 
than one fragment.  The generated fragments 
exhibit maximum coverage but low diversity.  
c) All eight reference shapes have been 
covered by the new set of fragments D, F, G, H, 
and each reference shape is only covered by 
one fragment.  The generated fragments 
exhibit maximum coverage and high 
diversity. 
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Library 1 (Figure 23, plot a) 
Reference 
Shape 
1 2 3 4 5 6 7 8 
Fragment A 0 1 1 0 1 0 0 0 
Fragment B 0 0 0 1 0 0 1 0 
Fragment C 1 1 0 1 0 0 0 0 
Fragment D 0 0 0 0 1 0 0 1 
Hits ≥1 
fragment 
1 1 1 1 1 0 1 1 
Library 2 (Figure 23, plot b) 
Fragment A 0 1 1 0 1 0 0 0 
Fragment C 1 1 0 1 0 0 0 0 
Fragment D 0 0 0 0 1 0 0 1 
Fragment E 0 0 0 1 0 1 1 0 
Hits ≥1 
fragment 
1 1 1 1 1 1 1 1 
Library 3 (Figure 23, plot c) 
Fragment D 0 0 0 0 1 0 0 1 
Fragment F 1 0 0 1 0 0 0 0 
Fragment G 0 1 1 0 0 0 0 0 
Fragment H 0 0 0 0 0 1 1 0 
Hits ≥1 
fragment 
1 1 1 1 1 1 1 1 
 
Table 4 Fingerprint analysis of libraries shown in Figure 23, plot a-c (libraries 1-3, respectively), with each 
set bit corresponding to a similarity of 0.7 Tanimoto or higher between the fragment and the reference shape 
(there are 8 reference shapes, i.e. 8 bits).  Here, 1 indicates the fragment’s correlation with the specific 
reference shape and 0 indicates a lack of correlation.  The coverage of each reference shape is then 
summarised for the library by indicating if they hit at least one fragment (where 1 indicates yes and 0 
indicates no). 
The number of reference shapes that are hit by at least 1 fragment (≥1 Hit) is then 
totalled and used in calculations for reference shape coverage (Table 6).  The composition 
score is 0 for all three libraries as the target value of 4 fragments per library was matched.  
The coverage score can be calculated; where coverage is “≥1 Hit” as a fraction of the total 
number of reference shapes (8 in this example).  The coverage scores of 0 calculated for 
libraries 2 and 3 indicate the maximum coverage of reference shapes by the library.   
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𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 =  1 − 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 
Diversity score is calculated based on the number of reference shapes that hit 2 fragments 
(A&B) as a fraction of the number of reference shapes that hit at least 1 fragment (A|B), 
and this is calculated for each pair of fragments individually and then summed.  These 
pairwise interactions can be illustrated by the overlap matrix showing 
𝐴&𝐵
𝐴|𝐵
 for fragments 
A-D in library 1 (Table 5), where ∑(
𝐴&𝐵
𝐴|𝐵
) refers to the sum of the values above the matrix 
diagonal (diagonal showing each fragment overlapping with itself to give 1 Tanimoto) and 
these values are also mirrored underneath the diagonal.  The matrix sum as a fraction of 
the number of entries (excluding the entries in the diagonal) gives rise to the diversity 
score (below and Table 6).  The score of 0 calculated for library 3 indicates maximum 
diversity, with library 2 the second most diverse.  Thus, library 3 is the most ideal out of 
the three. 
Fragment A B C D 
A 1 0 
1
5
 
1
4
 
B 0 1 
1
4
 0 
C 
1
5
 
1
4
 1 0 
D 
1
4
 0 0 1 
Table 5  
𝐴&𝐵
𝐴|𝐵
 values showing pairwise relationships for fragments A-D in library 1, where A&B is the number 
of reference shapes that hit 2 fragments and A|B is the number of reference shapes that hit at least 1 fragment. 
Library ≥1 Hit Coverage ∑(
𝐴&𝐵
𝐴|𝐵
) 
Coverage 
Score 
Diversity 
Score 
1 7 
7
8
 
7
10
 0.125 0.117 
2 8 1 
13
20
 0 0.108 
3 8 1 0 0 0 
Table 6 The number of reference shapes that are hit by at least 1 fragment (≥1 Hit) are totalled for libraries 
1-3 and used to calculate the coverage score of the libraries using  𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 =  1 − 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒.  Here, 
coverage is “≥1 Hit” as a fraction of the total number of reference shapes (8 in this example).  The scores of 0 
calculated for libraries 2 and 3 indicate the maximum coverage of reference shapes by the library.  ∑(
𝐴&𝐵
𝐴|𝐵
) 
values showing pairwise relationships are also calculated for fragments in libraries 1-3, and used to calculate 
the diversity score of the libraries using 𝐷𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒 =  
∑(
𝐴&𝐵
𝐴|𝐵
)×2
𝑇𝑜𝑡𝑎𝑙 ×(𝑇𝑜𝑡𝑎𝑙−1)
.  Here, A&B is the number of 
𝐷𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒 =  
∑(
𝐴&𝐵
𝐴|𝐵 ) ×2
𝑇𝑜𝑡𝑎𝑙 ×(𝑇𝑜𝑡𝑎𝑙 − 1)
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reference shapes that hit 2 fragments, and A|B is the number of reference shapes that hit at least 1 fragment.  
∑(
𝐴&𝐵
𝐴|𝐵
) Refers to the sum of the values above the diagonal of the matrix shown in Table 5 and total is the 
number of fragments.  The score of 0 calculated for library 3 indicates maximum diversity, with library 2 the 
second most diverse.  Thus, library 3 is the most ideal out of the three. 
Seven sets of conditions were attempted for different weightings of composition, 
coverage and diversity, and calculation of library scores were averaged over 10 trial runs 
for each set of conditions (Table 7).  Initially, the composition target was set to 25% virtual 
molecules, or 20 molecules out of the library of 80 fragments.  The scores given are the 
lowest scores out of the 5000 iterations, where average defines the average number of 
fragment hits per reference shape, with a lower average suggesting the fragment shapes 
are more unusual.  Lower standard deviation indicates higher consistency for the number 
of fragment hits per reference shape, and fewer zero hits mean that a greater number of 
reference shapes are hit by the selected fragments, or a greater fraction of shape space is 
covered. 
Highlighted in Table 7 are the lowest values per score column, where composition 
score = 0 means the target number of compounds in the chosen set has been matched, 
coverage score = 0 means the molecules in the chosen set hit 100% of those in the 
reference set, and diversity score = 0 means no overlap and maximum shape diversity.  It 
could be seen that although the weighting for composition : coverage : diversity = 1 : 10 : 
100 gave the same number of lowest values as composition : coverage : diversity = 1 : 100 : 
10, the former has a substantially higher number of reference shapes not hit by a fragment 
(higher zero hits) as well as deviates from the target number of virtual molecules 
(composition score doesn’t equal zero) - both factors which play an important role in the 
library.  As a result, the latter weighting was carried forward in order to find the ideal 
number of virtual target molecules (Table 8).  Again, these values were averaged over 10 
trial runs for each set of conditions. 
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Table 7 A comparisons of library scores achieved for differing weightings of composition, coverage and diversity, along with the average number of fragment hits per reference shape, 
standard deviation of fragment hits per reference shape and number of reference shapes which were not hit by fragments (zero hits).  For a detailed explanation of these terms, refer 
to the opening of Section 2.6.1.  Highlighted in the table are the lowest values per score column, and it was on this basis that the weighting composition : coverage : diversity = 1 : 100 : 
10 was carried forward. 
Composition 
Weighting 
Composition 
Score 
Coverage 
Weighting 
Coverage 
Score 
Diversity 
Weighting 
Diversity 
Score 
Average 
Standard 
Deviation 
Zero Hits 
10 0 10 0.0082 10 0.052 7.3 3.5 21.0 
1 0.015 10 0.0120 100 0.041 5.9 2.8 35.9 
1 0 100 0.0049 10 0.060 8.2 4.0 12.2 
10 0 1 0.0150 100 0.044 6.3 3.1 42.4 
100 0 1 0.0140 10 0.049 6.8 3.3 39.6 
10 0 100 0.0065 1 0.063 8.3 4.1 16.1 
100 0 10 0.0068 1 0.064 8.5 4.2 16.9 
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Table 8 A comparison of composition, coverage and diversity scores achieved for differing percentages of virtual compounds in the library, along with the total scores normalised to 
be independent of the weighting for each, average number of fragment hits per reference shape, standard deviation of fragment hits per reference shape and number of reference 
shapes which were not hit by a fragment (zero hits).  For a detailed explanation of these terms, refer to the opening of Section 2.6.1.  Highlighted in the table are the lowest values per 
score column, and it was on this basis that 25% composition of virtual molecules was chosen for the production run, along with an increased number of iterations (10,000) and a slower 
cooling rate (0.99). 
% Virtual 
Compounds 
Composition 
Score 
Coverage 
Score 
Diversity 
Score 
Normalised 
Total 
Average 
Standard 
Deviation 
Zero Hits 
0 0.070 0.0048 0.0597 0.0103 8.12 4.04 11.8 
10 0 0.0053 0.0602 0.0102 8.12 3.98 13.1 
25 0 0.0049 0.0603 0.0099 8.19 4.01 12.2 
50 0.016 0.0054 0.0657 0.0110 8.62 4.51 13.4 
Production 
run using 25% 
0 0.0035 0.0488 0.0076 6.97 3.28 8.8 
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Here, by focusing on only runs which gave a composition score of 0, the 
highlighted lowest values in runs consisting of 10 and 25% virtual molecules show an 
equal number of lowest scores.  Taking into consideration that 20 is a suitable number of 
compounds for synthesis, 25% was selected as the composition target.  Next, ten 
production runs were executed with the final set of conditions i.e. composition : coverage : 
diversity = 1 : 100 : 10, with a target of 25% virtual compounds.  An increased number of 
iterations (10,000) and a slower cooling rate (0.99, see Section 2.6.1) was used and the 
convergence value was also decreased to accommodate these changes in conditions, 
lowering the scores further.   
The graphs for one of the runs (Figure 24) illustrate the normalised combined 
score against number of iterations, and the frequency of hits per reference shape (with 
each reference shape represented as a bit string).  As predicted, smooth convergence can 
be observed in the run with some random jumps in score towards the beginning (plot a), 
which is desirable in order to prevent a premature local minimum, and an even spread of 
frequency of hits can also be seen (plot b). 
a     b   
Figure 24 a) Initial jumps in the score of a chosen set followed by smooth convergence.  b) A consistent 
frequency of hits per reference shape indicates an even coverage of reference shapes. 
Most libraries were discarded at this point due to stereochemistry of compounds 
that would be difficult to control, as a result of new stereocentres generated via a virtual 
derivatisation step.  This was the case with unsymmetrical ketone capping groups used in 
the final reductive amination step for many of the Ugi scaffolds.  In retrospect, if 
unsymmetrical ketones had been omitted from the enumeration, the final library would 
offer a more synthetically accessible selection of molecules.  Nevertheless, libraries from 
two runs were carried forward for the next stage of analysis.   
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2.6.2 Retrosynthetic Analysis of Fragments of Interest 
Retrosynthetic analysis of molecules from two compound libraries of interest 
(Section 2.6.1) were undertaken, with building blocks, key intermediates and reactions 
completed identified for each virtual molecule.  This is in order to evaluate the commercial 
availability of necessary reagents as well as the viability of the chemistry involved.  Shown 
in Scheme 10 are example compounds from one library (run 1); for the complete 
retrosynthetic analysis of compounds from the two libraries, refer to the Appendix (Table 
35).  Molecules produced by run 1 were taken forward for synthesis due to their 
chemistry being more developed than those produced by run 2.  A PMI and properties 
plot of the chosen library (Figure 25) indicates that Leeds fragments (blue) exhibit a 
higher 3D character than commercial fragments (grey), and slightly lower AlogP. 
 
Scheme 10 Detailed retrosynthetic analysis of example fragments.  
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Figure 25 a) PMI plot of the chosen library of 80 fragments.  It can be seen here that Leeds fragments (blue) 
exhibit a higher 3D character than commercial fragments (grey).  b) Lipophilicity vs. number of heavy atoms 
of the chosen library of 80 fragments.  It can be seen here that the Leeds fragments (blue) are slightly lower 
in AlogP than commercial fragments (grey). 
2.7  Analysis of the Chosen Library 
In order to further verify the shape diversity of the chosen set of compounds, two 
new PLP protocols were devised in order to compare the chosen set against randomly 
selected sets of compounds.  The first protocol focuses on the Tanimoto score of the 
library calculated using fingerprint comparison, where a lower score indicates higher 
shape diversity.  The second method analyses the number of frameworks present in the 
library, as well as the number of compounds per framework.  Here, framework is used as 
a unique identifier (refer to Section 1.4) for shape analysis.  Finally, the value added by 
the virtual fragments to the combined library of both virtual and ZINC fragments is 
investigated. 
2.7.1 Shape Diversity Analysis   
The shape diversity of the chosen set of compounds can be verified by calculating 
a shape similarity score for the library,s where a lower score indicates lower similarity, 
or higher shape diversity.  All 80 compounds were scored against one another using shape 
fingerprint comparison.  Tanimoto similarity scores (
𝐴&𝐵
𝐴|𝐵
, where 𝐴&𝐵 is the number of 
bits switched on in both fragments and 𝐴|𝐵 is the number of bits switched on in at least 1 
fragment, Section 2.6.1) were calculated where compound 1 was scored against 
compounds 1 to 80, and then compound 2 was scored against compounds 1 to 80 until 
this was completed for all 80 compounds.   
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The scores were then totalled for each compound, and where shape match is 
identical for compound 1 against itself, and compound 2 against itself etc., the score value 
of 1 per compound, or 80 per library, was removed from this total.  Next, the average score 
per compound was calculated as a determinant of the shape diversity of the set, where 
the lower score would mean higher shape diversity (less overlap).  The resulting score for 
the chosen library was calculated to be 3.5936.  The same process was applied to ten 
libraries of 80 random compounds, which gave an average of 8.6842 per library, with a 
standard deviation of 0.4733.  This is significantly more than two standard deviations 
higher than that of the target 80 compounds; therefore, it is true to say that the objective 
of identifying a shape-diverse set of 80 fragments has been reached. 
2.7.2 Framework Analysis 
Another way in which diversity can be evaluated is by identifying the different 
frameworks present in the library and the frequency of compounds containing each 
framework.  A new PLP protocol was therefore devised and applied to the combined 
library of 73,031 compounds as well as the chosen library of 80 compounds.  The 
framework type used to score, or categorize the libraries was “graph” only, which 
considers the connectivity of the molecule (Section 1.4).  The frameworks were ordered 
in decreasing frequency of compounds that contained each one, and those frequencies 
were then normalised in order to make them independent of the library size (Table 9).  
The same was done for a random library of 80 compounds (Appendix, Table 36) in order 
to compare the relationship between frequency of frameworks in the combined library to 
both the chosen and random library of 80. 
Table 9 For each framework type in the chosen library of 80 fragments, the frequency of compounds 
containing the framework has been summarised, as well as the corresponding frequency of compounds 
containing the same framework in the combined library.  The frameworks were ordered in decreasing 
frequency of compounds present in the chosen library of 80, and those frequencies were then normalised in 
order to make them independent of the library size.  (Seen on the following page) 
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Framework (Smiles) 
Frequency in Chosen 
Library of 80 
Normalised 
Frequency 
Frequency in 
Combined Library of 
73,031 
Normalised 
Frequency 
C1CCCCC1 13 0.1625 6714 0.0919 
C1CCC(CC1)C2CCCCC2 4 0.0500 2331 0.0319 
C1CCC(CC1)C2CCCC2 3 0.0375 2490 0.0341 
C(C1CCCC1)C2CCCCC2 3 0.0375 2209 0.0302 
C(CCC1CCCC1)CCC2CCCCC2 3 0.0375 1589 0.0218 
C(CC1CCCCC1)C2CCCCC2 2 0.0250 3156 0.0432 
C(C1CCCC1)C2CCCC2 2 0.0250 178 0.0024 
C(CC1CCCCC1)C2CC2 2 0.0250 426 0.0058 
C1CCCC1 2 0.0250 846 0.0116 
C(CC1CCCCCC1)C2CCCCC2 2 0.0250 112 0.0015 
C(CCC1CCCCC1)CC2CCCCC2 2 0.0250 2299 0.0315 
C(CC1CCCCC1C2CCCC2)C3CCCC3 1 0.0125 31 0.0004 
C1CCC(CC1)C2CCCC(C2)C3CCCC3 1 0.0125 90 0.0012 
C(CC1CCCC1)CC2CCCC2 1 0.0125 400 0.0055 
C(C1CCCCC1)C2CCC(CC3CCCCC3)C2 1 0.0125 48 0.0007 
C(CC1CCCC1)CC2CCC(C2)C3CCCC3 1 0.0125 83 0.0011 
C(C1CCCCC1)C2CCC3CCCC3C2 1 0.0125 219 0.0030 
C(CCC1CCCC1)CCC2CCC(C2)C3CCCCC3 1 0.0125 13 0.0002 
C(CC1CCCC1)C(CCC2CCCC2)C3CCCCC3 1 0.0125 3 0 
C(CC1CCCC1)CC2CCC(CC3CCCC3)CC2 1 0.0125 19 0.0003 
C(CCCC1CCCCC1)CCC2CCCC2 1 0.0125 749 0.0103 
C(CC1CCC2CCCCC2C1)C3CCCCC3 1 0.0125 328 0.0045 
C(CC1CCCC1)CC2CCC(CC3CCCC3)C2 1 0.0125 15 0.0002 
C(CC(CC1CCCC1)C2CC2)CC3CCCC3 1 0.0125 8 0.0001 
C(C1CCCC1)C2CCC(CC3CCCC3)CC2 1 0.0125 49 0.0007 
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C(CCCC1CC2CCCC2C1)CCC3CCCCC3 1 0.0125 3 0 
C(CC1CCCCC1)CC2CCCCC2 1 0.0125 2809 0.0385 
C(CC1CCC2CCCC2C1)C3CCCCC3 1 0.0125 370 0.0051 
C(C1CCCC1)C2CCCC2CC3CCCC3 1 0.0125 27 0.0004 
C(CC1CCCC1CCC2CCCC2)C3CCCC3 1 0.0125 2 0 
C(CC1CCCCCC1)C2CC2 1 0.0125 79 0.0011 
C(C1CC1)C2CCCCC2 1 0.0125 206 0.0028 
C(CC1CCCCC1)CC2CCCCCC2 1 0.0125 100 0.0014 
C(CC1CCCCC1)CC2CCCC(CC3CC3)C2 1 0.0125 8 0.0001 
C(CC1CCCCC1)CC2CCCC(C2)C3CCC3 1 0.0125 9 0.0001 
C1CCC(CC1)C2CCCC(CC2)C3CCCC3 1 0.0125 16 0.0002 
C(CC1CC1)CC2CCCC(C2)C3CC3 1 0.0125 2 0 
C(CC1CC1)CC2CCCCC2CCC3CC3 1 0.0125 5 0.0001 
C(C1CCCCC1)C2CCCC(C2)C3CCC3 1 0.0125 14 0.0002 
C1CCCCCC1 1 0.0125 328 0.0045 
C(C1CCCCC1)C2CCCC(C2)C3CCCCC3 1 0.0125 62 0.0008 
C(CCC1CCCCC1)CCC2CCCCC2 1 0.0125 1205 0.0165 
C(CCC1CCCCC1)CC2CCCC2 1 0.0125 2402 0.0329 
C(C1CCCCC1)C2CCCCC2 1 0.0125 2498 0.0342 
Linear 1 0.0125 187 0.0026 
C(CCCCC1CCCC1)CCCCC2CCCC2 1 0.0125 9 0.0001 
C(CC1CCCC1)C2CCCC2 1 0.0125 271 0.0037 
C1CC2CCCC2C1 1 0.0125 68 0.0009 
C1CCC2CCCC2C1 1 0.0125 1639 0.0224 
C(CC1CCCCC1)CC2CC3CCCC3C2 1 0.0125 31 0.0004 
C1CCCCCC2(CCCCC1)CCCC2 1 0.0125 2 0 
C(CCC1CCCC1)CCC2CCCC2 1 0.0125 305 0.0042 
C(CCCC1CCCCC1)CCCC2CCCCC2 1 0.0125 150 0.0021 
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Plots to show the relationship between normalised frequencies of each 
framework present in a) the combined library and the chosen library of 80 and b) the 
combined library and a random library of 80 (Figure 26).  It is clear that a closer 
relationship can be observed in plot b than in plot a, suggesting that the chosen library is 
more framework-diverse, whereas the random library has been selected simply based on 
the how frequently a framework appears in the combined library.   
a   
b  
Figure 26 Plots to show the relationship between normalised frequencies of each framework in a) the 
combined library and the chosen library of 80 and b) the combined library and a random library of 80.  A 
closer relationship can be observed in plot b than in plot a, suggesting that the chosen library is more 
framework-diverse; whereas the random library has been selected simply based on the how frequently a 
framework appears in the combined library. 
PC50C is a value which indicates the fraction of frameworks required to cover half 
of the total library of compounds, and can be an indicator of framework diversity, where 
the higher PC50C indicates a more framework-diverse library.47  Since the chosen library 
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of 80 contains a total of 53 frameworks, and 13 frameworks are required to cover 40 of 
the compounds (calculated using the cumulative total of compounds starting from the 
most frequently occurring framework, in decreasing order), its PC50C is calculated to be 
13 ÷ 53 = 0.245.  The same was done to ten randomly selected libraries of 80 molecules, 
seen in Table 10 and displayed graphically in Figure 27, which gave an average PC50C of 
0.254 and a standard deviation of 0.0319.   
Random Library No. Frameworks 
No. Frameworks 
Covering 50% 
Compounds 
PC50C 
1 53 14 0.264 
2 48 11 0.229 
3 59 19 0.322 
4 52 13 0.250 
5 50 11 0.220 
6 53 13 0.245 
7 51 11 0.216 
8 56 16 0.286 
9 53 13 0.245 
10 50 13 0.260 
Average 52.5 13.4 0.254 
Table 10 The total number of frameworks as well as the number of frameworks needed to cover 50% of 
compounds in each library was identified for ten random libraries of 80 molecules, and their PC50C values 
were calculated using 
𝑁𝑜.  𝐹𝑟𝑎𝑚𝑒𝑤𝑜𝑟𝑘𝑠 𝐶𝑜𝑣𝑒𝑟𝑖𝑛𝑔 50% 𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑠
𝑇𝑜𝑡𝑎𝑙 𝑁𝑜.  𝐹𝑟𝑎𝑚𝑒𝑤𝑜𝑟𝑘𝑠
.  The data gave an average PC50C of 0.254 for the 
ten random libraries and a standard deviation of 0.0319. 
  
The PC50C values for the chosen library of 80 differs from the mean PC50C of the 
random libraries by much less than two standard deviations, showing no significant 
difference between the framework diversity of the libraries (Figure 27).  Although it might 
have been expected that the chosen library would have a higher PC50C due to its high 
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Figure 27 
A comparison of 
PC50C of the chosen 
library with the 10 
randomly selected 
libraries of 80 
molecules (Table 10).   
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shape diversity, the similar values could be explained by that frameworks are not 
necessarily indicative of shape.   
2.7.3 Comparison of Virtual Compounds to Commercial Compounds 
In order to investigate the value added by the 20 virtual fragments to the 80-
compound library of both virtual and ZINC fragments, the score of the chosen library was 
compared to the score of a library of fragments selected when only commercial ZINC 
molecules are available.  This was done by generation of ten libraries of 80 fragments from 
the ZINC library using the same conditions for compound selection as that used for the 
chosen set.  It was observed that on average the ZINC set were unable to achieve a 
composition score of 0 (Table 11), a fundamental property of the chosen library 
(highlighted).  This indicates that under the same selection conditions, it is not possible 
to select 80 fragments from the ZINC library whilst achieving maximum reference shape 
coverage and maximum shape diversity (Section 2.6.1), thus proving the value of virtual 
fragments in the library.  A graphical display of Table 11 is seen in Figure 28. 
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Table 11 Scores for ten libraries selected using only commercial fragments from ZINC.  Displayed scores include composition, coverage and diversity, along with average number of 
fragment hits per reference shape, standard deviation of fragment hits per reference shape and number of references shapes which were not hit by a fragment (zero hits); this is shown 
graphically in Figure 27.  For a detailed explanation of these terms, refer to the opening of Section 2.6.1.  The average score has been calculated, indicating that a composition score of 
0 is unable to be achieved (highlighted), unlike within the chosen library. 
Run 
Composition 
Score 
Coverage Score Diversity Score Average Hits 
Standard 
Deviation 
Zero Hits 
1 0.025 0.0024223 0.047319 6.8050 3.2142 6 
2 0 0.0044409 0.050952 7.0949 3.2977 11 
3 0.025 0.0040371 0.046308 6.6605 3.2023 10 
4 0.0125 0.0032297 0.044882 6.5470 3.0699 8 
5 0.025 0.002826 0.049372 7.1397 3.313 7 
6 0.025 0.0040371 0.045083 6.6831 3.0893 10 
7 0.0125 0.0024223 0.041917 6.4287 3.0603 6 
8 0.025 0.0032297 0.046375 6.7804 3.1342 8 
9 0.0125 0.0024223 0.044761 6.7840 3.1547 6 
10 0 0.0036334 0.045401 6.6399 3.2907 9 
Average 0.01625 0.0032701 0.046237 6.7563 3.1826 8.1 
Chosen Library 0 0.0040371 0.055811 7.7085 3.7569 10 
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Figure 28 Graphical representation of properties of ten libraries selected using only commercial fragments 
from ZINC, seen in Table 11.  These include a) composition, coverage and diversity scores; b) average number 
of fragment hits per reference shape with standard deviations shown as error bars and c) number of 
references shapes which were not hit by a fragment (zero hits).  For a detailed explanation of these terms, 
refer to the opening of Section 2.6.1.  The average values have been calculated for each property and have 
been included in all three plots as well as the same properties for the chosen library.  This clearly indicates 
that a composition score of 0 is unable to be achieved using only commercial fragments from ZINC, unlike 
within the chosen library.   
2.8  Purchase of Commercial Fragments 
With the 20 fragments synthesised using Leeds chemistry completed, an attempt 
to source the remaining 60 commercial fragments revealed challenges due to high cost or 
lack of availability.  As a result, commercial fragments were reselected for the final library 
to overcome these issues, and this was done a total of three times (libraries E-G).  During 
each reselection of commercial molecules, ten alternative libraries were generated with 
the fragments already in hand remaining unaltered.  The library with the lowest 
composition, coverage and diversity score (Section 2.6.1) was selected until all 
compounds were successfully sourced.  The similar scores of the library of 80 compounds 
in each round of reselection (Section 3.2 describes how libraries A-D are directed at 
reselection of fragments synthesised using Leeds chemistry; here libraries E-G are 
described for reselection of commercial fragments) indicate that the shape-diversity of 
the final library has not been compromised from the initial target fragments (Table 12).  
This is denoted by the fact that all scores for libraries A-G contain values within two 
standard deviations of the average library score.  A graphical display of Table 12 can be 
seen in Figure 29.
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Table 12 A comparison of scores for the initial library (Library A), each regenerated library (Libraries B-F) and the final library (Library G).  Displayed scores include composition, 
coverage and diversity, along with the average number of fragment hits per reference shape, standard deviation of fragment hits per reference shape and number of reference shapes 
not hit by a fragment (zero hits); this is shown graphically in Figure 28.  For a detailed explanation of these terms, refer to the opening of Section 2.6.1.  The column averages and 
standard deviations of each property have also been calculated. 
Library 
Composition 
Score 
Coverage Score Diversity Score Average Hits 
Standard 
Deviation 
Zero Hits 
A 0 0.0032297 0.045488 6.5733 3.0824 8 
B 0 0.0032297 0.053412 7.3924 3.5084 8 
C 0 0.0052483 0.051173 7.1841 3.3662 13 
D 0 0.0036334 0.056421 7.7017 3.7268 9 
E 0 0.0040371 0.055811 7.7085 3.7569 10 
F 0 0.0036334 0.055451 7.7416 3.7811 9 
G 0 0.0032297 0.056052 7.7344 3.7480 8 
Average 0 0.0037488 0.053401 7.4337 3.5671 9.3 
Standard 
Deviation 
0 0.0006726 0.003659 0.4030 0.2446 1.7 
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Figure 29 Graphical representation of properties of the initial chosen library (Library A), each regenerated 
library (Libraries B-F) and the final library (Library G), seen in Table 12.  These include a) composition, 
coverage and diversity scores; b) average number of fragment hits per reference shape with standard 
deviations shown as error bars and c) number of reference shapes not hit by a fragment (zero hits).  For a 
detailed explanation of these terms, refer to the opening of Section 2.6.1.  The average values have been 
calculated for each property and have been included in all three plots, indicating that properties of each 
library are comparable. 
A PMI and properties plot of the final library, or Library G (Figure 30) indicates 
that Leeds fragments (blue) exhibit a higher 3D character than commercial fragments 
(grey), and slightly lower AlogP.  The structures for all 60 commercially purchased 
fragments can be seen in Table 13. 
 
Figure 30 a) PMI plot of Library G, the final library of 80 fragments.  It can be seen here that Leeds fragments 
(blue) exhibit a higher 3D character than commercial fragments (grey).  b) Lipophilicity vs. number of heavy 
atoms of Library G.  It can be seen here that the Leeds fragments (blue) are slightly lower in AlogP than 
commercial fragments (grey). 
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Table 13 Structures of all 60 commercially purchased fragments. 
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3 Synthesis of a Shape-Diverse Fragment Library 
This Chapter focuses on the work I have completed on the 20 synthetic 
compounds (Table 14) within my shape-diverse library of 80.  The Chapter has been 
divided into four sections focusing on the key chemistries for fragment formation.  Section 
3.3 describes fragments synthesised using Ugi chemistry, Section 3.4 describes fragments 
synthesised using amino acid chemistry, Section 3.5 describes fragments synthesised 
using Mitsunobu chemistry, and finally Section 3.6 describes fragments synthesised using 
iridium chemistry, in a key step for formation.  Each section is divided into sub-sections 
for the synthesis of building blocks, the key reaction connecting those building blocks 
together, the formation of scaffolds, and finally deprotection and decoration of the 
scaffolds in order to form the desired fragments. 
 72 
 
scaffold 1 (Amino acid) scaffold 2 (Iridium) scaffold 3 (Ugi) scaffold 4 (Ugi) scaffold 5 (Ugi) 
 
 
 
  
scaffold 6 (Ugi) scaffold 6 (Ugi) scaffold 7 (Ugi) scaffold 7 (Ugi) scaffold 8 (Ugi) 
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Table 14 The original library of 20 fragments selected for synthesis using chemistry developed at Leeds.  Each fragment has been labelled with the scaffold from which they originate 
as well as the chemistry used for their key stage for formation. 
scaffold 9 (Ugi) scaffold 10 (Ugi) scaffold 11 (Ugi) scaffold 11 (Ugi) scaffold 12 (Ugi) 
 
 
  
 
scaffold 13 (Ugi) scaffold 14 (Mitsunobu) scaffold 15 (Mitsunobu) scaffold 16 (Mitsunobu) scaffold 17 (Mitsunobu) 
  
  
 
 74 
 
3.1  Shape-Similar Alternative Fragments 
During encounters with fragments whose synthetic routes were exhausted and 
unsuccessful, an attempt was made to identify a shape-similar fragment.  Using PLP, 
shape-similar fragments to 50 (Section 3.3.4.1.2) was identified by calculating the 
Tanimoto score between the bit string of the target fragment’s fingerprint and that of the 
rest of the fragments in the Leeds library.  Tanimoto scores lie in the region of 0-1, where 
a score of 1 equates to an identical fragment in terms of shape and 0 equates to a complete 
lack of shape similarity.  The calculation is shown below (analogous to that used in Section 
2.7.1), where each bit indicates a match with a specific reference shape.  Here, “number of 
[and] bits” refers to the number of reference shapes covered by both the target fragment 
and the suggested alternative fragment, and “number of [or] bits” refers to the number of 
reference shapes covered by either the target fragment or the suggested alternative 
fragment. 
Tanimoto score = 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 [𝑎𝑛𝑑] 𝑏𝑖𝑡𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 [𝑜𝑟] 𝑏𝑖𝑡𝑠
 
The three highest similarity fragments could be identified by allowing the 
protocol to only select molecules which matched the target fragment with Tanimoto 
scores of >0.5 (Figure 31).  Unfortunately, two of these fragments 85 and 86 require 
decorations with an unreactive alkyl sulfonyl chloride capping group, similar to 50.  The 
synthesis of the third fragment 87 involves a reductive amination reaction that would 
likely result in a mixture of two diastereomers which would be challenging to separate.  
By using the same protocol to trial locating shape-similar alternative fragments for other 
compounds from the library, it was suggested that the target molecule 50 resided in an 
especially unpopulated area of shape space.  As a result, a new simulated annealing 
protocol was applied which selects a new library of 20 fragments with high coverage of 
reference shapes and diversity; this protocol would allow completed compounds to be 
included without relying on specific compounds similar in shape to problematic 
fragments such as 50. 
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Figure 31 The target fragment 50 for which a replacement is required and the proposed alternatives 85-87 
by PLP. 
3.2  Alternative Fragment Libraries 
An improved method to using a PLP protocol to locate shape-similar fragments 
was to generate a new simulated annealing protocol.  This was able to produce an 
alternative library of 20 fragments (Library B) to the original (Library A) selected from 
the Leeds virtual fragment library, with optimum coverage of reference shapes and 
diversity.  Alternative libraries were generated three times in total (libraries B-D), each 
time allowing completed compounds to be included whilst implementing new filters.  
Library B allowed removal of alkyl sulfonamides on the 6-membered and 7-membered 
ring scaffolds synthesised using the Ugi reaction, on the most hindered nitrogen within 
the ring (to avoid synthetically unfeasible fragments such as 50, Section 3.3.4.1.2).  On 
these same nitrogens, amide-ureas and amide-carbamates were also removed (to avoid 
synthetically unfeasible fragments leading to side-products such as 159, Section 3.3.4.3.2).  
Ten virtual fragment libraries were generated using the new filters where Library B was 
selected based on low reagent cost and ease of synthesis, as well as familiarity of the 
chemistry.   
Based on Library B, new challenges were identified and the same replacement 
process was implemented.  Library C was selected after exclusion of scaffolds formed 
using Mitsunobu cyclisation chemistry.  This was due to the unsuccessful connection of 
building blocks (Section 3.5.2), epimerisation of stereocentres as well as unsuccessful 
deprotection reactions (Section 3.5.4).  Library C was selected from a set of 10 new 
libraries generated by PLP. 
Based on Library C, new challenges were identified during formation of 
intermediates using the iridium-catalysed allylic amination reaction, and the same 
replacement process was implemented.  It was observed on one occasion that the iridium-
catalysed reaction was unable to selectively promote formation of the desired alkene 
(Section 3.6.2), and unfortunately the following aminoarylation reactions were also 
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unsuccessful. Library D was selected after exclusion of scaffolds formed using iridium 
chemistry in a key step (Table 15).  A summary of the library reselection process is shown 
in Figure 32 and libraries A-D can be seen in the Appendix (Table 37).  The synthesis of 
fragments as a result of the original as well as regenerated libraries has been discussed 
throughout. 
 
Figure 32 Summary of the library reselection process from Library A to Library D, including number of 
compounds kept and replaced in each round of selection as well as the synthetic challenges which were 
removed.  Library D was ultimately prepared.
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scaffold 1 (Amino acid) scaffold 2 (Amino acid) scaffold 3 (Amino acid) scaffold 4 (Amino acid) scaffold 5 (Amino acid) 
 
 
 
 
 
scaffold 6 (Ugi)* scaffold 6 (Ugi) scaffold 7 (Ugi)* scaffold 8 (Ugi)* scaffold 8 (Ugi)* 
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Table 15 Library D, the final library of 20 fragments selected from the Leeds virtual fragment library.  Each fragment has been labelled with the scaffold from which they originate as 
well as the chemistry used for their key stage for formation.   *Fragments that have remained from the original library. 
scaffold 8 (Ugi) scaffold 9 (Ugi)* scaffold 9 (Ugi)* scaffold 10 (Ugi) scaffold 11 (Ugi) 
 
 
 
 
 
scaffold 12 (Ugi) scaffold 12 (Ugi) scaffold 13 (Ugi) scaffold 13 (Ugi)* scaffold 14 (Ugi) 
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3.3  Synthesis of Fragments Using the Ugi Reaction as a Key Step 
3.3.1  Synthesis of Building Blocks  
3.3.1.1 Cyclic sulfamidates 
The formation of the cyclic sulfamidates 30, 92 and 96 (Scheme 11) began with 
Boc-protection61 of the corresponding commercially available amines followed by 
reaction with thionyl chloride, giving the cyclic sulfamidite.  A ruthenium-catalysed 
oxidation using sodium periodate yielded the cyclic sulfamidates on 10 g scales.62,63  The 
sulfamidate ring formation reaction was repeated on Boc-ethanolamine using 2.2 
equivalents of NaIO4 instead of 1.1 equivalents, where it was discovered that the oxidation 
step completed in just 4 hours whereas it is normally left to react overnight.  The yield 
improved from 23% to 71% and the crude material was pure enough to carry through to 
the next step after aqueous workup.  The formation of the cyclic sulfamidate 96 proceeded 
via an acetylated64 intermediate 95.  A mixture of mono-acylated intermediate and di-
acylated side product was recovered in this step.   
 
Scheme 11 Synthesis of cyclic sulfamidates. 
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3.3.1.2 Alkynyl sulfonamides 
Boc-protection of 2-nitrobenzenesulfonamide and a DEAD-promoted Mitsunobu 
reactioniv with corresponding alkynyl alcohols was followed by Boc-deprotection to yield 
sulfonamides 29 and 99 on 25 g scales (Scheme 12).   Purification of the propargyl 
sulfonamide 99 was difficult due to large amounts of triphenylphosphine oxide being 
present; the majority of which was removed by filtration prior to flash chromatography.  
 
Scheme 12 Synthesis of alkynyl sulfonamides. 
3.3.2  Connection of Building Blocks 
Cyclic sulfamidate ring opening of 30 with pentynyl sulfonamide 29 under basic 
conditions gave the sulfonamide 31.  Gold-mediated alkyne hydration65–68 of sulfonamide 
31, performed over 3 hr in a sealed tube at 120 °C, gave the ketone 32 
regioselectively.44,69–71 Larger scale alkyne hydration (1 g scale) proved difficult to drive 
to completion due to the small size of reaction tubes available.  One solution was to 
complete the reaction at reflux, using a longer reaction time (overnight) to compensate 
for the lower reaction temperature (100 °C).  This proved possible and the reaction was 
completed on a 6 g scale, where yield of the ketone 32 also improved from 56% to 86% 
(Scheme 13). 
The cyclic sulfamidate ring opening reaction was repeated using a range of other 
sulfamidates and sulfonamides, followed by gold-mediated hydroamination72–76 to give 
the desired tetrahydropyrazine.  Sulfonamide 100 was produced on a 4 g scale, followed 
by cyclisation to produce 101 (Table 16, Entry 1).  The methyl-substituted sulfonamide 
102 was produced as a presumed single enantiomer, with inversion of configuration at 
                                                             
iv DIAD was initially used in place of DEAD however this caused issues in purification. 
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the stereogenic centre.  The sulfonamide 102 then reacted in a gold-mediated 
hydroamination reaction to give the tetrahydropyrazine 103 on a 2 g scale (Table 16, 
Entry 2).  The same ring opening reaction using an acetate-substituted cyclic sulfamidate 
produced sulfonamide 104, which upon hydroamination yielded the tetrahydropyrazine 
105 on a 2 g scale (Table 16, Entry 3). 
 
Scheme 13 Synthesis of ketone 32. 
Entry Sulfonamide 
Cyclic 
Sulfamidate Product
a 
Yield 
/ % 
Productb 
Yield 
/ % 
1 
 
 
 
61 
 
62 
2 
 
 
 
49 
 
95 
3 
 
  
58 
 
73 
 
Table 16 Yields of products from the cyclic sulfamidate ring opening reaction and the following gold-
mediated hydroamination reaction; a) Conditions: NaH, DMF, RT; b) Conditions: 5 mol% Au(PPh3)Cl, 5 mol% 
AgSbF6, 1,4-dioxane, 100 °C. 
3.3.3  Synthesis of Scaffolds 
The two novel scaffolds 51 and 33 were generated using the Ugi reaction from the 
ketone 32 and two different isocyanides, proceeding via an iminium intermediate.  
Scaffold 51 was formed on a 600 mg scale and scaffold 33 was formed on a 1 g scale 
(Scheme 14).  Attempts were made to remove the trifluoroacetamide group via base 
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hydrolysis, using NaOH as well as K2CO3 in H2O–MeOH (30:70).  Fluorine NMR showed 
disappearance of fluorine atoms, and a slight shift in proton NMR could be observed.  
However, it was not possible to assign one additional peak in the carbon NMR at 156 ppm, 
and a mass peak of 26 greater than the product mass.  This was the case for both 
intermediates.  Upon further investigation it was identified that the reaction formed 
hydantoins 106 and 107 via an addition-elimination mechanism from the nucleophilic 
amide nitrogen, with the -CF3 anion as the leaving group.  This structure was confirmed 
by both HRMS and carbon NMR.  The proposed mechanism for the formation of the 
hydantoin structure77 can be seen in Scheme 15. 
 
Scheme 14 Synthesis of hydantoins 106 and 107. 
  
Scheme 15 Mechanism for the formation of the hydantoin structure. 
The structures of the hydantoins 106 and 107 were assigned on the basis of their 
IR and HMBC spectra.  The characteristic amide C=O peaks for hydantoin structures78 
around 1780 cm-1 and 1720 cm-1 were present in both IR spectra and the structure was 
also verified by HMBC, where correlations were seen between the carbonyl carbon 
previously belonging to the trifluoroacetamide group, and nearby protons (Figure 33).   
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Figure 33 HMBC correlations shown via arrows between the carbonyl carbon previously belonging to the 
trifluoroacetamide group, and nearby protons in hydantoins 106 and 107. 
Novel scaffold 108 synthesised using the Ugi reaction has been formed on a 1 g 
scale from ketone 32 (Scheme 16).  The 6-membered ring hydroamination product 101 
was also used in three Ugi reactions to give scaffold 109 (Table 17, Entry 1) on a 500 mg 
scale, and 110 (Table 17, Entry 2) and 111 (Table 17, Entry 3) on 1 g scales.  
 
Scheme 16 Synthesis of scaffold 108. 
Entry Tetrahydropyrazine Isocyanide Producta Yield / % 
1 
 
 
 
60 
2 
 
 
 
11 
3 
 
 
 
69 
 84 
 
4 
 
 
 
77 
5 
 
 
 
81 
6 
 
 
 
49 
7 
 
 
 
71 
8 
 
 
 
49 
Table 17 Yields of products from the Ugi reaction; a) Conditions: 1) TFA, DCM, RT, 2) isocyanide, EtOH, 
0 °C - RT. 
The piperazines 112-115 (Table 17, Entry 4-7) were synthesised 
diastereoselectively from tetrahydropyrazine 103 using three different isocyanides, on 
200 mg - 1.5 g scales.79  The tetrahydropyrazine 105 was treated with 18 equivalents of 
TFA- three times the amount of previous reactions to effect iminium formation- before 
undergoing the Ugi reaction with ethyl isocyanide to yield piperazine 116 on a 1 g scale 
(Table 17, Entry 8).  In the case of the piperazine 116, the relative configuration was 
determined by NOESY analysis (Figure 34); where an NOE was observed between the 
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methyl protons and the proton in the 6-membered ring attached to the same carbon as 
the methyl acetate substituent, they are indicated to be on the same face of the ring. 
 
Figure 34 Determination of configuration of scaffold 116.  
3.3.4  Synthesis of Fragments 
3.3.4.1 7-Membered ring fragments 
3.3.4.1.1 Benzylamide-substituted 7-membered rings 
One method to prevent the formation of hydantoins 106 and 107 (Section 3.3.3) 
would be to change the trifluoroacetyl protecting group in scaffolds 51 and 33.  However, 
this is difficult to achieve due to the nature of the Ugi reaction.  Instead, completing the 
reaction under reductive conditions using NaBH4 proved successful in the removal of the 
trifluoroacetamide group.80,81  The deprotected diazepane 117 was next decorated on the 
secondary amine by reductive amination82 using acetaldehyde to give the alkylated 
product 118 on a 300 mg scale.  The alkylated intermediate 118 was deprotected to 
remove the sulfonyl group,83 producing fragment 119 on a 1 g scale (Scheme 17). 
Scheme 17 Synthesis of fragment 117. 
Sulfonyl deprotection on scaffold 33 was completed to produce a negligible 
amount of the desired intermediate 120 as well as a major side-product with a mass of 
[M-18]+.  X-ray crystallography enabled determination of the structure of the side-product 
as cyclic zwitterion 121, which under conditions on the LCMS gave rise to the charged 
iminium species 123, accounting for the [M-18]+ peak observed (Scheme 19).  The 
formation of zwitterion 121 is promoted by the presence of a hydrogen bond between the 
oxy and ammonium ions stabilising the structure (Figure 35).  121 was subjected to 
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excess base which gave the expected hydantoin 122 (Scheme 18), suggesting it is an 
intermediate in the hydantoin formation reaction.84 
 
Scheme 18 Synthesis of hydantoin 122 via zwitterion 121 using sulfonyl deprotection conditions. 
                       
  
An alternative route was used to remake scaffold 33 using a benzyl protecting 
group in place of the sulfonyl group.  This route began with reductive amination of Boc-
ethylene diamine in the presence of benzaldehyde, followed by reaction with ethyl vinyl 
ketone to produce ketone 126 which reacted in an Ugi cyclisation to produce scaffold 127 
in three steps.  Scaffold 127 was used as crude in a transfer hydrogenation reaction to 
give the de-benzylated intermediate 120 on a 500 mg scale.  The following methylation 
of 120 using MeI regenerated the starting material.v  The alternative reductive amination 
however was successful, giving fragment 129 on a 50 mg scale after the final 
trifluoroacetyl reduction (Scheme 20). 
                                                             
v Methylation of Boc-ethylene diamine using MeI was attempted to produce a building block where the methyl 
substituent can be used as a protecting group as well as being present in the final fragment.  Unfortunately, 
the majority product isolated was dimethylated Boc-ethylene diamine.  Methylation was reattempted using 
formaldehyde under reductive conditions in order to prevent dimethylation but this was unsuccessful. 
 
Scheme 19 Formation of the [M-18]+ mass ion 
123  from zwitterion 121.  
 
Figure 35 X-ray crystal structure of zwitterion 121.  
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Scheme 20 Synthesis of fragment 129. 
3.3.4.1.2 2-Methoxyethylamide-substituted 7-membered rings 
The trifluoroacetyl group on scaffold 51 was removed by reduction to give the 
intermediate 130 on a 500 mg scale, which next required decoration.  The conditions in 
Table 18 were attempted for the formation of the sulfonylated85 diazepane 131 shown in 
Scheme 21.  Sulfonylation of intermediate 130 at the secondary amine under basic 
conditions either reproduced the starting material or caused decomposition of the 
reagents.  The reaction was attempted with bases DIPEA and Et3N, at room temperature 
and at reflux in reaction solvents DCM, MeCN and DMF.  A catalytic amount of DMAP was 
added in order to activate the sulfonyl chloride and the reaction was also attempted using 
benzylsulfonyl chloride in place of ethylsulfonyl chloride.  This was in order to test the 
reaction viability, as aromatic sulfonyl chlorides are known to have higher reactivity than 
its alkyl counterparts.  After heating at reflux overnight, the product peak could be 
observed, but decomposition occurred when the temperature was increased to 120 °C.   
As a result, the sulfonylation was repeated with 8 equivalents of ethylsulfonyl 
chloride at a lower temperature of 100 °C over two days in order to promote the reaction, 
using DIPEA as the reaction solvent, before later being heated in a microwave at 100 °C 
for 30 mins and later at 110 °C for 1 hr.  In summary, a small amount of product could be 
detected when using benzylsulfonyl chloride in the reaction, but no product nor 
identifiable by-product could be detected when the reaction was attempted using 
ethylsulfonyl chloride.  As a result, this reaction has been abandoned for an alternative 
fragment which was identified using a new PLP protocol (discussed in Section 3.1).   
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Scheme 21 The attempted synthesis of intermediate 131.86 
Entry 
Sulfonyl 
chloride (eq.) 
Base (eq.) Catalyst Solvent 
Temperature 
/ °C 
Time 
1 Ethyl (1.5) Et3N (2)  DCM 25 overnight 
2 Ethyl (1.5) DIPEA (2)  DCM 25 overnight 
3 Ethyl (3) DIPEA (4)  DCM 40 (reflux) overnight 
4 Ethyl (1.5) DIPEA (2) DMAP MeCN 80 (reflux) overnight 
5 Benzyl (1.5) DIPEA (2) DMAP MeCN 80 (reflux) overnight 
6 Benzyl (1.5) DIPEA (2) DMAP DMF 120 overnight 
7 Ethyl (8) DIPEA (10) DMAP  100 2 days 
8 Ethyl (8) DIPEA (10) DMAP  100 (µW) 30 mins 
9 Ethyl (8) DIPEA (10) DMAP  110 (µW) 1 hr 
Table 18 Conditions attempted for the synthesis of intermediate 131. 
3.3.4.1.3 Cyclopropylamide-substituted 7-membered rings 
Whilst attempting to remove the sulfonyl group on scaffold 108, it was found that 
the product was water soluble; therefore, changing the solvent from DMF to MeCN 
allowed ease of solvent removal due to the much lower boiling point of MeCN, without 
compromising on solvent polarity.  An unwanted hydantoin formed as the major product 
in the presence of base; in order to overcome this, the amount of base was reduced, and 
also added only after the addition of PhSH, allowing the -SPh anion to act as a buffer in the 
reaction solution.  Reagent amounts were changed from 1.2 equivalents of PhSH with 3 
equivalents of K2CO3 to 1 equivalent of PhSH with 1.5 equivalents of K2CO3.  The reaction 
was carefully monitored and stopped after 5 hours with no formation of hydantoin 
observed, although the unwanted cyclic zwitterion, analogous to 121 (Section 3.3.4.1.1) 
was present.  The reaction is found to complete faster (2 hr instead of 5 hr) by increasing 
PhSH from 1 equivalent to 1.5 equivalents and the yield improved drastically (by 70%) 
by changing the purification method from flash chromatography to basic SCX. 
The following acylation87 of 133 using methoxyacetyl chloride yielded 
intermediate 134 which was reduced to give the crude fragment 135 on a 2 g scale 
(Scheme 22).  Unfortunately, attempted purification of 135 using basic SCX cartridge, 
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flash chromatography as well as preparative HPLC failed to produce the pure compound, 
which decomposed under high temperature NMR.  Nevertheless, it is possible to use 
fragment 135 in a biological screen at its known purity of 70%. 
 
Scheme 22 Synthesis of fragment 135. 
3.3.4.2 6-Membered ring fragments 
3.3.4.2.1 Benzylamide-substituted 6-membered rings 
The sulfonyl deprotection product of scaffold 109 was difficult to purify using 
basic SCX, flash chromatography or preparative HPLC due to the desired product 136 
decomposing into the undesired zwitterion, analogous to 121 (Section 3.3.4.1.1).  
Intermediate 136 was therefore used as crude in an alkylation reaction with 2-
bromooxetane in order to form the desired product 137.vi  The alkylation of intermediate 
136 was completed using oxetan-3-one, under reductive amination conditions, and the 
following trifluoroacetyl deprotection worked in good yield, giving 138 on a 500 mg scale 
(Scheme 23). 
The same piperazine 136 was used as crude for the reductive amination reaction 
using cyclopropyl carboxaldehyde to give 139, but a mixture of two inseparable products 
with the same mass was formed.  As a result, 139 was used as crude for the final reduction 
step to produce fragment 140 on a 50 mg scale for which purification was completed by 
preparative HPLC.  136 was also used as crude in a sulfonylation reaction which was 
unable to reach completion due to lack of base used as a preventative measure to avoid 
hydantoin formation.  Intermediate 141 was then used as crude and reduced to remove 
the trifluoroacetyl protecting group to yield 142 successfully on a 1.5 g scale (Scheme 23).  
                                                             
vi The reaction carried out with 1.5 eq. Cs2CO3 whilst heating at 60 °C in DMF resulted in formation of the 
hydantoin.  Additionally, no reaction occurred when this method was attempted without base, and by heating 
in ether at reflux.   
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Scheme 23 Synthesis of fragments 138, 140 and 142. 
3.3.4.2.2 2-Methoxyethylamide-substituted 6-membered rings 
Scaffold 110 was reduced to remove its trifluoroacetamide protecting group 
giving intermediate 143 on an 80 mg scale.  The following acylation product was unable 
to be isolated by flash chromatography or preparative HPLC.  An alternative synthesis was 
attempted in which 2-thiophene carboxylic acid was added in excess (2 eq.) to 
tetrahydropyrazine 101 in the Ugi reaction after formation of the imine intermediate.  
Unfortunately, the majority product formed was the original scaffold 110.  The 
sulfonylation was repeated using 2-thiophenecarbonyl chloride as before but changing 
the solvent from MeOH to DCM with a catalytic amount of DMAP.  The reaction was 
successful and intermediate 144 was formed in good yield, before undergoing sulfonyl 
deprotection to produce the final fragment 145 (Scheme 24). 
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Scheme 24 Synthesis of fragment 145. 
The sulfonyl deprotection product of scaffold 110 proved difficult to purify by 
basic SCX, flash chromatography or preparative HPLC.  Intermediate 146 was used as 
crude for the following acylation reaction using cyclopropyl carbonyl chloride, and 147 
was purified by preparative HPLC.  Any rotameric forms which may have been present 
decomposed when subjected to high temperature NMR thus 147 was used as crude 
successfully for the final reduction to produce fragment 148 (Scheme 25). 
Scheme 25 Synthesis of fragment 148. 
3.3.4.2.3 Cyclopropylamide-substituted 6-membered rings 
The sulfonyl deprotection product of scaffold 111 was used as crude in a urea 
formation reaction with cyclopropyl isocyanate88 to produce intermediate 150.  The final 
reduction to remove the trifluoroacetyl protecting group was completed to yield 151 on 
a 300 mg scale (Scheme 26). 
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Scheme 26 Synthesis of fragment 151. 
3.3.4.3 Enantiomerically-enriched fragments 
3.3.4.3.1 Benzylamide-substituted 6-membered rings 
Sulfonyl deprotection of the dimethyl-substituted piperazine scaffold 112 on a 1 g 
scale produced a mixture of the trifluoroacetamide as well as the cyclised zwitterion.  The 
two products were able to be separated after the following reductive amination reaction 
with Boc-azetidinone to give 153 and the cyclised zwitterion 156.  Interestingly, both 153 
and 156 formed the same desired product after reduction of the trifluoroacetyl protecting 
group.  A final Boc-deprotection of intermediate 154 produced the desired fragment 155 
(Scheme 27). 
Scheme 27 Synthesis of fragment 155. 
3.3.4.3.2 2-Methoxyethylamide-substituted 6-membered rings 
Reduction was completed on scaffold 113 in order to remove the trifluoroacetyl 
protecting group and the following urea formation was successful, producing 158 on a 
300 mg scale.  However, although the final sulfonyl deprotection showed the product 
formation, 158 was unstable to cyclisation and only the undesired hydantoin 159 could 
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be isolated (Scheme 28).  Since the direct cyclisation with amides has been precedented 
for isocyanates, this compound was abandoned for an alternative in the newly generated 
library (discussed in Section 3.2).   
Scheme 28 Synthesis of hydantoin 159. 
3.3.4.3.3 Cyclopropylamide-substituted 6-membered rings 
Sulfonyl deprotection was performed on the dimethyl-substituted piperazine 
scaffold 114 on an 800 mg scale and the following decorated intermediates were used as 
crude for the final reduction reactions to produce fragments 162 and 164 (Scheme 29).   
Scheme 29 Synthesis of fragments 162 and 164. 
3.3.4.3.4 Ethylamide-substituted 6-membered rings 
Reduction was completed on scaffold 115 in order to remove the trifluoroacetyl 
protecting group, and the following acylation with isoxazole-5-carbonyl chloride was 
successful to produce intermediate 166.  The final sulfonyl deprotection step yielded 
fragment 167 on a 200 mg scale.  Intermediate 165 was also reacted with 4-
imidazolecarboxaldehyde in order to produce 168, which gave fragment 169 on a 100 mg 
scale upon deprotection (Scheme 30). 
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Scheme 30 Synthesis of fragments 167 and 169. 
Unfortunately, the trifluoroacetyl group on scaffold 116 could not be removed by 
reaction with a large excess of NaBH4 at room temperature, possibly due to the hindered 
nature of the nitrogen centre.  Thus, this reaction was heated to reflux overnight in MeOH 
where the acetate group was observed to undergo reduction followed by removal of the 
trifluoroacetyl group to produce 171.  This reduces the number of deprotection steps to 
the final fragment with no selectivity issues in the following acylation using propionyl 
chloride, as no increase in shift of the alkyl protons neighbouring the hydroxyl group was 
observed upon acylation.  The final sulfonyl deprotection yielded fragment 173 on a 
300 mg scale (Scheme 31). 
 
Scheme 31 Synthesis of fragment 173. 
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3.4  Synthesis of Fragments Using Amino Acid Chemistry 
3.4.1  Synthesis of Building Blocks  
3.4.1.1 Identification of a suitable method 
Formation of the amino ester 175 was attempted using a palladium- and nickel-
catalysed allylation of valine methyl ester hydrochloride in the presence of allyl acetate.89  
The desired product was isolated as crude; however, attempted purification by basic SCX 
cartridge caused the product to decompose.  The reaction was repeated in the hope of 
using the material as crude but unfortunately product formation was inconsistent.  The 
procedure was attempted once more using anhydrous DCE for the formation of the 
palladium complex and each reagent was added in quick succession; however, no material 
was isolatable. 
The synthesis of amino ester 175 was re-attempted using an alternative route, 
which began with imine formation before LiHMDS was used to deprotonate the acidic α-
proton.  The anion intermediate was quenched with allyl bromide and finally the imine 
functionality was hydrolysed using a citric acid work-up.  However, it appeared that any 
product which may have formed was unstable and only a small amount of non-allylated 
imine intermediate could be isolated.  The reaction was repeated with 3 equivalents of 
LiHMDS instead of 1.5 but again minimal product formation was observed (Scheme 32). 
 
Scheme 32 Attempted synthesis of amino ester 175. 
The synthesis of amino ester 175 was next attempted via formation of the 
azalactone intermediate 178.90  This route began with benzoyl protection of valine 
followed by cyclisation in the presence of ethyl chloroformate to produce azalactone 178.  
Allylation to produce intermediate 179 proceeded with ease in the presence of BEMPvii 
due to the increased reactivity of the α-carbon, before the azalactone ring is opened to 
                                                             
vii BEMP is the abbreviated name for the phosphazene base 2-tert-butylimino-2-diethylamino-1,3-dimethyl-
perhydro-1,3,2-diazaphosphorine. 
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give the allylated amino ester 180 formed on a 5 g scale. Unfortunately, reflux in HCl over 
two days in an attempt to remove the benzoyl protecting group yielded an undesired 
benzoyl derivative as well as a side product with loss of the methoxy group (Scheme 33). 
 
Scheme 33 Attempted synthesis of amino ester 175a. 
The formation of building block 175 via an imine intermediate was re-attempted 
using allyl iodide instead of allyl bromide in order to explore electrophiles with increased 
reactivity.  The desired amino ester 175 was isolated successfully on a 500 mg scale, 
which was used directly after aqueous workup (Scheme 34). 
 
Scheme 34 Synthesis of amino ester 175. 
3.4.1.2 Allylation of amino esters 
Allylation of amino esters 183 and 185 gave 184 and 186 on 2 g and 500 mg 
scales respectively (Scheme 35).  The formation of amino ester 183 began with 
commercially available 3-oxetanone, which reacted with Z-phosphonoglycine trimethyl 
ester to yield an alkenic intermediate 182.   182 produced the desired amino ester 183 
upon hydrogenation of the alkene functionality and removal of the Cbz protecting group.91 
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Scheme 35 Synthesis of amino esters. 
3.4.1.3 Amino ester formation 
Methylation of amino acid 187 produced methyl ester 188 on a 1 g scale (Scheme 
36).92 
 
Scheme 36 Synthesis of amino ester 188. 
3.4.2  Connection of Building Blocks 
Ureas93 were synthesised via the reaction of a range of amino esters and 
isocyanates in the presence of base.  The ureas 189 and 190 were synthesised by reaction 
with methoxyethyl isocyanate (Table 19, Entries 1 and 2, respectively) and urea 191 was 
synthesised by reaction with cyclopropyl isocyanate (Table 19, Entry 3).   
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Entry Amino Ester Isocyanate Producta Yield / % 
1 
 
 
 
58 
2 
 
 
 
52 
3 
 
 
 
40 
 
Table 19 Yields of products from the urea formation reaction; a) Conditions: Et3N, DCM, 0°C - RT. 
Allylation of amino ester 188 produced intermediate 192 which was used as 
crude in the formation of amide 195 via a TBTU- catalysed coupling reaction94,95 on a 500 
mg scale.  Reductive amination of amino ester 175 with 2-bromobenzaldehyde produced 
the desired intermediate 194 on a 1 g scale (Scheme 37). 
 
Scheme 37 Synthesis of intermediates 193 and 194. 
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3.4.3  Synthesis of Scaffolds 
Hydantoins 195-197 (Table 20, Entry 1-3) were synthesised from the 
intramolecular cyclisation of ureas in the presence of base. 
Entry Urea Producta Yield / % 
1 
  
67 
2 
  
80 
3 
  
92 
 
Table 20 Yields of products from the hydantoin formation reaction; a) Conditions: NaOtBu, toluene, 100 °C. 
Boc-deprotection96 of 193 revealed a free amine which was able to undergo 
intramolecular base-mediated cyclisation with the ester functionality present, producing 
diketopiperazine scaffold 198 on a 500 mg scale.  An intramolecular Heck reaction97 of 
alkene 194 under microwave conditions produced benzazepine scaffold 199 in moderate 
yield, on a 1 g scale (Scheme 38).   
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Scheme 38 Synthesis of scaffolds 198 and 199. 
3.4.4 Synthesis of Fragments 
3.4.4.1 Hydantoins 
The synthesis of fragments 201 and 203 proceeded via the ozonolysis98 of 
scaffolds 195 and 197 to produce corresponding aldehydes, which later reacted in 
reductive aminations with alternate amines to produce fragments 201 and 203, on 50 mg 
scales.  The ozonolysis of scaffold 196 followed by reduction of the aldehyde intermediate 
produced fragment 205 on a 50 mg scale (Scheme 39). 
 
Scheme 39 Synthesis of hydantoin fragments. 
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3.4.4.2 Diketopiperazine 
The alkene 198 was subjected to ozonolysis on a 100 mg scale; however the 
starting material was regenerated.  Alternatively, dihydroxylation followed by oxidative 
cleavage99 of 198 was difficult to monitor and the next reductive amination step with 1-
Boc-3-(amino)azetidine was carried out on the crude intermediate to give 207.  The final 
Boc-deprotection reached completion when TFA was used as the reaction solvent to 
produce fragment 208 (Scheme 40). 
Scheme 40 Synthesis of fragment 208. 
3.4.4.3 Tetrahydrobenzazepine 
Boc-protection was attempted on the tetrahydrobenzazepine scaffold 199 in 
order to produce an acid chloride intermediate for amide formation.  Unfortunately, no 
reaction was observed when using a stoichiometric amount of DMAP alongside Et3N, and 
by heating the solution at reflux in THF.  Scaffold 199 was next hydrolysed on a 100 mg 
scale in order to attempt a classical amide coupling route where it was found that heating 
the reaction was necessary due to the hindered nature of the ester.  Only a small amount 
of acid 210 formed after heating the reaction mixture at reflux in MeOH; however, heating 
the reaction mixture at 120 °C in DMF resulted in reaction completion.   
Removal of excess NaOH was difficult due to the zwitterionic nature of 210 and it 
was therefore carried forward to the next reaction.  The following amide coupling reaction 
was completed using a large excess of cyclopropylamine and by adding TBTU last to the 
reaction mixture in order to prevent polymerisation.  Purification using basic SCX was 
unsuccessful but the amide 211 was able to be isolated using aqueous workup followed 
by flash chromatography.  The final oxidation step to produce ketone 212 was attempted 
using ozonolysis on a 30 mg scale, unfortunately no significant product formation was 
observed along with a mixture of side-products. 
An osmium-mediated dihydroxylation and oxidative cleavage was attempted on 
alkene 211.  The mass of the dihydroxylated intermediate was observed, however the 
major isolated product after oxidative cleavage appeared to be the non-preventable over-
oxidised imine product 213 containing a cyclised hemiaminal.  Imine 213 was later 
reduced in the hope that the product conformation would be preferential for the ketone 
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212 over the hemiaminal 214, but unfortunately a mixture of the two could still be 
observed despite disappearance of the double bond (Scheme 41).  
 
Scheme 41 Synthesis of fragment 212. 
3.5  Synthesis of Fragments Using the Mitsunobu Reaction as a Key Step 
3.5.1  Synthesis of Building Blocks  
3.5.1.1 Cyclic Sulfamidates 
Formation of cyclic sulfamidates R-54 and S-54 began with ring opening of 
corresponding epoxides100 followed by cyclic sulfamidate ring formation to give the 
desired products on 5 g scales.  The cyclic sulfamidate ring formation from amide R-216 
proceeded via a sulfamidite intermediate; it was noted that although the intermediate 
formed fully, the following oxidation step was low-yielding, possibly due to the PMB 
protecting group being susceptible to undesired oxidation.  No oxidation was observed 
after 6 hours and starting material R-216 was regained overnight along with a mixture of 
side-products.  The oxidation step to form sulfamidate R-54 was repeated by reducing the 
amount of NaIO4 used from 2 equivalents to 1 in order to prevent over-oxidation.  The 
reaction reached completion after three days with no improvement in yield.  
During the formation of cyclic sulfamidate S-54, oxidation of the sulfamidite 
intermediate produced a mixture of side-products after 4 hours with consumption of 
starting material S-216.  The synthesis was reattempted using new NaIO4 as well as 
ruthenium catalyst and yield improved from 8 to 19%.  It was found that when remaking 
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the cyclic sulfamidate building block, using 4 equivalents of periodate instead of 2 in fact 
consumed the starting material in just three hours with only the desired product formed 
and none of the over-oxidised side-product.  This led to the conclusion that the cyclic 
sulfamidate must be the kinetic product whilst the over-oxidised side-product is 
thermodynamically favourable.  Pleasingly, the yield of S-54 more than doubled to 48% 
(Scheme 42). 
 
Scheme 42 Synthesis of cyclic sulfamidates. 
3.5.1.2 Amino alcohols 
The enantiomerically-enriched amino alcohols 218 and 221 were synthesised by 
reduction of their acid precursors 217 and 220 in the presence of LiAlH4,101,102 and later 
sulfonyl protection yielded amino alcohols 219 and 55 on 3 g and 500 mg scales, 
respectively.  The commercially available 3-amino-1-propanol was also protected to yield 
amino alcohol 223 on a 500 mg scale (Scheme 43). 
 
Scheme 43 Synthesis of amino alcohols. 
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Amino alcohol 229 was synthesised via a nitro intermediate, with the aid of the 
chiral ligand 226.  Protection of (R)-2-phenylglycinol followed by opening of the aziridine 
ring with diphenylethylenediamine produced ligand 226 on a 1 g scale.  226 was used to 
aid a copper-catalysed reaction of cyclopropyl carboxaldehyde with nitromethane to yield 
nitro intermediate 228.  Reduction of 228 produced the desired amine 229 which was 
later protected to yield building block 230 on a 1 g scale (Scheme 44). 
 
Scheme 44 Synthesis of amino alcohol 230. 
3.5.2  Connection of Building Blocks 
The cyclic sulfamidate ring opening reaction between R-54 and amino alcohol 
219 did not proceed at room temperature.  The reaction was heated to 70 °C overnight; 
the limiting reagent sulfamidate R-54 was consumed but only sulfonamide starting 
material 219 could be isolated (Table 21, Entry 1).  It is likely that the reaction is 
challenging due to steric hindrance from the substituted carbon of attack on cyclic 
sulfamidate R-54, as well as the bulky α-substituent of amino alcohol 219.42  This theory 
was validated by the ring opening reaction between sulfamidate S-54 and unsubstituted 
amino alcohol 223, which proceeded in reasonable yield (Table 21, Entry 2).   
It was hoped that the reduced steric bulk from the cyclopropyl ring in amino 
alcohol 55 compared to the isopropyl group in 219 would result in a successful ring 
opening with S-54; however, the product was unable to be isolated cleanly (Table 21, 
Entry 3).  The β–substituted amino alcohol 230 used in a sulfamidate ring opening 
reaction with S-54 on a 300 mg scale gave a mixture of diastereoisomers due to possible 
epimerisation under the reaction conditions.  These diastereoisomers were able to be 
separated (25% and 19% yield respectively) with the major product being carried 
forward (Table 21, Entry 4). 
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Entry Nucleophile Electrophile Desired Product Conditions Outcome 
1 
 
  
NaH, DMF, 70 °C 
Sulfonamide starting 
material isolated 
2 
 
  
NaH, DMF, 70 °C 32 % product isolated 
3 
 
  
NaH, DMF, 70 °C Mixture formed 
4 
 
  
NaH, DMF, RT 25% product isolated 
Table 21 Conditions attempted for the cyclic sulfamidate ring opening reaction. 
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3.5.3  Synthesis of Scaffolds 
Intermediate 234 was used in a Mitsunobu cyclisation103,104 reaction on a 200 mg 
scale to produce a mixture of diastereoisomers.105,106  This was possibly due to 
epimerisation of the chiral centre alpha to the carbonyl group, under reaction conditions.  
The two diastereoisomers were separated by preparative HPLC and NOESY was used to 
confirm the stereochemistry of the major product as the desired scaffold 235 (Scheme 
45).  Unfortunately, purification by preparative HPLC meant the product yield was 
significantly reduced. 
 
Scheme 45 Synthesis of scaffold 235. 
3.5.4  Synthesis of Fragments 
CAN was used to deprotect the PMB group107 of scaffold 235 on a 10 mg scale and 
it was observed on LCMS that each PMB group was removed in turn and the reaction only 
completed after a total of 8 equivalents of CAN was used; the product 236 was isolated 
using preparative HPLC.  CAN deprotection was repeated on the piperazine scaffold, 
where the Mitsunobu product 235 was carried forward as a mixture of diastereoisomers 
in order to avoid loss of material using preparative HPLC.  A white solid by-product was 
removed by filtration and the filtrate was purified by flash chromatography.  The isolated 
deprotected piperazine 236 was used as crude for the following sulfonylation step, which 
did not yield any isolatable products (Scheme 46). 
 
Scheme 46 Attempted synthesis of intermediate 237. 
Transfer hydrogenation108 in an attempt to remove the PMB groups from scaffold 
235 resulted in an unsurprising reduction of the nitrophenyl group to aniline, as well as 
removal of only one PMB group, presumably on the amine (Table 22, Entry 1).  Both reflux 
in TFA (Table 22, Entry 2) and DDQ oxidation109 (Table 22, Entry 3) showed starting 
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material remaining as well as the formation of an unknown side product.  In addition, the 
DDQ oxidation reaction also showed removal of only one PMB group, after reflux 
overnight.  It was decided at this stage that synthesis of fragments using Mitsunobu 
cyclisation chemistry would be abandoned and alternatives would be generated 
(discussed in Section 3.2). 
Entry Conditions Outcome 
1 
Ammonium formate, 5 mol% 
Pd(OH)2/C, EtOH, 70 °C 
Reduction of nitro group 
2 TFA, DCM, reflux Unknown product formed 
3 DDQ, H2O-DCM, 0 °C - 45 °C Removal of one PMB group 
Table 22 Range of conditions attempted for PMB deprotection. 
3.6  Synthesis of Fragments Using Iridium Chemistry 
3.6.1  Synthesis of Building Blocks  
The silyl-protected110 alcohol 56 was produced on a 10 g scale.  Boc-protection of 
3-amino-propanol was followed by a one-pot Parikh Doering oxidation111 to give the 
aldehyde in situ, before being quenched by carbethoxymethylene triphenyl phosphorane 
in a Wittig reaction to give the α,β-unsaturated ester 239.  The ester 239 was reduced110 
and later took part in an addition-elimination reaction with methyl chloroformate to give 
the allylic carbonate 45 on a 10 g scale (Scheme 47). 
 
Scheme 47 Synthesis of amino alcohol 56 and allylic carbonate 45. 
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A range of conditions were attempted in order to synthesise an alternative 
building block to 56; this would result in the desired fragment formed using fewer steps 
as the amino alcohol building block 246 is pre-decorated with the desired oxetane 
substituent.  Unfortunately, heating of the amino alcohol 89 (synthesis discussed in 
Section 3.3.1.1) overnight with bromooxetane resulted in loss of the Boc group only 
(Table 23, Entry 1).  The same reaction under phase transfer conditions at a lower 
temperature reproduced the starting material (Table 23, Entry 2).  A substitution reaction 
combining nucleophile 3-oxetanol with tosyl-protected amine 243 was equally 
unsuccessful (Table 23, Entry 3).  An attempt to form the acetonitrile derivative by 
reacting 3-oxetanol with bromoacetonitrile which could later be reduced to give the 
desired amine 246 gave a mixture of starting materials (Table 23, Entry 4).  Pleasingly, 
synthesis via a cyclic sulfamidate ring opening reaction with sulfamidate 30 (synthesis 
discussed in Section 3.3.1.1) and 3-oxetanol was successful, producing 245 in reasonable 
yield (Table 23, Entry 5).  Boc-deprotection yielded the desired amine 246 on a 2 g scale 
(Scheme 48). 
Entry Nucleophile Electrophile Conditions Outcome 
1 
  
Cs2CO3, DMF, 60 °C 
Loss of Boc 
group 
2 
  
Bu4NOH, 
H2O−MeCN, 40 °C 
Amino alcohol 
recovered 
3 
 
 
Cs2CO3, DMF, 50-
100 °C 
Mixture 
formed 
4 
 
 
K2CO3, acetone, 
60 °C, 4 hr 
Starting 
materials 
recovered 
5 
  
NaH, DMF, RT 41% yield 
Table 23 Range of conditions attempted for the synthesis of amine 245. 
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Scheme 48 Synthesis of amine 246. 
3.6.2  Connection of Building Blocks 
An iridium-catalysed allylic amination reaction between allylic carbonate 45 and 
amine 56 produced the alkene 57 enantioselectively on a 1 g scale.  Cbz-protection112 of 
alkene 57 on a 500 mg scale gave intermediate 247 as a mixture of rotamers.  The same 
allylic amination reaction using the alkylated amino alcohol 246 was unable to react to 
completion, producing alkene 248 in 17% yield on a 500 mg scale; this was later Cbz-
protected to produce 249.  
The allylic amination reaction using allylic carbonate 45 and azetidine was 
conducted at 40 °C instead of the 60 °C used in previous reactions.  The reduced 
temperature was implemented as well as a large excess of amine in order to prevent loss 
by evaporation of the volatile azetidine.  It was found in this instance that the undesired 
internal alkene was the only isolatable product as a result of an alternate mechanistic 
pathway (Scheme 49).  Thus, a replacement for the fragment based on intermediate 251 
was necessary (this procedure is discussed in Section 3.2). 
 
Scheme 49 Synthesis of alkenes. 
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3.6.3  Synthesis of Scaffolds 
Intermediate 57 was used in an aminoarylation reaction with 2-bromobenzoate, 
producing intermediate 58 as a mixture which was used as crude for the following 
hydrogenation step, where two major products were isolated.  The first isolated 
compound corresponded to the protonated mass of the product (617) and the second 
corresponded to an unknown compound of two mass units greater (619).  The free amine 
253 was used as crude in a base-mediated intramolecular cyclisation reaction where an 
unknown side-product was isolated that did not contain either the Boc or TBDPS group.  
An alternative route would be to avoid use of the silyl protecting group and begin 
synthesis with the oxetane decoration pre-installed on the oxygen, such as in alkene 249.  
Unfortunately, an unknown mixture was isolated from the aminoarylation reaction 
(Scheme 50).  It was decided at this stage that synthesis of fragments using iridium-
catalysed allylic aminations would be abandoned and alternatives would be generated 
(discussed in Section 3.2). 
Scheme 50 Attempted synthesis of intermediates 254 and 255. 
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4 Evaluation of a Shape-Diverse Fragment Library 
4.1  Screening of Fragment Library using X-ray Crystallography 
X-ray crystallography is an ideal screening technique because it reveals the 
experimental binding mode of weakly binding compounds, offering a useful starting point 
for fragment optimisation.  Biochemical and other biophysical techniques are also widely 
used but disadvantages include reduced sensitivity, high rates of false positives and 
screening concentrations are limited to the low micromolar range.113  In addition, hits 
generated using other biophysical techniques might yield compounds with physical 
properties that are less likely to give rise to X-ray hits.   An example of this would be where 
lower solubility fragments can be screened using ligand-detected NMR, this could yield 
hits which are more lipophilic than X-ray hits.114   
Although X-ray crystallography is ideal for detecting weakly binding fragments, it 
is a technique which has previously been time-consuming and low-throughput.   However, 
in recent years the efficiency of X-ray crystallography has increased greatly due to the 
introduction of robotics, improved algorithms and detectors, and technical advances at 
synchrotron facilities.  For example, at beamline I04-1 at Diamond Light Source (Harwell, 
UK), recent developments around soaking, harvesting and data analysis can allow the 
screening of a 1000-compound fragment library to be completed within a week.  More 
importantly, this enables the possibility of screening by soaking single compounds per 
crystal, rather than cocktails, allowing screening concentrations of >100 mM to be 
possible.113  Structure-based ligand design can then be used to improve the potency of 
fragment hits through iterative cycles of design, synthesis and screening.114 
The fragment screen used for my library was completed at Diamond Light Source 
by Dr. Daniel Foley (University of Leeds) and Patrick McIntyre (University of Leicester), 
with the assistance of Dr. Patrick Collins (Diamond Light Source) using high-throughput 
X-ray crystallography.  Protein crystals were firstly soaked with individual fragments, 
before being picked and later analysed using automated X-ray diffraction.  Fragment hits 
were confirmed through detection of additional electron density.  This process has been 
summarised in Figure 36 and has been described in more detail in Section 4.2.1.115 
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Figure 36 The screening process at Diamond Light Source, where protein crystals were grown, soaked in 
solutions of individual fragments before being picked and analysed using X-ray diffraction.  Bound fragments 
were further investigated using electron density mapping.  The screening process was conducted by 
Dr. Daniel Foley (University of Leeds) and Patrick McIntyre (University of Leicester), with the assistance of 
Dr. Patrick Collins (Diamond Light Source).115 
4.2  Aurora A Kinase as a Protein Target 
During the process of mitosis, errors in chromosome segregation can lead to 
change in the number of chromosomes, a distinct property of human tumour cells.116  
Cyclin-dependent kinases (CDKs) are renowned regulators of cell-cycle progression.   In 
addition to the CDKs, a number of other protein kinases also act as mitotic regulators, 
functioning either directly or in cooperation with CDKs.117  One example of a group of 
these is the Aurora kinase family, which has recently emerged as key mitotic regulators 
required for genome stability.   
Aurora A is a serine/ threonine kinase overexpressed in a wide range of different 
human tumours, indicating its essential role in tumour formation or progression, making 
Aurora A a useful therapeutic target.  The Aurora kinases have been conserved 
throughout eukaryotic evolution and members of this family have been studied at length 
in various model organisms.  The first discovery of Aurora A arose due to its 
overexpression in primary breast and colon tumour samples.116 
Molecules that target the active site of Aurora A often mimic the planar adenine 
base of ATP;114 previously reported inhibitors from fragment screens include ZM447439, 
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Hesperadin and VX-680.116  The binding pose of ATP within the hinge region of the protein 
can be seen in Figure 37.118  Within the active site, oxygen atoms in the ATP phosphate 
backbone are able to form hydrogen bonds (H-bonds) with adjacent polar atoms in 
residues K162, K143, D274 and N261. 
 
Figure 37 a) The binding pose of ATP (green) within the hinge region of the protein.  b) Within the active site, 
oxygen atoms in the ATP phosphate backbone are able to form H-bonds with adjacent polar atoms in residues 
K162, K143, D274 and N261, shown as black dotted lines.  Adapted from 118 
The kinase activity of Aurora A is also regulated by the binding of a protein called 
TPX2.  AurkinA was recently published as a novel chemical inhibitor of the Aurora A-TPX2 
interaction.118  AurkinA has been observed crystallographically to bind to a hydrophobic 
‘Y’-shaped pocket in the protein that normally accommodates a conserved YSY motif from 
TPX2, blocking the Aurora A-TPX2 interaction as a result (Figure 38).   
Further analysis suggests that AurkinA is able to form hydrophobic interactions 
between its quinoline and phenyl substituents and the hydrophobic base of the ‘Y’ pocket 
created by residues L178, V182, V206 and L208.  In addition, an ionic interaction is 
present between the carboxylic acid of AurkinA and the basic side chain of residue K166.  
More importantly, the binding of AurkinA to the ‘Y’ pocket has been reported to induce 
structural changes in Aurora A that inhibit catalytic activity in vitro and in cells, without 
affecting the binding of ATP to the active site, demonstrating a mechanism of allosteric 
inhibition.118 
 114 
 
  
Figure 38 a) Crystal structure of Aurora A liganded with ATP (green) and AurkinA (purple), overlayed with 
TPX2 (blue).  AurkinA is bound to the ‘Y’ pocket of Aurora A, which sits above the ATP site.  b) Detailed 
structure of AurkinA and TPX2 binding in the ‘Y’ pocket, a binding site of the YSY motif of TPX2.  c) Interaction 
of AurkinA with different residues within the ‘Y’ pocket, where hydrophobic interactions can be seen between 
its quinoline and phenyl substituents and the hydrophobic base of the cavity created by residues L178, V182, 
V206 and L208.  An ionic interaction is also present between the carboxylic acid of AurkinA and the basic side 
chain of residue K166 (shown using a black dotted line).  Adapted from 118 
4.2.1 Screening of Fragment Library against Aurora A Kinase 
All 20 Leeds fragments synthesised by myself (which will be referred to as “Leeds 
fragments” from hereon in) were screened at Diamond Light Source along with 60 
commercially purchased molecules against protein target Aurora A Kinase, using high-
throughput X-ray crystallography.  The screening team consisted of Dr. Daniel Foley 
(University of Leeds), Patrick McIntyre (University of Leicester) and Dr. Patrick Collins 
(Diamond Light Source).  Protein crystals were firstly soaked with individual fragments; 
Aurora A was used at 450 μM concentration in combination with 5mM ADP, Leeds and 
commercial fragments were soaked at 200 mM and 80 mM respectively.  The presence of 
ATP bound to the Aurora A active site increases the likelihood of fragment binding in 
alternative binding pockets.   
Crystals were then picked before being analysed using automated X-ray 
diffraction.  Diffraction data were collected on beamline I04–1 at the Diamond Light 
Source and processed using XChem Explorer and PanDDA (Pan-Dataset Density 
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Analysis).115  Fragment hits were confirmed through detection of additional electron 
density; polar and hydrophobic interactions with the protein were also identified using 
PyMOL.  
4.3  Fragment Hits against Aurora A Kinase 
4.3.1 Hit from Leeds Library against Aurora A Kinase 
214 was identified as a key novel hit against Aurora A Kinase, revealed to target 
the same site as that targeted by AurkinA, offering new opportunities for allosteric 
modulation of the enzyme.  The X-ray crystal structure of Aurora A with the ligand and 
ATP bound, as well as the detailed binding pose of 214 within the allosteric pocket can be 
seen in Figure 39.  Within the binding cavity, hydrophobic interactions were observed 
between the cyclopropyl and phenyl substituents of 214, and protein residues L169 and 
L178, respectively.  In addition, hydrogen bonding interactions can be identified between 
the amide CO of the fragment to residue K166, and the amine NH to Y199; here, the latter 
interaction is mediated by a water molecule.  More importantly, the H-bond between 
K166 and the amide CO in 214 mirrors that of the ionic interaction between the same 
residue and the carboxylic acid of Aurkin A.  The phenyl rings in both small molecules also 
exhibit hydrophobic interactions with L178 in Aurora A. 
 
Figure 39 a) The X-ray crystal structure 
of Aurora A with the bound hit 
compound 214 (green) and ATP 
(orange).  b) The detailed X-ray crystal 
structure of the allosteric binding 
pocket of Aurora A in which the hit 
molecule 214 is bound. c) A schematic 
illustration of interactions of 214 with 
nearby amino acid residues, where 
hydrophobic interactions have been 
observed between the cyclopropyl and 
phenyl substituents to L169 and L178, 
respectively, and hydrogen bonding 
interactions (≤3.5 Å) have been 
observed between the amide CO of 214 
to residue K166, and the amine NH of 
214 to Y99 via a bridging water 
molecule. 
a 
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b  c  
4.3.2 Hits from ZINC Commercial Library against Aurora A Kinase 
Nine fragments were found to target Aurora A from the library of 60 commercial 
fragments, where the fragment hits are bound to the protein with varying occupancy 
levels.  Table 24 summarises five hits which provided clear crystal densities, along with 
an evaluation of their binding modes.  The remaining fragment hits can be found in Table 
38 of the Appendix along with an observation of their respective electron densities.  Three 
of the five fragments shown in Table 24 were found to target the ‘Y’ pocket as 214 did 
(site 1); fragment 259 was observed to target a second site (site 2) on the same face of 
the protein.  Site 3 is another pocket situated on the opposite face of Aurora A, targeted 
by 260.  Figure 40 shows a comparison of sites 1-3, using exemplar fragments to 
demonstrate binding.  The binding modes of all five fragments can be seen in detail in 
Figure 41. 
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Compound Site of Target Binding Mode 
 
1 
A H-bond is observed between the amide CO and R179.  π-Stacking interactions are 
observed between the benzimidazole ring and Y199 and finally, hydrophobic interactions 
are observed between the phenyl ring and L178.   
 
1 Hydrophobic interactions are observed between the difluorophenyl ring and L178. 
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1 
A H-bond is observed between the lactam CO and Y199.  Hydrophobic interactions are also 
observed between the propyl side chain and L178, as well as between the tolyl ring and 
L169. 
 
2 
The benzene ring is observed to participate in a π-stacking interaction with F157 as well as 
an edge to face interaction with Y197. 
 
3 
Hydrophobic interactions are observed between the benzene ring and P138, as well as 
between the isoindolinone functionality and F165. 
 Table 24 Five hits from the library of 60 commercial fragments which showed clear electron densities, along with an evaluation of their binding modes. 
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Figure 40 The three different pockets in Aurora A targeted by commercial fragments (green), shown using 
example hit molecules. Here, site 1 is the ‘Y’ pocket also targeted by 214, shown using 256, site 2 is situated 
on the same face as site 1, occupied by 259 and site 3 is situated on the opposite face of the protein, occupied 
by 260. 
 
Figure 41  Binding modes of five hits (green) from the library of 60 commercial fragments which showed 
clear electron densities, targeting sites 1-3 within Aurora A.  The interactions of the fragments are described 
in detail in Table 24 and hydrogen bonds are shown using black dotted lines. 
Affinity measurements are challenging on small fragments due to their weak 
binding, as these are only starting points to a potent lead compound.  In the case of 
compounds from the ZINC commercial library, it could be argued that the better resolved 
a ligand's density, the tighter it is bound to the protein; however, other factors are 
involved which influence the final electron density of the observed crystal structures.  
Nevertheless, it is clear to say that the ‘Y’ pocket, or site 1, remains a popular allosteric 
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target site, with sites 2 and 3 being identified as a novel binding pockets.  Subsequent 
follow up by biophysical measurement of the affinity of the fragments for the protein 
would allow definitive prioritisation of hits for elaboration. 
4.4  Design of a Library of Analogues of a Hit Compound 
The electron density of 214 in the region of the binding pocket was well-defined 
and allowed scope for fragment growth.  Potential analogues of 214 were identified to 
allow optimisation of compound affinity to the allosteric cavity by exploiting structure 
activity relationships.  The retrosynthetic analysis of 214 can be seen in Scheme 51, where 
possible variation for substituents has been labelled as ‘R,’ and ‘X’ has been used in place 
of possible heteroatoms.  A range of commercially available, and functionality-compatible 
bromoaldehydes were identified to install a single substituent on the aryl ring of 214, and 
a range of cyclic amines was identified in the hope of exploring the space around its amide 
functionality.  Allylated glycine methyl ester was also used as a building block to explore 
compounds with reduced steric hindrance as well as to allow possible further decoration 
on the secondary amine functionality.  Furthermore, this would be able to confirm 
whether the presence of the isopropyl substituent on this series of compounds is 
important for the activity of the fragment. 
Modifications on 214 are summarised in Scheme 52, where different cyclic amide 
substituents (R2) can be used to explore the visible space around L169 in the ‘Y’ pocket.  
The isopropyl group (R) could also be substituted by hydrogen, which would allow further 
decoration on the adjacent secondary amine (R3) to explore the pocket in a new direction.  
R1 substitutions point downwards in the binding pocket towards L178 which could be 
explored with small groups on the arene.  In addition, by installing a nitrogen heteroatom 
on position X, it is possible to explore interactions with the adjacent Y199 in the binding 
pocket.  The proposed analogues can be seen in Scheme 53, all of which are synthesisable 
using commercially available reagents and based on established chemistry.   
The original hit 214 was remade and screened alongside intermediates 211 and 
214k.  The alkene intermediate 211 allowed the uncyclised amide precursor of 214 to be 
investigated, highlighting possible value of the cyclised hemiaminal motif within the final 
fragment.  Here, not only is 214k a precursor to analogue 214g, the Boc protecting group 
fulfils the role of an acyl decoration on the secondary amine.  Finally, the compounds 
shown in Scheme 53 were all screened as racemates. 
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Scheme 51 Retrosynthetic analysis of 214, where functionalities available for variation have been labelled 
using R groups, and X represents the presence of a possible heteroatom. 
 
Scheme 52 Modifications on 214 in different positions in order to produce a library of analogues.  These 
include varying the amino ester, bromobenzaldehyde and amine building blocks, as well as using different 
decorations on the secondary amine functionality. 
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Scheme 53 Proposed analogues of 214 to be synthesised. 
4.5  Synthesis of a Library of Analogues of a Hit Compound 
The synthetic sequence for reproduction of the original hit compound 214 can be 
seen in Scheme 54.  A slight improvement in yield was observed when changing reductive 
amination conditions from heating at 45 °C in THF to heating at reflux in DCM.  The yield 
for the Heck reaction improved from 26% to 76% by changing the catalyst and ligand 
from 10 mol% Pd(OAc)2 with PPh3 to 10 mol% Pd(PPh3)4.  Next, completing the hydrolysis 
of 199 at reflux in DMF instead of at 120 °C ensured the reaction consistently reached 
completion overnight resulting in an improved yield.  Finally, the oxidative cleavage step 
following dihydroxylation of 211 was monitored carefully and it was found that after 10 
minutes, virtually no over-oxidation to the imine occurred and thus the yield increased 
from 22% over two steps (which included an additional imine reduction, see Section 
3.4.4.3) to 49%, where the major product observed was the cyclised hemiaminal.  The 
synthetic route shown in Scheme 54 was completed on a 700 mg scale. 
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Scheme 54 Resynthesis of fragment 214. 
Reductive amination was completed on both substituted (Table 19, Entry 1 to 5) 
and unsubstituted amino esters (Table 19, Entry 6 to 9), using a range of bromoaldehydes.  
The procedure was performed in the presence of Na(OAc)3BH and 4Å MS (20% w/w), 
using DCM as the reaction solvent and by heating the mixture at reflux overnight.  In the 
case of entries 6 to 9, 274 also required the addition of 1 equiv. Et3N due to the presence 
of the hydrochloride salt.  The secondary amine products were isolated in good yields. 
Entry Amino Ester Bromoaldehyde Producta Yield / % 
1 
  
 
66 
2 
  
 
80 
3 
  
 
64 
 124 
 
4 
  
 
65 
5 
  
 
57 
6 
 
 
 
40b 
7 
 
 
 
46b 
8 
  
 
50b 
9 
 
 
 
54b 
Table 25 Yields of products from the reductive amination reaction; a) Conditions: 4Å MS, Na(OAc)3BH, DCM, 
reflux; b) Additional 1 equiv. Et3N used. 
Benzazepines and pyridoazepines were synthesised using Heck cyclisation 
reactions of both substituted (Table 26, Entry 1 to 5) and unsubstituted secondary amines 
(Table 26, Entry 6 to 9).  The catalyst used for the Heck reaction was Pd(PPh3)4 (10 mol%) 
 125 
 
in the presence of Et3N.  MeCN was used as the reaction solvent and the cyclisation 
completed after 1 hr, by heating at 125 °C under microwave conditions.  Excellent yields 
were achieved for the isopropyl substituted amines, with good yields achieved for the 
unsubstituted secondary amines. 
Entry Secondary Amine Producta Yield / % 
1 
 
 
81 
2 
 
 
88 
3 
 
 
91 
4 
 
 
92 
5 
 
 
91 
6 
 
 
57 
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7 
 
 
52 
8 
 
 
84 
9 
 
 
81 
Table 26 Yields of products from the Heck cyclisation reaction; a) Conditions: 10 mol% Pd(PPh3)4, Et3N, 
MeCN, µW, 125 °C, 1 hr. 
Amide coupling was completed on both substituted (Table 27, Entry 1 to 4) and 
unsubstituted benzazepines (Table 27, Entry 5 to 7), using a range of commercially 
available amines.  The first part of the procedure involved ester hydrolysis in the presence 
of NaOH, performed at reflux in DMF.  The harsh conditions used proved reliable, and 
necessary in the presence of the hindered centre adjacent to the ester functionality, for 
benzazepines in entries 1 to 4.  The second part of the one-pot procedure involved amide 
coupling in the presence of the desired amine, which was used in large excess, and using 
Et3N as base.  The procedure concluded with addition of the coupling agent TBTU, in order 
to avoid polymerisation of the starting material.  The reaction completed at RT overnight 
producing the desired amides in reasonable yields, except for 290 which was isolated in 
particularly high yield. 
The amide coupling of pyridoazepines 283 and 287 were unsuccessful due to the 
instability of the pyridine functionality during hydrolysis conducted at high temperatures.  
In addition, amide coupling between benzazepine 199 and 4-aminooxetane was also 
unsuccessful.  Due to time restraint, analogues 214d, 214e and 214j (see Section 4.4, 
Scheme 53) were abandoned. 
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Entry Benzazepine Amine Producta Yield / % 
1 
 
 
 
20 
2 
 
 
 
38 
3 
 
 
 
72 
4 
 
 
 
37 
5 
 
 
 
39 
6 
 
 
 
b 
7 
 
 
 
18 
Table 27 Yields of products from the amide coupling reaction; a) Conditions: 1) NaOH, DMF, reflux; 2) amine, 
Et3N, TBTU, DMF, RT; b) The crude reaction mixture was used without purification (See Table 29, Entry 2). 
Dihydroxylation followed by oxidative cleavage was completed on a range of 
substituted benzazepines (Table 28), with synthesis of fragment 214f requiring an 
additional imine reduction step as over-oxidation seemed to occur simultaneously to 
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ketone formation (see Section 3.4.4.3).  Conditions for dihydroxylation involved use of 
oxidising agent K2OsO42H2O (1mol%) in the presence of NMO.  The reaction was 
performed in an acetone-H2O solvent mixture and completed at RT overnight.   
The second part of the one-pot procedure involved oxidative cleavage of the diol 
product using 4 equiv. NaIO4 in a MeOH-H2O solvent mixture.  The reaction completed in 
10 min at room temperature and great care was taken to stop the reaction immediately 
after completion.  The desired fragments in entries 1 to 3 were isolated in good yields.  In 
the case of the benzazepine 291, over-oxidation to the imine side-product was observed 
within the same period and an extra reduction step was required to provide the final 
desired fragment in reasonable yield. 
Entry Benzazepine Producta Yield / % 
1 
  
36 
2 
  
66 
3 
  
83 
4 
 
 
16% over 
two stepsb 
Table 28 Yields of products from the dihydroxylation and oxidative cleavage reactions; a) Conditions: 1) NMO, 
1 mol% K2OsO42H2O, acetone-H2O, RT; 2) NaIO4, MeOH-H2O, RT, 10 min; b) Extra reduction step required 
due to over-oxidation to the imine side-product, conditions: 3) Na(OAc)3BH, DCM, RT. 
The same osmium-mediated dihydroxylation reaction was unsuccessful for the 
unsubstituted benzazepine 292, thus ozonolysis was attempted in order to convert the 
terminal alkene to a ketone.  Unfortunately, no identifiable product was observed.  
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Ozonolysis was then reattempted on Boc-amine 295 after protection of benzazepine 292 
on a 100 mg scale, with half of intermediate 214ka (see Scheme 56) being submitted for 
X-ray screening in order to identify any value to substitution on the secondary amine 
functionality.   
Boc-protection was later performed on a range of unsubstituted benzazepines 
(Table 29), followed by ozonolysis and finally deprotection (Table 30).  Boc-protection 
was completed in good yields in the presence of Boc2O, using DCM as reaction solvent 
with the mixture left at RT overnight.  Next, ozonolysis was completed at -78 °C-RT, using 
DCM as the reaction solvent and DMS as the reducing agent.  The final Boc-deprotection 
was performed in situ, using TFA as the reaction solvent to yield the final desired 
fragments in good to excellent yields. 
Entry Benzazepine Producta Yield / % 
1 
  
70 
2 
  
31% over 
two stepsb 
3 
  
c 
Table 29 Yields of products from Boc-protection reactions; a) Conditions: Boc2O, DCM, RT; b) See Table 27, 
Entry 6; c) The crude reaction mixture was used without purification (See Table 30, Entry 3). 
 
 
 
 
 
 
 
 
 
 130 
 
 
Entry Boc-amine Producta Yield / % 
1 
  
41 
2 
  
100 
3 
  
100% over 
two stepsb 
Table 30 Yields of products from ozonolysis and Boc-deprotection reactions; a) Conditions: 1) O3, DMS, DCM, 
-78 °C-RT, 2) TFA, RT; b) See Table 29, Entry 3. 
One notable observation was that in the case of fragments without an isopropyl 
substituent adjacent to the amide, the product favoured the open chain ketone form 
rather than the closed chain hemiaminal form.  This could be attributed to the Thorpe-
Ingold effect where the increasing number of substituents favours cyclisation to form the 
hemiaminal structure.  However, the open chain ketone form was favoured in the case 
where a larger substituent than the cyclopropyl group on the amide was present, such as 
in fragment 214ca, which contains a tetrahydropyran ring.  This is a possible result of 
steric clash between the large rings on the amide and the OH of the hemiaminal. 
The effects on the equilibrium between the open and closed chain forms of 
comparable fragments could also be due to solvent effects, where CDCl3 appears to favour 
formation of the cyclic hemiaminal and presence of MeOD appears to favour formation of 
the open chain amide, shown in Scheme 55.  A summary of the final submitted analogues, 
intermediates as well as the original hit can be seen in Scheme 56, shown as their major 
cyclised/uncyclised forms.  Fragments which were not synthesised have also been 
highlighted. 
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Scheme 55 Equilibrium observed between the open and close chain forms of fragments 214g, 214 and 214c.  
Here, the presence of the isopropyl substituent in 214 promotes formation of the cyclised hemiaminal.  
However, increased steric bulk such as from the tetrahydropyran substituent in 214ca means that the open 
chain amide form is favoured.  The solvents in which the structural NMR data was obtained have been 
indicated, as this could also affect the position of equilibrium.  
 132 
 
 
 
Scheme 56 Analogues of 214 shown as their major cyclised/uncyclised forms; A: Original hit molecule, B: 
successfully synthesised analogues, C: successfully synthesised intermediates, D: Fragments which were not 
prepared. 
4.6  Screening of Library of Analogues against Aurora A Kinase 
After conducting an X-ray screen of completed fragment analogues in Scheme 56, 
five molecules from the library were found to also target the ‘Y’ pocket of Aurora A.  Three 
of these hits showed clear electron densities and the remaining hits can be found in Table 
38 of the Appendix along with their observed electron densities.  One of the three binders 
is the resynthesized hit molecule 214, whose binding mode was replicated, another is the 
alkene precursor to 214, 211, and the final hit is a new analogue, 214b.  Within fragments 
211 and 214b, the cyclic amide substituents and benzene rings belonging to both 
compounds exhibit hydrophobic interactions towards L169 and L178, respectively.  In 
addition, a H-bond is observed between the amide CO of 214b and K166.  These binding 
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interactions can be seen crystallographically in Figure 42, as well as their overlayed 
structures with 214. 
  
Figure 42 The interactions of 214b and 211 (pink) within the Aurora A ‘Y’ binding pocket as well as the 
overlayed hits with 214 (green).  H-bonds formed between polar atoms of the fragment and nearby protein 
residues are marked using black dotted lines.  
Through initial evaluation of crystal density of the hits shown in Figure 42, 214b 
appears to be the most promising fragment within those screened against the Aurora A 
‘Y’ pocket, producing electron density with clarity comparable to that of the initial hit 
molecule 214.  Although 214b was isolated as the uncyclised ketone in its major form 
(see Section 4.5, Scheme 56), X-ray crystallography proves the active compound is in fact 
the hemiaminal structure. 
The superior crystal structure of 214b within the library of analogues is 
unsurprising since both 214b and 214 contain the cyclic hemiaminal motif.  Secondly, the 
binding poses of the two fragments overlap almost exactly, with the extra methyl 
substituent on the benzene ring of 214b reinforcing hydrophobic interactions with L178.  
In addition, the larger cyclobutyl substituent on the amide of 214b in place of the 
cyclopropyl group on 214 can further explore hydrophobic interactions with L169.  
Unsurprisingly, 211 produced weaker electron density than 214b, and little overlap 
exists between its binding pose and that of 214.  This is due to the contrasting open chain 
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amide motif of 211 as well as the lack of polar atom in the alkenic position, resulting in 
reduced potential polar interactions. 
4.6.1 Future Hit Development 
It would be worthwhile to further develop 214b into a potent lead compound, and 
one way to do this might be to explore larger substituents on the benzene ring to optimise 
hydrophobic interactions with L178 in the Aurora A ’Y’ pocket.  Overlaying the binding 
modes of commercial fragment 256 with 214b (Figure 43, a) shows an almost exact 
overlap between the benzene rings of the two fragments.  The conserved position of the 
benzene groups in the binding cavity is due to hydrophobic interactions with protein 
residue L178 as well as the H-bond observed between R179 and the amide CO of 256. 
The addition of a small methyl substituent when developing 214 to 214b simply 
grows the fragment in one plane.  However, the use of larger substitutions on the benzene 
ring would be ideal in order to explore potential π-stacking interactions, exhibited 
between the benzimidazole ring of 256 and Y199.  The position of the benzimidazole ring 
is also attributed to the amide CO of 256 interacting with R179, a useful motif to consider.  
It is clear in this case that the three-dimensional character of the molecule offers useful 
vectors along which to explore, and one of these might be functionalisation of the 
secondary amine, although challenges such as steric hindrance of the nitrogen centre 
must be considered.  Another viable position for fragment growth could be on the bridging 
CH2 of the 7-membered ring.  Possible positions for further functionalisation of 214b has 
been highlighted in yellow (Figure 43, b). 
 
Figure 43 a) The overlayed structures of commercial fragment 256 (pink) with analogue 214b (green), 
where H-bonds are shown using black dotted lines. b) Analogue 214b with key positions for further fragment 
growth highlighted in yellow.  These include using larger substituents on the benzene ring, as well as 
substitutions on the amine NH and fragment growth via the bridging CH2 of the 7-membered ring. 
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4.7  Project Summary 
Within this project, a set of 80 shape-diverse fragments was selected, 20 of which 
were synthesised using two key Leeds chemistry methodologies and 60 of which were 
purchased commercially.  These 80 molecules were successfully screened against the 
kinase target Aurora A using high-throughput X-ray crystallography.  A total of ten hits 
was identified, nine of which belonged to the ZINC commercial library and one of which 
was from the Leeds library.  The ‘Y’ binding site in Aurora A is of interest due to its known 
role in allosteric modulation of the protein target; 214 was found to target this key site 
along with five molecules from the ZINC commercial library.  Four other fragments from 
the ZINC commercial library was found to target two other novel binding sites within 
Aurora A. 
The hit compound 214 from the Leeds library was further developed through 
investigation of the ‘Y’ binding site for potential structure activity relationships.  A library 
of ten molecules was synthesized and screened as a result- seven of which were analogues 
to 214, two of which were intermediates to final fragments and one of which was the 
repeated synthesis of 214.  Five hits were identified from the X-ray screen of these ten 
molecules, in which the initial hit 214 was reconfirmed along with the alkene 
intermediate 211 and three analogue molecules.  Evaluation of crystal densities of these 
binders allowed an initial hierarchy of fragment hits to be proposed, where analogue 
214b appears to bind comparably to 214, allowing new opportunities for hit elaboration 
along useful vectors. 
4.7.1 Wider Outlook 
Based on the array of hits provided by the X-ray fragment screen it could be 
concluded that the library of 80 molecules was successful in its ability to investigate 
unexplored shape-space and present valuable hits against a worthwhile target.  However, 
since a higher hit rate was produced by the commercial library, it could be argued that the 
increased 3-dimensionality of the Leeds library has yet to prove its value.  Nevertheless, 
80 is a small number for a screening collection compared to that generally used in 
industry and it is only possible to confirm this observation when a much larger fragment 
collection is used.  In addition, it is necessary to branch out onto screening a wider range 
of targets in order to determine whether the fragments synthesised by myself add value 
to commercial fragments. 
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5 Experimental 
5.1  General Experimental 
All non-aqueous reactions were performed under an atmosphere of nitrogen.  
Solvents were removed in vacuo using a Büchi rotary evaporator and a Vacuubrand 
PC2001 Vario diaphragm pump.  THF, DCM, MeOH, EtOH, toluene and MeCN were dried 
and purified by means of a Pure Solv MD solvent purification system (Innovative 
Technology Inc.).  Anhydrous DMF, DMSO and 1,4-dioxane was obtained in Oxford 
sure/seal™ bottles from Sigma-Aldrich and all other solvents used were of 
chromatography or analytical grade.  Quantities of solvents and wash solutions were 
calculated with respect to the limiting reagent.  Commercially available starting materials 
were obtained from Acros Organics, Alfa Aesar, Fisher Scientific, Fluka, Fluorochem, 
Lancaster, Maybridge or Sigma–Aldrich.  Several isocyanides and isocyanates were 
obtained from Insight Biotechnology and the majority of screening compounds were 
sourced from Enamine. 
Ozonolysis was carried out using a LAB2B laboratory ozone generator (0.4-
0.6 psi).  Thin layer chromatography was carried out on aluminium backed silica (Merck 
silica gel 60 F254) plates supplied by Merck and visualisation of the plates was achieved 
using an ultraviolet lamp (λmax = 254 nm), and KMnO4.  Flash chromatography was carried 
out using silica gel 60 (35-70 μm particles).  Infrared spectra were recorded on a Bruker 
Alpha-P ATR FT-IR spectrometer.  Optical rotation measurements were carried out at the 
sodium D-line (589 nm) on an Optical Activity AA-1000 polarimeter instrument.  Melting 
points were determined on a Reichert hot stage microscope and are uncorrected.   
Proton, carbon and fluorine NMR data were collected on an Advance 500, Bruker 
DPX500, DPX400 and DPX300 spectrometer.  All shifts were recorded against an internal 
standard of tetramethylsilane.  CDCl3, MeOD and DMSO-d6 used for NMR experiments 
were obtained from Sigma-Aldrich.  Splitting patterns in this report have been recorded 
in an abbreviated manner; s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), 
hept (heptet) and m (multiplet).  NMR data was recorded in the following format; ppm 
(number of protons, splitting pattern, coupling constant (Hz), proton ID).  Signal 
assignments were made with the aid of DEPT 135, COSY, HMQC, HMBC and NOESY, and 
signals of substituents were assigned using the compound IUPAC name.  Where the 
compound exists as a mixture of two different forms, numbering of substituents were 
completed via their major form. 
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Low resolution mass spectra data were recorded on an Agilent 1200 series LC 
system comprising a Bruker HCT Ultra ion trap mass spectrometer, a high vacuum 
degasser, a binary pump, a high performance autosampler, an autosampler thermostat, a 
thermostated column compartment and a diode array detector.  The system used two 121 
solvent systems; MeCN–H2O + 0.1% formic acid with a Phenomenex Luna C18 50 × 2 mm 
5 micron column or MeCN–H2O with a Phenomenex Luna C18 50 × 2 mm 5 micron column.  
High resolution mass spectrometry, using electrospray ionisation, was recorded on a 
Bruker Maxis Impact. 
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5.2  General Procedures    
A. 2-Nitrobenzenesylfonyl protection 
2-Nitrobenzenesulfonyl chloride (1.0 eq.) was added to a solution of the amino 
alcohol (1.05 eq.) and Na2CO3 (1.05 eq.) in 1:1 H2O–DCM (0.8 M solution with respect to 
the limiting reagent).  The resulting mixture was stirred at room temperature overnight 
before being acidified to pH<2 and extracted with DCM (3 × ca. 10 mL/mmol).  The 
combined organic phases were washed with brine (ca. 10 mL/mmol), dried (MgSO4) and 
concentrated in vacuo to yield the crude product. 
B. Boc-protection 
Boc2O (1.0 eq.) was slowly added to a solution of the amine (1.0 eq.) in DCM (0.3 M 
solution with respect to the limiting reagent) at 0 °C and the resulting solution was 
warmed to room temperature and stirred overnight.  The residue was diluted with sat. 
K2CO3 (0.3 M solution with respect to the limiting reagent) and stirred for 2 hr to remove 
excess Boc2O, before being diluted with water.  The aqueous layer was extracted with 
DCM (3 × ca. 10 mL/mmol) and the combined organic phases were washed with sat. K2CO3 
(ca. 10 mL/mmol), water (ca. 10 mL/mmol), brine (ca. 10 mL/mmol), dried (MgSO4), and 
concentrated in vacuo to yield the crude product. 
C. Epoxide ring-opening 
A solution of 4-methoxybenzylamine (4.0 eq.) and the epoxide (1.0 eq.) was 
stirred at 60 °C for 3 hr.  The reaction mixture was diluted with 1:1 MeOH–DCM (ca. 
10 mL/mmol), filtered and the solid collected to yield the crude product. 
D. Cyclic sulfamidate ring formation 
The protected amine (1.0 eq.) in DCM (0.8 M solution with respect to the limiting 
reagent) was added slowly to a stirred solution of SOCl2 (1.1 eq.), Et3N (2.2 eq.) and 
imidazole (4.0 eq.) in DCM (0.2 M solution with respect to the limiting reagent), at –60 °C.  
The reaction mixture was stirred at –60 °C for 3 hr then at room temperature overnight, 
before being quenched with water.  The aqueous phase was extracted with DCM (3 × ca. 
10 mL/mmol) and the combined organic phases were washed with brine (ca. 
10 mL/mmol), dried (MgSO4), and concentrated in vacuo to give the crude cyclic 
sulfamidite.  The residue was dissolved in MeCN (0.3 M solution with respect to the 
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limiting reagent) and cooled to 0 °C before NaIO4 (2.0 eq.), RuCl3·3H2O (0.1 mol%) and 
water (0.3 M solution with respect to the limiting reagent) were added sequentially and 
the resulting mixture stirred for 4 hr.  The reaction mixture was diluted with water (ca. 
10 mL/mmol) and the aqueous phase was extracted with Et2O (3 × ca. 10 mL/mmol).  The 
combined organic phases were washed with brine (ca. 10 mL/mmol), dried (MgSO4), and 
concentrated in vacuo to yield the crude product. 
E. Alkynyl sulfonamide formation 
DEAD (1.3 eq.) was added to a solution of the alcohol (1.0 eq.), sulfonamide 
(1.1 eq.) and PPh3 (1.3 eq.) in THF (0.1 M solution with respect to the limiting reagent) at 
0 °C.  The resulting solution was warmed to room temperature and stirred overnight, 
before being concentrated in vacuo to give a residue which was purified by flash 
chromatography (SiO2, 25:25:50 Petrol–Et2O–CHCl3).  TFA (10 eq.) was added to a 
solution of the intermediate sulfonamide in DCM (0.1 M solution with respect to the 
limiting reagent) at room temperature and stirred overnight.  The reaction mixture was 
quenched by addition of sat. K2CO3 to pH>11 and the organic layer was extracted with 
DCM (3 × ca. 10 mL/mmol).  The combined organic phases were washed with brine (ca. 
10 mL/mmol), dried (MgSO4), and concentrated in vacuo to yield the crude product. 
F. Cyclic sulfamidate ring opening 
NaH (60% in oil, 1.1 eq.) was added to a solution of the sulfonamide (1.1 eq.) in 
DMF (0.2 M solution with respect to the limiting reagent) and stirred for 10 min.  The 
cyclic sulfamidate (1.0 eq.) was added and the resulting solution was stirred at room 
temperature overnight.  The reaction mixture was cooled to 0 °C, acidified with aq. HCl 
(5 M, 6 eq.), stirred for 1 hr and basified to pH>12 with sat. K2CO3.  The aqueous layer was 
extracted with EtOAc (3 × ca. 10 mL/mmol), the combined organic phases were washed 
with brine (ca. 10 mL/mmol), dried (MgSO4) and concentrated in vacuo to give the crude 
product. 
G. Gold-mediated alkyne hydration 
Au(IPr)Cl (1 mol%), AgSbF6 (1 mol%) and the sulfonamide (1.0 eq.) were 
combined in 1,4-dioxane (0.5 M solution with respect to the limiting reagent).  Water 
(0.8 M solution with respect to the limiting reagent) was added, and the resulting solution 
was stirred at 100 °C overnight.  The reaction mixture was cooled to room temperature 
and concentrated in vacuo to yield the crude product. 
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H. Gold-mediated hydroamination 
Au(PPh3)Cl (5 mol%), AgSbF6 (5 mol%) and the sulfonamide (1.0 eq.) were 
combined in 1,4-dioxane (0.2 M solution with respect to the limiting reagent) and stirred 
at 100 °C overnight.  The reaction mixture was cooled to room temperature and 
concentrated in vacuo to give the crude product. 
I. Allylic amination 
nBuNH2 (4 mol%) was added to a solution of [Ir(dbcot)Cl]2 (2 mol%) and 
phosphoramidite (4 mol%) in DMSO (1.0 M solution with respect to the limiting reagent).  
The mixture was stirred and heated to 60 °C for 30 min.  A solution of the allylic carbonate 
(1.0 eq.) and the amine (1.3 eq.) in DMSO (2.0 M solution with respect to the limiting 
reagent) was added and the resulting reaction mixture was stirred at 60 °C overnight, 
before being purified by basic SCX cartridge to give the crude product. 
J. Cbz-protection 
CbzCl (1.05 eq.) was added dropwise to a suspension of the amine (1.0 eq.) and 
NaHCO3 (2.0 eq.) in 1:1 THF–H2O (0.15 M solution with respect to the limiting reagent) at 
0 °C and the resulting solution was warmed to room temperature and stirred overnight.  
The reaction mixture was acidified with HCl (1M) to pH<2 and extracted with EtOAc (3 × 
ca. 10 mL/mmol).  The combined organic phases were washed with brine (ca. 
10 mL/mmol), dried (MgSO4) and concentrated in vacuo to give the crude product.   
K. Ugi reaction 
TFA (6.0 eq.) was added to a solution of the substrate (1.0 eq.) in DCM (0.1 M 
solution with respect to the limiting reagent) at room temperature, and stirred overnight.  
The crude reaction mixture was concentrated in vacuo to give an intermediate TFA salt.  
The isocyanide (2.0 eq.) was added to a solution of the salt in EtOH (0.05 M solution with 
respect to the limiting reagent) at 0 °C and stirred at room temperature overnight.  The 
reaction mixture was concentrated in vacuo to give the crude product. 
L. Trifluoroacetamide reduction 
NaBH4 (7.0 eq.) was added to a solution of the protected diazepane (1.0 eq.) in 
MeOH (0.1 M solution with respect to the limiting reagent) at 0 °C.  The reaction mixture 
was stirred at room temperature overnight before the solvent was removed in vacuo and 
the residue was treated with water (ca. 10 mL/mmol).  The aqueous layer was extracted 
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with EtOAc (3 × ca. 10 mL/mmol) and the combined organic phases were dried (MgSO4) 
and concentrated in vacuo. 
M. Reductive amination 
The aldehyde (4.0 eq. if commercial, 1.0 eq. if novel) and NaBH(OAc)3 (6.0 eq.) was 
added to a solution of the amine (1.0 eq. if novel, 4.0 eq. if commercial) in DCM (0.1 M 
solution with respect to the limiting reagent), and the reaction was stirred at room 
temperature overnight.  Water (ca. 10 mL/mmol) was added and the aqueous layer was 
extracted with DCM (3 × ca. 10 mL/mmol).  The combined organic phases were washed 
with brine (ca. 10 mL/mmol), dried (MgSO4) and concentrated in vacuo. 
N. Reductive amination (II) 
The aldehyde (2.0 eq.) was added to a mixture of the amino ester (1.0 eq.) in DCM 
(0.1 M solution with respect to the limiting reagent) in the presence of 4 Å mol. sieves (0.2 
w/w).  NaBH(OAc)3 (6.0 eq.) was added and the mixture stirred at reflux overnight.  Water 
(ca. 10 mL/mmol) was added and the aqueous layer was extracted with DCM (3 × ca. 
10 mL/mmol).  The combined organic layers were washed with water (ca. 10 mL/mmol), 
dried (MgSO4) and concentrated in vacuo.   
O. 2-Nitrobenzenesulfonyl deprotection 
K2CO3 (1.5 eq.) was added to a stirred solution of the protected diazepane (1.0 eq.) 
and PhSH (1.5 eq.) in MeCN (0.1 M solution with respect to the limiting reagent), and the 
mixture was stirred at room temperature until completion was observed by TLC.  Excess 
K2CO3 was removed by filtration and the reaction mixture was concentrated in vacuo to 
yield the crude product. 
P. Amino ester allylation 
Benzaldehyde (1.0 eq.) was added to a suspension of the methyl ester 
hydrochloride (1.0 eq.), Et3N (1.0 eq.) and 4 Å mol. sieves (0.2 w/w) in THF (0.2 M solution 
with respect to the limiting reagent).  The reaction mixture was stirred overnight before 
being filtered and concentrated in vacuo.  The residue was dissolved in THF (0.2 M 
solution with respect to the limiting reagent) and LiHMDS (1 M in THF, 3.0 eq.) was added 
dropwise at -78 °C.  The reaction mixture was stirred for 15 min then allyl iodide (1.5 eq.) 
was added dropwise.  The reaction mixture was stirred at -78 °C for 1 hr and at room 
temperature overnight.  Citric acid (30 wt% in water, 0.2 M solution with respect to the 
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limiting reagent) was added and the reaction was stirred for 1 hr before being partitioned 
with Et2O (3 × ca. 10 mL/mmol).  The aqueous layer was neutralised with NaHCO3(s) and 
extracted with DCM (3 × ca. 10 mL/mmol).  The combined organic layers were dried 
(MgSO4) and concentrated in vacuo to give the crude product. 
Q. Urea formation 
Et3N (2 eq.) and the isocyanate (1.5 eq.) were added to a solution of the amine 
(1.0 eq.) in DCM (0.1 M solution with respect to the limiting reagent) at 0 °C.  The reaction 
mixture was stirred for 1 hr at 0 °C and then at room temperature overnight.  The reaction 
mixture was diluted with water (ca. 10 mL/mmol) and the aqueous layer was extracted 
with DCM (3 × ca. 10 mL/mmol).  The combined organic layers were washed with water 
(ca. 10 mL/mmol), brine (ca. 10 mL/mmol), dried (MgSO4) and concentrated in vacuo to 
give the crude product. 
R. Hydantoin formation 
NaOtBu (1.0 eq.) was added to a solution of the urea (1.0 eq.) in toluene (0.1 M 
solution with respect to the limiting reagent) and the reaction mixture was stirred at 
100 °C for 8 hr, before being concentrated in vacuo to give the crude product. 
S. Heck reaction 
Et3N (2.5 eq.) was added to a stirred solution of the amino ester (1.0 eq.) and 
Pd(PPh3)4 (10 mol%) in MeCN (0.1 M solution with respect to the limiting reagent).  The 
reaction mixture was heated at 125 °C under µW for 1 hr before being concentrated in 
vacuo. 
T. Acylation 
Et3N (2.0 eq.) was added to a solution of the amine (1.0 eq.) and the acid chloride 
(2.0 eq.) in DCM (0.4 M solution with respect to the limiting reagent) at 0 °C.  DMAP (1 
mol%) was added and the reaction was stirred at room temperature overnight.  The 
solvent was removed in vacuo to give the crude product. 
U. Ozonolysis 
The alkene (1.0 eq.) was dissolved in DCM (0.1 M solution with respect to the 
limiting reagent) and O3 was bubbled through the solution at -78 °C until saturation was 
indicated by the appearance of a blue solution, and then stirred for a further 10 min.  The 
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solution was purged with O2 until it turned colourless, before DMS (1.1 eq.) was added 
and the reaction mixture stirred overnight.   Water (ca. 10 mL/mmol) was added and the 
aqueous layer was extracted with DCM (3 × ca. 10 mL/mmol), the combined organic 
layers were dried (MgSO4) and concentrated in vacuo to give the crude product. 
V. Amide coupling 
The amino ester (1.0 eq.) was dissolved in DMF (0.1 M solution with respect to the 
limiting reagent) and NaOH (6.0 eq.) was added.  The reaction mixture was stirred at 
reflux overnight before being cooled to room temperature.  Et3N (3.0 eq.) and the amine 
(10 eq.) was added to the solution, before TBTU (1.5 eq.) was then added and the reaction 
mixture stirred overnight.  Water (ca. 10 mL/mmol) and EtOAc (ca. 10 mL/mmol) were 
added and the aqueous layer was extracted with EtOAc (3 × ca. 10 mL/mmol).  The 
combined organic layers were washed with water (3 × ca. 10 mL/mmol), brine (3 × ca. 
10 mL/mmol), dried (MgSO4) and concentrated in vacuo. 
W. Osmium-mediated dihydroxylation and oxidative cleavage 
Potassium osmate dihydrate (1 mol%) was added to a solution of the alkene 
(1.0 eq.) and NMO (1.3 eq.) in a mixture of acetone (0.7 M solution with respect to the 
limiting reagent) and water (6 M solution with respect to the limiting reagent), and the 
mixture was stirred overnight at room temperature.  Sodium hydrosulfite (ca. 
100  mg/mmol) was added and the mixture stirred for 30 min before being filtered 
through Celite.  The filtrate was concentrated in vacuo and dissolved in a mixture of MeOH 
(0.5 M solution with respect to the limiting reagent) and water (5 M solution with respect 
to the limiting reagent).  NaIO4 (1.5 eq.) was added and the reaction mixture stirred 
overnight, before being concentrated in vacuo to yield the crude product. 
X. Osmium-mediated dihydroxylation and oxidative cleavage (II) 
Potassium osmate dihydrate (1 mol%) was added to a solution of the alkene 
(1.0 eq.) and NMO (1.3 eq.) in a mixture of acetone (0.7 M solution with respect to the 
limiting reagent) and water (6 M solution with respect to the limiting reagent), and the 
mixture was stirred overnight at room temperature.  Sodium hydrosulfite (ca. 
100 mg/mmol) was added and the mixture stirred for 30 min before being filtered 
through Celite.  The filtrate was concentrated in vacuo and dissolved in a mixture of MeOH 
(0.5 M solution with respect to the limiting reagent) and water (5 M solution with respect 
to the limiting reagent).  NaIO4 (4.0 eq.) was added and the reaction mixture stirred for 
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ten minutes before water (ca. 10 mL/mmol) and EtOAc (ca. 10 mL/mmol) were added.  
The aqueous layer was extracted with EtOAc (3 × ca. 10 mL/mmol) and the combined 
organic layers were washed with water (ca. 10 mL/mmol), brine (ca. 10 mL/mmol), dried 
(MgSO4) and concentrated in vacuo.    
Y. Boc-deprotection 
The protected amine (1 eq.) was dissolved in TFA (0.1 M solution with respect to 
the limiting reagent) and stirred at room temperature overnight.  The reaction mixture 
was concentrated in vacuo and purified by basic SCX cartridge.
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5.3 High-Throughput Protein Crystallography 
High-throughput protein crystallography was completed at Diamond Light Source 
(Harwell, UK) by Dr. Daniel Foley (University of Leeds) and Patrick McIntyre (University 
of Leicester), with the assistance of Dr. Patrick Collins (Diamond Light Source). 
Protein crystals were soaked with individual fragments; Aurora A was used at 
450 μM concentration in combination with 5mM ADP.  The protein buffer used was 20 
mM tris at pH 7.0, 200 mM NaCl, 5 mM MgCl2 and 10% glycerol.  The protein solution was 
mixed in a 1:1 ratio with the crystallisation buffer which contained 100 mM tris at pH 8.5, 
500 mM NaCl, 200 mM MgCl2 and 32.5% PEG 3350.  The stock concentration of the 
commercial fragments was 200 mM, soaked at a final concentration of 80 mM, and the 
stock concentration of the Leeds fragments was 500 mM, soaked at a final concentration 
of 200 mM.  Both sets of compounds contained 40% deuterated DMSO. 
200 nL droplets were used for diffraction and image resolution was 2.2 Å on 
average.  X-ray diffraction data were collected on beamline I04–1 at the Diamond Light 
Source and processed using XChem Explorer and PanDDA (Pan-Dataset Density 
Analysis).115   Where racemates were screened, both enantiomers were fitted to the 
electron density in the PanDDA event maps using COOT (Crystallographic Object-
Oriented Toolkit),119 then the enantiomer with the best fit was chosen. 
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5.4 Synthesis of Building Blocks  
(2R)-1-(4-Methylbenzenesulfonyl)-2-phenylaziridine, 225 
 
Tosyl chloride (3.06 g, 16.0 mmol) was added slowly to a solution of (R)-2- 
phenylglycinol (1.00 g, 7.29 mmol) and K2CO3 (4.03 g, 29.2 mmol) in MeCN (70 mL, 0.1 M) 
and stirred at room temperature overnight.  Toluene (35 mL) was added and any solid 
was removed by filtration.  The filtrate was concentrated in vacuo to give a crude residue 
which was purified by flash chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the 
aziridine120 225 (1.21 g, 61%) as a white solid, Rf = 0.53 (40:60 Petrol–EtOAc); δH (500 
MHz, CDCl3) 7.64 (2H, d, J 8.3, tolyl 2-H and tolyl 6-H), 7.25-7.22 (3H, m, phenyl 3-H, phenyl 
4-H and phenyl 5-H), 7.20 (2H, d, J 8.3, tolyl 3-H and tolyl 5-H), 7.12 (2H, dd, J 6.3 and 3.2, 
phenyl 2-H and phenyl 6-H), 5.50 (1H, d, J 6.7, 3-Ha), 4.44 (1H, dd, J 11.4 and 6.7, 3-Hb), 
3.79-3.76 (1H, m, 2-H) and 2.40 (3H, s, methyl); δC (126 MHz, CDCl3) 143.4 (tolyl C-1), 
137.6 (tolyl C-4), 137.1 (phenyl C-1), 129.5 (phenyl C-3 and phenyl C-5), 128.6 (phenyl C-
2 and phenyl C-6), 128.0 (phenyl C-4), 127.2 (tolyl C-2 and tolyl C-6), 126.9 (tolyl C-3 and 
tolyl C-5), 66.3 (C-2), 59.5 (C-3) and 21.5 (methyl). 
4-Methyl-N-[(1R)-2-{[(1S, 2S)-2-{[(2R)-2-(4-methylbenzenesulfonamido)-2-
phenylethyl] amino}-1,2-diphenylethy]amino}-1-phenylethyl]benzene-1-
sulfonamido, 226 
 
(1S, 2S)-1,2-diphenylethane-1,2-diamine (471 mg, 2.22 mmol) was added to the 
aziridine 225 (1.21 g, 4.43 mmol) in MeCN (50 mL, ~0.1 M) and stirred at reflux overnight.  
The solvent was removed in vacuo to give the tetramine121 226 (1.68 g, 100%) as a bright 
yellow solid which was used without purification, Rf = 0.72 (80:20 Petrol–EtOAc); δH (500 
MHz, CDCl3) 7.63 (4H, d, J 8.2, tolyl 2-H2 and tolyl 6-H2), 7.33-7.25 (10H, m, ethylphenyl 2-
H2, ethylphenyl 3-H2, ethylphenyl 5-H2, ethyldiphenyl 3-H2 and ethyldiphenyl 5-H2), 7.25-
7.21 (6H, m, ethylphenyl 6-H2, ethyldiphenyl 2-H2 and ethyldiphenyl 6-H2), 7.19 (4H, d, J 
8.2, tolyl 3-H2 and tolyl 5-H2), 7.15-7.09 (4H, m, ethylphenyl 4-H2 and ethyldiphenyl 4-H2), 
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4.48-4.39 (2H, m, phenylethyl 1-H2), 4.12 (2H, s, diphenylethyl 1-H2), 3.79-3.70 (4H, m, 
phenylethyl 2-H4) and 2.40 (6H, s, methyl), analysis given to one of the two identical 
halves of the molecule; δC (126 MHz, CDCl3) 143.3 (tolyl C-1), 143.0 (ethylphenyl C-1), 
137.7 (ethyldiphenyl C-1), 137.2 (tolyl C-4), 129.5 (tolyl C-2 and tolyl C-6), 128.6 
(ethylphenyl C-3 and ethylphenyl C-5), 128.3 (ethyldiphenyl C-3 and ethyldiphenyl C-5), 
127.9 (ethylphenyl C-4,), 127.2 (ethylphenyl C-2 and ethylphenyl C-6), 127.2 
(ethyldiphenyl C-4), 126.9 (ethyldiphenyl C-2 and ethyldiphenyl C-6), 126.9 (tolyl C-3 and 
tolyl C-5), 66.1 (phenylethyl C-2), 61.8 (diphenylethyl C-1), 59.6 (phenylethyl C-1) and 
21.5 (methyl), analysis given to one of the two identical halves of the molecule. 
(1R)-1-Cyclopropyl-2-nitroethan-1-ol, 228 
 
The ligand 226 (330 mg, 2.5 mol%) and Cu(OAc)2H2O (86.8 mg, 2.5 mol%) were 
suspended in EtOH (30 mL, ~0.5 M) and stirred at room temperature for 30 min.  
Cyclopropyl carboxaldehyde (1.29 mL, 17.2 mmol), then nitromethane (9.32 mL, 
172 mmol) were added and stirred overnight.  The reaction mixture was concentrated in 
vacuo and purified by flash chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the 
nitroalcohol 228 (670 mg, 30%) as a colourless oil, Rf = 0.55 (60:40  Petrol–EtOAc); 
νmax/ cm-1 (ATR) 3397 (br), 3010, 1247, 1378, 1079, 1051 and 1024; [α]D24 −0.19 (c = 1.90, 
CHCl3); δH (500 MHz, CDCl3) 4.58-4.48 (2H, m, 2-H2), 3.65 (1H, td, J 8.2 and 4.1, 1-H), 2.96 
(1H, br s, OH), 1.00-0.87 (1H, m, cyclopropyl 1-H), 0.66-0.56 (2H, m, cyclopropyl 2-H2), 
0.48-0.43 (1H, m, cyclopropyl 3-Ha) and 0.36-0.30 (1H, m, cyclopropyl 3-Hb); δC (126 MHz, 
CDCl3) 80.4 (C-2), 73.0 (C-1), 14.3 (cyclopropyl C-1), 3.1 (cyclopropyl C-2) and 2.2 
(cyclopropyl C-3); HRMS found [2M]H+, 263.1544.  C5H9NO3 requires [2M]H, 263.1242.   
ee. not determined in this case; an example ee. can be seen in literature122. 
(1R)-2-Amino-1-cyclopropylethan-1-ol, 229 
 
NaBH4 (1.03 g, 27.2 mmol) was added to a suspension of nitroalcohol 228 
(890 mg, 6.79 mmol) and Pd/C (361 mg, 5 mol%) in 1:1 MeOH–THF (70 mL, 0.1 M) at 0 °C.  
The reaction mixture was stirred at 0 °C for 2 hr and then at room temperature overnight, 
before being filtered through Celite and washed with MeOH.  The filtrate was 
concentrated in vacuo and the residue was purified by flash chromatography (SiO2, 20:80 
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sat. NH3 in MeOH–DCM) to yield the amino alcohol 229 (450 mg, 66%) as a colourless oil, 
Rf = 0.63 (30:70 sat. NH3 in MeOH–DCM); [α]D24 −0.87 (c = 0.51, CHCl3); νmax/ cm-1 (ATR) 
3348 (br), 2954, 1643, 1393, 1274, 1121 and 1017; δH (500 MHz, CDCl3) 2.74 (1H, d, J 11.1, 
2-Ha), 2.64 (1H, td, J 8.2 and 3.3, 1-H), 2.51 (1H, dd, J 11.1 and 8.2, 2-Hb), 1.84 (3H, br s, 
NH2 and OH), 0.74-0.56 (1H, m, cyclopropyl 1-H), 0.36-0.23 (2H, m, cyclopropyl 2-H2), 
0.13 (1H, ddd, J 8.9, 6.6 and 4.0, cyclopropyl 3-Ha) and 0.00 (1H, dt, J 8.9 and 4.7, 
cyclopropyl 3-Hb); δC (126 MHz, CDCl3) 76.7 (C-1), 47.3 (C-2), 15.0 (cyclopropyl C-1), 2.4 
(cyclopropyl C-2) and 1.8 (cyclopropyl C-3). 
(2R)-2-Cyclopropyl-2-hydroxy-5-(4-nitrophenyl)ethane-1-sulfonamido, 230 
 
By general procedure A, amino alcohol 229 (160 mg, 1.58 mmol) gave the 
protected amino alcohol 230 (370 mg, 86%) as a yellow oil which was used without 
further purification, Rf = 0.54 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3527 (br), 3342 (br), 
2883, 1537, 1360, 1337 and 1163; [α]D25 0.11 (c = 0.53, CHCl3); δH (500 MHz, CDCl3) 8.19-
8.15 (1H, m, nitrophenyl 3-H), 7.93-7.87 (1H, m, nitrophenyl 6-H), 7.81-7.74 (2H, m, 
nitrophenyl 4-H and nitrophenyl 5-H), 5.82 (1H, t, J 4.3, NH), 3.39 (1H, ddd, J 12.6, 7.5 and 
4.3, 1-Ha), 3.16 (1H, ddd, J 12.6, 7.5 and 4.3, 1-Hb), 3.06 (1H, td, J 7.5 and 3.3, 2-H), 1.89 
(1H, br s, OH), 0.99-0.84 (1H, m, cyclopropyl 1-H), 0.60-0.51 (2H, m, cyclopropyl 2-H2), 
0.37-0.32 (1H, m, cyclopropyl 3-Ha) and 0.29-0.25 (1H, m, cyclopropyl 3-Hb); δC (126 MHz, 
CDCl3) 148.1 (nitrophenyl C-2), 133.64 (nitrophenyl C-1), 133.58 (nitrophenyl C-5), 132.7 
(nitrophenyl C-4), 131.1 (nitrophenyl C-6), 125.4 (nitrophenyl C-3), 75.0 (C-2), 48.9 (C-1), 
15.1 (cyclopropyl C-1), 2.7 (cyclopropyl C-2) and 2.3 (cyclopropyl C-3); HRMS found MH+, 
287.0693.  C11H14N2O5S requires MH, 287.0701. 
(3R)-3-Amino-4-methylpetan-1-ol, 218 
 
Homovaline (2.50 g, 19.1 mmol) in THF (50 mL, ~0.4 M) was added dropwise to 
LiAlH4 (7.20 g, 191 mmol) in THF (150 mL, ~0.1 M) at 0 °C.  The reaction mixture was 
warmed to reflux and heated at reflux overnight before being cooled to 0 °C.  The reaction 
mixture was quenched with water (8 mL), followed by 4 M NaOH (8 mL), then water 
(24 mL), and stirred for 30 min.  The mixture was filtered and the filtrate concentrated in 
vacuo to give a residue which was purified by flash chromatography (SiO2, 15:85 sat. NH3 
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in MeOH–DCM) to yield the amino alcohol123 218 (370 mg, 17%) as a colourless 
amorphous solid, Rf = 0.42 (20:80 sat. NH3 in MeOH–DCM); δH (500 MHz, CDCl3) 3.81-3.68 
(2H, m, 1-H2), 2.77 (3H, br s, NH2, OH), 2.63 (1H, ddd, J 10.5, 5.0 and 2.7, 3-H), 1.59-1.48 
(2H, m, 2-H2), 1.47-1.36 (1H, m, 4-H), 0.84 (3H, d, J 6.7, 5-H3) and 0.81 (3H, d, J 6.7, methyl); 
δC (126 MHz, CDCl3) 62.6 (C-1), 57.8 (C-3), 35.1 (C-4), 34.6 (C-2), 18.6 (C-5) and 17.2 
(methyl); m/z (ES) 118.2 (80%, MH+) and 217.3 (100%). 
(3R)-1-Hydroxy-4-methyl-S-(2-nitrophenyl)pentane-3-sulfonamido, 219 
 
By general procedure A, amino alcohol 218 (370 mg, 3.16 mmol) gave the 
protected amino alcohol 219 (660 mg, 69%) as a colourless solid which was used without 
further purification, m.p. 110-112 °C; Rf = 0.38 (40:60  Petrol–EtOAc); νmax/ cm-1 (ATR) 
3339 (br), 2962, 2877, 1539, 1362, 1164 and 600; [α]D28 152 (c = 0.23, CHCl3); δH 
(500 MHz, CDCl3) 8.20-8.12 (1H, m, nitrophenyl 3-H), 7.93-7.86 (1H, m, nitrophenyl 6-H), 
7.81-7.68 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 5.36 (1H, d, J 9.0, NH), 3.93-3.78 
(1H, m, 3-H), 3.77-3.67 (1H, m, 1-Ha), 3.64-3.51 (1H, m, 1-Hb), 2.18 (1H, t, J 6.0, OH), 1.85-
1.77 (1H, m, 2-Ha), 1.77-1.70 (1H, m, 2-Hb), 1.60-1.49 (1H, m, 4-H), 0.85 (3H, d, J 6.9, 5-H3) 
and 0.77 (3H, d, J 6.8, methyl); δC (126 MHz, CDCl3) 147.9 (nitrophenyl C-2), 135.4 
(nitrophenyl C-1), 133.2 (nitrophenyl C-5), 132.7 (nitrophenyl C-4), 130.3 (nitrophenyl 
C-6), 125.2 (nitrophenyl C-3), 58.8 (C-1), 57.6 (C-3), 35.1 (C-2), 32.3 (C-4), 18.7 (C-5) and 
17.8 (methyl); HRMS found MH+, 303.1020.  C12H18N2O5S requires MH, 303.1014. 
(S)-2-Amino-2-cyclopropylethanol, 221 
 
L-Cyclopropylglycine (0.380 mL, 4.30 mmol) was dissolved in THF (5 mL, 1 M) 
and cooled to 0 °C.  LiAlH4 (8.69 mL, 1 M in THF) was added dropwise and the reaction 
mixture warmed to room temperature and stirred at room temperature overnight.  Water 
(5 mL) was added to quench the reaction mixture along with Celite (1 g), before any solid 
was removed by filtration through a pad of Celite.  The filtrate was concentrated in vacuo 
to yield the amino alcohol124 221 (242 mg, 55%) as a yellow oil which was used without 
further purification, νmax/ cm-1 (ATR) 3349 (br), 3280, 3002, 2862, 1584, 1372, 1049 and 
1017; δH (300 MHz, CDCl3) 3.69 (1H, dd, J 10.6 and 3.9, 1-Ha), 3.44 (1H, dd, J 10.6 and 7.8, 
1-Hb), 2.10 (1H, ddd, J 8.8, 7.8 and 3.9, 2-H), 1.99 (3H, br s, NH2, OH), 0.82-0.65 (1H, m, 
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cyclopropyl 1-H), 0.54-0.43 (2H, m, cyclopropyl 2-H2) and 0.25-0.13 (2H, m, cyclopropyl 
3-H2); δC (126 MHz, CDCl3) 66.8 (C-1), 57.9 (C-2), 15.2 (cyclopropyl C-1), 2.5 (cyclopropyl 
C-2) and 2.2 (cyclopropyl C-3); HRMS found MH+, 102.0909.  C5H11NO requires MH, 
102.0919. 
 (1S)-1-Cyclopropyl-2-hydroxy-S-(2-nitrophenyl)ethane-1-sulfonamido, 55 
 
By general procedure A, amino alcohol 221 (242 mg, 2.39 mmol) gave the 
protected amino alcohol 55 (513 mg, 79%) as a brown oil which was used without further 
purification, Rf = 0.38 (40:60  Petrol–EtOAc); νmax/ cm-1 (ATR) 3345 (br), 3008, 2883, 1539, 
1361, 1164 and 589; [α]D28 68 (c = 0.097, CHCl3); δH (500 MHz, CDCl3) 8.21-8.15 (1H, m, 
nitrophenyl 3-H), 7.95-7.91 (1H, m, nitrophenyl 6-H), 7.82-7.75 (2H, m, nitrophenyl 4-H 
and nitrophenyl 5-H), 5.79 (1H, d, J 6.8, NH), 3.79 (1H, dd, J 11.3 and 3.8, 2-Ha), 3.72 (1H, 
dd, J 11.3 and 5.5, 2-Hb), 2.82-2.72 (1H, m, 1-H), 2.04 (1H, br s, OH), 1.05-0.92 (1H, m, 
cyclopropyl 1-H), 0.63-0.51 (1H, m, cyclopropyl 2-Ha), 0.44-0.33 (1H, m, cyclopropyl 2-
Hb), 0.27 (1H, td, J 10.1 and 5.0, cyclopropyl 3-Ha) and 0.00 (1H, td, J 10.2 and 5.0, 
cyclopropyl 3-Hb); δC (126 MHz, CDCl3) 148.0 (nitrophenyl C-2), 135.1 (nitrophenyl C-1), 
133.3 (nitrophenyl C-5), 132.6 (nitrophenyl C-4), 130.8 (nitrophenyl C-6), 125.3 
(nitrophenyl C-3), 65.3 (C-2), 61.8 (C-1), 13.2 (cyclopropyl C-1), 3.52 (cyclopropyl C-2) 
and 3.48 (cyclopropyl C-3); HRMS found MH+, 287.0695.  C11H14N2O5S requires MH, 
287.0701. 
3-Hydroxy-S-(2-nitrophenyl)propane-1-sulfonamido, 223 
 
By general procedure A, 3-amino-1-propanol (0.510 mL, 6.66 mmol) gave the 
protected amino alcohol 223 (1.34 g, 81%) as a colourless oil which was used without 
further purification, Rf = 0.24 (40:60  Petrol–EtOAc); νmax/ cm-1 (ATR) 3329 (br), 2946, 
2884, 1537, 1334, 1161 and 588; δH (500 MHz, CDCl3) 8.07-7.99 (1H, m, nitrophenyl 3-H), 
7.78-7.72 (1H, m, nitrophenyl 6-H), 7.68-7.59 (2H, m, nitrophenyl 4-H and nitrophenyl 5-
H), 5.74 (1H, t, J 5.4, NH), 3.66 (2H, t, J 5.4, 1-H2), 3.15 (2H, q, J 6.1, 3-H2) and 1.73-1.61 (2H, 
m, 2-H2); δC (126 MHz, CDCl3) 148.2 (nitrophenyl C-2), 133.9 (nitrophenyl C-1), 133.4 
(nitrophenyl C-5), 132.6 (nitrophenyl C-4), 131.0 (nitrophenyl C-6), 125.2 (nitrophenyl 
C-3), 60.3 (C-1), 41.4 (C-3) and 31.8 (C-2); HRMS found MH+, 261.0560.  C9H12N2O5S 
requires MH, 261.0545. 
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tert-Butyl(3-hydroxypropyl)carbamate, 238 
 
By general procedure B, 3-amino-propanol (10.0 g, 133 mmol) gave the protected 
amino alcohol125 238 (23.3 g, 100%) as a colourless oil which was used without further 
purification, Rf = 0.31 (30:70  Petrol–EtOAc);  νmax/ cm-1 (ATR) 3354 (br), 2937, 1691, 1531 
and 1173;  δH (500 MHz, CDCl3) 4.98 (1H, s, NH), 3.61 (2H, q, J 5.9, 3-H2), 3.37 (1H, t, J 5.9, 
OH), 3.23 (2H, q, J 5.9, 1-H2), 1.63 (2H, quint, J 5.9, 2-H2) and 1.40 (9H, s, Boc);  δC (126 
MHz, CDCl3) 157.2 (CO), 79.6 (Boc), 59.4 (C-3), 37.1 (C-1), 32.9 (C-2) and 28.5 (Boc); m/z 
(ES) 198.1 (100%, MNa+).  
tert-Butyl N-(2-hydroxyethyl)carbamate, 89 
 
By general procedure B, ethanolamine (9.88 mL, 164 mmol) gave the protected 
amino alcohol125 89 (25.1 g, 95%) as a yellow oil which was used without further 
purification, Rf = 0.30 (50:50 Petrol–EtOAc);  νmax/cm-1  (ATR) 3336, 2977, 1685, 1514, 
1167 and 1066;  δH (500 MHz, CDCl3) 5.08 (1H, br s, NH), 3.70 (2H, q, J 4.9, 2-H2), 3.29 (2H, 
q, J 4.9, 1-H2), 2.87 (1H, br s, OH) and 1.46 (9H, s, Boc); δC (126 MHz, CDCl3) 146.9 (CO), 
85.3 (Boc), 62.7 (C-2), 43.3 (C-1) and 28.5 (Boc); m/z (ES) 184.0 (100%, MNa+). 
tert-Butyl(1,3-dihydroxypropan-2-yl)carbamate, 94 
 
By general procedure B, serinol (10.0 g, 110 mmol) gave a crude residue which 
was purified by flash chromatography (SiO2, 10:90 MeOH–DCM) to yield Boc-serinol44 94 
(11.1 g, 53%) as a colourless amorphous solid, Rf = 0.35 (100% EtOAc); δH (500 MHz, 
CDCl3) 5.35 (1H, d, J 7.6, 2-H), 3.87-3.79 (2H, m, 1-H2), 3.79-3.72 (2H, m, 3-H2), 3.69 (1H, 
br s, NH), 3.26 (2H, br s, OH) and 1.47 (9H, s, Boc); δC (126 MHz, CDCl3) 156.4 (CO), 80.0 
(Boc), 63.4 (C-1 and C-3), 53.1 (C-2) and 28.4 (Boc); m/z (ES) 214.0 (100%, MNa+). 
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2-{[(tert-Butoxy)carbonyl]amino}-3-hydroxypropyl acetate, 95 
 
Acetic anhydride (6.58 mL, 69.7 mmol) was added dropwise to a solution of the 
carbamate (11.1 g, 57.9 mmol) and Et3N (16.1 mL, 116 mmol) in DCM (550 mL, 0.1 M) at 
0 °C and the resulting solution was stirred at 0 °C for 2 hr.  The reaction mixture was 
warmed to room temperature, quenched by addition of aq. HCl (1 M) to pH<2 and 
extracted with DCM (3 × 300 mL).  The combined organic phases were washed with brine 
(300 mL), dried (MgSO4) and concentrated in vacuo.  The residue was purified by flash 
chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the acetylated amino alcohol44 95 
(8.36 g, 62%) as a colourless oil, Rf = 0.57 (30:70 Petrol–EtOAc); δH (500 MHz, CDCl3) 5.04-
5.05 (1H, m, 2-H), 4.21 (2H, d, J 5.6, 1-H2), 3.90 (1H, br s, NH), 3.72-3.66 (1H, m, 3-Ha), 
3.66-3.60 (1H, m, 3-Hb), 2.81 (1H, br s, OH), 2.10 (3H, s, methyl) and 1.46 (9H, s, Boc); δC 
(126 MHz, CDCl3) 171.4 (acetyl CO), 155.8 (Boc CO), 79.9 (Boc), 63.1 (C-1), 61.9 (C-3), 51.1 
(C-2), 28.3 (Boc) and 20.8 (methyl); m/z (ES) 256.0 (100%, MNa+). 
(R)-1-N[(1,1-dimethylethoxy)carbonyl]amino-2-propanol, 91 
 
By general procedure B, (R)-(-)-1-amino-2-propanol (10.4 mL, 133 mmol) gave 
the protected amino alcohol 91 (23.3 g, 100%) as a yellow oil, which was used without 
further purification, Rf = 0.52 (30:70 Petrol–EtOAc);  νmax/ cm-1 (ATR) 3343 (br), 2976, 
1684, 1520, 1366, 1249 and 1168; [α]D27 −11 (c = 1.1, MeOH); δH (500 MHz, CDCl3) 5.12 
(1H, br s, NH), 3.99-3.79 (1H, m, 1-Ha), 3.41-3.17 (1H, m, 1-Hb), 3.12-2.86 (2H, m, 2-H and 
OH), 1.45 (9H, s, Boc) and 1.17 (3H, d, J 6.3, 3-H3); δc (126 MHz, CDCl3) 156.8 (CO), 79.5 
(Boc), 67.5 (C-2), 48.0 (C-1), 28.4 (Boc) and 20.6 (C-3); HRMS found MNa+, 198.1102.  
C8H17NO3 requires MNa, 198.1106. 
Nα-Benzyl-Nω-tert-butoxycarbonylethylene diamine, 125 
 
Benzaldehyde (3.49 mL, 34.3 mmol) was added dropwise to a stirred suspension 
of N-Boc-ethylenediamine (4.94 mL, 31.2 mmol) and 4 Å mol. sieves (5 g) in DCM (50 mL, 
0.7 M) at room temperature and stirred overnight.  The reaction mixture was filtered and 
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washed with DCM (50 mL), before being concentrated in vacuo.  The residue was 
dissolved in MeOH (50 mL, 0.7 M) and cooled to 0 °C.  NaBH4 (2.36 g, 62.4 mmol) was 
added portion-wise over 10 min and the resulting solution was warmed to room 
temperature and stirred for 2 hr before being concentrated in vacuo.   The residue was 
diluted with water (50 mL) and aq. HCl (1 M) was added to acidify the solution.  EtOAc 
(50 mL) was added and the aqueous layer extracted with EtOAc (2 × 50 mL) to remove 
organic impurities before being basified with aq. NaOH (2 M) and extracted with DCM (3 × 
50 mL).  The combined  organic layers were dried (MgSO4) and concentrated in vacuo to 
yield the diamine126 125 (3.54 g, 45%) as a colourless amorphous solid which was used 
without further purification, Rf = 0.09 (30:70  Petrol–EtOAc); δH (500 MHz, CDCl3) 7.46-
7.40 (2H, m, benzyl 3-H and benzyl 5-H), 7.40-7.35 (2H, m, benzyl 2-H and benzyl 6-H), 
7.34-7.30 (1H, m, benzyl 4-H), 5.48 (2H, br s, NH), 3.92 (2H, s, benzylic-H2), 3.35 (2H, dd, 
J 12.5 and 6.5, 2-H2), 2.88 (2H, app t, J 5.3, 1-H2) and 1.45 (9H, s, Boc); δC (126 MHz, CDCl3) 
156.2 (CO), 135.9 (benzyl C-1), 129.0 (benzyl C-3 and benzyl C-5), 128.8 (benzyl C-2 and 
benzyl C-6), 128.1 (benzyl C-4), 79.5 (Boc), 52.6 (C-2), 48.0 (benzylic-C), 39.0 (C-1) and 
28.4 (Boc); m/z (ES) 195.0 (100%) and 251.0 (36%, MH+). 
(2-Aminoethoxy)(tert-butyl)diphenylsilane, 56 
 
Et3N (12.6 mL, 90.0 mmol), DMAP (5.00 g, 41.0 mmol) and TBDPSCl (23.4 mL, 
90.0 mmol) were added to a solution of ethanolamine (4.94 mL, 81.9 mmol) in DCM 
(150 mL, 0.5 M).  The reaction mixture was stirred at 40 °C overnight before being 
quenched with water (500 mL).  The organic phase was separated and washed with water 
(3 × 500 mL) and brine (500 mL), before being dried (MgSO4) and concentrated in vacuo.  
The residue was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to yield the 
protected alcohol127 56 (16.3 g, 67%) as a yellow oil, Rf = 0.27 (10:90 MeOH–DCM); δH 
(500 MHz, CDCl3) 7.75-7.70 (4H, m, phenyl 3-H and phenyl 5-H), 7.50-7.39 (6H, m, phenyl 
2-H, phenyl 4-H and phenyl 6-H), 3.72 (2H, t, J 5.3, 1-H2), 2.85 (2H, t, J 5.3, 2-H2), 1.49 (2H, 
s, NH2) and 1.11 (9H, s, tBu); δC (126 MHz, CDCl3) 135.6 (phenyl C-3 and phenyl C-5), 133.7 
(phenyl C-1), 129.69 (phenyl C-4), 127.72 (phenyl C-2 and phenyl C-6), 66.2 (C-1), 44.3 
(C-2), 26.9 (tBu) and 19.3 (Si-C). 
 154 
 
 (2R)-2-Hydroxy-N-[(4-methoxyphenyl)methyl]-3-{[(4methoxyphenyl)methyl] 
amino} propanamide, R-216 
 
By general procedure C, methyl (2R)-glycidate (5.00 g, 49.0 mmol) gave the 
amide100 R-216 (13.5 g, 80%) as a colourless amorphous solid which was used without 
further purification, Rf = 0.68 (5:95 MeOH–DCM); δH (500 MHz, CDCl3) 7.53 (1H, s, NH), 
7.22 (2H, d, J 8.5, 1-PMB 2-H and 3-PMB 2-H), 7.16 (2H, d, J 8.5, 1-PMB 6-H and 3-PMB 6-
H), 6.91-6.84 (4H, m, 1-PMB 3-H, 1-PMB 5-H, 3-PMB 3-H and 3-PMB 5-H), 4.41 (2H, d, J 
5.8, amide benzylic-H2), 4.06 (1H, t, J 6.0, 2-H), 3.83 (1H, s, OH), 3.83 (6H, s, 1-PMB methyl 
and 3-PMB methyl), 3.76-3.68 (2H, m, amine benzylic-H2) and 3.06 (1H, dd, J 12.3 and 6.0, 
3-Ha), 2.99 (1H, dd, J 12.3 and 6.0, 3-Hb); δC (126 MHz, CDCl3) 172.8 (C-1), 159.2 (1-PMB 
C-4), 159.1 (3-PMB C-4), 131.6 (1-PMB C-1), 130.3 (3-PMB C-1), 129.2 (1-PMB C-2 and 3-
PMB C-2), 129.0 (1-PMB C-6 and 3-PMB C-6), 114.2 (1-PMB C-3 and 3-PMB C-3), 114.1 
(1-PMB C-5 and 3-PMB C-5), 69.2 (C-2), 55.3 (1-PMB methyl), 55.3 (3-PMB methyl), 52.9 
(amide benzylic C-2), 51.2 (amine benzylic C-2) and 42.7 (C-3); m/z (ES) 345.4 (100%, 
MH+). 
(2S)-2-Hydroxy-N-[(4-methoxyphenyl)methyl]-3-{[(4-methoxyphenyl)methyl] 
amino} propanamide, S-216 
 
By general procedure C, methyl (2S)-glycidate (5.00 g, 49.0 mmol) gave the 
amide100 S-216 (13.1 g, 78%) as a colourless amorphous solid which was used without 
further purification; analytical data as R-216. 
Chloro(dibenzo[a,e]cyclooctatetraene)iridium(I)dimer, 298 
 
An oven-dried flask under N2 was charged with [Ir(COD)Cl]2 (510 mg, 0.760 mmol) 
and DCM (10 mL, ~0.1 M) was added.  A solution of dbcot (303 mg, 1.48 mmol) in DCM 
(10 mL, ~0.1 M) was added dropwise over 30 min.  The reaction mixture was stirred for 
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45 min before being cooled to 0 °C, filtered and washed with cyclohexane, before being 
dried in vacuo to yield the iridium dimer41 298 (162 mg, 25%) as a bright yellow solid, δH 
(500 MHz, C6D6) 6.57 (8H, dd, J 5.4 and 3.3, dbcot 1,4, 7 and 10-H8), 6.38 (8H, dd, J 5.4 and 
3.3, dbcot 2, 3, 8 and 9-H8) and 5.12 (8H, s, dbcot 5, 6, 11 and 12-H8). 
(E)-Ethyl 5-((tert-butoxycarbonyl)amino)pent-2-enoate, 239 
 
DMSO (98.0 mL, 1.38 mmol), Et3N (105 mL, 752 mmol) and SO3·Py complex 
(59.9 g, 376 mmol) were added to a 0 °C solution of the alcohol 238 (22.0 g, 125 mmol) in 
DCM (250 mL, ~0.5 M).  The reaction mixture was warmed to room temperature and 
stirred for 1 hr before carbethoxymethylene triphenyl phosphorane (87.4 g, 251 mmol) 
was added at 0 °C.  The reaction mixture was warmed to room temperature and stirred 
overnight, where it changed from yellow to red.  Water was added (100 mL) and the pH 
of the reaction mixture adjusted to ~3 using conc. HCl before the layers were separated 
and the aqueous phase was extracted with DCM (3 × 100 mL).  The combined organic 
phases were washed with aq. HCl (1 M, 100 mL), sat. NaHCO3 (100 mL), brine (100 mL), 
dried (MgSO4) and concentrated in vacuo to give a red oil which was purified by flash 
chromatography (SiO2, 80:20 Petrol–EtOAc) to yield the α, β-unsaturated ester128 239 
(27.6 g, 90%) as a pale yellow oil, Rf = 0.68 (60:40 Petrol–EtOAc);  νmax/cm-1  (ATR) 3373, 
2979, 1719, 1655, 1523 and 1174;  δH (500 MHz, CDCl3) 6.87 (1H, dt, J 15.7 and 6.4, 3-H), 
5.86 (1H, d, J 15.7, 2-H), 4.63 (1H, s, NH), 4.17 (2H, q, J 7.1, ethyl 1-H2), 3.25 (2H, q, J 6.4, 
5-H2), 2.38 (2H, q, J 6.4, 4-H2), 1.42 (9H, s, Boc) and 1.27 (3H, t, J 7.1, ethyl 2-H3);  δC (126 
MHz, CDCl3) 166.4 (Boc CO), 155.9 (C-1), 145.5 (C-3), 123.5 (C-2), 79.6 (Boc), 60.5 (ethyl 
C-1), 39.2 (C-5), 32.9 (C-4), 28.5 (Boc) and 14.4 (ethyl C-2); m/z (ES) 266.1 (100%, MNa+). 
(E)-tert-Butyl(5-hydroxypent-3-en-1-yl)carbamate, 240 
 
DIBAL-H (340 mL, 1 M in hexane) was added via cannula to a solution of the α, β-
unsaturated ester 239 (27.6 g, 113 mmol) in DCM (250 mL, ~0.5 M), at –78 °C over 30 min.  
The resulting mixture was stirred at –78 °C for 1 hr and warmed to room temperature 
and stirred for 3 hr.  The reaction mixture was quenched with sat. NH4Cl (300 mL) at –
78 °C over 30 min, and warmed to room temperature and stirred overnight.  The resulting 
salts were filtered through a pad of Celite and the aqueous layer was extracted with DCM 
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(3 × 300 mL).  The combined organic phases were washed with sat. NH4Cl (300 mL), brine 
(300 mL), dried (MgSO4), and concentrated in vacuo to yield the allylic alcohol129 240 
(8.94 g, 39%) as a yellow oil, which was used without further purification, Rf = 0.26 (60:40 
Petrol–EtOAc);  νmax/cm-1 (ATR)  3346, 2977, 2931, 1691, 1528 and 1172;  δH (500 MHz, 
CDCl3) 5.70 (1H, dt, J 15.6 and 4.9, 4-H2), 5.63 (1H, dt, J 15.6 and 6.5, 3-H2), 4.62 (1H, s, 
NH), 4.09 (2H, t, J 4.9, 5-H2), 3.17 (2H, q, J 6.5, 1-H2), 2.23 (2H, q, J 6.5, 2-H2), 1.83 (1H, s, 
OH) and 1.44 (9H, s, Boc);  δC (126 MHz, CDCl3) 156.0 (Boc CO), 131.6 (C-4), 129.0 (C-3), 
79.2 (Boc), 63.3 (C-5), 39.9 (C-1), 32.8 (C-2) and 28.4 (Boc); m/z (ES) 425.3 (100%, 
2MNa+). 
(E)-tert-Butyl(5-((methoxycarbonyl)oxy)pent-3-en-1-yl)carbamate, 45 
 
Methyl chloroformate (3.78 mL, 48.9 mmol) was added to a 0 °C solution of the 
allylic alcohol 240 (8.94 g, 44.4 mmol) and pyridine (3.96 mL, 48.9 mmol) in DCM 
(100 mL, ~0.5 M).  The resulting mixture was stirred for 1 hr at 0 °C, before being warmed 
to room temperature and stirred overnight.  Pyridine (3.59 mL, 44.4 mmol) and methyl 
chloroformate (1.72 mL, 22.2 mmol) was added at 0 °C and stirred for 1 hr at room 
temperature.  Sat. NH4Cl (50 mL) was added and the aqueous phase was extracted with 
DCM (3 × 50 mL), the combined organic phases were washed with water (50 mL), brine 
(50 mL), dried (MgSO4), and concentrated in vacuo to give a residue which was purified 
by flash chromatography (SiO2, 70:30 Petrol–EtOAc) to yield the allylic carbonate130 45 
(9.31 g, 81%) as a colourless oil, Rf = 0.64 (50:50 Petrol–EtOAc);  νmax/cm-1 (ATR) 3383, 
2977, 1749, 1713, 1520 and 1270;  δH (500 MHz, CDCl3) 5.74 (1H, dt, J 15.6 and 6.6, 4-H2), 
5.68-5.59 (1H, m, 3-H2), 4.56 (2H, d, J 6.6, 5-H2), 3.76 (3H, s, methyl), 3.17 (2H, q, J 6.4, 1-
H2), 2.23 (2H, q, J 6.4, 2-H2) and 1.41 (9H, s, Boc);  δC (126 MHz, CDCl3) 156.0 (Boc CO), 
155.7 (Carbonate CO), 133.4 (C-4), 125.9 (C-3), 79.3 (Boc), 68.3 (C-5), 54.8 (methyl), 39.7 
(C-1), 32.9 (C-2) and 28.5 (Boc); m/z (ES) 282.2 (100%, MNa+). 
tert-Butyl 2,2-dioxo-1,2,3-oxathiazolidine-3-carboxylate, 30 
 
By general procedure D, the protected amino alcohol 89 (5.84 g, 36.2 mmol) gave 
the cyclic sulfamidate44 30 (5.74 g, 71%) as a colourless solid, which was used without 
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further purification, Rf = 0.54 (50:50 Petrol–EtOAc);  νmax/cm-1 (ATR) 2985, 1713, 1351, 
1332, 1152 and 806;  δH (500 MHz, CDCl3) 4.61 (2H, t, J 6.4, 5-H2), 4.04 (2H, t, J 6.4, 4-CH2) 
and 1.56 (9H, s, Boc);  δC (126 MHz, CDCl3) 148.7 (CO), 85.6 (Boc), 65.5 (C-5), 45.3 (C-4) 
and 27.9 (Boc); m/z (ES) 469.5 (100%, 2MNa+). 
tert-Butyl-4-[(acetyloxy)methyl]-2,2-dioxo-1,2λ,3-oxathiazolidine-3-carboxylate, 
96 
 
By general procedure F, the protected amino alcohol 95 (8.36 g, 35.8 mmol) gave 
the cyclic sulfamidate44 96 (3.38 g, 32%) as a colourless amorphous solid, which was used 
without further purification, Rf = 0.19 (30:70  Petrol–EtOAc); δH (500 MHz, CDCl3) 4.70 
(1H, dd, J 9.7 and 6.4, 4-methyl-Ha), 4.59-4.52 (2H, m, 4-methyl-Hb and 4-H), 4.47 (1H, dd, 
J 11.5 and 6.1, 5-Ha), 4.33 (1H, dd, J 11.5 and 3.7, 5-Hb), 2.14 (3H, s, acetyl) and 1.59 (9H, 
s, Boc); δC (126 MHz, CDCl3) 170.5 (acetyl CO), 148.3 (Boc CO), 86.1 (Boc), 67.6 (4-methyl), 
61.5 (C-5), 55.5 (C-4), 27.9 (Boc) and 20.6 (acetyl); m/z (ES) 261.9 (100%, MH+). 
(R)-5-Methyl-2,2-dioxo[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester, 92 
 
By general procedure F, the protected amino alcohol 91 (23.3 g, 133 mmol) gave 
the cyclic sulfamidate 92 (24.4 g, 77%) as an orange amorphous solid, which was used 
without further purification, Rf = 0.56 (100% DCM); νmax/ cm-1 (ATR) 2983, 1716, 1366, 
1329, 1194, 1144 and 825; [α]D27 −17 (c = 0.28, MeOH); δH (500 MHz, CDCl3) 4.83-4.64 
(1H, m, 5-H), 3.86 (1H, dd, J 10.0 and 5.6, 4-Ha), 3.43 (1H, app t, J 10.0, 4-Hb), 1.36 (3H, d, J 
6.2, methyl) and 1.33 (9H, s, Boc); δc (126 MHz, CDCl3) 148.7 (CO), 85.4 (Boc), 76.2 (C-5), 
51.7 (C-4), 27.9 (Boc) and 18.1 (methyl); HRMS found MNa+, 260.0563.  C8H15NO5S 
requires MNa, 260.0569. 
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(5R)-N,3-bis[(4-methoxyphenyl)methyl]-2,2-dioxo-1,2λ6,3-oxathiazolidine-5-
carboxamide, R-54 
 
By general procedure D, the protected amino alcohol R-216 (7.16 g, 20.7 mmol) 
gave a crude residue which was purified by flash chromatography (SiO2, 60:40 Petrol–
EtOAc) to yield the cyclic sulfamidate42 R-54 (720 mg, 9%) as a colourless amorphous 
solid, Rf = 0.76 (30:70  Petrol–EtOAc); δH (500 MHz, CDCl3) 7.24 (4H, d, J 8.3, 1-PMB 2-H, 
1-PMB 6-H, 3-PMB 2-H and 3-PMB 6-H), 6.91 (4H, d, J 8.3, 1-PMB 3-H, 1-PMB 5-H, 3-PMB 
3-H and 3-PMB 5-H), 6.80 (1H, br s, NH), 4.95 (1H, dd, J 7.6 and 5.3, 5-H), 4.50-4.40 (2H, 
m, amide benzylic-H2), 4.18 (2H, s, sulfamidate benzylic-H2), 3.85 (3H, s, 1-PMB methyl), 
3.84 (3H, s, 3-PMB methyl), 3.72 (1H, dd, J 10.6 and 7.6, 4-Ha) and 3.59 (1H, dd, J 10.6 and 
5.3. 4-Hb); δC (126 MHz, CDCl3) 166.4 (CO), 160.1 (1-PMB C-4), 159.5 (3-PMB C-4), 130.1 
(1-PMB C-2 and 3-PMB C-2), 129.1 (1-PMB C-1), 129.0 (1-PMB C-6 and 3-PMB C-6), 125.5 
(3-PMB C-1), 114.5 (1-PMB C-3 and 3-PMB C-3), 114.4 (1-PMB C-5 and 3-PMB C-5), 75.5 
(C-5), 55.3 (1-PMB methyl and 3-PMB methyl), 51.4 (amide benzylic-C), 49.8 (sulfamidate 
benzylic-C) and 43.0 (C-4); m/z (ES) 428.9 (100%, MNa+). 
(5S)-N,3-bis[(4-methoxyphenyl)methyl]-2,2-dioxo-1,2λ6,3-oxathiazolidine-5-
carboxamide, S-54 
 
By general procedure D (with an additional 2 eq. of NaIO4 to promote formation 
of the kinetic product), the protected amino alcohol S-216 (2.08 g, 6.04 mmol) gave a 
crude residue which was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to 
yield the cyclic sulfamidate42 S-54 (1.18 g, 48%) as a colourless amorphous solid; data as 
R-54. 
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tert-Butyl-N-[(2-nitrophenyl)sulfonyl]carbamate, 98 
 
DMAP (450 mg, 0.370 mmol) was added to a stirred suspension of 2-
nitrobenzenesulfonamide (25.0 g, 124 mmol), Boc2O (27.0 g, 124 mmol) and Et3N 
(25.9 mL, 186 mmol) in DCM (125 mL, ~1 M), and the resulting solution was stirred at 
room temperature overnight.  The reaction mixture was quenched with aq. HCl (2 M) until 
pH <2 and extracted with DCM (6 × 50 mL).  The combined organic phases were washed 
with water (50 mL), brine (50 mL), dried (MgSO4) and concentrated in vacuo to yield the 
protected sulfonamide44 98 (27.1 g, 73%) as a pale brown solid which was used without 
further purification, Rf = 0.75 (50:50 Petrol–EtOAc);  νmax/ cm-1 (ATR) 3256, 2983, 1747, 
1721, 1544, 1361 and 1149;   δH (500 MHz, CDCl3) 8.38-8.32 (1H, m, 3-H), 7.89-7.85 (1H, 
m, 6-H), 7.83-7.76 (2H, m, 4-H and 5-H), 7.58 (1H, s, NH) and 1.43 (9H, s, Boc);  δC (126 
MHz, CDCl3) 148.6 (C-2), 134.7 (C-5), 133.3 (C-4), 132.5 (C-6), 132.0 (C-1), 125.1 (C-3), 
84.8 (Boc) and 27.9 (Boc), Boc CO not observed; m/z (ES) 301.0 (100%, [M-H]-).  
2-Nitro-N-(pent-2-yn-1-yl)benzene-1-sulfonamide, 29 
 
By general procedure  E, 2-pentyn-1-ol (3.61 mL, 39.0 mmol), and sulfonamide 98 
(13.0 g, 42.9 mmol) gave a crude product which was recrystallized from Petrol to yield 
the pentynyl sulfonamide44 29 (9.30 g, 89%) as a yellow solid, Rf = 0.74 (50:50 Petrol–
EtOAc);  νmax/ cm-1 (ATR) 3336, 3098, 2978, 1537, 1343 and 1165; δH (500 MHz, CDCl3) 
8.23-8.17 (1H, m, 3-H), 7.95-7.88 (1H, m, 6-H), 7.79-7.72 (2H, m, 4-H and 5-H), 5.60 (1H, 
t, J 6.2, NH), 3.97 (2H, dt, J 6.2 and 2.2, pentynyl 1-H2), 1.83 (2H, qt, J 7.5 and 2.2, pentynyl 
4-H2) and 0.82 (3H, t, J 7.5, pentynyl 5-H3); δC (126 MHz, CDCl3) 148.1 (C-2), 134.5 (C-1), 
133.7 (C-5), 132.9 (C-4), 131.8 (C-6), 125.5 (C-3), 87.4 (pentynyl C-2), 73.1 (pentynyl C-
3), 34.1 (pentynyl C-1), 13.5 (pentynyl C-4) and 12.1 (pentynyl C-5); m/z (ES) 423.5 
(100%) and 291.1 (67%, MNa+).   
 
 
 
 160 
 
2-Nitro-N-(prop-2-yn-1-yl)benzene-1-sulfonamide, 99 
 
By general procedure  E, propargyl alcohol (1.78 mL, 30.6 mmol) and sulfonamide 
98 (10.2 g, 33.6 mmol) gave a crude product which was recrystallized from 50:50 Petrol–
CHCl3 to give the propargyl sulfonamide44 99 (5.85 g, 80%) as a colourless solid, Rf = 0.55 
(50:50 Petrol–EtOAc); νmax/cm-1 (ATR) 3294, 3094, 1536, 1415, 1368, 1332, 1162, 1072 
and 605; δH (500 MHz, CDCl3) 8.29-8.15 (1H, m, nitrophenyl 3-H), 8.01-7.88 (1H, m, 
nitrophenyl 6-H), 7.82-7.76 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 5.73 (1H, t, J 
5.5, NH), 4.05 (2H, dd, J 5.5 and 2.5, 1-H2) and 2.00 (1H, t, J 2.5, 3-H); δC (126 MHz, CDCl3) 
148.0 (nitrophenyl C-1), 134.0 (nitrophenyl C-2), 133.8 (nitrophenyl C-5), 132.9 
(nitrophenyl C-4), 131.6 (nitrophenyl C-6), 125.5 (nitrophenyl C-3), 77.4 (C-3), 73.3 (C-2) 
and 33.4 (C-1); m/z (ES) 263.0 (100%, MNa+). 
N-Benzyloxycarbonyl-α-β-didehydro-(3-oxetanyl)-glycine, methyl ester, 182 
 
1,1,3,3-Tetramethylguanidine (1.80 mL, 14.4 mmol) was added to a solution of N-
benzyloxycarbonyl-(phosphonoglycine)-trimethyl ester (5.00 g, 15.1 mmol) in THF 
(30 mL, ~0.5 M) at -78 °C, and stirred at -78 °C for 1 hr.  3-Oxetanone (0.920 mL, 14.4 
mmol) was added and the reaction mixture was stirred at room temperature overnight, 
before being diluted with EtOAc (50 mL), filtered and washed.  The combined organic 
phases were washed with 1% citric acid (3 × 50mL), brine (50 mL), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, 30:70 
Petrol–EtOAc) to give the alkene91 182 (1.80 g, 45%) as a colourless amorphous solid, Rf 
= 0.67 (30:70 Petrol–EtOAc); δH (500 MHz, CDCl3) 7.46-7.34 (5H, m, benzyl-H), 6.79 (1H, 
s, NH), 5.48 (2H, s, benzylic-H2), 5.46-5.41 (2H, m, oxetanyl 2-Ha and oxetanyl 4-Ha), 5.14 
(2H, app s, oxetanyl 2-Hb and oxetanyl 4-Hb) and 3.83 (3H, s, methyl); δC (126 MHz, CDCl3) 
197.9 (ester CO), 163.6 ( carbamate CO), 152.7 (C-1), 135.7 (benzyl C-1), 128.7 (benzyl C-
3 and benzyl C-5), 128.5 (benzyl C-2 and benzyl C-6), 128.3 (benzyl C-4), 115.9 (C-2), 78.7 
(oxetanyl C-2), 67.5 (oxetanyl C-4) and 52.7 (methyl); m/z (ES) 300.2 (100%, MNa+). 
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Methyl 2-amino-2-(oxetan-3-yl)acetate, 183 
 
Hydrogen was bubbled through a suspension of Pd(OH)2/C (217 mg, 5 mol%) and 
alkene 182 (1.71 g, 6.17 mmol) in 1:1 MeOH–DCM (120 mL, ~0.05 M) and the reaction 
mixture was stirred at room temperature overnight before being filtered through Celite.  
The solvent was concentrated in vacuo and the residue was purified by basic SCX cartridge 
to yield the amino ester91 183 (530 mg, 59%) as a yellow oil, Rf = 0.54 (5:95 MeOH–DCM); 
δH (500 MHz, CDCl3) 4.84-4.69 (2H, m, oxetanyl 2-Ha and oxetanyl 4-Ha), 4.67-4.57 (2H, m, 
oxetanyl 2-Hb and oxetanyl 4-Hb), 3.76 (1H, d, J 9.2, 2-H), 3.72 (3H, s, methyl), 3.24-3.10 
(1H, m, oxetanyl 1-H) and 1.59 (2H, br s, NH2); δC (126 MHz, CDCl3) 174.6 (C-1), 74.3 
(oxetanyl C-2), 74.1 (oxetanyl C-4), 56.5 (C-2), 51.9 (methyl) and 39.1 (oxetanyl C-1); m/z 
(ES) 146.5 (100%, MH+). 
Methyl 2-amino-2-(2-fluorophenyl)acetate, 188 
 
Thionyl chloride (0.470 mL, 6.50 mmol) was added dropwise to a suspension of 
2-fluorophenyl amino acid (1.00 g, 5.91 mmol) in MeOH (20 mL, ~0.3 M) at -10 °C.  The 
resulting mixture was stirred at reflux overnight, before being concentrated in vacuo and 
recrystallized from MeOH–Et2O to yield the amino ester salt92 188 (1.13 g, 87%) as an 
amorphous yellow solid, Rf = 0.64 (30:70 Petrol–EtOAc); δH (500 MHz, MeOD) 7.59 (1H, 
dddd, J 8.4, 7.6, 5.4 and 1.7, fluorophenyl 4-H), 7.54 (1H, td, J 7.6 and 1.6, fluorophenyl 3-
H), 7.36 (1H, td, J 7.6, and 1.0, fluorophenyl 5-H), 7.32 (1H, ddd, J 10.1, 8.4 and 0.9, 
fluorophenyl 6-H), 5.47 (1H, s, 2-H) and 3.87 (3H, s, methyl). 
Methyl 2-amino-2-isopropyl pent-4-enoate, 175 
 
By general procedure P, valine methyl ester hydrochloride (2.00 g, 11.9 mmol) 
gave the allylated amino ester 175 (1.53 g, 75%) as a brown oil which was used without 
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further purification, Rf = 0.37 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 2964, 1730, 1436, 
1213, 1160 and 1134; δH (500 MHz, CDCl3) 5.53 (1H, dddd, J 16.7, 9.9, 8.4 and 6.5, 4-H), 
5.04-4.94 (2H, m, 5-H2), 3.58 (3H, s, methyl), 2.39 (1H, dd, J 13.4 and 6.5 3-Ha), 2.15 (1H, 
dd, J 13.4 and 8.4, 3-Hb), 1.89 (1H, hept, J 6.9, isopropyl 2-H), 1.58 (2H, br s, NH2), 0.82 (3H, 
d, J 6.9, isopropyl-MeA) and 0.72 (3H, d, J 6.9, isopropyl-MeB); δC (126 MHz, CDCl3) 177.1 
(CO), 133.2 (C-4), 119.3 (C-5), 64.2 (C-2), 51.9 (methyl), 42.1 (C-3), 35.4 (isopropyl C-2), 
17.8 (isopropyl-MeA) and 16.2 (isopropyl-MeB); HRMS found MH+, 172.1366.  C9H17NO2 
requires MH, 172.1337. 
Methyl 2-amino-2-(oxetan-3-yl)pent-4-enoate, 184 
 
By general procedure P, amino ester 183 (126 mg, 0.870 mmol) gave the allylated 
amino ester 184 (67.0 mg, 42%) as a yellow oil which was used without further 
purification, Rf = 0.69 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 2952, 2879, 1727, 1436, 
1216, 977 and 918; δH (300 MHz, CDCl3) 5.61-5.36 (1H, m, 5-Ha), 5.03-5.01 (1H, m, 4-H), 
5.00-4.93 (1H, m, 5-Hb), 4.60-4.50 (3H, m, 2-Ha and oxetanyl 4-H2), 4.41 (1H, t, J 6.6, 
oxetanyl 2-Hb), 3.57 (3H, s, methyl), 3.33-3.14 (1H, m, oxetanyl 1-H), 2.30 (1H, ddt, J 13.5, 
6.5 and 1.2, 3-Ha), 2.05 (1H, dd, J 13.5 and 8.2, 3-Hb) and 1.64 (2H, br s, NH2); δC (126 MHz, 
CDCl3) 175.6 (C-1), 132.1 (C-4), 119.6 (C-5), 72.4 (oxetanyl C-2), 72.1 (oxetanyl C-4), 60.3 
(C-2), 52.1 (methyl), 42.1 (oxetanyl C-1) and 41.5 (C-3); HRMS found MH+, 186.1155.  
C9H15NO3 requires MH, 186.1130. 
Methyl-2-amino-2-[(4-fluorophenyl)methyl]pent-4-enoate, 186 
 
By general procedure P (but excluding addition of Et3N), 4-fluoro-DL-
phenylalaninemethyl ester hydrochloride (500 mg, 2.14 mmol) gave the allylated amino 
ester 186 (282 mg, 56%) as a yellow oil which was used without further purification, 
Rf = 0.54 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 2952, 2919, 1732, 1509, 1441, 1219 and 
840, ; δH (500 MHz, CDCl3) 7.22-7.07 (2H, m, fluorophenyl 2-H and fluorophenyl 6-H), 
7.04-6.91 (2H, m, fluorophenyl 3-H and fluorophenyl 5-H), 5.71 (1H, dddd, J 16.7, 10.0, 8.5 
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and 6.4, 4-H), 5.25-5.15 (2H, m, 5-H2), 3.72 (3H, s, methyl), 3.16 (1H, d, J 13.4, benzylic-
Ha), 2.78 (1H, d, J 13.4, benzylic-Hb), 2.72 (1H, dd, J 13.5 and 6.4, 3-Ha) and 2.33 (1H, dd, J 
13.5 and 8.5, 3-Hb), δC (126 MHz, CDCl3) 176.4 (C-1), 162.1 (d, J 245.3, fluorophenyl C-4), 
132.3 (C-4), 131.9 (d, J 3.3, fluorophenyl C-1), 131.4 (d, J 7.9, fluorophenyl C-2 and 
fluorophenyl C-6), 119.9 (C-5), 115.3 (d, J 21.2, fluorophenyl C-3 and fluorophenyl C-5), 
61.9 (C-2), 52.0 (methyl), 44.9 (benzylic-C) and 44.3 (C-3); δF (282 MHz, CDCl3) -115.9; 
HRMS found MH+, 238.1264.  C13H16FNO2 requires MH, 238.1243. 
5.5 Connection of Building Blocks 
tert-Butyl-N-{2-[N-(pent-2′-yn-1′-yl)(2-nitrophenyl)sulfonamido]ethyl}carbamate, 
31 
 
By general procedure F, pentynyl sulfonamide 29 (4.84 g, 18.0 mmol) and cyclic 
sulfamidate 30 (3.66 g, 16.4 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 25:25:50 Petrol–Et2O–CHCl3) to yield the sulfonamide44 31 (3.78 g, 
56%) as a yellow solid, Rf = 0.65 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3419 (br), 2978, 
2937, 1708, 1545, 1366 and 1167; δH (500 MHz, CDCl3) 8.06 (1H, dd, J 7.4 and 1.8, 
nitrophenyl 3-H), 7.72-7.65 (2H, m, nitrophenyl 4-H and 5-H), 7.63 (1H, dd, J 7.4 and 1.8, 
nitrophenyl 6-H), 4.82 (1H, s, NH), 4.20 (2H, s, pentynyl 1-H2), 3.51 (2H, t, J 5.8, 2-H2), 3.36 
(2H, q, J 5.8, 1-H2), 2.04 (2H, q, J 7.5, pentynyl 4-H2), 1.44 (9H, s, Boc) and 0.98 (3H, t, J 7.5, 
pentynyl 5-H3); δC (126 MHz, CDCl3) 148.5 (C-2), 133.7 (C-5), 133.0 (C-1), 131.6 (C-4), 
131.2 (C-6), 124.2 (C-3), 88.2 (pentynyl C-2), 79.7 (Boc), 72.3 (pentynyl C-3), 46.7 
(pentynyl C-1), 38.3 (ethyl C-1), 37.6 (ethyl C-2), 28.5 (Boc), 13.7 (pentynyl C-5) and 12.3 
(pentynyl C-4), Boc CO not observed; m/z (ES) 420.2 (100%, MNa+).   
tert-Butyl-N-{2-[N-(prop-2-yn-1-yl)(2-nitrophenyl)sulfonamido]ethyl}carbamate, 
100 
 
By general procedure F, propargyl sulfonamide 99 (5.98 g, 24.9 mmol) and cyclic 
sulfamidate 30 (5.05 g, 22.6 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 100% DCM) to yield the sulfonamide44 100 (8.15 g, 94%) as a 
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yellow solid, Rf = 0.41 (100% DCM); νmax/cm-1 (ATR) 3289, 2978, 1697, 1591, 1543, 1365, 
1163 and 589; δH (500 MHz, CDCl3) 8.07 (1H, dd, J 7.4 and 1.7, nitrophenyl 3-H), 7.76-7.68 
(2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.66 (1H, dd, J 7.4 and 1.7, nitrophenyl 6-
H), 4.88 (1H, br s, NH), 4.27 (2H, d, J 2.2, propargyl 1-H2), 3.55 (2H, t, J 5.9, 2-H2), 3.43-3.33 
(2H, m, 1-H2), 2.22 (1H, t, J 2.2, propargyl 3-H) and 1.44 (9H, s, Boc); δC (126 MHz, CDCl3) 
171.1 (Boc CO), 148.3 (nitrophenyl C-2), 133.8 (nitrophenyl C-5), 132.6 (nitrophenyl C-
1), 131.7 (nitrophenyl C-4), 131.0 (nitrophenyl C-6), 124.2 (nitrophenyl C-3), 79.6 (Boc), 
77.3 (propargyl C-2), 74.2 (propargyl C-3), 46.7 (C-2), 38.0 (C-1), 37.0 (propargyl C-1) and 
28.3 (Boc); m/z (ES) 406.1 (100%, MNa+). 
2-{[(tert-Butoxy)carbonyl]amino}-3-[N-(prop-2-yn-1-yl)2-nitrobenzene 
sulfonamido]propyl acetate, 104 
 
By general procedure F, propargyl sulfonamide 99 and cyclic sulfamidate 95 
(3.38 g, 11.5 mmol) gave a crude residue which was purified by flash chromatography 
(SiO2, 10:90 Et2O–DCM) to yield the sulfonamide44 104 (3.05 g, 58%) as an orange 
amorphous solid, Rf = 0.48 (10:90 Et2O–DCM); δH (500 MHz, CDCl3) 8.07 (1H, dd, J 7.6 and 
1.7, nitrophenyl 3-H), 7.78-7.69 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.65 (1H, 
dd, J 7.4 and 1.7, nitrophenyl 6-H), 4.91 (1H, d, J 7.9, NH), 4.42 (1H, d, J 18.7, propargyl 1-
Ha), 4.25 (1H, dd, J 18.7 and 2.4, propargyl 1-Hb), 4.23-4.12 (3H, m, 2-H and 3-H2), 3.67 
(1H, dd, J 13.7 and 10.0, 1-Ha), 3.55-3.37 (1H, m, 1-Hb), 2.19 (1H, t, J 2.4, propargyl 3-H), 
2.14 (3H, s, methyl) and 1.46 (9H, s, Boc); δC (126 MHz, CDCl3) 170.8 (acetyl CO), 155.6 
(Boc CO), 148.3 (nitrophenyl C-2), 133.9 (nitrophenyl C-5), 132.6 (nitrophenyl C-1), 131.7 
(nitrophenyl C-4), 131.0 (nitrophenyl C-6), 124.2 (nitrophenyl C-3), 80.1 (Boc), 76.2 
(propargyl C-3), 74.5 (propargyl C-2), 64.1 (propargyl C-1), 47.4 (C-1), 46.7 (C-2), 36.8 (C-
3), 28.3 (methyl) and 20.7 (Boc); m/z (ES) 356.0 (100%) and 478.1 (43%, MNa+). 
tert-Butyl-N-{(2S)-2-[N-(prop-2-yn-1-yl)(2-nitrophenyl)sulfonamido]propyl} 
carbamate, 102 
 
By general procedure F, propargyl sulfonamide 99 (2.63 g, 11.0 mmol) and cyclic 
sulfamidate 91 (2.36 g, 9.95 mmol) gave a crude residue which was purified by flash 
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chromatography (SiO2, 100% DCM) to yield the sulfonamide 102 (1.92 g, 49%) as a yellow 
amorphous solid, Rf = 0.14 (100% DCM ); νmax/ cm-1 (ATR) 3428 (br), 3291, 2979, 1706, 
1544, 1367, 1159 and 584; [α]D28 −39 (c = 0.28, MeOH); δH (500 MHz, CDCl3) 8.15 (1H, dd, 
J 7.4 and 1.6, nitrophenyl 3-H), 7.73-7.66 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.64 (1H, dd, J 7.2 and 2.0, nitrophenyl 6-H), 4.90 (1H, t, J 6.7, NH), 4.19 (1H, dd, J 18.9 and 
2.4, propargyl 1-Ha), 4.16-4.07 (2H, m, propargyl 1-Hb and 2-H), 3.28 (2H, app t, J 6.7, 1-
H2), 2.21 (1H, t, J 4.2, propargyl 3-H), 1.40 (9H, s, Boc) and 1.20 (3H, d, J 6.8, methyl); δc 
(126 MHz, CDCl3) 155.9 (CO), 147.9 (nitrophenyl C-2), 133.7 (nitrophenyl C-5), 133.6 
(nitrophenyl C-1), 131.9 (nitrophenyl C-4), 131.7 (nitrophenyl C-6), 124.2 (nitrophenyl 
C-3), 72.8 (propargyl C-2), 54.3 (C-2), 43.2 (C-1), 32.0 (propargyl C-1), 28.4 (Boc), 16.1 
(methyl) and 14.1 (propargyl C-3), Boc quaternary carbons not observed; HRMS found 
MH+, 398.1380.  C17H23N3O6S requires MH, 398.1386. 
tert-Butyl N-[2-(oxetan-3-yloxy)ethyl]carbamate, 245 
 
By general procedure F, 3-oxetan-ol (0.310 mL, 4.93 mmol) and cyclic sulfamidate 
30 (1.00 g, 4.48 mmol) gave a crude product which was purified by flash chromatography 
(SiO2, 20:30:50 Petrol–Et2O–CHCl3) to yield the protected amine 245 (400 mg, 41%) as a 
colourless oil, Rf = 0.59 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3338, 2973, 2872, 1690, 
1513, 1248, 1166, 1115 and 968; δH (500 MHz, CDCl3) 4.92 (1H, br s, NH), 4.83-4.77 (2H, 
m, oxetanyl 2-Ha and oxetanyl 4-Ha), 4.65-4.60 (2H, m, oxetanyl 2-Hb and oxetanyl 4-Hb), 
4.60-4.53 (1H, m, oxetanyl 1-H), 3.45 (2H, t, J 5.1, 2-H2), 3.34 (2H, dd, J 9.9 and 4.7, 1-H2) 
and 1.48 (9H, s, Boc); δC (126 MHz, CDCl3) 155.9 (CO), 79.5 (Boc), 78.6 (oxetanyl C-2 and 
oxetanyl C-4), 72.5 (oxetanyl C-1), 67.8 (C-2), 40.5 (C-1) and 28.4 (Boc); HRMS found MH+, 
218.1386.  C10H19NO4 requires MH, 218.1392. 
2-(Oxetan-3-yloxy)ethyl amine, 246 
 
By general procedure Y, amine 245 (400 mg, 1.84 mmol) gave a crude product 
which was purified by flash chromatography (SiO2, 100% EtOAc) to yield the deprotected 
amine 246 (215 mg, 100%) as a colourless oil, Rf = 0.22 (100% EtOAc); νmax/ cm-1 (ATR) 
3305 (br), 2942, 2883, 1706, 1156, 909 and 727; δH (500 MHz, MeOD) 3.76 (2H, t, J 5.4, 2-
H2), 3.67 (2H, dd, J 11.6 and 4.5, oxetanyl 2-Ha and oxetanyl 4-Ha), 3.60 (2H, dd, J 11.6 and 
5.8, oxetanyl 2-Hb and oxetanyl 4-Hb), 3.52 (2H, t, J 5.4, 1-H2) and 3.47 (1H, tt, J 5.8 and 4.5, 
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oxetanyl 1-H); δC (126 MHz, MeOD) 82.9 (oxetanyl C-1), 68.9 (C-2), 62.5 (oxetanyl C-2 and 
oxetanyl C-4) and 41.2 (C-1); HRMS found MNa+, 140.0315.  C5H11NO2 requires MNa, 
140.0687. 
tert-Butyl-N-{2-[N-(3′-oxopentyl)(2-nitrophenyl)sulfonamido]ethyl}carbamate, 32 
 
By general procedure G, the sulfonamide 31 (3.78 g, 9.19 mmol) gave a crude 
product which was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to yield 
the ketone44 32 (3.39 g, 86%) as an orange solid, Rf = 0.26 (50:50 Petrol–EtOAc);   νmax/ 
cm-1 (ATR) 3403 (br), 2978, 1709, 1544, 1367 and 1164; δH (500 MHz, CDCl3) 8.01 (1H, d, 
J 7.3, 3-H), 7.76-7.67 (2H, m, 4-H and 5-H), 7.63 (1H, d, J 7.3, 6-H), 4.85 (1H, t, J 6.3, NH), 
3.56 (2H, t, J 6.3, ethyl 2-H2), 3.40 (2H, t, J 6.5, oxopentyl 2-H2), 3.31 (2H, q, J 6.3, ethyl 1-
H2), 2.81 (2H, t, J 6.5, oxopentyl 1-H2), 2.43 (2H, q, J 7.3, oxopentyl 4-H2), 1.43 (9H, s, Boc) 
and 1.03 (3H, t, J 7.3, oxopentyl 5-H3); δC (126 MHz, CDCl3) 209.3 (oxopentyl C-3), 133.9 
(nitrophenyl C-5), 132.7 (nitrophenyl C-1), 131.9 (nitrophenyl C-4), 131.2 (nitrophenyl 
C-6), 124.4 (nitrophenyl C-3), 48.5 (C-2), 43.5 (oxopentyl C-2), 41.7 (C-1), 39.3 (oxopentyl 
C-1), 36.4 (oxopentyl C-4), 28.5 (Boc) and 7.7 (oxopentyl C-5), Boc quaternary carbons 
and nitrophenyl C-2 not observed; m/z (ES) 452.1 (100%, MNa+).   
tert-Butyl N-{2-[benzyl(3-oxypentyl)amino]ethyl}carbamate, 126 
 
Ethyl vinyl ketone (1.50 mL, 15.2 mmol) was added dropwise to a solution of 
diamine 125 (1.90 g, 7.59 mmol) in EtOH (15 mL, 0.5 M) at room temperature and stirred 
overnight.  The reaction mixture was concentrated in vacuo and purified by flash 
chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the amino ketone 126 (1.24 g, 49%) 
as a colourless oil, Rf = 0.58 (30:70  Petrol–EtOAc); νmax/ cm-1 (ATR) 3352 (br), 2974, 2809, 
1705, 1495, 1167 and 736; δH (500 MHz, CDCl3) 7.35-7.30 (2H, m, benzyl 3-H and benzyl 
5-H), 7.30-7.23 (3H, m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 4.95 (1H, s, NH), 3.58 (2H, 
s, benzylic-H2), 3.24-3.17 (2H, m, 1-H2), 2.81 (2H, t, J 6.9, oxopentyl 1-H2), 2.62-2.48 (4H, 
m, 2-H2 and oxopentyl 2-H2), 2.38 (2H, q, J 7.3, oxopentyl 4-H2), 1.46 (9H, s, Boc) and 1.05 
(3H, t, J 7.3, oxopentyl 5-H3); δC (126 MHz, CDCl3) 210.7 (oxopentyl C-3), 156.0 (Boc), 
139.0 (benzyl C-1), 128.8 (benzyl C-3 and benzyl C-5), 128.3 (benzyl C-2 and benzyl C-6), 
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127.1 (C-4), 78.9 (Boc), 58.7 (oxopentyl C-1), 53.3 (C-1), 48.7 (benzylic-C), 40.2 (C-2), 38.1 
(oxopentyl C-2), 36.2 (oxopentyl C-4), 28.5 (Boc) and 7.6 (oxopentyl C-5); HRMS found 
MH+, 335.2350.  C19H30N2O3 requires MH, 335.2334. 
tert-Butyl-6-methyl-4-[(2-nitrophenyl)sulfonyl]-1,2,3,4-tetrahydropyrazine-1-
carbamate, 101 
 
By general procedure H, the sulfonamide 100 (3.69 g, 9.62 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 70:30 Petrol–EtOAc) to yield 
the tetrahydropyrazine44 101 (2.84 g, 77%) as a yellow solid, Rf = 0.61 (50:50 Petrol–
EtOAc); νmax/ cm-1 (ATR) 2977, 2933, 1702, 1455, 1369, 1171 and 776; δH (500 MHz, CDCl3) 
7.99 (1H, dd, J 7.4 and 1.7, nitrophenyl 3-H), 7.78-7.70 (2H, m, nitrophenyl 4-H and 
nitrophenyl 5-H), 7.66 (1H, dd, J 7.4 and 1.7, nitrophenyl 6-H), 6.01 (1H, s, 5-H), 3.68-3.64 
(2H, m, 3-H2), 3.64-3.60 (2H, m, 2-H2), 2.09 (3H, s, methyl) and 1.50 (9H, s, Boc); δC 
(126 MHz, CDCl3) 152.5 (Boc CO), 148.3 (nitrophenyl C-2), 134.0 (nitrophenyl C-5), 131.7 
(nitrophenyl C-4), 131.3 (nitrophenyl C-1), 130.7 (nitrophenyl C-6), 124.2 (nitrophenyl 
C-3), 120.2 (C-6), 108.0 (C-5), 81.7 (Boc), 44.6 (C-3), 41.6 (C-2), 28.3 (Boc) and 20.1 
(methyl); m/z (ES) 406.1 (100%, MNa+). 
tert-Butyl 2-[(acetyloxy)methyl]-6-methyl-4-(2-nitrobenzenesulfonyl)-1,2,3,4-
tetrahydropyrazine-1-carboxylate, 105 
 
By general procedure H, the sulfonamide 104 (2.25 g, 4.94 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 100% DCM) to yield the 
tetrahydropyrazine 105 (1.65 g, 73%) as a yellow oil, Rf = 0.65 (10:90 Et2O–DCM); δH (500 
MHz, CDCl3) 8.02 (1H, dd, J 7.6 and 1.6, nitrophenyl 3-H), 7.81-7.71 (2H, m, nitrophenyl 4-
H and nitrophenyl 5-H), 7.68 (1H, dd, J 7.5 and 1.7, nitrophenyl 6-H), 6.03 (1H, s, 5-H), 
4.88-4.71 (1H, m, 2-H), 4.09 (1H, app dt, J 12.5 and 1.7, 2-methyl-Ha), 3.97 (1H, dd, J 11.1 
and 7.4, 3-Ha), 3.88 (1H, dd, J 11.1 and 7.3, 3-Hb), 3.30 (1H, dd, J 12.5 and 3.4, 2-methyl-
Hb), 2.10 (3H, s, acetyl), 2.02 (3H, s, 6-methyl) and 1.50 (9H, s, Boc); δC (126 MHz, CDCl3) 
170.4 (acetyl CO), 152.3 (Boc CO), 148.1 (nitrophenyl C-2), 134.2 (nitrophenyl C-5), 131.8 
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(nitrophenyl C-4), 131.2 (nitrophenyl C-1), 130.7 (nitrophenyl C-6), 124.4 (nitrophenyl 
C-3), 116.6 (C-6), 107.5 (C-5), 82.1 (Boc), 60.5 (2-methyl), 48.2 (C-2), 44.2 (C-3), 28.2 
(Boc), 20.7 (acetyl) and 20.4 (C-6); HRMS found MH+, 456.1552.  C19H25N3O8S requires MH, 
456.1440. 
tert-Butyl-(3S)-3,6-dimethyl-4-[(2-nitrophenyl)sulfonyl]-1,2,3,4-
tetrahydropyrazine-1-carbamate, 103 
 
By general procedure H, the sulfonamide 102 (1.92 g, 4.83 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 30:20:50 Petrol–Et2O–CHCl3) 
to give the tetrahydropyrazine 103 (1.82 g, 95%) as an orange oil, Rf = 0.81 (30:70 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3099, 2977, 2933, 1701, 1545, 1366, 1246 and 1176; [α]D28 182 
(c = 0.060, MeOH); δH (500 MHz, CDCl3) 8.07-7.93 (1H, m, nitrophenyl 3-H), 7.80-7.69 (2H, 
m, nitrophenyl 4-H and nitrophenyl 5-H), 7.68-7.60 (1H, m, nitrophenyl 6-H), 5.95 (1H, 
app t, J 1.1, 5-H), 4.36-4.27 (1H, m, 3-H), 4.19 (1H, dd, J 13.1 and 1.9, 2-Ha), 2.58 (1H, dd, J 
13.1 and 2.3, 2-Hb), 2.11 (3H, d, J 1.1, 6-methyl), 1.50 (9H, s, Boc) and 1.17 (3H, d, J 6.6, 3-
methyl); δC (126 MHz, CDCl3) 153.2 (CO), 148.3 (nitrophenyl C-2), 133.9 (nitrophenyl C-
5), 131.7 (nitrophenyl C-1), 131.6 (nitrophenyl C-4), 130.8 (nitrophenyl C-6), 124.2 
(nitrophenyl C-3), 119.5 (C-6), 106.5 (C-5), 81.5 (Boc), 49.8 (C-3), 46.1 (C-2), 28.2 (Boc), 
20.0 (6-methyl) and 17.1 (3-methyl); HRMS found MH+, 398.1387.  C17H23N3O6S requires 
MH, 398.1386. 
Methyl 2-{[(2-methoxyethyl)carbamoyl]amino}-2-(prop-2-yl)pent-4-enoate, 189 
 
By general procedure Q, 2-methoxyethyl isocyanate (70.0 µL, 0.780 mmol) and 
amino ester  175 (89.4 mg, 0.520 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the urea 189 (82.5 mg, 58%) as a 
colourless amorphous solid, Rf = 0.31 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3351 (br), 
2933, 2880, 1732, 1635, 1555, 1227 and 1121; δH (500 MHz, CDCl3) 5.76-5.60 (1H, m, 4-
H), 5.53 (1H, s, NH), 5.15-4.98 (2H, m, 5-H2), 4.84 (1H, s, methoxyethyl 1-NH), 3.78 (3H, s, 
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methyl), 3.48 (2H, t, J 5.0, methoxyethyl 2-H2), 3.39 (3H, s, methoxyethyl 4-H3), 3.37-3.33 
(2H, m, methoxyethyl 1-H2), 3.31 (1H, dd, J 13.9 and 7.2, 3-Ha), 2.74 (1H, dd, J 13.9 and 7.4, 
3-Hb), 2.56 (1H, app hept, J 6.9, isopropyl 2-H), 1.00 (3H, d, J 6.9, isopropyl-MeA) and 0.93 
(3H, d, J 6.9, isopropyl-MeB); δC (126 MHz, CDCl3) 173.8 (C-1), 156.6 (urea CO), 133.9 (C-
4), 117.8 (C-5), 72.2 (methoxyethyl C-2), 67.5 (C-2), 58.6 (methyl), 51.9 (methoxyethyl C-
4), 40.4 (methoxyethyl C-1), 36.9 (C-3), 33.9 (isopropyl C-2), 17.8 (isopropyl-MeA) and 
17.7 (isopropyl-MeB); HRMS found MH+, 273.1833.  C13H24N2O4 requires MH, 273.1814. 
3 Cyclopropyl-5-(oxetan-3-yl)-5-(prop-2-en-1-yl)imidazolidine-2,4-dione, 191 
 
By general procedure Q, isocyanato cyclopropane (50.0 µL, 1.05 mmol) and amino 
ester 184 (130 mg, 0.700 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 100% EtOAc) to yield the urea 191 (75.8 mg, 40%) as a colourless 
amorphous solid, Rf = 0.13 (100% EtOAc); νmax/ cm-1 (ATR) 3358 (br), 2956, 2888, 1734, 
1646, 1557 and 1226; δH (500 MHz, CDCl3) 6.00 (1H, s, 2-NH), 5.82-5.65 (1H, m, 4-H), 5.21 
(1H, d, J 6.0, 5-Ha), 5.18 (1H, s, cyclopropyl-NH), 4.80 (1H, t, J 6.7, oxetanyl 2-Ha), 4.78-4.70 
(3H, m, 5-Hb and oxetanyl 4-H2), 4.64 (1H, t, J 6.8, oxetanyl 2-Hb), 3.98-3.88 (1H, m, 
oxetanyl 1-H), 3.83 (3H, s, methyl), 3.00 (1H, dd, J 13.9 and 8.0, 3-Ha), 2.72 (1H, dd, J 13.9 
and 6.8, 3-Hb), 2.50 (1H, tt, J 6.8 and 3.6, cyclopropyl 1-H), 0.86-0.70 (2H, m, cyclopropyl 
2-H2) and 0.68-0.56 (2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 173.1 (C-1), 157.8 
(urea CO), 132.2 (C-4), 119.8 (C-5), 73.2 (oxetanyl C-2), 72.9 (oxetanyl C-4), 62.5 (C-2), 
52.8 (methyl), 41.2 (oxetanyl C-1), 37.6 (C-3), 22.6 (cyclopropyl C-1), 7.7 (cyclopropyl C-
2) and 7.5 (cyclopropyl C-3); HRMS found MH+, 269.1508.  C13H20N2O4 requires MH, 
269.1501. 
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Methyl 2-[(4-fluorophenyl)methyl]-2-{[(2-methoxyethyl)carbamoyl]amino}pent-
4-enoate, 190 
 
By general procedure Q, 2-methoxyethyl isocyanate (0.160 mL, 1.79 mmol) and 
amino ester 186 (282 mg, 1.19 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the urea 190 (210 mg, 52%) as a 
colourless amorphous solid, Rf = 0.42 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3344 (br), 
2930, 1740, 1636, 1556, 1509 and 1221; δH (500 MHz, CDCl3) 6.98-6.92 (2H, m, 
fluorophenyl 2-H and fluorophenyl 6-H), 6.88-6.82 (2H, m, fluorophenyl 3-H and 
fluorophenyl 5-H), 5.58 (1H, ddt, J 17.3, 10.1 and 7.4, 4-H), 5.17 (1H, s, urea NH), 5.09-4.90 
(2H, m, 5-H2), 4.63 (1H, t, J 5.5, methoxyethyl 1-NH), 3.68 (3H, s, methyl), 3.65 (1H, d, J 
13.6, benzylic-Ha), 3.38 (2H, t, J 5.0, methoxyethyl 2-H2), 3.33-3.19 (6H, m, 3-Ha, 
methoxyethyl 1-H2 and methoxyethyl 4-H3), 3.02 (1H, d, J 13.6, benzylic-Hb) and 2.49 (1H, 
dd, J 13.8 and 7.7, 3-Hb); δC (126 MHz, CDCl3) 173.6 (C-1), 161.9 (d, J 244.8 Hz, 
fluorophenyl C-4), 156.5 (urea CO), 132.7 (C-4), 132.5 (d, J 3.3, fluorophenyl C-1), 131.3 
(d, J 7.9, fluorophenyl C-2 and fluorophenyl C-6), 118.8 (C-5), 114.9 (d, J 21.1, fluorophenyl 
C-3 and fluorophenyl C-5), 72.1 (methoxyethyl C-2), 65.4 (C-2), 58.7 (methyl), 52.5 
(methoxyethyl C-4), 40.3 (benzylic C) and 40.2 (C-3 and methoxyethyl C-1); δF (282 MHz, 
CDCl3) -116.3; HRMS found MH+, 339.1744.  C17H23FN2O4 requires MH, 339.1720. 
Methyl 2-{[(2-bromophenyl)methyl]amino}-2-(propan-2-yl)pent-4-enoate, 194 
 
2-Bromobenzaldehyde (2.12 mL, 18.2 mmol) was added to the amino ester 175 
(1.56 g, 9.11 mmol) in DCM (40 mL, ~0.2 M) in the presence of 4 Å mol. sieves (312 mg, 
0.2 w/w).  NaBH(OAc)3 (7.73 g, 36.4 mmol) was added and the mixture stirred at reflux 
overnight.  The mixture was concentrated in vacuo and the residue was purified by flash 
chromatography (SiO2, 95:5 Petrol–EtOAc), then again (SiO2, 95:5 Petrol–EtOAc) to yield 
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the alkylated amine 194 (2.07 g, 67%) as a yellow oil, Rf = 0.76 (80:20 Petrol–EtOAc); νmax/ 
cm-1 (ATR) 2962, 1725, 1464, 1437, 1212 and 1025; δH (500 MHz, CDCl3) 7.59-7.49 (2H, 
m, bromobenzyl 3-H and 6-H), 7.34-7.28 (1H, m, bromobenzyl 4-H), 7.12 (1H, app td, J 7.7, 
1.6, bromobenzyl 5-H), 6.06-5.89 (1H, m, 4-H), 5.18 (1H, dd, J 17.2 and 1.4, 5-Ha), 5.13 (1H, 
dd, J 10.2 and 0.8, 5-Hb), 3.87 (1H, d, J 13.0, benzylic-Ha), 3.79-3.72 (4H, m, methyl and 
benzylic-Hb), 2.72 (1H, ddt, J 15.0, 6.3 and 1.4, 3-Ha), 2.67-2.55 (1H, m, 3-Hb), 2.13 (1H, 
hept, J 6.9, isopropyl 2-H), 2.03 (1H, s, NH) and 1.00 (6H, d, J 6.9, isopropyl-MeA and 
isopropyl-MeB); δC (126 MHz, CDCl3) 175.1, (CO), 139.9 (bromobenzyl C-2), 134.3 
(bromobenzyl C-3), 132.6 (C-4), 130.2 (bromobenzyl C-6), 128.4 (bromobenzyl C-4), 
127.6 (bromobenzyl C-5), 123.9 (bromobenzyl C-1), 117.7 (C-5), 67.7 (C-2), 51.5 (methyl), 
47.3 (benzylic-C), 36.4 (C-3), 33.8 (isopropyl C-2), 17.8 (isopropyl-MeA) and 17.2 
(isopropyl-MeB); HRMS found MH+, 340.1011.  C16H22BrNO2 requires MH, 340.0912. 
Methyl 2-{[(2-bromo-4-methylphenyl)methyl]amino}-2-(propan-2-yl)pent-4-
enoate, 269 
 
By general procedure N, amino ester 175 (430 mg, 2.51 mmol) and 2-bromo-4-
methylbenzaldehyde (1.00 g, 5.02 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 95:5 Petrol–EtOAc) to yield the alkylated amine 269 (590 mg, 66%) 
as a colourless oil, Rf = 0.57 (90:10 Petrol–EtOAc); νmax/ cm-1 (ATR) 3073, 2964, 2877, 
1725, 1464, 1433, 1212 and 1141 ; δH (400 MHz, CDCl3) 7.41-7.36 (2H, m, bromobenzyl 
5-H and bromobenzyl 6-H), 7.10 (1H, d, J 7.8, bromobenzyl 3-H), 6.03-5.89 (1H, m, 4-H), 
5.23-5.14 (1H, m, 5-Ha), 5.12 (1H, d, J 10.1, 5-Hb), 3.81 (1H, d, J 12.7, benzylic-Ha), 3.74 (3H, 
s, methyl), 3.69 (1H, d, J 12.7, benzylic-Hb), 2.71 (1H, dd, J 15.0 and 6.3, 3-Ha), 2.62 (1H, dd, 
J 15.0 and 7.8, 3-Hb), 2.33 (3H, s, tolyl), 2.18-2.06 (1H, m, isopropyl 2-H), 1.97 (1H, br s, 
NH) and 0.98 (6H, d, J 6.9, isopropyl-MeA and isopropyl-MeB); δC (101 MHz, CDCl3) 175.2 
(C-1), 138.5 (bromobenzyl C-1), 136.8 (bromobenzyl C-2), 134.3 (C-4), 133.0 
(bromobenzyl C-6), 130.1 (bromobenzyl C-5), 128.3 (bromobenzyl C-3), 123.7 
(bromobenzyl C-4), 117.6 (C-5), 67.7 (C-2), 51.5 (methyl), 47.0 (benzylic-C), 36.3 (C-3), 
33.8 (isopropyl C-2), 20.7 (tolyl), 17.8 (isopropyl-MeA) and 17.2 (isopropyl-MeB); HRMS 
found MH+, 354.1085.  C17H24BrNO2 requires MH, 354.1068. 
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Methyl 2-{[(2-bromo-5-methylphenyl)methyl]amino}-2-(propan-2-yl)pent-4-
enoate, 270 
 
By general procedure N, amino ester 175 (430 mg, 2.51 mmol) and 2-bromo-5-
methylbenzaldehyde (1.00 g, 5.02 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 90:10 Petrol–EtOAc) to yield the alkylated amine 270 (710 mg, 
80%) as a colourless oil, Rf = 0.53 (90:10 Petrol–EtOAc); νmax/ cm-1 (ATR) 3356, 3075, 
2964, 1726, 1466, 1212, 1024 and 807; δH (400 MHz, CDCl3) 7.19 (1H, d, J 8.1, 
bromobenzyl 3-H), 7.08 (1H, d, J 1.9, bromobenzyl 6-H), 6.72 (1H, dd, J 8.1 and 1.9, 
bromobenzyl 4-H), 5.81-5.68 (1H, m, 4-H), 5.00-4.93 (1H, m, 5-Ha), 4.93-4.88 (1H, m, 5-
Hb), 3.59 (1H, d, J 12.6, benzylic-Ha), 3.53 (3H, s, methyl), 3.50-3.43 (1H, m, benzylic-Hb), 
2.50 (1H, dd, J 15.0 and 6.3, 3-Ha), 2.40 (1H, dd, J 15.0 and 7.8, 3-Hb), 2.10 (3H, s, tolyl), 
1.97-1.86 (1H, m, isopropyl 2-H), 1.78 (1H, br s, NH) and 0.77 (6H, d, J 6.9, isopropyl-MeA 
and isopropyl-MeB); δC (101 MHz, CDCl3) 175.1 (C-1), 139.3 (bromobenzyl C-1), 137.4 
(bromobenzyl C-2), 134.3 (C-4), 132.3 (bromobenzyl C-3), 131.1 (bromobenzyl C-6), 
129.3 (bromobenzyl C-4), 120.6 (bromobenzyl C-5), 117.7 (C-5), 67.7 (C-2), 51.5 (methyl), 
47.3 (benzylic-C), 36.3 (C-3), 33.7 (isopropyl C-2), 21.0 (tolyl), 17.8 (isopropyl-MeA) and 
17.2 (isopropyl-MeB); HRMS found MH+, 354.1083.  C17H24BrNO2 requires MH, 354.1068. 
Methyl 2-{[(2-bromo-5-fluorophenyl)methyl]amino}-2-(propan-2-yl)pent-4-
enoate, 271 
 
By general procedure N, amino ester 175 (500 mg, 2.92 mmol) and 2-bromo-5-
fluorobenzaldehyde (1.19 g, 5.84 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 95:5 Petrol–EtOAc) to yield the alkylated amine 271 (670 mg, 64%) 
as a colourless oil, Rf = 0.69 (90:10 Petrol–EtOAc); νmax/ cm-1 (ATR) 3074, 2966, 1727, 
1464, 1434, 1215 and 1142; δH (400 MHz, CDCl3) 7.25 (1H, dd, J 8.7 and 5.3, bromobenzyl 
6-H), 7.13 (1H, dd, J 8.7 and 3.1, bromobenzyl 3-H), 6.63 (1H, td, J 8.7 and 3.1, bromobenzyl 
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4-H), 5.74-5.61 (1H, m, 4-H), 4.97-4.85 (2H, m, 5-H2), 3.62-3.49 (5H, m, benzylic-H2 and 
methyl), 2.46 (1H, dd, J 15.0 and 6.4, 3-Ha), 2.38 (1H, dd, J 15.0 and 7.8, 3-Hb), 1.95-1.84 
(1H, m, isopropyl 2-H), 1.76 (1H, br s, NH) and 0.77 (6H, d, J 6.9, isopropyl-MeA and 
isopropyl-MeB); δC (101 MHz, CDCl3) 175.1 (C-1), 162.2 (d, J 246.2, bromobenzyl C-5), 
142.4 (d, J 7.3, bromobenzyl C-1), 134.1 (C-4), 133.5 (d, J 8.0, bromobenzyl C-6), 117.9 (C-
5), 117.4 (d, J 3.0, bromobenzyl C-2), 116.9 (d, J 23.5, bromobenzyl C-3), 115.3 (d, J 22.7, 
bromobenzyl C-4), 67.7 (C-2), 51.6 (methyl), 47.0 (benzylic -C), 36.6 (C-3), 34.0 (isopropyl 
C-2), 17.8 (isopropyl-MeA) and 17.2 (isopropyl-MeB); δF (376 MHz, CDCl3) -114.6; HRMS 
found MH+, 358.0834.  C16H21BrFNO2 requires MH, 358.0818. 
Methyl 2-{[(2-bromo-4-fluorophenyl)methyl]amino}-2-(propan-2-yl)pent-4-
enoate, 272 
 
By general procedure N, amino ester 175 (500 mg, 2.92 mmol) and 2-bromo-4-
fluorobenzaldehyde (1.19 g, 5.84 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 90:10 Petrol–EtOAc) to yield the alkylated amine 272 (700 mg, 
67%) as a colourless oil, Rf = 0.53 (90:10 Petrol–EtOAc); νmax/ cm-1 (ATR) 3356, 3074, 
2966, 1726, 1598, 1484, 1215 and 857; δH (400 MHz, CDCl3) 7.51 (1H, dd, J 8.3 and 6.2, 
bromobenzyl 3-H), 7.28 (1H, dd, J 8.3 and 2.6, bromobenzyl 6-H), 7.02 (1H, td, J 8.3 and 
2.6, bromobenzyl 5-H), 6.01-5.83 (1H, m, 4-H), 5.16 (1H, dd, J 17.2 and 1.5, 5-Ha), 5.13-
5.07 (1H, m, 5-Hb), 3.81 (1H, d, J 13.0, benzylic-Ha), 3.75 (3H, s, methyl), 3.70 (1H, d, J 13.0, 
benzylic-Hb), 2.69 (1H, dd, J 15.0 and 6.3, 3-Ha), 2.60 (1H, dd, J 15.0 and 7.8, 3-Hb), 2.17-
2.05 (1H, m, isopropyl 2-H), 1.95 (1H, br s, NH) and 0.98 (6H, d, J 6.9, isopropyl-MeA and 
isopropyl-MeB); δC (101 MHz, CDCl3) 175.0 (C-1), 161.3 (d, J 249.3, bromobenzyl C-4), 
135.9 (d, J 3.5, bromobenzyl C-2), 134.2 (C-4), 131.1 (d, J 8.3, bromobenzyl C-3), 123.6 (d, 
J 9.5, bromobenzyl C-1), 119.7 (d, J 24.3, bromobenzyl C-6), 117.7 (C-5), 114.5 (d, J 20.6, 
bromobenzyl C-5), 67.7 (C-2), 51.5 (methyl), 46.6 (benzylic-C), 36.4 (C-3), 33.9 (isopropyl 
C-2), 17.8 (isopropyl-MeA) and 17.2 (isopropyl-MeB); δF (376 MHz, CDCl3) -114.1; HRMS 
found MH+, 358.0832.  C16H21BrFNO2 requires MH, 358.0818. 
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Methyl 2-(((3-bromopyridin-4-yl)methyl)amino)-2-isopropylpent-4-enoate, 273 
 
By general procedure N, amino ester 175 (461 mg, 2.69 mmol) and 3-bromo-4-
pyridine carboxaldehyde (1.00 g, 5.38 mmol) gave a crude residue which was purified by 
flash chromatography (SiO2, 80:20 Petrol–EtOAc) to yield the alkylated amine 273 
(520 mg, 57%) as a colourless oil, Rf = 0.16 (90:10 Petrol–EtOAc); νmax/ cm-1 (ATR) 3075, 
2965, 2877, 1727, 1468, 1434, 1218 and 1022; δH (400 MHz, CDCl3) 8.42 (1H, s, 
bromopyridyl 2-H), 8.27 (1H, d, J 4.9, bromopyridyl 6-H), 7.35 (1H, d, J 4.9, bromopyridyl 
5-H), 5.78-5.51 (1H, m, 4-H), 4.89 (2H, t, J 13.4, 5-H2), 3.59 (2H, d, J 6.5, benzylic-H2), 3.53 
(3H, s, methyl), 2.44 (1H, dd, J 15.0 and 6.4, 3-Ha), 2.36 (1H, dd, J 15.0 and 7.9, 3-Hb), 1.94-
1.84 (1H, m, isopropyl 2-H), 1.77 (1H, br s, NH) and 0.77 (6H, d, J 6.9, isopropyl-MeA and 
isopropyl-MeB); δC (101 MHz, CDCl3) 175.0 (CO), 151.4 (bromopyridyl C-2), 149.2 
(bromopyridyl C-3), 148.4 (bromopyridyl C-6), 133.9 (C-4), 124.2 (bromopyridyl C-5), 
121.9 (bromopyridyl C-4), 118.1 (C-5), 67.7 (C-2), 51.7 (methyl), 46.3 (benzylic-C), 36.8 
(C-3), 34.1 (isopropyl C-2), 17.8 (isopropyl-MeA and 17.2 (isopropyl-MeB); HRMS found 
MH+, 341.1004.  C15H21BrN2O2 requires MH, 341.0864. 
Methyl 2-{[(2-bromophenyl)methyl]amino}pent-4-enoate, 275 
 
Et3N (0.420 mL, 3.02 mmol) was added to a mixture of methyl 2-aminopent-4-
enoate hydrochloride (500 mg, 3.02 mmol) and bromobenzaldehyde (1.12 g, 6.04 mmol), 
which by general procedure N, gave a crude residue which was purified by flash 
chromatography (SiO2, 95:5 Petrol–EtOAc) to yield the alkylated amine 275 (560 mg, 62%) 
as a colourless oil, Rf = 0.45 (80:20 Petrol–EtOAc); νmax/ cm-1 (ATR) 3331 (br), 3073, 2980, 
2949, 2841, 1733, 1435, 1195 and 748; δH (400 MHz, CDCl3) 7.55 (1H, d, J 7.6, 
bromobenzyl 6-H), 7.43 (1H, dd, J 7.6 and 1.6, bromobenzyl 3-H), 7.29 (1H, t, J 7.6, 
bromobenzyl 4-H), 7.13 (1H, td, J 7.6 and 1.6, bromobenzyl 5-H), 5.78 (1H, ddt, J 17.2, 10.1 
and 7.1, 4-H), 5.17-5.12 (1H, m, 5-Ha), 5.12-5.09 (1H, m, 5-Hb), 3.93 (1H, d, J 14.0, benzylic-
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Ha), 3.79 (1H, d, J 14.0, benzylic-Hb), 3.72 (3H, s, methyl), 3.40 (1H, t, J 6.5, 2-H), 2.54-2.40 
(2H, m, 3-H2) and 2.06 (1H, br s, NH); δC (101 MHz, CDCl3) 174.7 (C-1), 138.8 
(bromobenzyl C-2), 133.6 (C-4), 132.8 (bromobenzyl C-6), 130.2 (bromobenzyl C-3), 
128.7 (bromobenzyl C-4), 127.4 (bromobenzyl C-5), 124.1 (bromobenzyl C-1), 118.2 (C-
5), 60.4 (methyl), 51.9 (benzylic-C), 51.7 (C-2) and 37.7 (C-3); HRMS found MH+, 298.0452.  
C13H16BrNO2 requires MH, 298.0442. 
Methyl 2-{[(2-bromo-4-fluorophenyl)methyl]amino}pent-4-enoate, 276 
 
Et3N (0.420 mL, 3.02 mmol) was added to a mixture of methyl 2-aminopent-4-
enoate hydrochloride (500 mg, 3.02 mmol) and 2-bromo-4-fluoro benzaldehyde (1.23 g, 
6.04 mmol), which by general procedure N, gave a crude residue which was purified by 
flash chromatography (SiO2, 95:5 to 85:15 Petrol–EtOAc) to yield the alkylated amine 276 
(440 mg, 46%) as a colourless oil, Rf = 0.40 (80:20 Petrol–EtOAc); νmax/ cm-1 (ATR) 3077, 
2950, 2842, 1734, 1484, 1220, 1172, 876 and 858; δH (400 MHz, CDCl3) 7.41 (1H, dd, J 8.4 
and 6.1, bromobenzyl 3-H), 7.30 (1H, dd, J 8.4 and 2.6, bromobenzyl 6-H), 7.02 (1H, td, J 
8.4 and 2.6, bromobenzyl 5-H), 5.85-5.70 (1H, m, 4-H), 5.17-5.12 (1H, m, 5-Ha), 5.12-5.09 
(1H, m, 5-Hb), 3.89 (1H, d, J 14.0, benzylic-Ha), 3.81-3.68 (4H, m, benzylic-Hb and methyl), 
3.37 (1H, t, J 6.5, 2-H), 2.53-2.37 (2H, m, 3-H2) and 1.97 (1H, br s, NH); δC (101 MHz, CDCl3) 
174.7 (C-1), 161.5 (d, J 250.1, bromobenzyl C-4), 134.7 (bromobenzyl C-2), 133.5 (C-4), 
131.0 (d, J 8.2, bromobenzyl C-3), 123.9 (d, J 9.3, bromobenzyl C-1), 119.9 (d, J 24.3, 
bromobenzyl C-6), 118.2 (C-5), 114.4 (d, J 20.6, bromobenzyl C-5), 60.3 (C-2), 51.8 
(methyl), 51.1 (benzylic-C) and 37.7 (C-3); δF (376 MHz, CDCl3) -113.7; HRMS found MH+, 
316.0410.  C13H15BrFNO2 requires MH, 316.0348. 
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Methyl 2-{[(2-bromo-5-fluorophenyl)methyl]amino}pent-4-enoate, 277 
 
Et3N (0.420 mL, 3.02 mmol) was added to a mixture of methyl 2-aminopent-4-
enoate hydrochloride (500 mg, 3.02 mmol) and 2-bromo-5-fluoro benzaldehyde (1.23 g, 
6.04 mmol), which by general procedure N, gave a crude residue which was purified by 
flash chromatography (SiO2, 95:5 to 80:20 Petrol–EtOAc) to yield the alkylated amine 277 
(480 mg, 50%) as a colourless oil, Rf = 0.73 (70:30 Petrol–EtOAc); νmax/ cm-1 (ATR) 3345 
(br), 3077, 2951, 2843, 1734, 1464, 1435, 1197 and 1149; δH (400 MHz, CDCl3) 7.47 (1H, 
dd, J 8.9 and 5.3, bromobenzyl 6-H), 7.24 (1H, dd, J 8.9 and 3.1, bromobenzyl 3-H), 6.85 
(1H, td, J 8.9 and 3.1, bromobenzyl 4-H), 5.87-5.71 (1H, m, 4-H), 5.20-5.09 (2H, m, 5-H2), 
3.90 (1H, d, J 14.8, benzylic-Ha), 3.76-3.68 (4H, m, benzylic-Hb and methyl), 3.38 (1H, t, J 
6.4, 2-H), 2.54-2.39 (2H, m, 3-H2) and 2.00 (1H, br s, NH); δC (101 MHz, CDCl3) 174.7 (C-
1), 162.1 (d, J 246.7, bromobenzyl C-5), 141.2 (d, J 7.1, bromobenzyl C-1), 133.7 (d, J 8.0, 
bromobenzyl C-6), 133.4 (C-4), 118.3 (C-5), 117.6 (d, J 3.1, bromobenzyl C-2), 116.8 (d, J 
23.6, bromobenzyl C-3), 115.5 (d, J 22.6, bromobenzyl C-4), 60.4 (methyl), 51.8 (C-2), 51.5 
(benzylic-C) and 37.7 (C-3); δF (376 MHz, CDCl3) -114.7; HRMS found MH+, 316.0345.  
C13H15BrFNO2 requires MH, 316.0348. 
Methyl 2-{[(3-bromopyridin-4-yl)methyl]amino}pent-4-enoate, 278 
 
Et3N (0.420 mL, 3.02 mmol) was added to a mixture of methyl 2-aminopent-4-
enoate hydrochloride (500 mg, 3.02 mmol) and 3-bromo-4-pyridine carboxaldehyde 
(1.12 g, 6.04 mmol), which by general procedure N, gave a crude residue which was 
purified by flash chromatography (SiO2, 70:30 Petrol–EtOAc) to yield the alkylated amine 
278 (490 mg, 54%) as a colourless oil, Rf = 0.44 (70:30 Petrol–EtOAc); νmax/ cm-1 (ATR) 
3322 (br), 2950, 1734, 1198, 1171, 1147, 1016 and 991; δH (400 MHz, CDCl3) 8.57 (1H, s, 
bromopyridyl 2-H), 8.41 (1H, d, J 5.0, bromopyridyl 6-H), 7.39 (1H, dd, J 5.0 and 0.8, 
bromopyridyl 5-H), 5.84-5.64 (1H, m, 4-H), 5.14-5.02 (2H, m, 5-H2), 3.86 (1H, dd, J 15.7 
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and 0.9, benzylic-Ha), 3.68-3.59 (4H, m, benzylic-Hb and methyl), 3.29 (1H, dd, J 6.7 and 
6.0, 2-H), 2.50-2.29 (2H, m, 3-H2) and 1.91 (1H, br s, NH); δC (101 MHz, CDCl3) 174.6 (C-
1), 151.6 (bromopyridyl C-2), 148.4 (bromopyridyl C-6), 148.0 (bromopyridyl C-3), 133.3 
(C-4), 124.0 (bromopyridyl C-5), 122.0 (bromopyridyl C-4), 118.5 (C-5), 60.5 (methyl), 
51.9 (C-2), 50.6 (benzylic-C) and 37.7 (C-3); HRMS found MH+, 299.0352.  C12H15BrN2O2 
requires MH, 299.0395. 
Methyl 2-(2-{[(tert-butoxy)carbonyl]amino}acetamido)-2-(2-fluorophenyl)pent-4-
enoate, 193 
 
By general procedure P, the methyl ester 188 (560 mg, 2.55 mmol) gave the crude 
allylated amino ester.  TBTU (732 mg, 2.28 mmol) was added to a stirred solution of N-
Boc-glycine (399 mg, 2.28 mmol) in DCM (15.0 mL, ~0.1 M).  The crude amino ester 
(340 mg, 1.52 mmol) and Et3N (0.320 mL, 2.28 mmol) was added and the reaction mixture 
was stirred overnight, before being extracted with DCM (3 × 20 mL), and washed with 
water (20 mL) and brine (20 mL).  The combined organic layers were dried (MgSO4) and 
concentrated in vacuo before being purified by flash chromatography (SiO2, 50:50 Petrol–
EtOAc) to yield the amide 193 (520 mg, 54% over two steps) as a yellow oil, Rf = 0.78 
(40:60 Petrol–EtOAc); νmax/ cm-1 (ATR) 3390, 2979, 1682, 1491, 1231 and 1164; δH (500 
MHz, CDCl3) 7.65 (1H, td, J 8.0 and 1.1, fluorophenyl 4-H), 7.50 (1H, s, NH), 7.35-7.30 (1H, 
m, fluorophenyl 3-H), 7.21 (1H, td, J 8.0 and 1.0, fluorophenyl 5-H), 7.03 (1H, ddd, J 11.7, 
8.0 and 1.1, fluorophenyl 6-H), 5.75-5.65 (1H, m, 4-H), 5.20 (1H, d, J 2.6, 5-Ha), 5.17 (1H, 
app s, 5-Hb), 5.06 (1H, br s, glycine-Ha), 3.91 (1H, dd, J 13.3 and 6.5, 3-Ha), 3.84-3.70 (4H, 
m, methyl and glycine-Hb), 2.92 (1H, dd, J 13.3 and 8.0, 3-Hb) and 1.48 (9H, s, Boc); δC (126 
MHz, CDCl3) 172.1 (ester-CO), 167.8 (glycine C-1), 159.1 (fluorophenyl C-2), 131.4 (C-4), 
129.9 (d, J 8.9, fluorophenyl C-4), 128.9 (d, J 3.2, fluorophenyl C-3), 126.8 (fluorophenyl 
C-1), 123.8 (d, J 3.4, fluorophenyl C-5), 119.9 (C-5), 115.8 (d, J 22.2, fluorophenyl C-6), 62.3 
(C-2), 53.3 (methyl), 45.0 (glycine C-2), 37.2 (C-3) and 28.3 (Boc), Boc quaternary carbons 
not observed; δF (282 MHz, CDCl3) -113.9; HRMS found MH+, 381.1827.  C19H25FN2O5 
requires MH, 381.1826. 
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(2R)-2-[N-(3-Hydroxypropyl)2-nitrobenzenesulfonamido]-N-[(4-methoxyphenyl) 
methyl]-3-{[(4-methoxyphenyl)methyl]amino}propanamide, 232 
 
By general procedure F, propargyl sulfonamide 223 (169 mg, 0.650 mmol) and 
cyclic sulfamidate S-54 (240 mg, 0.590 mmol) gave a crude residue which was purified 
by flash chromatography (SiO2, 100% EtOAc) to yield the sulfonamide 232 (110 mg, 32%) 
as a yellow oil, Rf = 0.24 (100% EtOAc); νmax/ cm-1 (ATR) 3392 (br), 2936, 2837, 1667, 
1542, 1512 and 1247; [α]D27 121 (c = 0.057, CHCl3); δH (500 MHz, CDCl3) 8.20-8.14 (1H, m, 
nitrophenyl 3-H), 8.09 (1H, t, J 5.1, 1-NH), 7.69-7.61 (2H, m, nitrophenyl 4-H and 
nitrophenyl 5-H), 7.56-7.49 (1H, m nitrophenyl 6-H), 7.17 (2H, d, J 8.6, 1-PMB 2-H and 3-
PMB 2-H), 7.03 (2H, d, J 8.6, 1-PMB 6-H and 3-PMB 6-H), 6.87 (2H, d, J 8.6, 1-PMB 3-H and 
3-PMB 3-H), 6.80 (2H, d, J 8.6, 1-PMB 5-H and 3-PMB 5-H), 4.53 (1H, dd, J 8.5 and 6.0, 2-
H), 4.37-4.24 (2H, m, 1-benzylic-H2), 3.83 (3H, s, 1-PMB-methyl), 3.82 (3H, s, 3-PMB-
methyl), 3.69 (1H, d, J 12.8, 3-benzylic-Ha), 3.65 (1H, d, J 12.8, 3-benzylic-Hb), 3.59 (2H, t, 
J 5.7, hydroxypropyl 3-H2), 3.53 (2H, t, J 7.1, hydroxypropyl 1-H2), 3.16 (1H, dd, J 12.2 and 
8.5, 3-Ha), 3.06 (1H, dd, J 12.2 and 6.0, 3-Hb), 2.13 (2H, br s, 3-NH and OH) and 1.90-1.71 
(2H, m, hydroxypropyl 2-H2); δC (126 MHz, CDCl3) 169.1 (C-1), 159.1 (1-PMB C-4), 158.9 
(3-PMB C-4), 147.9 (nitrophenyl C-2), 133.7 (nitrophenyl C-5), 133.0 (nitrophenyl C-1), 
131.8 (nitrophenyl C-4), 131.2 (nitrophenyl C-6), 131.0 (1-PMB C-1), 129.8 (3-PMB C-1), 
129.4 (1-PMB C-2 and 3-PMB C-2), 129.2 (1-PMB C-6 and 3-PMB C-6), 124.2 (nitrophenyl 
C-3), 114.1 (1-PMB C-3 and 3-PMB C-3), 113.9 (1-PMB C-5 and 3-PMB C-5), 59.5 (C-2), 
59.3 (hydroxypropyl C-3), 55.31 (1-PMB methyl), 55.28 (3-PMB methyl), 52.9 (3-PMB 
benzylic-C), 49.0 (hydroxypropyl C-1), 43.8 (C-3), 43.1 (1-PMB benzylic-C) and 32.7 
(hydroxypropyl C-2); HRMS found MH+, 587.2207.  C28H34N4O8S requires MH, 587.2175. 
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(2R)-2-{N-[(2R)-2-Cyclopropyl-2-hydroxyethyl]-2-nitrobenzenesulfonamido}-N-
[(4-methoxyphenyl)methyl]-3-{[(4-methoxyphenyl)methyl]amino}propanamide, 
234 
 
By general procedure F, sulfonamide 230 (370 mg, 1.29 mmol) and cyclic 
sulfamidate S-54 (476 mg, 1.17 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 30:70 Petrol–EtOAc) to yield the sulfonamide 234 (177 mg, 25%) 
as a yellow oil, Rf = 0.12 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3378 (br), 2927, 1542, 
1514, 1249, 1177 and 1025; [α]D25 12 (c = 1.1, CHCl3); δH (500 MHz, CDCl3) 8.03 (1H, t, J 
5.2, 1-NH), 7.95 (1H, dd, J 7.5 and 1.6, nitrophenyl 3-H), 7.45-7.38 (2H, m, nitrophenyl 4-
H and nitrophenyl 5-H), 7.32 (1H, dd, J 7.5 and 1.6, nitrophenyl 6-H), 6.91 (2H, d, J 8.6, 1-
PMB 3-H and 1- PMB 5-H), 6.84 (2H, d, J 8.5, 3-PMB 3-H and 3-PMB 5-H), 6.62 (2H, d, J 8.6, 
1-PMB 2-H and 1-PMB 6-H), 6.57 (2H, d, J 8.5, 3-PMB 2-H and 3-PMB 6-H), 4.42 (1H, t, J 
7.3, 3-NH), 4.07 (2H, d, J 5.2, 1-PMB benzylic-H2), 3.59 (3H, s, 1-PMB methyl), 3.57 (3H, s, 
3-PMB methyl), 3.57-3.54 (1H, m, 2-H), 3.54-3.43 (3H, m, 3-H2 and ethyl 1-Ha), 3.13 (1H, 
dd, J 15.1 and 10.1, ethyl 1-Hb), 3.01-2.92 (3H, m, 3-PMB benzylic-H2 and ethyl 2-H), 0.55-
0.47 (1H, m, cyclopropyl 1-H), 0.30-0.19 (2H, m, cyclopropyl 2-H2), 0.14-0.08 (1H, m, 
cyclopropyl 3-Ha) and 0.07-0.00 (1H, m, cyclopropyl 3-Hb); δC (126 MHz, CDCl3) 169.6 (C-
1), 159.2 (1-PMB C-4), 159.1 (3-PMB C-4), 148.0 (nitrophenyl C-2), 133.8 (nitrophenyl C-
5), 133.0 (nitrophenyl C-1), 132.1 (nitrophenyl C-4), 131.4 (nitrophenyl C-6), 129.8 (1-
PMB C-3 and 1-PMB C-5), 129.7 (1-PMB C-1 and 3-PMB C-1), 129.2 (3-PMB C-3 and 3-
PMB C-5), 124.1 (nitrophenyl C-3), 114.13 (1-PMB C-2 and 1-PMB C-6), 114.06 (3-PMB C-
2 and 3-PMB C-6), 73.6 (ethyl C-2), 59.4 (C-2), 55.31 (1-PMB methyl), 55.28 (3-PMB 
methyl), 53.1 (C-3), 52.7 (ethyl C-1), 49.2 (3-PMB benzylic-C), 43.2 (1-PMB benzylic-C), 
15.2 (cyclopropyl C-1), 2.5 (cyclopropyl C-2) and 1.7 (cyclopropyl C-3); HRMS found MH+, 
613.2335.  C30H36N4O8S requires MH, 613.2332. 
 
 
 180 
 
tert-Butyl N-[(3R)-3-({2-[(tert-butyldiphenylsilyl)oxy]ethyl}amino)pent-4-en-1-yl] 
carbamate, 57 
 
By general procedure I, allylic carbonate 45 (1.00 g, 3.86 mmol), amine 56 (1.50 g, 
1.3 mmol), and phosphoramidite S-21 (83.7 mg, 4 mol%) gave a crude residue which was 
purified by flash chromatography (SiO2, 70:30 Petrol–EtOAc) to give the alkene 57 
(790 mg, 42%) as a yellow oil, Rf = 0.44 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3341 (br), 
2930, 1698, 1505, 1248, 1169 and 1109; [α]D25 −2.9 (c = 0.39, CHCl3); δH (500 MHz, CDCl3) 
7.72-7.67 (4H, m, phenyl 3-H and phenyl 5-H), 7.49-7.38 (6H, m, phenyl 2-H, phenyl 4-H 
and phenyl 6-H), 5.72-5.57 (1H, m, 4-H), 5.18-5.11 (2H, m, 5-H2), 5.10 (1H, br s, NH), 3.84-
3.74 (2H, m, ethyl 2-H2), 3.25 (1H, dt, J 12.5 and 5.8, 1-Ha), 3.17 (1H, dt, J 19.1 and 6.5, 1-
Hb), 3.10 (1H, dd, J 13.8 and 6.9, 3-H), 2.85-2.77 (1H, m, ethyl 1-Ha), 2.64 (1H, dt, J 11.9 and 
5.0, ethyl 1-Hb), 1.66 (2H, dd, J 13.8 and 6.5, 2-H2), 1.46 (9H, s, Boc) and 1.08 (9H, s, tBu); 
δC (126 MHz, CDCl3) 156.0 (CO), 140.4 (C-4), 135.6 (phenyl C-3 and phenyl C-5), 133.7 
(1H, d, J 2.5, phenyl C-1), 129.7 (phenyl C-4), 127.70 (phenyl C-2), 127.69 (phenyl C-6), 
116.2 (C-5), 63.3 (ethyl C-2), 60.0 (C-3), 48.8 (ethyl C-1), 38.0 (C-1), 35.3 (C-2), 28.5 (Boc), 
26.9 (tBu) and 19.2 (Si-C); HRMS found MH+, 483.3139.  C28H42N2O3Si requires MH, 
483.3043. 
tert-Butyl N-[(3R)-3-(9,9-dimethyl-3-oxo-1,8,8-triphenyl-2,7-dioxa-4-aza-8-
siladecan-4-yl)pent-4-en-1-y]carbamate, 247 
 
By general procedure J, amine 57 (395 mg, 0.820 mmol) gave the protected amine 
247 (450 mg, 89%) as a yellow oil which was used without further purification, Rf = 0.70 
(70:30 Petrol–EtOAc); νmax/ cm-1 (ATR) 3347, 2890, 2857, 1697, 1412, 1168 and 1111; 
[α]D25 5.5 (c = 1.7, CHCl3); δH (501 MHz, MeOD) 7.47 (4H, d, J 7.4, phenyl 3-H and phenyl 
5-H), 7.30-7.24 (2H, m, phenyl 4-H), 7.21 (4H, t, J 7.4, phenyl 2-H and phenyl 6-H), 7.16-
7.05 (4H, m,  benzyl-H), 5.64 (1H, ddd, J 17.1, 10.5 and 6.4, 4-H), 4.98-4.85 (4H, m, 5-H2 
and siladecanyl 1-H2), 4.22 (1H, dd, J 13.0 and 7.0, 1-Ha), 3.66-3.51 (2H, m, siladecanyl 6-
H2), 3.26-3.16 (2H, m, siladecanyl 5-H2), 2.90-2.70 (2H, m, 1-Hb and 3-H), 1.63-1.54 (2H, 
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m, 2-H2), 1.25 (9H, s, Boc) and 0.87 (9H, s, tBu); δC (126 MHz, MeOD) 158.1 (siladecanyl C-
3), 157.9 (CO), 138.1 (C-4), 137.9 (benzyl C-1), 136.6 (phenyl C-3 and phenyl C-5), 134.8 
(phenyl C-1), 130.8 (phenyl C-4), 129.4 (benzyl C-3 and benzyl C-5), 129.0 (benzyl C-4), 
128.8 (benzyl C-2 and benzyl C-6), 128.7 (phenyl C-2), 128.7 (phenyl C-6), 117.4 (C-5), 
68.3 (siladecanyl C-1), 61.4 (siladecanyl C-6), 58.3 (C-3), 47.5 (siladecanyl C-5), 38.6 (C-
1), 33.2 (C-2), 28.8 (Boc), 27.4 (tBu) and 19.9 (Si-C); HRMS found MH+, 617.3429.  
C36H48N2O5Si requires MH, 617.3410. 
tert-Butyl N-[(3R)-3-{[2-(oxetan-3-yloxy)ethyl]amino}pent-4-en-1-yl]carbamate, 
248 
 
By general procedure I, the amine 246 (90.0 mg, 0.770 mmol), allylic carbonate 
45 (154 mg, 0.590 mmol) and phosphoramidite S-21 (12.8 mg, 4 mol%) gave a crude 
residue which was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) and then 
again (SiO2, 5:95 MeOH–DCM) to give the alkene 248 (30.0 mg, 17%) as a yellow oil, Rf = 
0.16 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 3314 (br), 2960, 2930, 1693, 1511, 1249 and 
1170 ; [α]D25 −4.9 (c = 0.16, CHCl3); δH (500 MHz, MeOD) 5.59-5.48 (1H, m, 4-H), 5.24-5.15 
(2H, m, 5-H2), 3.15 (1H, dd, J 13.2 and 8.4, 3-H), 3.09-2.99 (1H, m, 1-Ha), 2.92 (1H, dt, J 14.0 
and 7.1, 1-Hb), 2.67-2.58 (1H, m, ethyl 2-Ha), 2.55-2.45 (1H, m, ethyl 2-Hb), 1.71 (1H, td, J 
13.2 and 7.1, 2-Ha), 1.52 (1H, ddd, J 20.6, 13.2 and 7.1, 2-Hb), 1.48-1.39 (2H, m, ethyl 1-H2), 
1.34 (9H, s, Boc), 1.28 (2H, dd, J 15.0 and 7.4, oxetanyl 2-Ha and oxetanyl 4-Ha) and 0.85 
(3H, app t, J 7.4, oxetanyl 1-H, oxetanyl 2-Hb and oxetanyl 4-Hb); δC (126 MHz, MeOD) 158.6 
(CO), 138.1 (C-4), 120.2 (C-5), 80.1 (Boc), 60.8 (C-3), 47.3 (C-1), 37.9 (ethyl C-2), 35.2 (C-
2), 31.4 (ethyl C-1), 28.7 (Boc), 21.2 (oxetanyl C-2 and oxetanyl C-4) and 14.1 (oxetanyl C-
1); HRMS found MH+, 301.2124.  C15H28N2O4 requires MH, 301.2127. 
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tert-Butyl N-[(3R)-3-{[(benzyloxy)carbonyl][2-(oxetan-3-yloxy)ethyl]amino}pent-
4-en-1-yl]carbamate, 249 
 
By general procedure J, amine 248 (70.0 mg, 0.230 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to give the 
protected amine 249 (81.4 mg, 81%) as a yellow oil, Rf = 0.76 (70:30 Petrol–EtOAc); 
νmax/ cm-1 (ATR) 2961, 2933, 2873, 2495, 1663, 1414, 1155 and 698; [α]D20 32 (c = 0.597, 
CHCl3); δH (501 MHz, MeOD) 7.28-7.22 (4H, m, benzyl 2-H, benzyl 3-H, benzyl 5-H and 
benzyl 6-H), 7.21-7.17 (1H, m, benzyl 4-H), 5.81 (1H, ddd, J 17.1, 10.7 and 6.6, 4-H), 5.07 
(1H, d, J 10.7, 5-Ha), 5.06-5.04 (1H, m, 5-Hb), 5.02 (2H, app d, J 3.3, benzylic-H2), 4.27 (1H, 
dd, J 13.3 and 6.6, 3-H), 3.06 (2H, app td, J 7.2 and 2.7, ethyl 1-H2), 2.99-2.87 (2H, m, 1-H2), 
1.75 (2H, app q, J 7.1, 2-H2), 1.48-1.40 (2H, m, ethyl 2-H2), 1.32 (9H, s, Boc), 1.22-1.13 (2H, 
m, oxetanyl 2-Ha and oxetanyl 3-H) and 0.78 (3H, app t, J 7.4, oxetanyl 2-Hb and oxetanyl 
4-H2); δC (126 MHz, MeOD) 158.2 (Boc), 158.0 (CO), 138.4 (C-4), 138.1 (benzyl C-1), 129.4 
(benzyl C-2 and benzyl C-6), 129.0 (benzyl C-3 and benzyl C-5), 128.9 (benzyl C-4), 117.1 
(C-5), 68.2 (benzylic-C), 58.7 (C-3), 46.2 (ethyl C-1), 38.8 (C-1), 33.4 (C-2), 32.9 (ethyl C-
2), 28.7 (Boc), 21.1 (oxetanyl C-2 and oxetanyl C-4) and 13.9 (oxetanyl C-3), Boc 
quaternary carbon not observed. 
5.6  Synthesis of Scaffolds 
N-Methoxyethyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-4-(trifluoroacetyl)-1,4-
diazepane-5-carboxamide, 51 
 
By general procedure K, ketone 32 (450 mg, 1.05 mmol) and 2-methoxyethyl 
isocyanide (179 mg, 2.10 mmol) gave a crude product which was purified by flash 
chromatography (SiO2, 30:70 Petrol–EtOAc) to yield the diazepane 51 (380 mg, 71%) as 
a yellow oil, Rf = 0.26 (20:80 Petrol–EtOAc); νmax/ cm-1 (ATR) 3280 (br), 2937, 1742, 1698, 
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1682, 1545, 1372 and 1162; δH (500 MHz, CDCl3) 8.01-7.92 (1H, m, nitrophenyl 3-H), 7.77-
7.63 (3H, m, nitrophenyl 4-H, nitrophenyl 5-H and nitrophenyl 6-H), 5.99 (1H, t, J 4.7, NH), 
4.20 (1H, dd, J 16.5 and 5.9, 3-Ha), 4.15-4.03 (1H, m, 2-Ha), 3.86 (1H, dd, J 14.1 and 6.7, 7-
Ha), 3.63-3.54 (1H, m, 7-Hb), 3.53-3.43 (4H, m, 2-Hb, 3-Hb and methoxyethyl 1-H2), 3.42-
3.30 (5H, m, methoxyethyl 2-H2 and methoxyethyl 4-H3), 2.72-2.51 (2H, m, ethyl 1-H2), 
1.93 (1H, dd, J 18.7 and 6.7, 6-Ha), 1.65 (1H, dt, J 18.7 and 7.3, 6-Hb) and 0.93 (3H, t, J 7.2, 
ethyl 2-H3); δC (126 MHz, CDCl3) 170.9 (amide CO), 148.1 (nitrophenyl C-2), 133.8 
(nitrophenyl C-5), 132.6 nitrophenyl (C-1), 131.9 (nitrophenyl C-4), 130.6 (nitrophenyl 
C-6), 124.4 (nitrophenyl C-3), 70.8 (C-3), 69.2 (C-5), 58.8 (methoxyethyl C-4), 49.9 (C-2), 
48.4 (C-7), 44.0 (methoxyethyl C-1), 39.6 (methoxyethyl C-2), 37.3 (ethyl C-1), 26.9 (C-6) 
and 7.9 (ethyl C-2), trifluoroacetyl carbons not observed; δF (282 MHz, CDCl3) -68.4; 
HRMS found MH+, 511.1485.  C19H25F3N4O7S requires MH, 511.1474. 
9a-Ethyl-2-(2-methoxyethyl)-7-(2-nitrophenylsulfonyl)-octahydro-1H-
imidazolidino[1,5-d][1,4]diazepine-1,3-dione, 106 
 
K2CO3 (1.02 g, 7.40 mmol) was added to a solution of the diazepane 51 (380 mg, 
0.740 mmol) in MeOH (18.5 mL, 0.04 M) and water (8.22 mL, 0.09 M).  The reaction 
mixture was stirred at room temperature overnight before being concentrated in vacuo, 
diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL).  The combined organic 
phases were washed with brine (20 mL), dried (MgSO4) and concentrated in vacuo.  The 
residue was purified by flash chromatography (SiO2, 30:70 Petrol–EtOAc) to yield the 
hydantoin 106 (280 mg, 86%) as a yellow oil, Rf = 0.26 (20:80 Petrol–EtOAc); νmax/ cm-1 
(ATR) 2936, 1769, 1708, 1544, 1451, 1368 and 1165; δH (500 MHz, CDCl3) 8.01 (1H, dd, J 
7.6 and 1.6, nitrophenyl 3-H), 7.77-7.69 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.67 (1H, dd, J 7.2 and 1.8, nitrophenyl 6-H), 4.25-4.16 (1H, m, 5-Ha), 3.91-3.82 (2H, m, 6-
Ha and 8-Ha), 3.81-3.70 (2H, m, methoxyethyl 1-H2), 3.62-3.55 (2H, m, 6-Hb and 8-Hb), 3.32 
(3H, s, methoxyethyl 4-H3), 3.19-3.09 (2H, m, methoxyethyl 2-H2), 2.69-2.57 (2H, m, 5-Hb 
and 9-Ha), 2.11-2.02 (1H, m, 9-Hb), 1.92 (1H, dq, J 14.6 and 7.3, ethyl 1-Ha), 1.74 (1H, dq, J 
14.6 and 7.3, ethyl 1-Hb) and 0.80 (3H, t, J 7.3, ethyl 2-H3); δC (126 MHz, CDCl3) 175.3 (C-
1), 156.4 (C-3), 147.9 (nitrophenyl C-2), 133.9 (nitrophenyl C-5), 132.6 (nitrophenyl C-1), 
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131.8 (nitrophenyl C-4), 130.9 (nitrophenyl C-6), 124.4 (nitrophenyl C-3), 68.5 (C-5), 68.1 
(C-9a), 58.5 (methoxyethyl C-4), 48.0 (C-6), 44.8 (C-8), 41.7 (methoxyethyl C-1), 39.4 
(methoxyethyl C-2), 38.3 (ethyl C-1), 29.0 (C-9) and 7.3 (ethyl C-2); HRMS found MH+, 
441.1446.  C18H24N4O7S requires MH, 441.1444. 
Analysis of the HMBC spectrum showed correlations between C-3 and 5-Ha, C-3 
and methoxyethyl 1-H2, C-3 and methoxyethyl 2-H2. 
N-Benzyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-4-(trifluoroacetyl)-1,4-diazepane-5-
carboxamide, 33 
 
By general procedure K, ketone 32 (700 mg, 1.63 mmol) and benzyl isocyanide 
(0.400 mL, 3.26 mmol) gave a crude product which was purified by flash chromatography 
(SiO2, 60:40 DCM–EtOAc) to yield the diazepane44 33 (710 mg, 80%) as a colourless 
amorphous solid, Rf = 0.44 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3422 (br), 2977, 1695, 
1666, 1543, 1371 and 1152; δH (500 MHz, CDCl3) 7.97 (1H, dd, J 10.1 and 4.9, nitrophenyl 
3-H), 7.78-7.70 (2H, m, nitrophenyl 4-H and 5-H), 7.68 (1H, dd, J 7.4 and 1.6, nitrophenyl 
6-H), 7.41-7.26 (5H, m, benzyl-H), 5.92 (1H, t, J 5.2, NH), 4.54-4.39 (2H, m, benzylic-H2), 
4.25 (1H, dd, J 16.8 and 5.7, 3-Ha), 4.11 (1H, dd, J 14.4 and 5.7, 2-Ha), 3.90 (1H, dd, J 14.8 
and 7.0, 7-Ha), 3.64 (1H, dd, J 14.8 and 10.7, 7-Hb), 3.52 (1H, dd, J 16.8 and 9.0, 3-Hb), 3.39 
(1H, dd, J 14.4 and 9.0, 2-Hb), 2.76-2.56 (2H, m, ethyl 1-H2), 1.94 (1H, dd, J 16.8 and 7.0, 6-
Ha), 1.69-1.58 (1H, m, 6-Hb) and 0.96 (3H, t, J 7.2, ethyl 2-H3); δC (126 MHz, CDCl3) 170.7 
(amide CO), 157.0 (app d, J 35.5, trifluoroacetyl C-1)148.1 (nitrophenyl C-2), 137.8 
(benzyl C-1), 133.9 (nitrophenyl C-5), 132.5 (nitrophenyl C-1), 131.9 (nitrophenyl C-4), 
130.5 (nitrophenyl C-6), 128.9 (benzyl C-3 and benzyl C-5), 127.7 (benzyl C-2, benzyl C-4 
and benzyl C-6), 124.5 (nitrophenyl C-3), 116.3 (q, J 287.9, trifluoroacetyl C-2), 69.2 (C-5), 
49.8 (benzylic-C), 48.5 (C-3), 44.0 (C-2), 43.9 (C-7), 37.4 (ethyl C-1), 26.9 (C-6) and 7.9 
(ethyl C-2); δF (282 MHz, CDCl3) -68.3; m/z (ES) 565.2 (100%, MNa+). 
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2-Benzyl-9a-ethyl-7-(2-nitrophenylsulfonyl)-octahydro-1H-imidazolidino[1,5-d] 
[1,4]diazepine-1,3-dione, 107 
 
K2CO3 (1.60 g, 11.6 mmol) was added to a solution of the diazepane 33 (630 mg, 
1.16 mmol) in MeOH (30 mL, ~0.04 M) and water (13 mL, 0.09 M).  The reaction mixture 
was stirred at room temperature overnight before being concentrated in vacuo, diluted 
with water (30 mL) and extracted with EtOAc (3 × 30 mL).  The combined organic phases 
were washed with brine (30 mL), dried (MgSO4) and concentrated in vacuo.  The residue 
was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the hydantoin 
107 (200 mg, 36%) as a yellow solid, m.p. 145-147 °C; Rf = 0.43 (20:80 Petrol–EtOAc); 
νmax/ cm-1 (ATR) 2927, 1767, 1709, 1544, 1449, 1366 and 1165; δH (500 MHz, CDCl3) 8.01 
(1H, m, nitrophenyl 3-H), 7.86-7.60 (3H, m, nitrophenyl 4-H, nitrophenyl 5-H and 
nitrophenyl 6-H), 7.50-7.18 (5H, m, benzyl-H), 4.74-4.63 (2H, m, benzylic-H2), 4.28-4.15 
(1H, m, 5-Ha), 3.97-3.77 (2H, m, 6-Ha and 8-Ha), 3.23-3.04 (2H, m, 6-Hb and 5-Hb), 2.68-
2.48 (2H, m, 8-Hb and 9-Ha), 2.13-2.00 (1H, m, 9-Hb), 1.89 (1H, dq, J 14.7 and 7.4, ethyl 1-
Ha), 1.73 (1H, dq, J 14.7 and 7.4, ethyl 1-Hb) and 0.64 (3H, t, J 7.4, ethyl 2-H3); δC (126 MHz, 
CDCl3) 175.0 (C-1), 156.2 (C-3), 147.9 (nitrophenyl C-2), 136.0 (benzyl C-1), 133.9 
(nitrophenyl C-5), 132.5 (nitrophenyl C-1), 131.8 (nitrophenyl C-4), 130.9 (nitrophenyl 
C-6), 128.7 (benzyl C-3 and benzyl C-5), 128.5 (benzyl C-2 and benzyl C-6), 128.0 (benzyl 
C-4), 124.4 (nitrophenyl C-3), 67.9 (C-9a), 48.1 (benzylic-C), 44.9 (C-5), 42.7 (C-6), 41.8 
(C-8), 39.2 (ethyl C-1), 29.1 (C-9) and 7.3 (ethyl C-2); HRMS found MH+, 473.1490.  
C22H24N4O6S requires MH, 473.1495. 
Analysis of the HMBC spectrum showed correlations between C-3 and benzylic-
H2, C-3 and 5-Ha, C-3 and 5-Hb. 
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N-Cyclopropyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-4-(trifluoroacetyl)-1,4-
diazepane-5-carboxamide, 108 
 
By general procedure K, ketone 32 (910 mg, 2.12 mmol) and cyclopropyl 
isocyanide (0.340 mL, 4.24 mmol) gave a crude product which was purified by flash 
chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the diazepane 108 (690 mg, 66%) as 
a colourless amorphous solid, Rf = 0.36 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3401 (br), 
2975, 1693, 1664, 1543, 1451, 1370, 1143 and 729; δH (500 MHz, CDCl3) 7.87 (1H, dd, J 
7.3 and 1.9, nitrophenyl 3-H), 7.68-7.61 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.59 (1H, dd, J 7.5 and 1.7, nitrophenyl 6-H), 5.75 (1H, s, NH), 4.13 (1H, dd, J 16.7 and 5.7, 
3-Ha), 4.01 (1H, dd, J 14.3 and 5.7, 2-Ha), 3.78 (1H, dd, J 14.7 and 6.8, 7-Ha), 3.53 (1H, dd, J 
14.7 and 10.7, 7-Hb), 3.39 (1H, dd, J 16.7 and 8.9, 3-Hb), 3.29 (1H, dd, J 14.3 and 8.9, 2-Hb), 
2.61-2.54 (1H, m, cyclopropyl 1-H), 2.53-2.44 (2H, m, ethyl 1-Ha and ethyl 1-Hb), 1.78 (1H, 
dd, J 16.4 and 6.8, 6-Ha), 1.54-1.42 (1H, m, 6-Hb), 0.85 (3H, t, J 7.4, ethyl 2-H3), 0.73-0.63 
(2H, m, cyclopropyl 2-H2), 0.51-0.44 (1H, m, cyclopropyl 3-Ha) and 0.40-0.31 (1H, m, 
cyclopropyl 3-Hb); δC (126 MHz, CDCl3) 172.3 (amide CO), 157.0 (app d, J 35.6, 
trifluoroacetyl C-1), 148.1 (nitrophenyl C-2), 133.9 (nitrophenyl C-5), 132.5 (nitrophenyl 
C-1), 132.0 (nitrophenyl C-4), 130.5 (nitrophenyl C-6), 124.4 (nitrophenyl C-3), 116.3 (q, 
J 288.4, trifluoroacetyl C-2), 68.9 (C-5), 49.8 (C-3), 48.4 (C-2), 43.9 (C-7), 37.1 (C-6), 26.8 
(ethyl C-1), 22.9 (cyclopropyl C-1), 7.8 (cyclopropyl C-2), 6.8 (cyclopropyl C-3) and 6.4 
(ethyl C-2); δF (282 MHz, CDCl3) -68.4; HRMS found MH+, 493.1363.  C19H23F3N4O6S 
requires MH, 493.1368. 
N-Methoxyethyl-2-methyl-4-[(2-nitrophenyl)sulfonyl]-1-(trifluoroacetyl) 
piperazine-2-carboxamide, 110 
 
By general procedure K, tetrahydropyrazine 101 (564 mg, 1.47 mmol) and 2-
methoxyethyl isocyanide (250 mg, 2.94 mmol) gave a crude product which was purified 
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by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the piperazine 110 (680 mg, 
96%) as a yellow oil, Rf = 0.43 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3358 (br), 2927, 
1719, 1545, 1370, 1168 and 555; δH (500 MHz, CDCl3) 8.04-8.00 (1H, m, nitrophenyl 3-H), 
7.78-7.70 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.70-7.62 (1H, m, nitrophenyl 6-
H), 6.57 (1H, br s, NH), 4.06 (1H, dt, J 15.4 and 2.0, 5-Ha), 3.65-3.57 (1H, m, 5-Hb), 3.55-
3.48 (4H, m, 3-Ha and methoxyethyl 2-H2), 3.46 (3H, s, methoxyethyl 4-H3), 3.43-3.37 (1H, 
m, 6-Ha), 3.29-3.17 (2H, m, methoxyethyl 1-H2), 2.98 (1H, d, J 12.9, 3-Hb), 1.50-1.45 (1H, 
m 6-Hb) and 1.39 (3H, s, methyl); δC (126 MHz, CDCl3) 173.9 (amide CO), 148.2 
(nitrophenyl C-2), 133.8 (nitrophenyl C-5), 131.8 (nitrophenyl C-1), 131.7 (nitrophenyl 
C-4), 131.3 (nitrophenyl C-6), 124.2 (nitrophenyl C-3), 69.7 (C-5), 59.9 (C-2), 59.2 
(methoxyethyl C-4), 51.0 (C-3), 45.4 (methoxyethyl C-2), 40.1 (C-6), 38.6 (methoxyethyl 
C-1) and 19.5 (methyl), trifluoroacetyl carbons not observed; δF (282 MHz, CDCl3) -81.6; 
HRMS found MH+, 483.1122.  C17H21F3N4O7S requires MH, 483.1161. 
N-Benzyl-2-methyl-4-[(2-nitrophenyl)sulfonyl]-1-(trifluoroacetyl)piperazine-2-
carboxamide, 109 
 
By general procedure K, tetrahydropyrazine 101 (650 mg, 1.70 mmol) and benzyl 
isocyanide (0.41 mL, 3.40 mmol) gave a crude product which was purified by flash 
chromatography (SiO2, 80:20 DCM–Et2O) to yield the piperazine44 109 (750 mg, 86%) as 
a colourless amorphous solid, Rf = 0.53 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3368 (br), 
2937, 1699, 1673, 1542, 1370, 1216, 1145 and 732; δH (500 MHz, CDCl3) 8.03 (1H, dd, J 
7.6 and 1.2, nitrophenyl 3-H), 7.81-7.72 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.70 (1H, dd, J 7.6 and 1.3, nitrophenyl 6-H), 7.43-7.35 (2H, m, benzyl 3-H and benzyl 5-
H), 7.34-7.25 (3H, m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 6.20 (1H, t, J 5.0, NH), 4.52-
4.36 (2H, m, benzylic-H2), 4.03-3.92 (1H, m, 5-Ha), 3.88-3.75 (3H, m, 3-Ha, 5-Hb and 6-Ha), 
3.70 (1H, d, J 13.8, 3-Hb), 3.59-3.46 (1H, m, 6-Hb) and 1.72 (3H, s, methyl); δC (126 MHz, 
CDCl3) 169.2 (amide CO), 156.9 (q, J 36.6, trifluoroacetyl C-1), 148.1 (nitrophenyl C-2), 
137.4 (nitrophenyl C-1), 134.3 (nitrophenyl C-5), 132.0 (nitrophenyl C-4), 131.4 (benzyl 
C-1), 131.2 (nitrophenyl C-6), 128.8 (benzyl C-3 and benzyl C-5), 127.8 (benzyl C-2 and 
benzyl C-6), 127.7 (benzyl C-4), 124.5 (nitrophenyl C-3), 115.9 (q, J 288.5, trifluoroacetyl 
C-2), 64.3 (C-2), 51.8 (C-3), 44.3 (C-5), 44.2 (C-6), 41.4 (benzylic-C) and 18.2 (methyl); δF 
(282 MHz, CDCl3) -69.6; m/z (ES) 515.1 (100%, MNa+). 
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N-Cyclopropyl-2-methyl-4-[(2-nitrobenzene)sulfonyl]-1-(trifluoroacetyl) 
piperazine-2-carboxamide, 111 
 
By general procedure K, tetrahydropyrazine 101 (810 mg, 2.11 mmol) and 
cyclopropyl isocyanide (0.340 mL, 4.22 mmol) gave a crude residue which was purified 
by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the piperazine 111 (680 mg, 
69%) as a colourless amorphous solid, Rf = 0.48 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 
3341 (br), 3015, 1699, 1543, 1363, 1215 and 1144; δH (500 MHz, CDCl3) 8.04 (1H, dd, J 
7.6 and 1.7, nitrophenyl 3-H), 7.81-7.73 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.71 (1H, dd, J 7.5 and 1.7, nitrophenyl 6-H), 6.04 (1H, s, NH), 4.02-3.90 (1H, m, 5-Ha), 3.83-
3.71 (3H, m, 3-Ha, 5-Hb and 6-Ha), 3.63 (1H, d, J 13.8, 3-Hb), 3.58-3.51 (1H, m, 6-Hb), 2.67-
2.57 (1H, m, cyclopropyl 1-H), 1.66 (3H, s, methyl), 0.81-0.71 (2H, m, cyclopropyl 2-H2) 
and 0.60-0.51 (2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 170.7 (CO), 156.9 (q, J 30.6, 
trifluoroacetyl C-1), 148.1 (nitrophenyl C-2), 134.3 (nitrophenyl C-5), 132.0 (nitrophenyl 
C-4), 131.5 (nitrophenyl C-1), 131.2 (nitrophenyl C-6), 124.5 (nitrophenyl C-3), 115.8 
(app d, J 288.2, trifluoroacetyl C-2), 64.1 (C-2), 51.6 (C-5), 44.3 (C-3), 41.2 (q, J 4.1, C-6), 
23.1 (cyclopropyl C-1), 18.0 (methyl), 6.6 (cyclopropyl C-2) and 6.4 (cyclopropyl C-3); δF 
(282 MHz, CDCl3) -69.7; HRMS found MH+, 465.1063.  C17H19F3N4O6S requires MH, 
465.1055. 
N-Methoxyethyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]-1-
(trifluoroacetyl) piperazine-2-carboxamide, 113 
 
By general procedure K, tetrahydropyrazine 103 (584 mg, 1.47 mmol) and 2-
methoxyethyl isocyanide (250 mg, 2.94 mmol) gave a crude residue which was purified 
by flash chromatography (SiO2, 10:90 Petrol–EtOAc) to yield the piperazine 113 (590 mg, 
81%) as a colourless amorphous solid, Rf = 0.37 (10:90 Petrol–EtOAc); νmax/ cm-1 (ATR) 
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3368, 2934, 1700, 1543, 1361, 1216 and 1154, ; [α]D22 92 (c = 0.16, CHCl3); δH (500 MHz, 
CDCl3) 8.12 (1H, dd, J 6.9 and 2.4, nitrophenyl 3-H), 7.80-7.71 (3H, m, nitrophenyl 4-H, 
nitrophenyl 5-H and nitrophenyl 6-H), 6.28 (1H, t, J 5.0, NH), 4.43-4.33 (1H, m, 5-H), 3.95-
3.91 (2H, m, 3-H2), 3.52-3.43 (4H, m, 6-H2 and methoxyethyl 1-H2), 3.43-3.37 (1H, m, 
methoxyethyl 2-Ha), 3.36 (3H, s, methoxyethyl 4-H3), 3.22-3.13 (1H, m, methoxyethyl 2-
Hb), 1.73 (3H, s, 2-methyl) and 1.28 (3H, d, J 6.4, 5-methyl); δC (126 MHz, CDCl3) 169.1 
(CO), 148.0 (nitrophenyl C-2), 134.0 (nitrophenyl C-5), 133.6 (nitrophenyl C-1), 132.1 
(nitrophenyl C-4), 131.4 (nitrophenyl C-6), 124.6 (nitrophenyl C-3), 70.6 (C-3), 64.9 (C-2), 
58.7 (C-5), 51.1 (methoxyethyl C-4), 49.8 (C-6), 46.6 (methoxyethyl C-1), 39.6 
(methoxyethyl C-2), 18.7 (2-methyl) and 18.0 (5-methyl), trifluoroacetyl carbons not 
observed; δF (282 MHz, CDCl3) -69.3; HRMS found MH+, 497.1332.  C18H23F3N4O7S requires 
MH, 497.1318. 
N-Benzyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]-1-(trifluoroacetyl) 
piperazine-2-carboxamide, 112 
 
By general procedure K, tetrahydropyrazine 103 (350 mg, 0.880 mmol)and 
benzyl isocyanide (0.210 mL, 1.76 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 30:70 Petrol–EtOAc) to yield the piperazine 112 (356 mg, 77%) as 
a colourless amorphous solid, Rf = 0.40 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3367 (br), 
2935, 1699, 1543, 1362, 1216 and 1154; [α]D28 49 (c = 0.050, MeOH); δH (500 MHz, CDCl3) 
8.15-8.10 (1H, m, nitrophenyl 3-H), 7.81-7.73 (2H, m, nitrophenyl 4-H and nitrophenyl 5-
H), 7.73-7.68 (1H, m, nitrophenyl 6-H), 7.39-7.33 (2H, m, benzyl 3-H and benzyl 5-H), 
7.32-7.25 (4H, m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 6.18 (1H, t, J 5.3, NH), 4.52 (1H, 
dd, J 14.9 and 5.3, benzylic-Ha), 4.37-4.31 (1H, m, 5-H), 4.28 (1H, dd, J 14.9 and 5.3, 
benzylic-Hb), 3.99 (1H, d, J 14.2, 3-Ha), 3.90 (1H, dd, J 14.7 and 4.7, 6-Ha), 3.57-3.47 (2H, m, 
3-Hb and 6-Hb) and 1.31-1.27 (6H, m, 2-methyl and 5-methyl); δc (126 MHz, CDCl3) 169.2 
(CO), 157.3 (app d, J 36.3, trifluoroacetyl C-1), 137.5 (nitrophenyl C-2), 134.1 (nitrophenyl 
C-4), 133.3 (nitrophenyl C-1), 132.1 (nitrophenyl C-5), 131.4 (nitrophenyl C-6), 128.7 
(benzyl C-3 and benzyl C-5), 127.7 (benzyl C-2 and benzyl C-6), 127.6 (benzyl C-4), 124.6 
(nitrophenyl C-3), 115.9 (app d, J 288.5, trifluoroacetyl C-2), 64.9 (C-2), 51.0 (C-5), 49.9 
(C-3), 46.8 (C-6), 44.2 (benzylic-C), 19.0 (2-methyl) and 18.0 (5-methyl); δF (282 MHz, 
CDCl3) -69.2; HRMS found MH+, 529.1376.  C22H23F3N4O6S requires MH, 529.1368. 
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(2S, 5S)-N-Cyclopropyl-2,5-dimethyl-4-(2-nitrobenzenesulfonyl)-1-
(trifluoroacetyl)piperazine-2-carboxamide, 114 
 
By general procedure K, tetrahydropyrazine 103 (1.36 g, 3.42 mmol) and 
cyclopropyl isocyanide (0.550 mL, 6.84 mmol) gave a crude residue which was purified 
by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the piperazine 114 (800 mg, 
49%) as a white amorphous solid, Rf = 0.30 (40:60 Petrol–EtOAc); νmax/ cm-1 (ATR) 3350 
(br), 3096, 3013, 2936, 1698, 1543, 1363, 1216, 1150, 735 and 580; [α]D20 107 (c = 2.78, 
CHCl3); δH (500 MHz, CDCl3) 8.14-8.09 (1H, m, nitrophenyl 3-H), 7.80-7.75 (2H, m, 
nitrophenyl 4-H and nitrophenyl 5-H), 7.75-7.72 (1H, m, nitrophenyl 6-H), 6.09 (1H, s, 
NH), 4.40-4.31 (1H, m, 5-H), 3.96-3.87 (2H, m, 3-Ha and 6-Ha), 3.46 (1H, d, J 14.5, 6-Hb), 
3.40 (1H, dd, J 14.8 and 7.6, 3-Hb), 2.47-2.33 (1H, m, cyclopropyl 1-H), 1.66 (3H, s, 2-
methyl), 1.23 (3H, d, J 6.3, 5-methyl), 0.74-0.62 (2H, m, cyclopropyl 2-H2) and 0.60-0.47 
(2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 171.2 (CO), 156.9 (q, J 36.3, trifluoroacetyl 
C-1), 147.9 (nitrophenyl C-1), 134.2 (nitrophenyl C-5), 133.5 (nitrophenyl C-2), 132.3 
(nitrophenyl C-4), 131.4 (nitrophenyl C-6), 124.7 (nitrophenyl C-3), 115.8 (q, J 288.3, 
trifluoroacetyl C-2), 64.7 (C-2), 51.1 (C-5), 49.5 (C-3), 46.4 (d, J 3.6, C-6), 22.9 (cyclopropyl 
C-1), 18.4 (2-methyl), 17.7 (5-methyl) 6.3 (cyclopropyl C-2) and 6.2 (cyclopropyl C-3); δF 
(282 MHz, CDCl3) -69.3; HRMS found MH+, 479.1320.  C18H21F3N4O6S requires MH, 
479.1212. 
N-Ethyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]-1-(trifluoroacetyl) 
piperazine-2-carboxamide, 115 
 
By general procedure K, tetrahydropyrazine 103 (220 mg, 0.550 mmol)and ethyl 
isocyanide (60.6 mg, 1.10 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 30:70 Petrol–EtOAc) to yield the piperazine 115 (182 mg, 71%) as 
a colourless amorphous solid, Rf = 0.49 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3368, 2980, 
2938, 1698, 1667, 1541, 1357 and 1139; [α]D23 77 (c = 0.31, CHCl3); δH (500 MHz, CDCl3) 
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8.10 (1H, dd, J 7.1 and 1.6, nitrophenyl 3-H), 7.84-7.67 (3H, m, nitrophenyl 4-H, 
nitrophenyl 5-H and nitrophenyl 6-H), 5.92 (1H, t, J 5.0, NH), 4.42-4.24 (1H, m, 5-H), 4.02-
3.85 (2H, m, 3-H2), 3.58-3.43 (2H, m, 6-H2), 3.34-3.21 (1H, m, ethyl 1-Ha), 3.21-3.07 (1H, 
m, ethyl 1-Hb), 1.72 (3H, s, 2-methyl), 1.26 (3H, app t, J 6.4, 5-methyl) and 1.12 (3H, t, J 7.2, 
ethyl 2-H3); δC (126 MHz, CDCl3) 169.0 (CO), 157.1 (app d, J 36.4, trifluoroacetyl C-1), 
148.0 (nitrophenyl C-2), 134.2 (nitrophenyl C-5), 133.3 (nitrophenyl C-1), 132.2 
(nitrophenyl C-4), 131.3 (nitrophenyl C-6), 124.5 (nitrophenyl C-3), 115.9 (q, J 288.5, 
trifluoroacetyl C-2), 64.9 (C-2), 51.0 (C-5), 49.8 (C-3),  46.7 (app d, J 3.6, C-6), 35.1 (ethyl 
C-1), 18.8 (2-methyl), 17.9 (5-methyl) and 14.3 (ethyl C-2); δF (282 MHz, CDCl3) -69.2; 
HRMS found MH+, 467.1222.  C17H21F3N4O6S requires MH, 467.1212. 
[6-(Ethylcarbamoyl)-6-methyl-4-(2-nitrobenzenesulfonyl)-1-(trifluoroacetyl) 
piperazin-2-yl]methyl acetate, 116 
 
By general procedure K (with an additional 12 eq. TFA), tetrahydropyrazine 105 
(1.03 g, 2.27 mmol) and ethyl isocyanide (250 mg, 4.54 mmol) gave a crude residue which 
was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) the again (SiO2, 20:80 
Et2O–DCM) to yield the piperazine 116 (580 mg, 49%) as a pale yellow solid, m.p. 85-87 °C; 
Rf = 0.41 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3275 (br), 2989, 2944, 1722, 1546, 1372 
and 1168; δH (500 MHz, CDCl3) 8.04 (1H, dd, J 7.6 and 1.5, nitrophenyl 3-H), 7.82-7.72 (2H, 
m, nitrophenyl 4-H and nitrophenyl 5-H), 7.70 (1H, dd, J 7.5 and 1.5, nitrophenyl 6-H), 
4.83 (1H, s, NH), 4.28-4.19 (1H, m, 6-H), 4.14 (1H, dd, J 10.9 and 5.9, 6-methyl-Ha), 4.06-
3.97 (1H, m, 5-Ha), 3.54-3.48 (1H, m, 5-Hb), 3.47-3.38 (3H, m, 3-H2 and 6-methyl-Hb), 3.34-
3.24 (2H, m, ethyl 1-H2), 2.10 (3H, s, acetyl), 1.46 (3H, s, 2-methyl) and 1.22 (3H, t, J 7.2, 
ethyl 2-H3); δC (126 MHz, CDCl3) 173.5 (acetyl CO), 170.7 (amide CO), 148.1 (nitrophenyl 
C-2), 134.3 (nitrophenyl C-5), 132.0 (nitrophenyl C-4), 131.5 (nitrophenyl C-6), 131.3 
(nitrophenyl C-1), 124.5 (nitrophenyl C-3), 121.8 (app d, J 288.2, trifluoroacetyl C-2), 64.0 
(C-5), 59.1 (C-2), 51.2 (6-methyl), 47.0 (C-6), 45.7 (C-3), 35.8 (ethyl C-1), 24.0 (acetyl), 
20.8 (2-methyl), and 13.1 (ethyl C-2), trifluoroacetyl C-1 not observed; δF (282 MHz, CDCl3) 
-82.4; HRMS found MH+, 525.1197.  C19H23F3N4O8S requires MH, 525.1267. 
Stereochemistry has been determined where analysis of the NOESY spectrum 
showed correlation between the 6-H and 2-methyl protons. 
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3-(2-Methoxyethyl)-5-(prop-2-en-1-yl)-5-(propan-2-yl)imidazolidine-2,4-dione, 
195 
 
By general procedure R, the urea 189 (82.5 mg, 0.300 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to yield the 
hydantoin 195 (48.6 mg, 67%) as a colourless amorphous solid Rf = 0.55 (10:90 MeOH–
DCM); νmax/ cm-1 (ATR) 3276 (br), 2967, 1771, 1708, 1448 and 1119; δH (500 MHz, CDCl3) 
5.73-5.63 (1H, m, propenyl 2-H), 5.21-5.13 (2H, m propenyl 3-H2), 3.74-3.67 (2H, m, 
methoxyethyl 2-H2), 3.56 (2H, t, J 5.7, methoxyethyl 1-H2), 3.35 (3H, s, methoxyethyl 4-
H3), 2.59-2.45 (2H, m, propenyl 1-H2), 2.10 (1H, hept, J 6.9, propyl 2-H), 1.00 (3H, d, J 6.9, 
propyl 1-H2) and 0.94 (3H, d, J 6.9, propyl 3-H2); δC (126 MHz, CDCl3) 175.4 (C-4), 157.1 
(C-2), 130.7 (propenyl C-2), 120.2 (propenyl C-3), 68.8 (methoxyethyl C-2), 67.9 (C-5), 
58.3 (methoxyethyl C-4), 39.3 (methoxyethyl C-1), 37.7 (propenyl C-1), 33.6 (propyl C-2), 
16.7 (propyl C-1) and 16.3 (propyl C-3); HRMS found MH+, 241.1554.  C12H20N2O3 requires 
MH, 241.1552. 
3-Cyclopropyl-5-(oxetane-3-yl)-5-(prop-2-en-1-yl)imidazolidine-2,4-dione, 197 
 
By general procedure R, the urea 191 (75.8 mg, 0.280 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 100% EtOAc) to yield the hydantoin 
197 (61.0 mg, 92%) as a yellow oil, Rf = 0.58 (10:90 MeOH–DCM); δH (501 MHz, CDCl3) 
6.17 (1H, s, NH), 5.71-5.53 (1H, m, propenyl 2-H), 5.24-5.12 (2H, m, propenyl 3-H2), 4.80 
(1H, dd, J 8.3 and 6.5, oxetanyl 2-Ha), 4.66 (1H, dd, J 8.3 and 6.5, oxetanyl 4-Ha), 4.43 (2H, 
app t, J 6.5, oxetanyl 2-Hb and oxetanyl 4-Hb), 3.47 (1H, tt, J 8.3 and 6.5, oxetanyl 1-H), 2.66-
2.54 (1H, m, cyclopropyl 1-H), 2.41 (1H, dd, J 13.9 and 7.7, propenyl 1-Ha), 2.32 (1H, dd, J 
13.9 and 7.1, propenyl 1-Hb), 0.99-0.94 (2H, m, cyclopropyl 2-H2) and 0.93-0.87 (2H, m, 
cyclopropyl 3-H2); δC (126 MHz, CDCl3) 174.3 (C-4), 157.0 (C-2), 129.5 (propenyl C-2), 
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121.3 (propenyl C-3), 72.1 (oxetanyl C-2), 71.3 (oxetanyl C-4), 63.6 (C-5), 40.2 (oxetanyl 
C-1), 39.3 (propenyl C-1), 21.8 (cyclopropyl C-1), 5.0 (cyclopropyl C-2) and 4.9 
(cyclopropyl C-3). 
5-[(4-Fluorophenyl)methyl]-3-(2-methoxyethyl)-5-(prop-2-en-1-yl)imidazolidine-
2,4-dione, 196 
 
By general procedure R, the urea 190 (210 mg, 0.621 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the 
hydantoin 196 (153 mg, 80%) as a colourless solid, m.p. 49-51 °C; Rf = 0.38 (50:50 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3273 (br), 2928, 1771, 1706, 1509, 1449 and 1223; δH (500 MHz, 
CDCl3) 7.19-7.09 (2H, m, fluorophenyl 2-H and fluorophenyl 6-H), 7.07-6.88 (2H, m, 
trifluoroacetyl 3-H and fluorophenyl 5-H), 6.19 (1H, s, NH), 5.77-5.60 (1H, m, propenyl 3-
Ha), 5.24-5.22 (1H, m, propenyl 3-Hb), 5.21-5.17 (1H, m, propenyl 2-H), 3.52 (2H, t, J 5.9, 
methoxyethyl 1-H2), 3.35-3.27 (2H, m, methoxyethyl 2-H2), 3.25 (3H, s, methoxyethyl 4-
H3), 3.11 (1H, d, J 13.9, benzylic-Ha), 2.90 (1H, d, J 13.9, benzylic-Hb), 2.65 (1H, dd, J 14.0 
and 7.3, propenyl 1-Ha) and 2.48 (1H, dd, J 14.0 and 7.4, propenyl 1-Hb); δC (126 MHz, 
CDCl3) 175.0 (C-4), 162.2 (d, J 246.2, fluorophenyl C-4), 156.8 (C-2), 131.8 (d, J 7.9, 
fluorophenyl C-2 and fluorophenyl C-6), 130.2 (propenyl C-2), 129.9 (d, J 2.8, fluorophenyl 
C-1), 121.1 (propenyl C-3), 115.3 (d, J 21.4, fluorophenyl C-3 and fluorophenyl C-5), 68.7 
(methoxyethyl C-1), 65.7 (C-5), 58.6 (methoxyethyl C-4), 41.5 (methoxyethyl C-2), 41.0 
(methyl) and 37.8 (propenyl C-1); δF (282 MHz, CDCl3) -115.1; HRMS found MH+, 
307.1488.  C16H19FN2O3 requires MH, 307.1458. 
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Methyl 5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-benzazepine-3-
carboxylate, 199 
 
By general procedure S, the amino ester 194 (518 mg, 1.52 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 70:30 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 199 (300 mg, 76%) as a yellow oil, Rf = 0.79 (40:60 Petrol–
EtOAc); νmax/ cm-1 (ATR) 2949, 1727, 1464, 1433, 1202 and 1242; δH (500 MHz, CDCl3) 
7.45-7.39 (1H, m, 9-H), 7.23-7.16 (2H, m, 7-H and 8-H), 7.11-7.05 (1H, m, 6-H), 5.40 (1H, 
d, J 1.4, alkene-Ha), 5.07 (1H, app s, alkene-Hb), 4.06 (1H, d, J 16.5, 1-Ha), 3.97 (1H, d, J 16.5, 
1-Hb), 3.74 (3H, s, methyl), 3.02 (1H, d, J 14.0, 4-Ha), 2.87 (1H, d, J 14.0 , 4-Hb), 2.19-2.03 
(1H, m, isopropyl 2-H), 1.02 (3H, d, J 4.0, isopropyl-MeA) and 1.00 (3H, d, J 4.0, isopropyl-
MeB); δC (126 MHz, CDCl3) 175.3 (CO), 145.3 (C-5a), 140.3 (C-9a), 139.6 (C-5), 127.9 (C-
9), 127.7 (C-8), 127.4 (C-7), 126.8 (C-6), 115.4 (alkene), 69.3 (C-3), 51.6 (methyl), 49.2 (C-
1), 40.6 (C-4), 34.9 (isopropyl C-2), 18.2 (isopropyl-MeA) and 17.1 (isopropyl-MeB); HRMS 
found MH+, 260.1772.  C16H21NO2 requires MH, 260.1650. 
Methyl 7-methyl-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxylate, 279 
 
By general procedure S, amino ester 269 (590 mg, 1.67 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 80:20 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 279 (370 mg, 81%) as a yellow oil, Rf = 0.65 (70:30 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3356, 3082, 2950, 1731, 1464, 1203, 1172, 890 and 811; δH (300 
MHz, CDCl3) 7.21 (1H, s, 6-H), 7.02-6.93 (2H, m, 8-H and 9-H), 5.37 (1H, d, J 1.6, alkene-
Ha), 5.03 (1H, app s, alkene-Hb), 4.00 (1H, d, J 16.4, 1-Ha), 3.91 (1H, d, J 16.4, 1-Hb), 3.72 
(3H, s, methyl), 2.99 (1H, d, J 13.8, 4-Ha), 2.83 (1H, d, J 13.8, 4-Hb), 2.33 (3H, s, tolyl), 2.14-
1.99 (1H, m, isopropyl 2-H), 1.02-0.96 (6H, m, isopropyl-MeA and isopropyl-MeB); δC (101 
MHz, CDCl3) 145.4 (C-5), 145.2 (C-7), 138.9 (C-9a), 136.2 (C-5a), 128.3 (C-6), 128.0 (C-9), 
127.8 (C-8), 115.1 (alkene), 69.3 (C-3), 51.6 (methyl), 48.9 (C-1), 40.7 (C-4), 34.9 
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(isopropyl C-2), 21.0 (tolyl), 18.1 (isopropyl-MeA) and 17.1 (isopropyl-MeB); HRMS found 
MH+, 274.1821.  C17H23NO2 requires MH, 274.1807. 
Methyl 8-methyl-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxylate, 280 
 
By general procedure S, amino ester 270 (710 mg, 2.00 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 80:20 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 280 (480 mg, 88%) as a yellow oil, Rf = 0.62 (70:30 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3359, 2950, 1728, 1463, 1201, 907 and 731; δH (400 MHz, CDCl3) 
7.31 (1H, d, J 7.8, 6-H), 7.00 (1H, d, J 7.8, 7-H), 6.88 (1H, s, 9-H), 5.35 (1H, d, J 1.5, alkene-
Ha), 5.01 (1H, app s, alkene-Hb), 4.01 (1H, d, J 16.5, 1-Ha), 3.91 (1H, d, J 16.5, 1-Hb), 3.73 
(3H, s, methyl), 2.98 (1H, d, J 13.9, 4-Ha), 2.84 (1H, d, J 13.9, 4-Hb), 2.32 (3H, s, tolyl), 2.15-
2.00 (1H, m, isopropyl 2-H), 1.02-0.97 (6H, m, isopropyl-MeA and isopropyl-MeB); δC (101 
MHz, CDCl3) 175.4 (CO), 145.1 (C-5), 139.7 (C-9a), 137.4 (C-8), 137.1 (C-5a), 128.6 (C-6), 
127.6 (C-7), 127.5 (C-9), 114.6 (alkene), 69.3 (C-3), 51.6 (methyl), 49.2 (C-1), 40.8 (C-4), 
34.9 (isopropyl C-2), 20.9 (tolyl), 18.2 (isopropyl-MeA) and 17.1 (isopropyl-MeB); HRMS 
found MH+, 274.1826.  C17H23NO2 requires MH, 274.1807. 
Methyl 8-fluoro-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxylate, 281 
 
By general procedure S, amino ester 271 (670 mg, 1.87 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 80:20 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 281 (470 mg, 91%) as a yellow oil, Rf = 0.75 (70:30 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3359, 3084, 2952, 1728, 1465, 1219, 1201 and 1128; δH 
(300 MHz, CDCl3) 7.36 (1H, dd, J 8.6 and 5.7, 6-H), 6.87 (1H, td, J 8.6 and 2.7, 7-H), 6.77 
(1H, dd, J 8.6 and 2.7, 9-H), 5.33 (1H, d, J 1.4, alkene-Ha), 5.03 (1H, app s, alkene-Hb), 4.01 
(1H, d, J 16.7, 1-Ha), 3.90 (1H, d, J 16.7, 1-Hb), 3.73 (3H, s, methyl), 2.97 (1H, d, J 14.0, 4-Ha), 
2.82 (1H, d, J 14.0, 4-Hb), 2.15-1.97 (1H, m, isopropyl 2-H), 1.04-0.95 (6H, m, isopropyl-
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MeA and isopropyl-MeB); δC (101 MHz, CDCl3) 175.3 (CO), 163.2 (C-8), 144.4 (C-5), 142.0 
(C-9a), 136.3 (C-5a), 129.4 (d, J 8.0, C-6), 115.3 (alkene), 114.3 (d, J 21.3, C-7), 113.4 (d, J 
21.1, C-9), 69.2 (C-3), 51.7 (methyl), 49.0 (C-1), 40.6 (C-4), 34.8 (isopropyl C-2), 18.1 
(isopropyl-MeA) and 17.1 (isopropyl-MeB); δF (376 MHz, CDCl3) -115.9; HRMS found MH+, 
278.1570.  C16H20FNO2 requires MH, 278.1556. 
Methyl 7-fluoro-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxylate, 282 
 
By general procedure S, amino ester 272 (700 mg, 1.95 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 80:20 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 282 (500 mg, 92%) as a yellow oil, Rf = 0.62 (70:30 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3358, 2952, 1727, 1580, 1214, 1127, 904 and 731; δH (400 MHz, 
CDCl3) 7.00 (1H, dd, J 8.3 and 2.7, 9-H), 6.93 (1H, dd, J 8.3 and 5.8, 6-H), 6.77 (1H, td, J 8.3 
and 2.7, 8-H), 5.30 (1H, d, J 1.2, alkene-Ha), 5.01 (1H, app s, alkene-Hb), 3.91 (1H, d, J 16.4, 
1-Ha), 3.81 (1H, d, J 16.4, 1-Hb), 3.64 (3H, s, methyl), 2.89 (1H, d, J 14.0, 4-Ha), 2.75 (1H, d, 
J 14.0, 4-Hb), 2.04-1.93 (1H, m, isopropyl 2-H), 0.93-0.87 (6H, m, isopropyl-MeA and 
isopropyl-MeB); δC (101 MHz, CDCl3) 175.3 (CO), 161.66 (d, J 243.8, C-7), 144.5 (d, J 1.9, C-
5), 142.25 (d, J 7.2, C-9a), 135.6 (C-5a), 129.3 (d, J 8.2, C-9), 116.4 (alkene), 114.2 (d, J 22.0, 
C-6), 113.9 (d, J 21.3, C-8), 69.2 (C-3), 51.7 (methyl), 48.6 (C-1), 40.2 (C-4), 34.9 (isopropyl 
C-2), 18.1 (isopropyl-MeA) and 17.0 (isopropyl-MeB); δF (376 MHz, CDCl3) -117.0; HRMS 
found MH+, 278.1573.  C16H20FNO2 requires MH, 278.1556. 
Methyl 7-isopropyl-9-methylene-6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepine-7- 
carboxylate, 283 
 
By general procedure S, amino ester 273 (520 mg, 1.52 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 10:90 MeOH–EtOAc) to yield 
the tetrahydrobenzazepine 283 (360 mg, 91%) as a yellow oil, Rf = 0.61 (20:80 MeOH–
EtOAc); νmax/ cm-1 (ATR) 3359 (br), 2952, 2878, 1727, 1204 and 1130; δH (400 MHz, CDCl3) 
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8.61 (1H, s, 11-H), 8.37 (1H, d, J 5.0, 2-H), 6.97 (1H, d, J 5.0, 3-H), 5.48 (1H, d, J 0.8, alkene-
Ha), 5.13 (1H, app s, alkene-Hb), 4.03 (1H, d, J 17.1, 5-Ha), 3.94 (1H, d, J 17.1, 5-Hb), 3.76 
(3H, s, methyl), 2.99 (1H, d, J 13.9, 8-Ha), 2.85 (1H, d, J 13.9, 8-Hb), 2.22-2.00 (1H, m, 
isopropyl 2-H) and 1.00 (6H, t, J 7.2, isopropyl-MeA and isopropyl-MeB); δC (101 MHz, 
CDCl3) 175.0 (CO), 148.5 (C-11), 148.3 (C-2), 148.1 (C-9), 141.9 (C-4), 135.7 (C-10), 122.1 
(C-3), 116.4 (alkene-C), 69.3 (C-7), 51.8 (methyl), 48.3 (C-5), 40.7 (C-8), 34.6 (isopropyl 
C-2), 18.1 (isopropyl-MeA) and 17.1 (isopropyl-MeB); HRMS found MH+, 261.1620.  
C15H20N2O2 requires MH, 261.1603. 
Methyl 5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3-carboxylate, 284 
 
By general procedure S, amino ester 275 (360 mg, 1.21 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 284 (150 mg, 57%) as a yellow oil, Rf = 0.20 (60:40 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3346 (br), 3063, 3015, 2950, 2846, 1736, 1434, 1200, 1172, 774 
and 744; δH (400 MHz, CDCl3) 7.28-7.23 (1H, m, 9-H), 7.17-7.09 (2H, m, 7-H and 8-H), 7.05-
7.01 (1H, m, 6-H), 5.18 (1H, d, J 1.5, alkene-Ha), 5.10 (1H, app s, alkene-Hb), 4.02 (1H, d, J 
15.9, 1-Ha), 3.87 (1H, d, J 15.9, 1-Hb), 3.75 (1H, dd, J 9.4 and 4.4, 3-H), 3.69 (3H, s, methyl), 
2.90 (1H, dd, J 13.4 and 4.4, 4-Ha), 2.56 (1H, dd, J 13.4 and 9.4, 4-Hb) and 1.99 (1H, br s, 
NH); δC (101 MHz, CDCl3) 173.6 (CO), 146.8 (C-5), 141.7 (C-9a), 139.2 (C-5a), 128.2 (C-9), 
128.0 (C-8), 127.5 (C-7), 127.2 (C-6), 116.0 (alkene), 62.6 (C-3), 52.1 (methyl), 51.5 (C-1) 
and 40.4 (C-4); HRMS found MH+, 218.1183.  C13H15NO2 requires MH, 218.1181. 
Methyl 7-fluoro-5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3- 
carboxylate, 285 
 
By general procedure S, amino ester 276 (440 mg, 1.39 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 285 (170 mg, 52%) as a yellow oil, Rf = 0.19 (50:50 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3347, 2952, 1737, 1582, 1436, 1276, 1213 and 1173; δH (400 
MHz, CDCl3) 7.11-7.01 (2H, m, 6-H and 9-H), 6.89 (1H, td, J 8.3 and 2.7, 8-H), 5.28 (1H, d, J 
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1.4, alkene-Ha), 5.23 (1H, app s, alkene-Hb), 4.08 (1H, d, J 15.8, 1-Ha), 3.92 (1H, d, J 15.8, 1-
Hb), 3.83 (1H, dd, J 9.3 and 4.3, 3-H), 3.78 (3H, s, methyl), 2.98 (1H, dd, J 13.5 and 4.3, 4-
Ha), 2.64 (1H, dd, J 13.5 and 9.3, 4-Hb) and 2.00 (1H, br s, NH); δC (101 MHz, CDCl3) 173.4 
(CO), 161.8 (d, J 245.2, C-7), 145.9 (C-9a), 143.7 (d, J 7.3, C-5), 135.1 (C-5a), 129.6 (d, J 8.1, 
C-9), 116.9 (alkene), 115.0 (d, J 22.0, C-6), 113.8 (d, J 21.1, C-8), 62.5 (C-3), 52.1 (methyl), 
50.8 (C-1) and 40.1 (C-4); δF (376 MHz, CDCl3) -116.3; HRMS found MH+, 236.1099.  
C13H14FNO2 requires MH, 236.1087. 
Methyl 8-fluoro-5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3- 
carboxylate, 286 
 
By general procedure S, amino ester 277 (480 mg, 1.52 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield 
the tetrahydrobenzazepine 286 (300 mg, 84%) as a yellow oil, Rf = 0.36 (40:60 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3340 (br), 3081, 2952, 2845, 1736, 1492, 1272 and 1219; δH (400 
MHz, CDCl3) 7.21 (1H, dd, J 8.8 and 6.0, 9-H), 6.81 (1H, td, J 8.8 and 2.6, 6-H), 6.74 (1H, dd, 
J 8.8 and 2.5, 7-H), 5.15 (1H, d, J 1.1, alkene-Ha), 5.08 (1H, app s, alkene-Hb), 3.98 (1H, d, J 
16.0, 1-Ha), 3.84 (1H, d, J 16.0, 1-Hb), 3.74 (1H, dd, J 9.3 and 4.5, 3-H), 3.69 (3H, s, methyl), 
2.88 (1H, dd, J 13.4 and 4.5, 4-Ha) and 2.54 (1H, dd, J 13.4 and 9.3, 4-Hb); δC (101 MHz, 
CDCl3) 173.4 (CO), 161.9 (d, J 247.1, C-8), 145.8 (C-5), 141.5 (C-9a), 137.6 (C-5a), 129.9 (d, 
J 8.0, C-9), 116.0 (alkene), 114.7 (d, J 21.4, C-6), 113.6 (d, J 20.9, C-7), 62.4 (C-3), 52.1 
(methyl), 51.2 (C-1) and 40.2 (C-4); δF (376 MHz, CDCl3) -115.7; HRMS found MH+, 
236.1101.  C13H14FNO2 requires MH, 236.1087. 
Methyl 9-methylene-6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepine-7-carboxylate, 
287 
 
By general procedure S, amino ester 278 (490 mg, 1.64 mmol) gave a crude 
residue which was purified by flash chromatography (SiO2, 100% EtOAc to 10:90 MeOH–
EtOAc) to yield the tetrahydrobenzazepine 287 (290 mg, 81%) as a yellow oil, Rf = 0.28 
(10:90 MeOH–EtOAc); νmax/ cm-1 (ATR) 3342 (br), 2951, 1736, 1435, 1274, 1207 and 1157; 
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δH (400 MHz, CDCl3) 8.57 (1H, s, 11-H), 8.43 (1H, d, J 4.9, 2-H), 7.03 (1H, d, J 4.9, 3-H), 5.37 
(1H, d, J 1.0, alkene-Ha), 5.27 (1H, app s, alkene-Hb), 4.14 (1H, d, J 16.5, 5-Ha), 3.96 (1H, d, 
J 16.5, 5-Hb), 3.86 (1H, dd, J 9.1 and 4.9, 7-H), 3.80 (3H, s, methyl), 3.01 (1H, dd, J 13.5 and 
4.9, 8-Ha) and 2.68 (1H, dd, J 13.5 and 9.1, 8-Hb); δC (101 MHz, CDCl3) 173.3 (CO), 148.7 
(C-11), 147.7 (C-2), 142.9 (C-9), 136.7 (C-4), 132.1 (C-10), 122.2 (C-3), 117.1 (alkene), 
62.0 (C-7), 52.2 (methyl), 50.4 (C-5) and 40.0 (C-8); HRMS found MH+, 219.1141.  
C12H14N2O2 requires MH, 219.1133. 
3-(2-Fluorophenyl)-3-(prop-2-en-1-yl)piperazine-2,5-dione, 198 
 
TFA (1.05 mL, 13.7 mmol) was added to a stirred solution of amide 193 (520 mg, 
1.37 mmol) in DCM (15.0 mL, ~0.1 M) at 0 °C and stirred for 10 min before being warmed 
to room temperature and stirred overnight.  The reaction mixture was concentrated in 
vacuo and dissolved in DMF (30 mL, ~0.05 M).  Cs2CO3 (893 mg, 2.74 mmol) was added 
and the reaction mixture heated at reflux for 1 hr, before being concentrated in vacuo.  The 
residue was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to yield the 
piperazine 198 (250 mg, 71%) as an amorphous pale orange solid, Rf = 0.50 (10:90 MeOH–
DCM); νmax/ cm-1 (ATR) 3195, 3078, 2923, 1678, 1453 and 773; δH (501 MHz, MeOD) 7.43 
(1H, td, J 8.0 and 1.4, fluorophenyl 4-H), 7.30 (1H, dddd, J 8.0, 7.4, 5.2 and 1.7, fluorophenyl 
3-H), 7.13 (1H, td, J 8.0 and 1.2, fluorophenyl 5-H), 7.05 (1H, ddd, J 12.2, 8.0 and 1.4, 
fluorophenyl 6-H), 5.84-5.72 (1H, m, propenyl 2-H), 5.24-5.16 (2H, m, propenyl 3-H2), 
3.86 (2H, d, J 0.5, 6-H2), 3.08 (1H, dd, J 13.3 and 6.7, propenyl 1-Ha) and 2.80 (1H, dd, J 13.3 
and 7.7, propenyl 1-Hb); δC (126 MHz, MeOD) 169.9 (C-1), 167.8 (C-4), 163.2 
(fluorophenyl C-2), 132.4 (propenyl C-2), 131.6 (d, J 9.0, fluorophenyl C-4), 129.8 (d, J 10.7, 
fluorophenyl C-1), 128.7 (d, J 3.1, fluorophenyl C-3), 125.4 (d, J 3.4, fluorophenyl C-5), 
121.8 (propenyl C-3), 117.2 (d, J 22.4, fluorophenyl C-6), 62.7 (C-3), 45.7 (C-6) and 42.8 
(propenyl C-1); δF (282 MHz, CDCl3) -112.8; HRMS found MH+, 249.1035.  C13H13FN2O2 
requires MH, 249.1039. 
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(2R, 5S)-5-Cyclopropyl-N, 4-bis[(4-methoxyphenyl)methyl]-1-(2-nitrobnzene 
sulfonyl)piperazine-2-carboxamide, 235 
 
DEAD (59.0 µL, 0.370 mmol) was added dropwise to a solution of the alcohol 234 
(177 mg, 0.290 mmol), PPh3 (106 mg, 0.406 mmol) in THF (5.80 mL, 0.05 M) at 0 °C.  The 
resulting solution was warmed to room temperature and stirred overnight, before being 
concentrated in vacuo and purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) 
then again (SiO2, 60:40 Petrol–EtOAc), before being purified by mass-directed preparative 
HPLC to yield the piperazine 235 (14.6 mg, 8%) as a yellow oil, Rf = 0.71 (30:70 Petrol–
EtOAc); δH (500 MHz, CDCl3) 8.12 (1H, d, J 7.6, nitrophenyl 3-H), 7 7.66 (1H, t, J 7.6, 
nitrophenyl 4-H), 7.62 (1H, t, J 7.6, nitrophenyl 5-H), 7.51 (1H, d, J 7.6, nitrophenyl 6-H), 
7.08 (2H, d, J 8.4, 2-PMB 3-H and 2-PMB 5-H), 7.00 (2H, d, J 8.4, 4-PMB 3-H and 4-PMB 5-
H), 6.78 (4H, dd, J 12.6 and 8.4, 2-PMB 2-H, 2-PMB 6-H, 4-PMB 2-H and 4-PMB 6-H), 4.39 
(1H, app s, 2-H), 4.30 (1H, dd, J 14.4 and 5.5, 2-benzylic-Ha), 4.13 (1H, dd, J 14.4 and 5.5, 
2-benzylic-Hb), 3.90 (1H, d, J 13.2, 4-benzylic-Ha), 3.80 (3H, s, 2-PMB methyl), 3.78-3.76 
(4H, m, 4-PMB methyl and 6-Ha), 3.63 (1H, d, J 13.2, 4-benzylic-Hb), 3.49 (1H, dd, J 13.0 
and 2.9, 6-Hb), 3.22 (1H, d, J 12.3, 3-Ha), 3.15 (1H, dd, J 12.3 and 4.2, 3-Hb), 1.94 (1H, d, J 
10.0, 5-H), 1.24-1.10 (1H, m, cyclopropyl 1-H), 0.75-0.61 (1H, m, cyclopropyl 2-Ha), 0.35-
0.22 (2H, m, cyclopropyl 2-Hb and cyclopropyl 4-Ha) and −0.09-−0.22 (1H, m, cyclopropyl 
4-Hb); δC (126 MHz, CDCl3) 168.2 (CO), 159.1 (2-PMB C-4), 159.0 (4-PMB C-4), 147.5 
(nitrophenyl C-2), 133.9 (nitrophenyl C-5), 133.1 (nitrophenyl C-1), 132.1 (nitrophenyl 
C-4), 132.1 (nitrophenyl C-6), 130.1 (2-PMB C-1 and 4-PMB C-1), 129.9 (2-PMB C-3 and 
2-PMB C-5), 129.3 (4-PMB C-3 and 4-PMB C-5), 124.6 (nitrophenyl C-3), 114.2 (2-PMB C-
2 and 2-PMB C-6), 113.9 (4-PMB C-2 and 4-PMB C-6), 61.8 (C-5), 58.5 (C-6), 56.7 (C-2), 
55.5 (2-PMB methyl), 55.3 (4-PMB methyl), 48.5 (4-PMB benzylic-C), 46.3 (C-3), 43.2 (2-
PMB benzylic-C), 6.9 (cyclopropyl C-2), 4.8 (cyclopropyl C-1) and 0.8 (cyclopropyl C-4). 
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5.7  Synthesis of Fragments 
N-Methoxyethyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-1,4-diazepane-5-
carboxamide, 130 
 
By general procedure L, the protected diazepane 51 (379 mg, 0.740 mmol) gave a 
crude residue which was purified by flash chromatography (SiO2, 100% EtOAc) to yield 
the deprotected diazepane 130 (239 mg, 78%) as a yellow oil, Rf = 0.09 (30:70 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3383, 3285, 2933, 1714, 1639, 1605, 1544, 1345, 1272 and 577; 
δH (500 MHz, CDCl3) 8.03 (1H, d, J 7.9, nitrophenyl 3-H), 7.95 (1H, br s, amide NH), 7.74-
7.68 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.65 (1H, d, J 8.4, nitrophenyl 6-H), 
3.71-3.56 (2H, m, 2-Ha and 3-Ha), 3.50-3.41 (4H, m, 2-Hb, 3-Hb and 7-H2), 3.39-3.29 (4H, m, 
methoxyethyl 2-Ha and methoxyethyl 4-H3), 3.24-3.10 (2H, m, methoxyethyl 1-H2), 2.98 
(1H, dd, J 14.7 and 6.6, methoxyethyl 2-Hb), 2.38 (1H, dd, J 15.8 and 8.4, ethyl 1-Ha), 1.97 
(1H, dd, J 15.8 and 8.4, ethyl 1-Hb), 1.89-1.77 (1H, m, 6-Ha), 1.65 (1H, br s, NH), 1.60-1.47 
(1H, m, 6-Hb) and 0.84 (3H, app t, J 8.4, ethyl 2-H3); δC (126 MHz, CDCl3) 175.1 (amide CO), 
148.0 (nitrophenyl C-2), 133.5 (nitrophenyl C-5), 132.9 (nitrophenyl C-1), 131.6 
(nitrophenyl C-4), 131.0 (nitrophenyl C-6), 124.1 (nitrophenyl C-3), 71.4 (C-3), 65.3 (C-5), 
58.7 (methoxyethyl C-4), 51.7 (C-2), 44.2 (C-7), 44.0 (methoxyethyl C-1), 39.0 
(methoxyethyl C-2), 37.7 (ethyl C-1), 31.9 (C-6) and 8.1 (ethyl C-2); HRMS found MH+, 
415.1717.  C17H26N4O6S requires MH, 415.1651. 
N-Benzyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-1,4-diazepane-5-carboxamide, 117 
 
By general procedure L, the protected diazepane 33 (890 mg, 1.64 mmol) gave a 
crude residue which was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to 
yield the deprotected diazepane 117 (250 mg, 34%) as a yellow oil, Rf = 0.18 (40:60 
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Petrol–EtOAc); νmax/ cm-1 (ATR) 3349 (br), 2932, 1653, 1543, 1454, 1370, 1163 and 577; 
δH (500 MHz, CDCl3) 8.03 (1H, dd, J 7.6 and 1.7, nitrophenyl 3-H), 7.99 (1H, t, J 5.7, NH), 
7.77-7.68 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.66 (1H, dd, J 7.4 and 1.7, 
nitrophenyl 6-H), 7.43-7.20 (5H, m, benzyl-H), 4.49 (1H, dd, J 14.7 and 5.7, benzylic-Ha), 
4.42 (1H, dd, J 14.7 and 5.7, benzylic-Hb), 3.73-3.55 (2H, m, 2-Ha and 3-Ha), 3.35 (1H, dd, J 
13.9 and 7.2, 7-Ha), 3.25 (1H, dd, J 13.9 and 9.1, 7-Hb), 3.16 (1H, dd, J 14.9 and 6.5, 3-Hb), 
2.98 (1H, dd, J 14.9 and 6.2, 2-Hb), 2.43 (1H, dd, J 15.5 and 8.1, ethyl 1-Ha), 2.02 (1H, dd, J 
15.5 and 8.1, ethyl 1-Hb), 1.87 (1H, td, J 15.1 and 7.2, 6-Ha), 1.70-1.55 (1H, m, 6-Hb) and 
0.86 (3H, app t, J 8.1, ethyl 2-H3); δC (75 MHz, CDCl3) 148.0 (nitrophenyl C-2) , 138.4 
(benzyl C-1), 133.6 (nitrophenyl C-5), 132.7 (nitrophenyl C-1), 131.7 (nitrophenyl C-4), 
131.0 (nitrophenyl C-6), 128.7 (benzyl C-3 and benzyl C-5), 127.7 (benzyl C-2 and benzyl 
C-6), 127.5 (benzyl C-4), 124.2 (nitrophenyl C-3), 65.7 (C-5), 51.0 (C-3), 44.3 (benzylic-C), 
44.0 (C-2), 43.5 (C-7), 37.2 (C-6), 31.9 (ethyl C-1) and 8.2 (ethyl C-2), amide CO not 
observed; HRMS found MH+, 447.1721.  C21H26N4O5S requires MH, 447.1702. 
N-Benzyl-5-ethyl-1-[(2-nitrophenyl)sulfonyl]-4-(ethyl)-1,4-diazepane-5-
carboxamide, 118 
 
By general procedure M, acetaldehyde (0.130 mL, 2.24 mmol) and diazepane 117 
(250 mg, 0.560 mmol) gave a crude residue which was  purified by flash chromatography 
(SiO2, 30:70 Petrol–EtOAc) to yield the alkylated diazepane 118 (170 mg, 64%) as a 
yellow oil, Rf = 0.66 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3371 (br), 2968, 1662, 1542, 
1501, 1362, 1162, 729 and 575; δH (500 MHz, CDCl3) 7.98 (1H, dd, J 7.6 and 1.6, 
nitrophenyl 3-H), 7.74-7.66 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.63 (1H, dd, J 
7.5 and 1.6, nitrophenyl 6-H), 7.57 (1H, t, J 5.8, NH), 7.36-7.32 (2H, m, benzyl 3-H and 
benzyl 5-H), 7.31-7.26 (3H, m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 4.51 (1H, dd, J 14.6 
and 5.8, benzylic-Ha), 4.38 (1H, dd, J 14.6 and 5.8, benzylic-Hb), 3.90 (1H, dd, J 13.0 and 6.8, 
2-Ha), 3.75 (1H, dd, J 14.7 and 7.1, 7-Ha), 3.22 (1H, ddd, J 15.4, 7.6 and 2.4, 2-Ha), 3.15 (1H, 
dd, J 14.7 and 9.7, 7-Hb), 2.97 (1H, ddd, J 13.0, 7.6 and 2.6, 3-Hb), 2.82 (1H, ddd, J 15.4, 6.8 
and 2.6, 2-Hb), 2.71-2.51 (2H, m, 4-ethyl 1-H2), 2.29 (1H, dd, J 15.6 and 7.4, 5-ethyl 1-Ha), 
2.08-2.03 (1H, m, 5-ethyl 1-Hb), 1.92-1.70 (2H, m, 6-H2) and 0.97 (6H, t, J 7.4, 4-ethyl 2-H3 
and 5-ethyl 2-H3); δC (126 MHz, CDCl3) 175.0 (amide CO), 148.1 (nitrophenyl C-2), 138.5 
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(benzyl C-1), 133.5 (nitrophenyl C-5), 132.7 (nitrophenyl C-1), 131.6 (nitrophenyl C-4), 
130.8 (nitrophenyl C-6), 128.7 (benzyl C-3 and benzyl C-5), 127.8 (benzyl C-2 and benzyl 
C-6), 127.5 (benzyl C-4), 124.1 (nitrophenyl C-3), 69.5 (C-5), 49.2 (4-ethyl C-1), 46.4 (C-
2), 43.7 (benzylic-C), 43.5 (C-3), 43.0 (C-7), 35.6 (C-6), 28.5 (5-ethyl C-1), 14.2 (4-ethyl C-
2) and 9.5 (5-ethyl C-2); HRMS found MH+, 475.2028.  C23H30N4O5S requires MH, 475.2015. 
N-Benzyl-5-ethyl-4-(ethyl)-1,4-diazepane-5-carboxamide, 119 
 
By general procedure O, the protected diazepane 118 (170 mg, 0.358 mmol) gave 
a crude residue which was purified by basic SCX cartridge to yield the deprotected 
diazepane 119 (70.4 mg, 68%) as a yellow oil, Rf = 0.64 (10:90 MeOH–DCM); νmax/ cm-1 
(ATR) 3361 (br), 2967, 2934, 2854, 1657, 1503, 1455 and 700; δH (500 MHz, CDCl3) 7.87 
(1H, t, J 5.4, NH), 7.40-7.34 (2H, m, benzyl 3-H and benzyl 5-H), 7.33-7.30 (3H, m, benzyl 
2-H, benzyl 4-H and benzyl 6-H), 4.58 (1H, dd, J 14.6 and 6.7, benzylic-Ha), 4.35 (1H, dd, J 
14.6 and 5.4, benzylic-Hb), 3.27-3.19 (2H, m, 2-Ha and 3-Ha), 3.12 (1H, dd, J 14.0 and 7.1, 
7-Ha), 2.96 (1H, dd, J 12.6 and 9.7, 2-Hb), 2.77-2.68 (2H, m, 7-Hb and 3-Hb, 2.61-2.52 (2H, 
m, 4-ethyl 1-Ha and 5-ethyl 1-Ha), 2.26-2.12 (2H, m, 5-ethyl 1-Hb and 6-Ha), 2.01 (1H, dq, J 
15.3 and 7.8, 4-ethyl 1-Hb), 1.81 (1H, td, J 14.8 and 7.1, 6-Hb), 1.09 (3H, app t, J 7.8, 4-ethyl 
2-H3) and 0.94 (3H, t, J 7.0 5-ethyl 2-H3); δC (126 MHz, CDCl3) 176.1 (CO), 138.6 (benzyl C-
1), 128.8 (benzyl C-3 and benzyl C-5), 127.8 (benzyl C-2 and benzyl C-6), 127.5 (benzyl C-
4), 68.9 (C-5), 52.0 (C-3), 47.9 (C-2), 45.6 (C-7), 43.6 (benzylic-C), 43.6 (4-ethyl C-1), 38.0 
(5-ethyl C-1), 27.0 (C-6), 14.5 (4-ethyl C-2) and 9.6 (5-ethyl C-2); HRMS found MH+, 
290.2247.  C17H27N3O requires MH, 290.2232. 
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N-Benzyl-5-ethyl-4-(trifluoroacetyl)-1,4-diazepane-5-carboxamide, 120 
 
By general procedure K (with an additional 6 eq. TFA), ketone 126 (533 mg, 
1.60 mmol) and benzyl isocyanide (0.387 mL, 3.19 mmol) gave a crude residue which was 
purified by flash chromatography (SiO2, 60:40 DCM–EtOAc).  Ammonium formate 
(578 mg, 9.16 mmol) and 20% Pd(OH)2/C (128 mg, 10 mol%) was added to a solution of 
the crude piperazine (820 mg, 1.83 mmol) in EtOH (20 mL, 0.1 M).  The resulting mixture 
was stirred at 70 °C for 4 hr before being cooled to room temperature and filtered through 
Celite.  The filtrate was concentrated in vacuo and the residue was diluted with sat. 
NaHCO3 (20 mL) and DCM (20 mL).  The aqueous layer was extracted with DCM (3 × 
20 mL) and the combined organic layers were dried (MgSO4) and concentrated in vacuo.  
The residue was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the 
deprotected piperazine 120 (230 mg, 40% over two steps) as a yellow oil, Rf = 0.67 (30:70 
Petrol–EtOAc); νmax/ cm-1 (ATR) 3340 (br), 2936, 1680, 1455, 1177, 1135 and 698; δH 
(501 MHz, DMSO) 8.25 (1H, app q, J 4.2, NH), 7.34-7.24 (4H, m, benzyl 2-H, benzyl 3-H, 
benzyl 5-H and benzyl 6-H), 7.23-7.18 (1H, m, benzyl 4-H), 4.36-4.27 (2H, m, benzylic-H2), 
3.70-3.55 (1H, m, 3-Ha), 3.55-3.43 (3H, m, 2-Ha and 7-H2), 2.97 (1H, dt, J 14.6 and 3.7, 6-
Ha), 2.84-2.63 (2H, m, 6-Hb and 3-Hb), 2.30 (0.5H, dd, J 15.2 and 6.2, 2-Hb), 2.21 (0.5H, dd, 
J 15.3 and 6.6, 2-Hb), 1.72-1.66 (1H, m, J 14.0 and 7.0, NH), 1.60-1.48 (2H, m, ethyl 1-H2) 
and 0.74 (3H, t, J 7.5, ethyl 2-H3); δC (126 MHz, DMSO) 174.7 (CO), 174.5 (CO), 139.8 
(benzyl C-1), 128.2 (benzyl C-3 and benzyl C-5), 127.24 (benzyl C-2), 127.22 (benzyl C-6), 
126.7 (benzyl C-4), 64.3 (C-5), 64.2 (C-5), 49.7 (C-3), 49.4 (C-3), 43.4 (benzylic-C), 42.4 (C-
2), 42.2 (C-7), 42.1 (C-7), 37.1 (C-6), 32.6 (ethyl C-1), 32.4 (ethyl C-1) and 8.1 (ethyl C-2), 
trifluoroacetyl carbons not observed; δF (282 MHz, DMSO) -67.6 and -67.8; HRMS found 
MH+, 358.1757.  C17H22F3N3O2 requires MH, 358.1742. 
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N-Benzyl-5-ethyl-methyl-4-(trifluoroacetyl)-1,4-diazepane-5-carboxamide, 128 
 
Acetic acid (0.180 mL, 3.08 mmol) was added to a solution of piperazine 120 
(274 mg, 0.770 mmol), 37% formaldehyde (86.0 µL, 1.16 mmol) and zinc dust (101 mg, 
1.54 mmol) in dioxane (3.85 mL, 0.2 M).  The resulting mixture was stirred at 30 °C for 6 
hr and at room temperature overnight, before being filtered and concentrated in vacuo.  
Sat. NaHCO3 (5 mL) was added to basify the mixture before the aqueous layer was 
extracted with DCM (3 × 5 mL).  The combined organic phases were washed with water 
(5 mL), brine (5 mL), dried (MgSO4) and concentrated in vacuo.  The residue was purified 
by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the alkylated piperazine 128 
(102 mg, 36%) as a yellow oil, Rf = 0.67 (30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3367, 2970, 
2938, 1683, 1507, 1173 and 1139; δH (501 MHz, MeOD) 7.27-7.17 (4H, m, benzyl 2-H, 
benzyl 3-H, benzyl 5-H and benzyl 6-H), 7.16-7.10 (1H, m, benzyl 4-H), 4.32 (1H, d, J 14.9, 
benzylic-Ha), 4.27 (1H, d, J 14.9, benzylic-Hb), 3.97-3.86 (1H, m, 3-Ha), 3.83 (0.5H, dd, J 14.1 
and 7.1, 2-Ha), 3.68 (0.5H, dd, J 15.7 and 5.9, 2-Ha), 3.44-3.30 (1H, m, 7-Ha), 3.19-3.13 (1H, 
m, 6-Ha), 3.03-2.95 (2H, m, 3-Hb and 7-Hb), 2.38-2.35 (2H, m, 2-Hb and methyl), 2.27 (2H, 
s, methyl), 1.72-1.63 (1H, m, 6-Hb), 1.60-1.50 (2H, m, ethyl 1-H2) and 0.72 (3H, td, J 7.5 and 
2.6, ethyl 2-H3); δC (126 MHz, MeOD) 140.2 (app d, J 4.8, trifluoroacetyl C-1), 129.4 (benzyl 
C-3 and benzyl C-5), 128.9 (benzyl C-2 and benzyl C-6), 128.2 (benzyl C-4), 118.1 (app d, 
J 287.0, trifluoroacetyl C-2), 70.4 (C-5) 51.3 (C-3), 50.3 (C-2), 44.2 (benzylic-C), 43.2 (C-7), 
34.9 (methyl), 34.6 (methyl), 33.1 (C-6), 32.4 (C-6), 32.3 (ethyl C-1), 31.8 (ethyl C-1) and 
9.3 (ethyl C-3), amide CO and benzyl C-1 not observed; HRMS found MH+, 372.1913.  
C18H24F3N3O2 requires MH, 372.1899. 
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N-Benzyl-5-ethyl-methyl-1,4-diazepane-5-carboxamide, 129 
 
By general procedure L (with an additional 14 eq. NaBH4), the protected 
piperazine 128 (21.0 mg, 57.0 µmol) gave the deprotected piperazine 129 (12.9 mg, 82%) 
as a yellow oil which was used without further purification, Rf = 0.77 (30:70 MeOH–DCM); 
νmax/ cm-1 (ATR) 3335 (br), 2937, 2808, 1652, 1498, 1454 and 699; δH (500 MHz, CDCl3) 
7.89 (1H, s, NH), 7.33-7.17 (5H, m, benzyl-H), 4.43-4.34 (2H, m, J 14.7 and 5.8, benzylic-
H2), 3.10 (1H, dd, J 14.5 and 8.5, 3-Ha), 2.97 (1H, dd, J 12.5 and 5.5, 2-Ha), 2.87 (1H, dd, J 
13.3 and 7.1, 7-Ha), 2.75-2.62 (2H, m, 2-Hb and 7-Hb), 2.58 (1H, dd, J 14.5 and 5.5, 3-Hb), 
2.34 (3H, s, methyl), 2.11 (1H, dd, J 15.1 and 6.8, 6-Ha), 1.92-1.78 (2H, m, ethyl 1-H2), 1.76-
1.64 (1H, m, 6-Hb) and 0.93 (3H, t, J 7.5, ethyl 2-H3); δC (126 MHz, CDCl3) 176.0 (CO), 138.8 
(benzyl C-1), 128.7 (benzyl C-3 and benzyl C-5), 127.8 (benzyl C-2 and benzyl C-6), 127.4 
(benzyl C-4), 68.5 (C-5), 54.6 (C-3), 51.0 (C-2), 44.1 (C-7), 43.5 (benzylic-C), 39.7 (methyl), 
38.5 (C-6), 27.8 (ethyl C-1) and 9.3 (ethyl C-2); HRMS found MH+, 276.2186.  C16H25N3O 
requires MH, 276.2076. 
2-Benzyl-9a-ethyl-1-oxo-3-(trifluoromethyl)-octahydro-1H-imidazolidino[1,5-d] 
[1,4]diazepin-7-ium-3-olate, 121 
 
K2CO3 (271 mg, 1.96 mmol) was added to a stirred solution of the protected 
piperazine 33 (710 mg, 1.31 mmol) and PhSH (0.200 mL, 1.96 mmol) in MeCN (13.1 mL, 
0.1 M), and the mixture was stirred at room temperature overnight.  Excess K2CO3 was 
removed by filtration and the reaction mixture was concentrated in vacuo.  The residue 
was purified by flash chromatography (SiO2, 10:90 MeOH–DCM) to yield the zwitterion 
121 (330 mg, 70%) as a colourless solid, m.p. 140-142 °C; Rf = 0.32 (10:90 MeOH–DCM); 
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νmax/ cm-1 (ATR) 3305 (br), 2963, 2936, 2880, 1707, 1453, 1294 and 1164; δH (500 MHz, 
CDCl3) 7.44 (2H, d, J 7.3, benzyl 3-H and benzyl 5-H), 7.35-7.30 (2H, m, benzyl 2-H and 
benzyl 6-H), 7.28-7.22 (1H, m, benzyl 4-H), 4.70 (1H, d, J 15.4, benzylic-Ha), 4.65 (1H, d, 
J 15.3, benzylic-Hb), 3.73-3.62 (1H, m, 5-Ha), 3.16 (1H, ddd, J 15.9, 7.3 and 3.4, 6-Ha), 2.95-
2.85 (3H, m, 6-Hb and 8-H2), 2.85-2.78 (1H, m, 5-Hb), 2.09-1.94 (3H, m, 9-H2 and NH), 1.78 
(1H, dq, J 14.8 and 7.4, ethyl 1-Ha), 1.61 (1H, dq, J 14.8 and 7.4, ethyl 1-Hb) and 0.91 (3H, t, 
J 7.4, ethyl 3-H3); δc (126 MHz, CDCl3) 174.8 (CO), 137.5 (benzyl C-1), 128.5 (benzyl C-3 
and benzyl C-5), 128.1 (benzyl C-2 and benzyl C-6), 127.1 (benzyl C-4), 122.6 (app d, J 
289.7, C-3), 96.9 (app d, J 33.0, trifluoromethyl), 67.2 (C-9a), 43.8 (benzylic-C), 41.9 (C-5), 
40.8 (C-6), 40.1 (C-8), 34.5 (ethyl C-1), 30.5 (C-9) and 8.1 (ethyl C-2); δF (282 MHz, CDCl3) 
-79.8; HRMS found MH+, 358.1732.  C17H22F3N3O2 requires MH, 358.1742. 
2-Benzyl-9a-ethyl-octahydro-1H-imidazolidino[1,5-d][1,4]diazepine-1,3-dione, 
122 
 
K2CO3 (522 mg, 3.78 mmol) was added to a solution of the zwitterion 121 (270 mg, 
0.760 mmol) in EtOH (3.80 mL, 0.2 M) and stirred at 70 °C for 4 hr.  The reaction mixture 
was concentrated in vacuo, diluted with water (5 mL) and extracted with EtOAc (3 × 5 mL).  
The combined organic phases were washed with brine (5 mL), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, 10:90 
MeOH–DCM) to yield the hydantoin 122 (89.1 mg, 41%) as a yellow oil, Rf = 0.24 (10:90 
MeOH–DCM); νmax/ cm-1 (ATR) 3341 (br), 2967, 2937, 1764, 1703, 1448 and 1350; δH (501 
MHz, CDCl3) 7.42-7.36 (2H, m, benzyl 3-H and benzyl 5-H), 7.34-7.23 (3H, m, benzyl 2-H, 
benzyl 4-H and benzyl 6-H), 4.71-4.63 (2H, m, benzylic-H2), 4.10-4.00 (1H, m, 5-Ha), 3.00-
2.83 (4H, m, 5-Hb, 6-H2 and 8-Ha), 2.51 (1H, dd, J 15.2 and 6.4, 8-Hb), 2.18 (1H, dd, J 14.7 
and 10.7, 9-Ha), 1.84 (1 H , dq, J 14.6 and 7.4, ethyl 1-Ha), 1.74 (1H, ddd, J 14.7, 10.8 and 
1.3, 9-Hb), 1.69-1.58 (2H, m, ethyl 1-Hb and NH) and 0.62 (3H, t, J 7.4, ethyl 2-H3); δC (126 
MHz, CDCl3) 175.8 (C-1), 156.6 (C-3), 136.4 (benzyl C-1), 128.6(benzyl C-4), 128.5 (benzyl 
C-3 and benzyl C-5), 127.8 (benzyl C-2 and benzyl C-6), 68.5 (C-9a), 48.2 (benzylic-C), 44.9 
(C-5), 43.2 (C-6), 42.5 (C-8), 41.5 (ethyl C-1), 29.8 (C-9) and 7.4 (ethyl C-2); HRMS found 
MH+, 288.1716.  C16H21N3O2 requires MH, 288.1712. 
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N-Cyclopropyl-5-ethyl-4-(trifluoroacetyl)-1,4-diazepane-5-carboxamide, 133 
 
By general procedure O, the protected diazepane 108 (520 mg, 1.06 mmol) gave 
a crude residue which was purified by basic SCX cartridge to yield the deprotected 
diazepane 133 (320 mg, 98%) as an orange amorphous solid Rf = 0.76 (20:80 MeOH–
DCM); νmax/ cm-1 (ATR) 3340 (br), 2968, 2937, 1682, 1512, 1460, 1181 and 1139; δH 
(500 MHz, CDCl3) 7.66 (0.55H, s, NH), 7.53 (0.45H, s, NH), 3.97 (0.45H, dd, J 14.2, 8.0, 3-
Ha), 3.90 (0.55H, dd, J 13.1, 8.9, 3-Ha), 3.84-3.66 (1H, m, 2-Ha), 3.64-3.53 (1.55H, m, 7-Ha 
and 7-Hb), 3.41 (0.45H, dd, J 14.4, 9.2, 7-Hb), 3.23-3.15 (0.55H, m, 3-Hb), 3.14-3.06 (0.45H, 
m, 3-Hb), 3.04-2.93 (1H, m, 2-Hb), 2.82-2.72 (1H, m, cyclopropyl 1-H), 2.55 (0.55H, dd, J 
15.3, 7.0, cyclopropyl 2-Ha), 2.43 (0.45H, dd, J 15.5, 7.7, cyclopropyl 2-Hb), 1.95-1.76 (2H, 
m, cyclopropyl 2-Hb and 6-Ha), 1.73-1.51 (1H, m, 6-Hb), 0.93-0.78 (5H, m, cyclopropyl 3-
H2 and ethyl 2-H3) and 0.58-0.44 (2H, m, ethyl 1-H2); δC (126 MHz, CDCl3) 156.5 (app d, J 
35.0, trifluoroacetyl C-1), 116.6 (q, J 288.0, trifluoroacetyl C-2), 65.3 (C-5), 65.1 (C-5), 43.9 
(C-3), 43.18 (C-2), 43.15 (C-2), 42.8 (C-7), 42.5 (C-7), 32.6 (C-6), 31.9 (C-6), 22.6 
(cyclopropyl C-1), 22.5 (cyclopropyl C-1), 8.2 (ethyl C-2), 8.2 (ethyl C-2), 6.6 (cyclopropyl 
C-2), 6.5 (cyclopropyl C-3), 6.48 (ethyl C-1) and 6.47 (ethyl C-1), amide CO not observed; 
δF (282 MHz, CDCl3) -68.6; HRMS found MH+, 308.1613.  C13H20F3N3O2 requires MH, 
308.1586. 
N-Cyclopropyl-5-ethyl-(methoxyacetyl)-4-(trifluoroacetyl)-1,4-diazepane-5-
carboxamide, 134 
 
By general procedure T, the diazepane 133 (269 mg, 0.880 mmol) and 
methoxyacetyl chloride (0.160 mL, 1.75 mmol) gave a crude residue which was purified 
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by flash chromatography (SiO2, 10:90 MeOH–DCM) to yield the acylated diazepane 134 
(258 mg, 78%) as a yellow oil, Rf = 0.70 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3327 (br), 
2948, 1688, 1656, 1461, 1208, 1182 and 1142; δH (500 MHz, CDCl3) 5.81 (1H, d, J 8.3, NH), 
4.64 (0.5H, dd, J 13.1 and 4.7, 3-Ha), 4.46 (0.5H, dd, J 14.4 and 6.9, 3-Ha), 4.29-4.19 (1H, m, 
methoxyacetyl 2-Ha), 4.18-4.07 (1H, m, 2-Ha), 4.05-3.96 (1H, m, methoxyacetyl 2-Hb), 
3.91-3.79 (1H, m, 7-Ha), 3.63-3.55 (1H, m, 7-Hb), 3.50 (1.4H, s, methoxyacetyl 4-H3), 3.48 
(1.6H, s, methoxyacetyl 4-H3), 3.33-3.23 (1H, m, 3-Hb), 3.22-3.15 (1H, m, 2-Hb), 2.77-2.68 
(1H, m, cyclopropyl 1-H), 2.63-2.49 (1H, m, ethyl 1-Ha), 2.24 (1H, ddd, J 15.4, 10.1 and 5.2, 
6-Ha), 1.96 (0.5H, dd, J 16.3 and 6.9, ethyl 1-Hb), 1.88 (0.5H, dd, J 16.2 and 6.7, ethyl 1-Hb), 
1.60-1.53 (1H, m, 6-Hb), 0.93-0.90 (3H, m, ethyl 2-H3), 0.87-0.75 (2H, m, cyclopropyl 2-H2), 
0.63-0.54 (1H, m, cyclopropyl 3-Ha), 0.51-0.42 (1H, m, cyclopropyl 3-Hb); δC (126 MHz, 
CDCl3) 173.91 (amide CO), 173.87 (amide CO), 170.34 (methoxyacetyl CO), 170.27 
(methoxyacetyl CO), 73.4 (C-3), 73.2 (C-3), 67.0 (C-5), 66.8 (C-5), 59.11 (methoxyacetyl 
C-4), 59.09 (methoxyacetyl C-4), 48.7 (methoxyacetyl C-2), 48.4 (methoxyacetyl C-2), 47.5 
(C-2), 42.0 (C-7), 36.6 (ethyl C-1), 36.0 (ethyl C-1), 27.5 (C-6), 27.3 (C-6), 22.9 (cyclopropyl 
C-1), 8.1 (ethyl C-2), 6.99 (cyclopropyl C-2), 6.96 (cyclopropyl C-2), 6.4 (cyclopropyl C-3), 
6.3 (cyclopropyl C-3), trifluoroacetyl carbons not observed; δF (282 MHz, CDCl3) -68.0, -
68.1; HRMS found MH+, 380.1790.  C16H24F3N3O4 requires MH, 380.1797. 
N-Cyclopropyl-5-ethyl-(methoxyacetyl)-1,4-diazepane-5-carboxamide, 135 
 
By general procedure L, the protected piperazine 134 (170 mg, 0.450 mmol) gave 
a crude residue which was purified by basic SCX cartridge to yield the deprotected 
piperazine 135 (29.0 mg, 27%) as a yellow oil in 70% purity, νmax/ cm-1 (ATR) 3323 (br), 
2931, 1640, 1457 and 1122; δH (500 MHz, CDCl3) 7.87 (1H, s, NH), 4.16 (1H, d, J 4.4, 
methoxyacetyl 1-Ha), 3.74 (1H, ddd, J 14.2, 5.6 and 2.9, 3-Ha), 3.67-3.54 (1H, m, 
methoxyacetyl 1-Hb), 3.54-3.47 (1H, m, 2-Ha), 3.45 (2H, s, methoxyacetyl 4-H3), 3.43 (1H, 
s, methoxyacetyl 4-H3), 3.36-3.27 (1H, m, 3-Hb), 3.13 (1H, ddd, J 14.8, 5.8 and 2.9, 7-Ha), 
2.96 (1H, ddd, J 14.8, 8.5 and 2.9, 7-Hb), 2.82-2.69 (1H, m, cyclopropyl 1-H), 2.56-2.43 (1H, 
m, 2-Hb), 1.94-1.84 (1H, m, ethyl 1-Ha), 1.83-1.74 (1H, m, 6-Ha), 1.73-1.61 (1H, m, 6-Hb), 
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0.89 (2H, t, J 7.5, ethyl 2-H3), 0.87-0.78 (4H, m, cyclopropyl 2-H2, ethyl 1-Hb and ethyl 2-H3) 
and 0.56-0.48 (2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 174.4 (5-CO), 169.0 (1-CO), 
71.4 (C-3), 65.4 (C-5), 59.2 (methoxyacetyl C-4), 46.5 (methoxyacetyl C-1), 43.6 (C-2), 
42.6 (C-7), 36.4 (ethyl C-1), 33.2 (C-6), 22.6 (cyclopropyl C-1), 8.3 (ethyl C-2), 6.5 
(cyclopropyl C-2) and 6.4 (cyclopropyl C-3); HRMS found MH+, 284.1982.  C14H25N3O3 
requires MH, 284.1974. 
N-Methoxyethyl-2-methyl-4-[(2-nitrophenyl)sulfonyl]piperazine-2-carboxamide, 
143 
 
By general procedure L, the protected piperazine 110 (450 mg, 0.930 mmol) gave 
the deprotected piperazine 143 (240 mg, 67%) as a yellow oil which was used without 
further purification, Rf = 0.38 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 3335 (br), 2930, 1667, 
1543, 1372, 1166, 1125 and 577; δH (500 MHz, CDCl3) 8.12-8.07 (1H, m, nitrophenyl 3-H), 
7.77-7.72 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 7.72-7.67 (1H, m, nitrophenyl 6-
H), 7.39-7.31 (1H, m, NH), 4.09 (1H, d, J 12.8, 3-Ha), 3.74-3.65 (1H, m, 5-Ha), 3.45-3.39 (4H, 
m, 5-Hb, 6-H2 and methoxyethyl 2-Ha), 3.37 (3H, s, methoxyethyl 4-H3), 3.14-3.09 (1H, m, 
methoxyethyl 2-Hb), 3.09-3.00 (2H, m, methoxyethyl 1-H2), 2.89 (1H, d, J 12.8, 3-Hb) and 
1.35 (3H, s, methyl); δC (126 MHz, CDCl3) 171.8 (CO), 148.2 (nitrophenyl C-2), 133.8 
(nitrophenyl C-5), 131.8 (nitrophenyl C-1), 131.8 (nitrophenyl C-4), 131.7 (nitrophenyl 
C-6), 124.3 (nitrophenyl C-3), 70.9 (C-3), 58.8 (methoxyethyl C-4), 58.7 (C-2), 51.4 (C-5), 
45.1 (C-6), 41.8 (methoxyethyl C-2), 39.3 (methoxyethyl C-1) and 24.1 (methyl); HRMS 
found MH+, 387.1155.  C15H22N4O6S requires MH, 387.1338. 
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N-Methoxyethyl-2-methyl-4-[(2-nitrobenzene)sulfonyl]-1-(2-thiophenecarbonyl) 
piperazine-2-carboxamide, 144 
 
By general procedure T, the piperazine 143 (348 mg, 0.900 mmol) gave a crude 
residue which was purified by mass-directed preparative HPLC to yield the acylated 
piperazine 144 (185 mg, 41%) as a yellow oil, Rf = 0.54 (10:90 MeOH–DCM); νmax/ cm-1 
(ATR) 3352, 2933, 2894, 1669, 1630, 1542, 1361 and 1163; δH (500 MHz, CDCl3) 8.12-
8.05 (1H, m, nitrophenyl 3-H), 7.80-7.73 (2H, m, nitrophenyl 4-H and nitrophenyl 5-H), 
7.73-7.69 (1H, m, nitrophenyl 6-H), 7.54 (1H, dd, J 5.0 and 1.0, thiophene 5-H), 7.45 (1H, 
dd, J 3.7 and 1.0, thiophene 3-H), 7.10 (1H, dd, J 5.0 and 3.7, thiophene 4-H), 6.68 (1H, t, J 
4.9, NH), 4.00 (1H, ddd, J 14.0, 6.6 and 3.7, 5-Ha), 3.86 (1H, ddd, J 14.0, 7.8 and 3.6, 5-Hb), 
3.78 (1H, d, J 13.0, 3-Ha), 3.70 (1H, ddd, J 11.1, 6.6 and 3.6, 6-Ha), 3.57 (1H, ddd, J 11.1, 7.8 
and 3.7, 6-Hb), 3.51 (3H, s, methoxyethyl 4-H3), 3.49-3.45 (2H, m, methoxyethyl 1-H2), 
3.44-3.41 (1H, m, 3-Hb), 3.41-3.30 (2H, m, methoxyethyl 2-H2) and 3.27 (3H, s, methyl); δC 
(126 MHz, CDCl3) 171.1 (2-CO), 166.8 (1-CO), 148.1 (nitrophenyl C-2), 137.2 (nitrophenyl 
C-1), 134.0 (nitrophenyl C-5), 131.9 (nitrophenyl C-4), 131.8 (thiophene C-1), 131.5 
(nitrophenyl C-6), 130.4 (thiophene C-4 and thiophene C-5), 127.3 (thiophene C-3), 124.4 
(nitrophenyl C-3), 70.9 (C-5), 63.1 (C-2), 58.7 (methoxyethyl C-4), 52.7 (C-3), 45.6 (C-6), 
45.3 (methoxyethyl C-1), 39.5 (methoxyethyl C-2) and 18.9 (methyl); HRMS found MH+, 
497.1182.  C20H24N4O7S2 requires MH, 497.1164. 
N-Methoxyethyl-2-methyl-1-(2-thiophenecarbonyl)piperazine-2-carboxamide, 
145 
 
By general procedure O, the protected piperazine 144 (185 mg, 0.37 mmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–DCM) to 
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yield the deprotected piperazine 145 (105 mg, 91%) as a yellow oil, Rf = 0.43 (10:90 
MeOH–DCM); νmax/ cm-1 (ATR) 3318 (br), 2931, 2874, 1625, 1522, 1422 and 1374; δH (500 
MHz, CDCl3) 7.58 (1H, s, NH), 7.55 (1H, dd, J 5.0 and 1.0, thiophene 5-H), 7.47 (1H, dd, J 3.7 
and 1.0, thiophene 3-H), 7.11 (1H, dd, J 5.0 and 3.7, thiophene 4-H), 3.87 (1H, dt, J 14.0 and 
3.9, 5-Ha), 3.54-3.49 (4H, m, 3-Ha, 5-Hb and 6-H2), 3.49-3.45 (1H, m, methoxyethyl 2-Ha), 
3.35 (3H, s, methoxyethyl 4-H3), 3.34-3.26 (1H, m, methoxyethyl 2-Hb), 3.05 (2H, dd, J 6.3 
and 4.1, methoxyethyl 1-H2), 2.74 (1H, d, J 13.6, 3-Hb) and 1.65 (3H, s, methyl); δC (126 
MHz, CDCl3) 173.7 (2-CO), 168.3 (1-CO), 138.3 (thiophene C-1), 130.6 (thiophene C-4), 
130.5 (thiophene C-5), 127.3 (thiophene C-3), 71.2 (C-5), 62.8 (C-2), 58.8 (methoxyethyl 
C-4), 54.7 (C-6), 48.1 (C-3), 45.1 (methoxyethyl C-2), 39.2 (methoxyethyl C-1) and 21.3 
(methyl); HRMS found MH+, 312.1398.  C14H21N3O3S requires MH, 312.1382. 
N-Methoxyethyl-2-methyl-4-cyclopropanecarbonyl-piperazine-2-carboxamide, 
148 
 
By general procedure O, the protected piperazine 110 (306 mg, 0.634 mmol) gave 
a crude residue which was purified by basic SCX cartridge to give the crude deprotected 
piperazine (162 mg, 0.545 mmol).  This was combined with cyclopropanecarbonyl 
chloride (99.0 µL, 1.09 mmol)  and subjected to general procedure T to give the crude 
acylated piperazine (224 mg, 0.610 mmol) which by general procedure L gave a crude 
product which was purified by basic SCX cartridge, and later by mass-directed 
preparative HPLC to yield the deprotected piperazine 148 (72.1 mg, 43% over three steps) 
as a yellow oil, Rf = 0.60 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3299 (br), 2928, 2874, 1614, 
1437, 1121 and 1091; δH (501 MHz, MeOD) 4.65-4.55 (1H, m, methoxyethyl 2-Ha), 4.03 
(1H, d, J 9.4, 3-Ha), 3.46-3.42 (3H, m, 5-H2 and methoxyethyl 2-Hb), 3.41-3.37 (1H, m, 3-
Hb), 3.36-3.34 (1H, m, methoxyethyl 1-Ha), 3.33 (3H, s, methoxyethyl 4-H3), 2.99 (1H, d, J 
13.4, 6-Ha), 2.91 (1H, dt, J 13.4 and 3.0, 6-Hb), 2.74 (1H, dt, J 10.3 and 2.8, methoxyethyl 1-
Hb), 2.09-1.99 (1H, m, cyclopropyl 1-H), 1.24 (3H, s, methyl), 0.95-0.88 (1H, m, cyclopropyl 
2-Ha) and 0.83-0.73 (3H, m, cyclopropyl 2-Hb and cyclopropyl 3-H2); δC (126 MHz, MeOD) 
176.4 (4-CO), 174.6 (2-CO), 71.8 (C-3), 58.9 (methoxyethyl C-4), 53.2 (C-5), 43.7 
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(methoxyethyl C-2), 42.6 (methoxyethyl C-1), 40.1 (C-6), 25.0 (cyclopropyl C-1), 11.8 
(methyl), 8.2 (cyclopropyl C-2) and 7.6 (cyclopropyl C-3); HRMS found MH+, 270.1843.  
C13H23N3O3 requires MH, 270.1817. 
N-Benzyl-2-methyl-4-oxetane-1-(trifluoroacetyl)piperazine-2-carboxamide, 137 
 
By general procedure O, the protected piperazine 109 (550 mg, 1.07 mmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–DCM).  
Oxetane-3-one (90.0 µL, 1.42 mmol) was added to a solution of the crude deprotected 
piperazine (389 mg, 1.18 mmol) in THF (2.36 mL, 0.5 M).  NaBH(OAc)3 (500 mg, 
2.36 mmol) was slowly added at 0 °C and the solution was warmed to room temperature 
and stirred overnight.  The solvent was removed in vacuo and the residue was diluted 
with water (5 mL) and EtOAc (5 mL).  The aqueous layer was extracted with EtOAc (3 × 
5 mL) and the combined organic layers were washed with brine (5 mL), dried (MgSO4) 
and concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, 5:95 
MeOH–DCM) to yield the alkylated piperazine 137 (409 mg, 98% over two steps) as a 
colourless amorphous solid, Rf = 0.30 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 3327 (br), 
2949, 2876, 1701, 1669, 1208 and 1146; δH (500 MHz, CDCl3) 7.42-7.30 (5H, m, benzyl-
H), 6.30 (1H, t, J 5.5, NH), 4.67 (2H, td, J 6.6 and 4.5, oxetanyl 2-Ha and oxetanyl 4-Ha), 4.57-
4.51 (2H, m, oxetanyl 2-Hb and oxetanyl 4-Hb), 4.50 (2H, d, J 5.5, benzylic-H2), 3.88 (1H, dt, 
J 13.1 and 4.0, 6-Ha), 3.63-3.54 (2H, m, 3-Ha and 6-Hb), 2.67 (1H, d, J 11.9, 3-Hb), 2.64 (1H, 
td, J 4.5 and 1.5, oxetanyl 1-H), 2.59 (1H, dd, J 11.1 and 4.0, 5-Ha), 2.52 (1H, dd, J 11.1 and 
1.4, 5-Hb) and 1.68 (3H, s, methyl); δC (126 MHz, CDCl3) 170.6 (CO), 138.0 (benzyl C-1), 
128.8 (benzyl C-3 and benzyl C-5), 127.9 (benzyl C-2 and benzyl C-6), 127.7 (benzyl C-4), 
75.0 (oxetanyl C-4), 74.8 (oxetanyl C-2), 63.3 (C-6), 58.3 (oxetanyl 1-H), 57.8 (C-3), 48.1 
(benzylic-C), 44.1 (C-5) and 17.9 (methyl), trifluoroacetyl carbons not observed; δF 
(282 MHz, CDCl3) -69.2; HRMS found MH+, 386.1711.  C18H22F3N3O3 requires MH, 
386.1691. 
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N-Benzyl-2-methyl-4-oxetanepiperazine-2-carboxamide, 138 
 
By general procedure L, the protected piperazine 137 (409 mg, 1.06 mmol) gave 
the deprotected piperazine 138 (238 mg, 78%) as a yellow oil which was used without 
further purification, Rf = 0.64 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3308 (br), 2946, 2872, 
1655, 1517, 973 and 698; δH (500 MHz, CDCl3) 7.96 (1H, t, J 5.6, NH), 7.40-7.33 (4H, m, 
benzyl 2-H, benzyl 3-H, benzyl 5-H and benzyl 6-H), 7.33-7.30 (1H, m, benzyl 4-H), 4.67 
(2H, dd, J 6.6 and 1.6, oxetanyl 2-Ha and oxetanyl 4-Ha), 4.63 (2H, app dd, J 7.7 and 6.6, 
oxetanyl 2-Hb and oxetanyl 4-Hb), 4.57 (1H, dd, J 14.8 and 5.6, benzylic-Ha), 4.47 (1H, dd, J 
14.8 and 5.6, benzylic-Hb), 3.52-3.43 (1H, m, oxetanyl 1-H), 3.25 (1H, dd, J 11.1 and 1.2, 3-
Ha), 2.96-2.84 (2H, m, 5-H2), 2.55 (1H, ddd, J 10.9, 4.2 and 2.8, 6-Ha), 1.90 (1H, td, J 10.9 
and 3.5, 6-Hb), 1.74 (1H, d, J 11.1, 3-Hb) and 1.28 (3H, s, methyl); δC (126 MHz, CDCl3) 174.4 
(CO), 138.7 (benzyl C-1), 128.7 (benzyl C-3 and benzyl C-5), 127.7 (benzyl C-2 and benzyl 
C-6), 127.3 (benzyl C-4), 75.4 (oxetanyl C-2), 75.2 (oxetanyl C-4), 59.0 (oxetanyl C-1), 57.8 
(C-2), 57.2 (C-5), 50.1 (C-3), 43.4 (benzylic-C), 42.3 (C-6) and 25.6 (methyl); HRMS found 
MH+, 290.1898.  C16H23N3O2 requires MH, 290.1868. 
N-Benzyl-2-methyl-4-(cyclopropylmethyl)piperazine-2-carboxamide, 140 
 
By general procedure O, the protected piperazine 109 (70.1 mg, 0.136 mmol) 
gave a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–
DCM) to give the crude deprotected piperazine (49.5 mg, 0.150 mmol).  This was 
combined with cyclopropane carboxaldehyde (0.450 mL, 0.600 mmol) which by general 
procedure M, gave the crude alkylated piperazine (50.2 mg, 0.130 mmol).  This was then 
subjected to general procedure L (with an additional 21 eq. NaBH4) to give a crude residue 
which was purified by mass-directed preparative HPLC to yield the deprotected piperazine 
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140 (9.60 mg, 24% over three steps) as a yellow oil, Rf = 0.49 (10:90 MeOH–DCM); νmax/ 
cm-1 (ATR) 3285 (br), 2926, 2785, 1654, 1521, 1454 and 698; δH (500 MHz, CDCl3) 8.12 
(1H, t, J 5.2, NH), 7.36-7.27 (5H, m, benzyl-H), 6.07 (1H, s, NH), 4.50 (1H, dd, J 14.8 and 5.2, 
benzylic-Ha), 4.45 (1H, dd, J 14.8 and 5.2, benzylic-Hb), 3.60 (1H, d, J 12.2, 3-Ha), 3.09-2.95 
(3H, m, 5-Ha and 6-H2), 2.53-2.41 (3H, m, 5-Hb and 4-methyl), 2.38 (1H, d, J 12.2, 3-Hb), 
1.38 (3H, s, 2-methyl), 1.02-0.79 (1H, m, cyclopropyl 1-H), 0.68-0.40 (2H, m, cyclopropyl 
2-H2) and 0.35-0.02 (2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 173.2 (CO), 138.2 
(benzyl C-1), 128.7 (benzyl C-3 and benzyl C-5), 127.8 (benzyl C-2 and benzyl C-6), 127.5 
(benzyl C-4), 62.5 (C-3), 57.9 (C-2), 57.7 (C-6), 51.6 (C-5), 43.7 (benzylic-C), 40.8 (4-
methyl), 25.0 (2-methyl), 7.1 (cyclopropyl C-1), 4.4 (cyclopropyl C-2) and 3.8 (cyclopropyl 
C-3); HRMS found MH+, 288.2093.  C17H25N3O requires MH, 288.2076. 
N-Benzyl-4-methanesulfonyl-2-methylpiperazine-2-carboxamide, 142 
 
By general procedure O, the protected piperazine 109 (1.53 g, 2.97 mmol) gave 
the crude deprotected piperazine which was dissolved in DCM (30 mL, 0.1 M) and 
methanesulfonyl chloride (0.330 mL, 4.33 mmol) was added at 0 °C.  The reaction was 
warmed to room temperature and stirred overnight before more methanesulfonyl 
chloride (0.990 mL, 13.0 mmol) and DMAP (35.0 mg, 0.288 mmol) was added.  Water 
(30 mL) was added and the aqueous layer was extracted with DCM (3 × 30 mL).  The 
combined organic phases were washed with brine (30 mL), dried (MgSO4) and 
concentrated in vacuo to give a residue which was purified by flash chromatography (SiO2, 
80:20 Et2O–DCM) to yield the crude decorated piperazine.  By general procedure L, the 
crude decorated piperazine gave the deprotected piperazine 142 (169 mg, 18% over three 
steps) as a yellow oil, Rf = 0.41 (20:20:60 MeOH–Petrol–EtOAc); νmax/ cm-1 (ATR) 3329 
(br), 2927, 1664, 1518, 1324 and 1153; δH (500 MHz, CDCl3) 7.48 (1H, t, J 6.4, NH), 7.41-
7.34 (2H, m, benzyl 3-H and benzyl 5-H), 7.33-7.26 (3H, m, benzyl 2-H, benzyl 4-H and 
benzyl 6-H), 4.51 (1H, dd, J 14.8 and 6.4, benzylic-Ha), 4.46 (1H, dd, J 14.8 and 6.4, benzylic-
Hb), 4.19 (1H, dd, J 12.2 and 1.5, 3-Ha), 3.64-3.54 (1H, m, 5-Ha), 2.97 (1H, dt, J 13.3 and 2.8, 
5-Hb), 2.89 (3H, s, SO2-methyl), 2.87-2.80 (1H, m, 6-Ha), 2.75 (1H, td, J 11.2 and 2.8, 6-Hb), 
2.61 (1H, d, J 12.2, 3-Hb) and 1.33 (3H, s, 2-methyl); δC (126 MHz, CDCl3) 173.2 (CO), 138.3 
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(benzyl C-1), 128.7 (benzyl C-3 and benzyl C-5), 127.7 (benzyl C-2 and benzyl C-6), 127.5 
(benzyl C-4), 58.3 (C-2), 52.1 (C-3), 45.1 (C-5), 43.6 (benzylic-C), 42.3 (C-6), 37.4 (SO2-
methyl) and 25.1 (2-methyl); HRMS found MH+, 312.1417.  C14H21N3O3S requires MH, 
312.1382. 
N2-Cyclopropyl-N4-cyclopropyl-(2-methyl)-1-(trifluoroacetyl)piperazine-1,4-
dicarboxamide, 150 
 
By general procedure O, the protected piperazine 111 (340 mg, 0.73 mmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–DCM) to 
give the crude deprotected piperazine (129 mg, 0.460 mmol).  This was combined with 
cyclopropyl isocyanate (57.0 mg, 0.690 mmol) and subjected to general procedure Q 
(excluding addition of Et3N) to give a crude residue which was purified by flash 
chromatography (SiO2, 5:95 MeOH–DCM) to yield the urea 150 (42.4 mg, 16% over two 
steps) as a yellow oil, Rf = 0.67 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 2978, 1744, 1696, 
1544, 1367, 1347 and 1180; δH (500 MHz, MeOD) 4.08-3.99 (1H, m, 3-Ha), 3.97-3.87 (2H, 
m, 5-Ha and 6-Ha), 3.69 (1H, d, J 14.3, 3-Hb), 3.62 (1H, ddd, J 12.6, 8.3 and 4.4, 5-Hb), 3.49 
(1H, ddd, J 10.9, 6.4 and 4.2, 6-Hb), 2.65-2.49 (2H, m, 2-cyclopropyl 1-H and 4-cyclopropyl 
1-H), 1.59 (3H, s, methyl), 0.75-0.67 (4H, m, 2-cyclopropyl 2-H2 and 4-cyclopropyl 2-H2), 
0.61-0.55 (2H, m, 2-cyclopropyl 3-H2) and 0.53-0.49 (2H, m, 4-cyclopropyl 3-H2); δC (126 
MHz, MeOD) 173.9 (amide CO), 160.7 (urea CO), 157.3 (q, J 37.2, trifluoroacetyl C-1), 
117.4 (app d, J 287.3, trifluoroacetyl C-2), 66.8 (C-2), 48.0 (C-3), 44.1 (C-5), 41.6 (q, J 4.0, 
C-6), 24.1 (2-cyclopropyl C-1), 23.7 (4-cyclopropyl C-1), 18.7 (methyl), 6.9 (2-cyclopropyl 
C-2), 6.8 (4-cyclopropyl C-2), 6.5 (2-cyclopropyl C-3) and 6.4 (4-cyclopropyl C-3). 
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N2-Cyclopropyl-N4-cyclopropyl-(2-methyl)-piperazine-1,4-dicarboxamide, 151 
 
By general procedure L, the protected piperazine 150 (42.4 mg, 0.120 mmol) gave 
a crude residue which was purified by basic SCX cartridge to yield the deprotected 
piperazine 151 (19.5 mg, 61%) as a yellow oil; Rf = 0.34 (10:90 MeOH–DCM); νmax/ cm-1 
(ATR) 3307 (br), 2928, 2855, 1645, 1529, 1455 and 1272; δH (500 MHz, MeOD) 4.89 (2H, 
s, NH), 4.29-4.17 (1H, m, 3-Ha), 3.85-3.75 (1H, m, 3-Hb), 2.88-2.78 (2H, m, 5-H2), 2.76-2.66 
(2H, m, 6-H2), 2.66-2.60 (1H, m, 2-cyclopropyl 1-H), 2.60-2.53 (1H, m, 4-cyclopropyl 1-H), 
1.20 (3H, d, J 4.7, methyl), 0.82-0.74 (2H, m, 2-cyclopropyl 2-H2), 0.73-0.65 (2H, m, 4-
cyclopropyl 2-H2) and 0.61-0.44 (4H, m, 2-cyclopropyl 3-H2 and 4-cyclopropyl 3-H2); δC 
(126 MHz, MeOD) 178.5 (amide CO), 160.9 (urea CO), 59.5 (C-2), 51.5 (C-3), 44.7 (C-5), 
43.0 (C-6), 24.7 (2-cyclopropyl C-1), 24.1 (4-cyclopropyl C-1), 23.4 (methyl), 7.1 (2-
cyclopropyl C-2 and 2-cyclopropyl C-3), 6.6 (4-cyclopropyl C-2) and 6.4 (4-cyclopropyl C-
3); HRMS found MH+, 267.1823.  C13H22N4O2 requires MH, 267.1821. 
N-Methoxyethyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]piperazine-2-
carboxamide, 157 
 
By general procedure L, the protected piperazine 113 (590 mg, 1.19 mmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 10:90 Petrol–EtOAc) 
to yield the deprotected piperazine 157 (220 mg, 46%) as a yellow oil, Rf = 0.70 (10:90 
MeOH–DCM); νmax/ cm-1 (ATR) 3351 (br), 2975, 2931, 1665, 1540, 1348, 1156 and 577; 
[α]D27 −6.7 (c = 0.063, CHCl3); δH (500 MHz, CDCl3) 8.25-8.18 (1H, m, nitrophenyl 3-H), 
7.81-7.67 (3H, m, nitrophenyl 4-H, nitrophenyl 5-H and nitrophenyl 6-H), 7.46 (1H, t, J 5.8, 
NH), 4.12-4.04 (2H, m, methoxyethyl 1-H2), 3.39-3.35 (1H, m, 5-H), 3.34 (3H, s, 
 218 
 
methoxyethyl 4-H3), 3.33-3.27 (2H, m, methoxyethyl 2-H2), 3.26-3.21 (1H, m, 3-Ha), 3.19 
(1H, dd, J 14.3 and 4.2, 6-Ha), 2.85 (1H, d, J 13.1, 3-Hb), 2.69 (1H, dd, J 14.3 and 1.1, 6-Hb), 
1.31 (3H, d, J 6.6, 5-methyl) and 1.20 (3H, s, 2-methyl); δC (126 MHz, CDCl3) 172.3 (CO), 
133.4 (nitrophenyl C-5), 133.3 (nitrophenyl C-1), 132.2 (nitrophenyl C-4), 131.8 
(nitrophenyl C-6), 124.3 (nitrophenyl C-3), 71.1 (methoxyethyl C-1), 58.7 (C-5), 57.6 (C-
2), 46.68 (C-3), 46.67 (methoxyethyl C-2), 45.0 (methoxyethyl C-4), 39.0 (C-6), 25.9 (5-
methyl) and 14.8 (2-methyl), nitrophenyl C-2 not observed; HRMS found MH+, 401.1514.  
C16H24N4O6S requires MH, 401.1495. 
(2S, 5S)-N1-Ethyl-N2-(2-methoxyethyl)-(2,5-dimethyl)-4[(2-nitrobenzene) 
sulfonyl]piperazine-1,2-dicarboxamide, 158 
 
By general procedure Q (with additional 1.5 eq. isocyanate), ethyl isocyanate 
(60.0 µL, 0.820 mmol) and piperazine 157 (110 mg, 0.270 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 100% EtOAc) to yield the urea 158 
(89.0 mg, 70%) as a yellow oil, Rf = 0.37 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3342 (br), 
2973, 2931, 1653, 1539, 1352, 1157, and 576; [α]D23 104 (c = 0.14, CHCl3); δH (500 MHz, 
CDCl3) 8.10-8.04 (1H, m, nitrophenyl 3-H), 7.68-7.60 (3H, m, nitrophenyl 4-H, nitrophenyl 
5-H and nitrophenyl 6-H), 7.11 (1H, t, J 5.8, amide NH), 4.75 (1H, t, J 4.7, urea NH), 4.29-
4.19 (1H, m, 5-H), 3.97 (1H, dd, J 14.2 and 5.6, 6-Ha), 3.90 (1H, d, J 14.5, 3-Ha), 3.49 (1H, dt, 
J 19.5 and 5.8, methoxyethyl 1-Ha), 3.39 (2H, t, J 5.8, methoxyethyl 2-H2), 3.26 (3H, s, 
methoxyethyl 4-H3), 3.20-3.11 (4H, m, 3-Hb, methoxyethyl l-Hb and ethyl 1-H2), 2.84 (1H, 
dd, J 14.2 and 8.6, 6-Hb), 1.41 (3H, s, 2-methyl), 1.05 (3H, t, J 7.2, ethyl 2-H3) and 0.96 (3H, 
d, J 6.3, 5-methyl); δC (126 MHz, CDCl3) 172.2 (amide CO), 158.9 (urea CO), 135.0 
(nitrophenyl C-1), 133.7 (nitrophenyl C-5), 132.1 (nitrophenyl C-4), 131.4 (nitrophenyl 
C-6), 124.6 (nitrophenyl C-3), 70.5 (C-3), 63.4 (C-2), 58.6 (C-5), 51.3 (methoxyethyl C-4), 
50.0 (methoxyethyl C-1), 46.3 (methoxyethyl C-2), 39.4 (ethyl C-1), 35.9 (C-6), 19.1 (2-
methyl), 16.5 (ethyl C-2) and 15.2 (5-methyl), nitrophenyl C-2 not observed; HRMS found 
MH+, 472.1888.  C19H29N5O7S requires MH, 472.1866. 
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tert-Butyl 3-[(2S, 5S)-5-(benzylcarbamoyl)-2,5-dimethyl-4-(trifluoroacetyl) 
piperazine-1-yl]azetidine-1-carboxylate, 153 
 
By general procedure O, the protected piperazine 112 (770 mg, 1.46 mmol) gave 
a residue which was purified by flash chromatography (SiO2, 5:95 to 10:90 MeOH–DCM) 
to yield the crude product.  The crude deprotected piperazine was combined with Boc-
azetidinone (1.00 g, 5.84 mmol) and by general procedure M, gave a crude residue which 
was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to give the decorated 
piperazine 153 (90.0 mg, 12% over two steps) as a yellow oil, Rf = 0.24 (40:60 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3347 (br), 2976, 1695, 1412, 1392 and 1143; [α]D25 39 (c = 0.77, 
CHCl3); δH (500 MHz, CDCl3) 7.39-7.33 (2H, m, benzyl 3-H and benzyl 5-H), 7.33-7.27 (3H, 
m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 6.54 (1H, t, J 5.2, NH), 4.60 (1H, dd, J 14.4 and 
5.2, benzylic-Ha), 4.35 (1H, dd, J 14.4 and 5.2, benzylic-Hb), 4.21-4.10 (1H, m, 2-Ha), 4.00-
3.93 (1H, m, 2-Hb), 3.88 (1H, dd, J 13.0 and 3.9, piperazine 3-Ha), 3.83 (1H, dd, J 9.2 and 
4.3, 4-Ha), 3.75 (1H, dd, J 9.2 and 5.6, 4-Hb), 3.71 (1H, dd, J 8.6 and 5.7, piperazine 3-Hb), 
3.60-3.54 (1H, m, 3-H), 3.24-3.11 (1H, m, piperazine 2-H), 2.81-2.73 (2H, m, piperazine 6-
H2), 1.61 (3H, s, piperazine 5-methyl), 1.47 (9H, s, Boc) and 1.01 (3H, d, J 5.9, piperazine 
2-methyl); δC (101 MHz, CDCl3) 170.7 (Boc), 156.0 (amide CO), 138.0 (benzyl C-1), 129.0 
(benzyl C-3 and benzyl C-5), 128.0 (benzyl C-2 and benzyl C-6), 128.0 (benzyl C-4), 79.9 
(Boc), 64.0 (piperazine C-5), 60.4 (azetidine C-2), 53.4 (azetidine C-4), 52.7 (piperazine C-
2), 51.0 (piperazine C-6), 49.7 (C-3), 46.9 (piperazine C-3), 43.9 (benzylic-C), 28.4 (Boc), 
17.1 (piperazine 5-methyl) and 14.2 (piperazine 2-methyl), trifluoroacetyl carbons not 
observed; HRMS found MH+, 499.2558.  C24H33F3N4O4 requires MH, 499.2532. 
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(6S, 8aS)-2-Benzyl-7-{1-[(tert-butoxy)carbonyl]azetidin-3-yl}-6,8a-dimethyl-1-
oxo-3-(trifluoromethyl)-octahydroimidazolidino[1,5-a]piperazin-7-ium-3-olate, 
156 
 
By general procedure O, the protected piperazine 112 (770 mg, 1.46 mmol) gave 
a residue which was purified by flash chromatography (SiO2, 5:95 to 10:90 MeOH–DCM) 
to yield the crude product.  The crude deprotected piperazine was combined with Boc-
azetidinone (1.00 g, 5.84 mmol) and by general procedure M, gave a crude residue which 
was purified by flash chromatography (SiO2, 50:50 Petrol–EtOAc) to give the 
piperaziniumolate 156 (450 mg, 62% over two steps) as a yellow oil, Rf = 0.24 (40:60 
Petrol–EtOAc); νmax/ cm-1 (ATR) 3217, 2978, 1699, 1412, 1366 and 1163; [α]D25 41 (c = 
0.45, CHCl3); δH (500 MHz, CDCl3) 7.38 (2H, d, J 7.3, benzyl 3-H and benzyl 5-H), 7.33 (2H, 
t, J 7.3, benzyl 2-H and benzyl 6-H), 7.29-7.25 (1H, m, benzyl 4-H), 4.85 (1H, d, J 15.2, 
benzylic-Ha), 4.44 (1H, d, J 15.2, benzylic-Hb), 3.96-3.91 (1H, m, 5-Ha), 3.85 (1H, t, J 7.4, 
azetidine 2-Ha), 3.60-3.52 (3H, m, azetidine 2-Hb and 4-H2), 3.45 (1H, dt, J 13.1 and 7.4, 
azetidine 3-H), 3.18 (1H, dd, J 14.3 and 5.3, 6-H), 2.67 (1H, d, J 12.7, 8-Ha), 2.56 (1H, dd, J 
15.6 and 8.3, 5-Hb), 2.34 (1H, d, J 12.7, 8-Hb), 1.48 (9H, s, Boc), 1.34 (3H, s, 8a-methyl) and 
0.86 (3H, d, J 5.3, 6-methyl); δC (126 MHz, CDCl3) 175.9 (Boc), 155.8 (C-1), 137.0 (benzyl 
C-1), 128.5 (benzyl C-3 and benzyl C-5), 128.3 (benzyl C-2 and benzyl C-6), 127.7 (benzyl 
C-4), 97.5 (C-4), 79.8 (Boc), 62.6 (C-8a), 51.3 (C-6), 49.0 (azetidine C-3), 47.6 (C-8), 45.29 
(C-5), 45.28 (azetidine C-2 and azetidine C-4), 43.8 (benzylic-C), 28.4 (Boc), 21.0 (8a-
methyl) and 11.5 (6-methyl); HRMS found MH+, 499.2545.  C24H33F3N4O4 requires MH, 
499.2532. 
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tert-Butyl 3-[(2S, 5S)-5-(benzylcarbamoyl)-2,5-dimethylpiperazine-1-yl]azetidine-
1-carboxylate, 154 
 
By general procedure L, the piperaziniumolate 156 (450 mg, 0.900 mmol) gave 
the deprotected piperazine 154 (362 mg, 100%) as a yellow oil, Rf = 0.28 (10:90 MeOH–
DCM); νmax/ cm-1 (ATR) 2984, 1735, 1372, 1236, 1044, 915 and 727; [α]D25 105 (c = 0.37, 
CHCl3); δH (501 MHz, CDCl3) 7.77 (1H, t, J 5.7, NH), 7.36-7.31 (2H, m benzyl 3-H and benzyl 
5-H), 7.31-7.24 (3H, m, benzyl 2-H, benzyl 4-H and benzyl 6-H), 4.52 (1H, dd, J 14.8 and 
5.7, benzylic-Ha), 4.43 (1H, dd, J 14.8 and 5.7, benzylic-Hb), 3.91-3.79 (4H, m, 2-H2 and 4-
H2), 3.41-3.32 (1H, m, 3-H), 3.07-2.97 (2H, m, piperazine 3-Ha and piperazine 6-Ha), 2.71-
2.63 (1H, m, piperazine 2-H), 2.58 (1H, dd, J 13.2 and 3.0, piperazine 3-Hb), 2.28 (1H, d, J 
11.6, piperazine 6-Hb), 1.53 (1H, br s, NH), 1.44 (9H, s, Boc), 1.28 (3H, s, piperazine 5-
methyl) and 0.94 (3H, d, J 6.7, piperazine 2-methyl); δC (126 MHz, CDCl3) 174.5 (Boc), 
156.3 (amide CO), 138.8 (benzyl C-1), 128.6 (benzyl C-3 and benzyl C-5), 127.6 (benzyl C-
2 and benzyl C-6), 127.3 (benzyl C-4), 79.2 (Boc), 57.8 (piperazine C-5), 56.0 (C-2 and C-
4), 53.9 (C-3), 51.0 (piperazine C-2), 48.9 (piperazine C-6), 48.1 ((piperazine C-3), 43.4 
(benzylic-C), 28.4 (Boc), 25.1 (piperazine 5-methyl) and 9.1 (piperazine 2-methyl); HRMS 
found MH+, 403.2733.  C22H34N4O3 requires MH, 403.2709. 
[(2S, 5S)-5-(Benzylcarbamoyl)-2,5-dimethylpiperazin-1-yl]azetidine-1-
carboxylate, 155 
 
By general procedure Y, the protected azetidine 154 (362 mg, 0.900 mmol) gave 
the deprotected azetidine 155 (230 mg, 84%) as a yellow oil, Rf = 0.43 (20:80 sat. NH3 in 
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MeOH–DCM); νmax/ cm-1 (ATR) 3296 (br), 2962, 2931, 1653, 1518, 1453, 1367, 1175 and 
697; [α]D24 21 (c = 1.77, CHCl3); δH (500 MHz, MeOD) 7.38-7.33 (4H, m, benzyl 2-H, benzyl 
3-H, benzyl 5-H and benzyl 6-H), 7.31-7.25 (1H, m, benzyl 4-H), 4.51-4.39 (2H, m, 
benzylic-H2), 3.69-3.58 (2H, m, azetidine 2-H2), 3.56-3.42 (3H, m, azetidine 1-H and 
azetidine 4-H2), 3.02 (1H, dd, J 13.8 and 4.5, 3-Ha), 2.89 (1H, d, J 11.6, 6-Ha), 2.66-2.60 (2H, 
m, 2-H and 3-Hb), 2.28 (1H, d, J 11.6, 6-Hb), 1.28 (3H, s, 5-methyl) and 0.99 (3H, d, J 6.5, 2-
methyl); δC (126 MHz, MeOD) 177.5 (CO), 140.1 (benzyl C-1), 129.5 (benzyl C-3 and 
benzyl C-5), 128.4 (benzyl C-2 and benzyl C-6), 128.1 (benzyl C-4), 58.8 (C-5), 57.0 
(azetidine C-1), 53.0 (azetidine C-2), 51.5 (azetidine C-4), 50.9 (C-2), 50.1 (C-3), 48.7 (C-
6), 44.0 (benzylic-C), 24.9 (5-methyl) and 9.8 (2-methyl); HRMS found MH+, 303.2209.  
C17H26N4O requires MH, 303.2185. 
[(2S, 5S)-N-Cyclopropyl-4-(2-methoxyacetyl)-2,5-dimethylpiperazine-2-
carboxamide, 162 
 
By general procedure O, the protected piperazine 114 (400 mg, 0.835 mmol) gave 
a residue which was purified by flash chromatography (SiO2, 20:80 MeOH–DCM) to yield 
the crude deprotected piperazine which was combined with methoxyacetyl chloride 
(0.150 mL, 1.60 mmol) and by general procedure T, gave a crude residue which was 
purified by flash chromatography (SiO2, 10:90 MeOH–DCM).  By general procedure L, the 
crude decorated piperazine gave a crude residue which was purified by flash 
chromatography (SiO2, 100% EtOAc) then again (SiO2, 30:70 Petrol–EtOAc) to yield 
piperazine 162 (43.1 mg, 19% over three steps) as a yellow oil, Rf = 0.33 (10:90 MeOH–
DCM); νmax/ cm-1 (ATR) 3300 (br), 2975, 2930, 1639, 1454, 1267, 1170 and 1116; [α]D20 
57 (c = 0.085, CHCl3); δH (400 MHz, CDCl3) 7.32 (1H, s, cyclopropyl-NH), 5.52 (1H, s, NH), 
4.38 (1H, d, J 14.8, 3-Ha), 4.00 (2H, s, methoxyacetyl 2-H2), 3.98-3.92 (1H, m, 5-H), 3.34 
(3H, s, methoxyacetyl 4-H3), 2.97 (1H, dd, J 13.6 and 1.6, 6-Ha), 2.91 (1H, d, J 14.8, 3-Hb), 
2.74-2.64 (1H, m, cyclopropyl 1-H), 2.55 (1H, dd, J 13.6 and 3.2, 6-Hb), 1.40-1.26 (6H, m, 
2- methyl and 5-methyl), 0.69 (2H, dt, J 7.4 and 3.8, cyclopropyl 2-H2), 0.48-0.42 (1H, m, 
cyclopropyl 3-Ha) and 0.41-0.34 (1H, m, cyclopropyl 3-Hb); δC (101 MHz, CDCl3) 176.4 
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(methoxyacetyl C-1), 168.6 (CO), 71.5 (methoxyacetyl C-2), 64.8 (C-2), 59.2 
(methoxyacetyl C-4), 49.2 (C-5), 47.0 (C-6), 43.8 (C-3), 23.3 (cyclopropyl C-1), 23.2 (2-
methyl), 15.2 (5-methyl), 6.5 (cyclopropyl C-2) and 6.0 (cyclopropyl C-3); HRMS found 
MH+, 270.1828.  C13H23N3O3 requires MH, 270.1817. 
[(3S, 6S)-N3-Cyclopropyl-N1-(cyclopropylmethyl)-3,6-dimethylpiperazine-1,3-
dicarboxamide, 164 
 
By general procedure O, the protected piperazine 114 (400 mg, 0.835 mmol) gave 
a residue which was purified by flash chromatography (SiO2, 20:80 MeOH–DCM) to yield 
the crude deprotected piperazine which was combined with cyclopropylmethyl 
isocyanate (117 mg, 1.20 mmol) and by general procedure Q, gave a crude residue which 
was purified by flash chromatography (SiO2, 100% EtOAc).  By general procedure L, the 
crude decorated piperazine gave a crude residue which was purified by flash 
chromatography (SiO2, 10:90 MeOH–DCM) to yield piperazine 164 (65.7 mg, 26% over 
three steps) as a yellow oil, Rf = 0.34 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3300 (br), 
2970, 2926, 2488, 1607, 1452, 1432 and 1173; [α]D20 124 (c = 0.182, CHCl3); δH (400 MHz, 
MeOD) 4.00 (1H, d, J 13.7, NH), 3.87-3.77 (1H, m, 6-H), 3.11 (1H, dt, J 3.1 and 1.5, 
cyclopropyl 1-H), 2.87-2.74 (2H, m, cyclopropyl methyl-H2), 2.62-2.53 (2H, m, 2-Ha and 5-
Ha), 2.49-2.44 (1H, m, 2-Hb), 2.42 (1H, dd, J 13.7 and 2.0, 5-Hb), 1.01-0.94 (6H, m, 3-methyl 
and 6-methyl), 0.86-0.71 (1H, m, cyclopropyl methyl 1-H), 0.58-0.44 (2H, m, cyclopropyl 
2-H2), 0.34-0.22 (4H, m, cyclopropyl 3-H2 and cyclopropyl methyl 2-H2) and 0.04-0.00 (2H, 
m, cyclopropyl methyl 3-H2); δC (101 MHz, MeOD) 176.5 (6-CO), 157.7 (3-CO), 57.1 (C-3), 
45.0 (cyclopropyl methyl), 44.2 (C-6), 44.1 (C-2), 43.3 (C-5), 22.9 (3-methyl), 21.1 
(cyclopropyl C-1), 12.1 (6-methyl), 9.9 (cyclopropyl methyl C-1), 4.3 (cyclopropyl C-2), 
4.2 (cyclopropyl C-3), 1.43 (cyclopropyl methyl C-2) and 1.41 (cyclopropyl methyl C-3); 
HRMS found MH+, 295.2293.  C15H26N4O2 requires MH, 295.2134. 
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N-Ethyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]piperazine-2-
carboxamide, 165 
 
By general procedure L, the protected piperazine 115 (182 mg, 0.390 mmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to 
yield the deprotected piperazine 165 (75.2 mg, 52%) as a yellow oil, Rf = 0.67 (5:95 MeOH–
DCM); νmax/ cm-1 (ATR) 3351 (br), 2974, 2933, 1662, 1542, 1373, 1349 and 1157; [α]D23 
122 (c = 0.23, CHCl3); δH (500 MHz, CDCl3) 8.25-8.16 (1H, m, nitrophenyl 3-H), 7.81-7.71 
(3H, m, nitrophenyl 4-H, nitrophenyl 5-H and nitrophenyl 6-H), 7.10 (1H, t, J 3.7, NH), 
4.14-4.05 (2H, m, 3-Ha and 5-H), 3.18 (1H, dd, J 14.2 and 4.2, 6-Ha), 3.15-3.05 (2H, m, ethyl 
1-H2), 2.87 (1H, d, J 13.2, 3-Hb), 2.67 (1H, dd, J 14.2 and 1.1, 6-Hb), 1.31 (3H, d, J 6.8, 5-
methyl), 1.19 (3H, s, 2-methyl) and 1.02 (3H, t, J 7.3, ethyl 2-H3); δC (126 MHz, CDCl3) 172.0 
(CO), 147.6 (nitrophenyl C-2), 133.4 (nitrophenyl C-5), 133.3 (nitrophenyl C-1), 132.2 
(nitrophenyl C-4), 131.8 (nitrophenyl C-6), 124.3 (nitrophenyl C-5), 57.5 (C-2), 46.8 (C-3), 
46.7 (C-5), 45.0 (ethyl C-1), 34.2 (C-6), 25.9 (5-methyl), 14.8 (2-methyl) and 14.6 (ethyl 
C-2); HRMS found MH+, 371.1415.  C15H22N4O5S requires MH, 371.1389. 
N-Ethyl-(2S,5S)-2,5-(dimethyl)-4-[(2-nitrobenzene)sulfonyl]-1-(1H-imidazole-4-
ylmethyl)piperazine-2-carboxamide, 168 
 
Acetic acid (27.0 µL, 0.480 mmol) and NaBH(OAc)3 (271 mg, 1.28 mmol) were 
added to a solution of the piperazine 165 (118 mg, 0.320 mmol) and 4-
imidazolecarboxaldehyde (61.5 mg, 0.640 mmol) in DCE (1.07 mL, 0.3 M), and stirred 
overnight.  More 4-imidazolecarboxaldehyde (61.5 mg, 0.640 mmol) and NaBH(OAc)3 
(203 mg, 0.960 mmol) were added in two portions over the next two days. The reaction 
mixture was diluted with DCM (5 mL) and sat. NaHCO3 (5 mL).  The aqueous layer was 
extracted with DCM (3 × 5 mL) and the combined organic layers were washed with brine 
(5 mL), dried (MgSO4) and concentrated in vacuo.  The residue was purified by basic SCX 
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cartridge and then twice by flash chromatography (SiO2, 5:95 sat. NH3 in MeOH–DCM) to 
yield the alkylated piperazine 168 (20.4 mg, 14%) as a colourless amorphous solid, Rf = 
0.15 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3213 (br), 2972, 1738, 1651, 1542, 1370, 1350 
and 1158; [α]D23 129 (c = 0.060, CHCl3); δH (500 MHz, CDCl3) 8.11-7.93 (2H, m, nitrophenyl 
3-H and imidazole 2-H), 7.78-7.53 (4H, m, nitrophenyl 4-H, nitrophenyl 5-H, nitrophenyl 
6-H and imidazole 5-H), 7.00 (1H, s, amide NH), 4.12-3.94 (1H, m, 5-H), 3.84 (1H, d, J 14.4, 
3-Ha), 3.68 (1H, d, J 14.3, 1-methyl-Ha), 3.58 (1H, d, J 14.3, 1-methyl-Hb), 3.51 (1H, s, 
imidazole NH), 3.31 (1H, d, J 14.4, 3-Hb), 3.28-3.17 (1H, m, ethyl 1-Ha), 3.14-3.02 (1H, m, 
ethyl-1-Hb), 2.92 (1H, dd, J 12.8 and 5.9, 6-Ha), 2.42 (1H, dd, J 12.8 and 8.2, 6-Hb), 1.35 (3H, 
s, 2-methyl), 1.11 (3H, t, J 7.3, ethyl 2-H3) and 0.96 (3H, d, J 6.4, 5-methyl); δC (126 MHz, 
CDCl3) 173.6 (CO), 147.8 (nitrophenyl C-2), 135.4 (imidazole C-2 and imidazole C-5), 
134.7 (nitrophenyl C-1), 133.5 (nitrophenyl C-5), 131.9 (nitrophenyl C-4), 130.9 
(nitrophenyl C-6), 124.3 (nitrophenyl C-3), 63.4 (C-2), 52.4 (C-5), 50.5 (C-3), 49.7 (1-
methyl), 47.2 (ethyl C-1), 34.5 (C-6), 16.2 (2-methyl), 15.6 (ethyl C-2) and 14.4 (C-5), 
imidazole C-4 not observed; HRMS found MH+, 451.1785.  C19H26N6O5S requires MH, 
451.1763. 
N-Ethyl-(2S,5S)-2,5-(dimethyl)-1-(1H-imidazole-4-ylmethyl)piperazine-2-
carboxamide, 169 
 
By general procedure O, the protected piperazine 168 (68.4 mg, 0.150 mmol) 
gave a crude residue which was purified by basic SCX cartridge and then by flash 
chromatography (SiO2, 10:90 sat. NH3 in MeOH–DCM) to yield the deprotected piperazine 
169 (23.5 mg, 59%) as a colourless amorphous solid, Rf = 0.50 (20:80 MeOH–DCM); νmax/ 
cm-1 (ATR) 3189 (br), 2972, 2831, 1644, 1516, 1154, 1089 and 731; [α]D24 −26 (c = 0.10, 
CHCl3); δH (500 MHz, CDCl3) 8.18 (1H, s, imidazole 2-H), 7.56 (1H, s, imidazole 5-H), 6.81 
(1H, s, NH), 3.45 (1H, d, J 13.9, 3-Ha), 3.34-3.18 (2H, m, 6-Ha and ethyl 1-Ha), 3.05 (1H, d, J 
13.9, 3-Hb), 2.89 (1H, d, J 12.6, 1-methyl-Ha), 2.82 (1H, d, J 12.6, 1-methyl-Hb), 2.76-2.68 
(1H, m, ethyl 1-Hb), 2.63 (1H, dd, J 11.5 and 3.1, 6-Hb), 1.86 (1H, app t, J 11.1, 5-H), 1.26 
(3H, s, 2-methyl), 1.09 (3H, t, J 7.3, ethyl 2-H3) and 0.94 (3H, d, J 6.4, 5-methyl); δC (126 
MHz, CDCl3) 175.9 (CO), 135.2 (imidazole C-2 and imidazole C-5), 62.9 (C-2), 56.8 (C-3), 
54.0 (C-5), 50.9 (1-methyl), 50.3 (ethyl C-1), 34.3 (C-1), 19.6 (2-methyl), 14.7 (ethyl C-2) 
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and 9.7 (5-methyl), imidazole C-4 not observed; HRMS found MH+, 266.2009.  C13H23N5O 
requires MH, 266.1981. 
N-Ethyl-(2S,5S)-2,5-(dimethyl)-4[(2-nitrobenzene)sulfonyl]-1-(isoxazole-5-
carbonyl) piperazine-2-carboxamide, 166 
 
Et3N (0.110 mL, 0.800 mmol) and isoxazole-5-carbonyl chloride (60.0 µL, 0.600 
mmol) were added to a solution of piperazine 165 (75.2 mg, 0.200 mmol) in DCM (10 mL, 
0.02 M), and stirred at room temperature overnight.  The reaction mixture was diluted 
with sat. NaHCO3 (10 mL) and the aqueous layer was extracted with DCM (3 × 10 mL).  
The combined organic layers were washed with water (10 mL), brine (10 mL), dried 
(MgSO4) and concentrated in vacuo.  The residue was purified by flash chromatography 
(SiO2, 10:90 MeOH–DCM) and then again (SiO2, 5:95 MeOH–DCM) to yield the acylated 
piperazine 166 (50 mg, 54%) as a yellow oil, Rf = 0.41 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 
3289 (br), 2981, 1738, 1652, 1543, 1408 and 732; [α]D23 28 (c = 0.15, CHCl3); δH (500 MHz, 
CDCl3) 8.28 (1H, d, J 1.8, isoxazole 3-H), 8.15-8.02 (1H, m, nitrophenyl 3-H), 7.71-7.60 (3H, 
m, nitrophenyl 4-H, nitrophenyl 5-H and nitrophenyl 6-H), 6.81 (1H, d, J 1.8, isoxazole 4-
H), 6.14 (1H, t, J 5.1, NH), 4.40-4.26 (1H, m, 5-H), 3.94 (1H, d, J 14.2, 3-Ha), 3.81 (1H, dd, J 
14.4 and 4.7, 6-Ha), 3.48 (1H, dd, J 14.4 and 6.0, 6-Hb), 3.30 (1H, d, J 14.2, 3-Hb), 3.22-3.09 
(1H, m, ethyl 1-Ha), 3.09-2.99 (1H, m, ethyl 1-Hb), 1.63 (3H, s, 2-methyl), 1.24 (3H, d, J 6.5, 
5-methyl) and 1.00 (3H, t, J 7.3, ethyl 2-H3); δC (126 MHz, CDCl3) 169.8 (amide CO), 163.3 
(isoxazole CO), 159.5 (isoxazole C-5), 150.5 (isoxazole C-3), 147.8 (nitrophenyl C-2), 
133.9 (nitrophenyl C-5), 133.8 (nitrophenyl C-1), 132.1 (nitrophenyl C-6), 131.7 
(nitrophenyl C-4), 124.6 (nitrophenyl C-3), 109.0 (isoxazole C-4), 64.4 (C-2), 50.7 (C-5), 
49.0 (C-3), 48.6 (C-6), 34.9 (ethyl C-1), 20.2 (3-methyl), 16.8 (5-methyl) and 14.4 (ethyl 
C-2); HRMS found MH+, 466.1417.  C19H23N5O7S requires MH, 466.1396. 
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N-Ethyl-(2S,5S)-2,5-(dimethyl)-1-(isoxazole-5-carbonyl)piperazine-2-
carboxamide, 167 
 
By general procedure O, the protected piperazine 166 (45.0 mg, 97.0 µmol) gave 
a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–DCM) 
and again (SiO2, 5:95 MeOH–DCM) to yield the deprotected piperazine 167 (7.20 mg, 26%) 
as a yellow oil, Rf = 0.71 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3327 (br), 2975, 2932, 1645, 
1532, 1442 and 1378; [α]D28 7.7 (c = 0.073, CHCl3); δH (501 MHz, MeOD) 8.40 (1H, d, J 1.9, 
isoxazole 3-H), 6.71 (1H, d, J 1.9, isoxazole 4-H), 3.76 (1H, dd, J 13.6 and 3.9, 3-Ha), 3.16-
3.09 (2H, m, ethyl 1-H2), 3.03-2.98 (1H, m, 5-H), 2.96 (1H, d, J 13.6, 3-Hb), 2.83 (1H, d, J 
11.0, 6-Ha), 2.80 (1H, d, J 11.0, 6-Hb), 1.47 (3H, s, 2-methyl) and 1.03-0.98 (6H, m, ethyl 2-
H3 and 5-methyl); δC (126 MHz, MeOD) 174.7 (amide CO), 164.2 (isoxazole CO), 161.5 
(isoxazole C-5), 151.5 (isoxazole C-3), 107.8 (isoxazole C-4), 62.3 (C-2), 55.0 (C-3), 50.4 
(C-5), 49.9 (ethyl C-1), 35.6 (C-6), 18.9 (2-methyl), 16.1 (5-methyl) and 14.7 (ethyl C-2); 
HRMS found MH+, 281.1636.  C13H20N4O3 requires MH, 281.1613. 
N-Ethyl-6-(hydroxymethyl)-2-methyl-4-(2-nitrobenzenesulfonyl)piperazine-2-
carboxamide, 171 
 
By general procedure L (with an additional 7 eq. NaBH4 and heating at reflux for 
4 hr), the protected piperazine 116 (290 mg, 0.555 mmol) gave a crude residue which 
was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to yield the deprotected 
piperazine 171 (112 mg, 53%) as a yellow oil, Rf = 0.38 (10:90 MeOH–DCM); νmax/ cm-1 
(ATR) 3359 (br), 2931, 1652, 1544, 1373, 1355, 1165 and 587; δH (500 MHz, CDCl3) 8.10 
(1H, dd, J 5.6 and 3.4, nitrophenyl 3-H), 7.76 (2H, dd, J 5.6 and 3.1, nitrophenyl 4-H and 
nitrophenyl 5-H), 7.69 (1H, dd, J 5.6 and 3.1, nitrophenyl 6-H), 6.81 (1H, s, NH), 4.25 (1H, 
d, J 12.8, 3-Ha), 3.84 (1H, d, J 11.5, 6-methyl-Ha), 3.74 (1H, dd, J 11.1 and 3.5, 5-Ha), 3.66 
(1H, dd, J 11.1 and 4.1, 5-Hb), 3.31-3.18 (2H, m, ethyl 1-H2), 3.05-2.98 (1H, m, 6-H), 2.70 
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(1H, app t, J 11.5, 6-methyl-Hb), 2.59 (1H, d, J 12.8, 3-Hb), 1.94 (1H, br s, NH), 1.62 (1H, br 
s, OH), 1.26 (3H, s, 2-methyl) and 1.11 (3H, t, J 7.2, ethyl 2-H3); δC (126 MHz, CDCl3) 172.7 
(CO), 133.8 (nitrophenyl C-5), 131.8 (nitrophenyl C-4), 131.6 (nitrophenyl C-6), 124.2 
(nitrophenyl C-3), 63.7 (C-3), 58.4 (C-2), 52.8 (C-6), 51.1 (6-methyl C-1), 47.0 (C-5), 34.5 
(ethyl C-1), 25.8 (2-methyl) and 14.6 (ethyl C-2), nitrophenyl C-1 and nitrophenyl C-2 not 
observed; HRMS found MH+, 387.1363.  C15H22N4O6S requires MH, 387.1338. 
N-Ethyl-6-(hydroxymethyl)-2-methyl-4-(2-nitrobenzenesulfonyl)-1-propanoyl 
piperazine-2-carboxamide, 172 
 
Propionyl chloride (29.0 µL, 0.320 mmol) was added to a solution of piperazine 
171 (112 mg, 0.290 mmol) and DIPEA (0.150 mL, 0.870 mmol) in THF (5.80 mL, 0.05 M).  
The reaction mixture was stirred at room temperature overnight before being 
concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, 10:90 
MeOH–DCM) to yield the decorated piperazine 172 (65.1 mg, 51%) as a yellow oil, Rf = 
0.75 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3368 (br), 2979, 1737, 1665, 1545, 1373, 1168 
and 587; δH (500 MHz, CDCl3) 8.06-8.00 (1H, m, nitrophenyl 3-H), 7.70-7.64 (2H, m, 
nitrophenyl 5-H and nitrophenyl 6-H), 7.63-7.58 (1H, m, nitrophenyl 4-H), 6.73 (1H, t, J 
5.3, NH), 4.18 (1H, dd, J 12.7 and 1.3, 5-Ha), 4.04 (1H, dd, J 11.3 and 6.2, ethyl 1-Ha), 3.99 
(1H, dd, J 11.3 and 6.2, ethyl 1-Hb), 3.79 (1H, ddd, J 12.1, 3.3 and 1.3, 6-H), 3.18-3.02 (3H, 
m, 3-H2 and 5-Hb), 2.56-2.40 (2H, m, 6-methyl), 2.32 (2H, q, J 7.6, propanoyl 2-H2), 1.53 
(1H, br s, OH), 1.14 (3H, s, 2-methyl), 1.10 (3H, t, J 7.6, propanoyl 3-H3) and 0.98 (3H, t, J 
6.2, ethyl 2-H3); δC (126 MHz, CDCl3) 173.9 (1-CO), 172.2 (2-CO), 133.6 (nitrophenyl C-5), 
132.1 (nitrophenyl C-1), 131.7 (nitrophenyl C-4), 131.6 (nitrophenyl C-6), 124.2 
(nitrophenyl C-3), 64.8 (C-5), 58.4 (C-2), 51.3 (ethyl C-1), 50.8 (C-6), 47.4 (C-3), 34.4 (6-
methyl), 27.4 (propanoyl C-2), 25.7 (2-methyl), 14.5 (propanoyl C-3) and 9.0 (ethyl C-2), 
nitrophenyl C-2 not observed; HRMS found MH+, 443.1624.  C18H26N4O7S requires MH, 
443.1600. 
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N-Ethyl-6-(hydroxymethyl)-2-methyl-1-propanoylpiperazine-2-carboxamide, 173 
 
By general procedure O, the protected piperazine 172 (57.5 mg, 0.130 mmol) 
gave a crude residue which was purified by flash chromatography (SiO2, 10:90 MeOH–
DCM) to yield the deprotected piperazine 173 (29.9 mg, 89%) as a yellow oil, Rf = 0.23 
(10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3309 (br), 2971, 1735, 1644, 1527, 1185 and 805; 
δH (500 MHz, CDCl3) 7.42 (1H, t, J 5.0, NH), 3.93 (2H, qd, J 11.3 and, 5.0, ethyl 1-H2), 3.57 
(1H, d, J 12.6, 3-Ha), 3.31-3.19 (2H, m, 5-H2), 2.98-2.83 (2H, m, 6-methyl), 2.35-2.27 (3H, 
m, 6-H and propanoyl 2-H2), 2.25 (1H, d, J 12.6, 3-Hb), 1.11 (3H, s, 2-methyl) and 1.11-1.06 
(6H, m, ethyl 2-H3 and propanoyl 3-H3); δC (126 MHz, CDCl3) 174.3 (1-CO), 174.0 (2-CO), 
65.7 (ethyl C-1), 57.6 (C-2), 52.7 (C-3), 51.5 (C-6), 48.2 (C-5), 34.0 (6-methyl), 27.4 
(propanoyl C-1), 26.0 (2-methyl), 14.8 (ethyl C-2) and 9.0 (propanoyl C-3); HRMS found 
MH+, 258.1853.  C12H23N3O3 requires MH, 258.1817. 
2-[1-(2-Methoxyethyl)-2,5-dioxo-4-(propan-2-yl)imidazolidin4-yl]acetaldehyde, 
200 
 
By general procedure U, the hydantoin 195 (48.6 mg, 0.200 mmol) gave the 
aldehyde 200 (34.6 mg, 71%) as a yellow oil which was used without further purification, 
Rf = 0.54 (10:90  MeOH–DCM); νmax/ cm-1 (ATR) 3288 (br), 2967, 1773, 1706, 1449, 1345 
and 1151; δH (500 MHz, CDCl3) 9.63-9.53 (1H, m, acetaldehyde 2-H), 6.17 (1H, s, NH), 3.73-
3.59 (2H, m, methoxyethyl 2-H2), 3.51 (2H, t, J 5.7, methoxyethyl 1-H2), 3.26 (3H, s, 
methoxyethyl 4-H3), 2.96 (1H, dd, J 17.7 and 1.8, acetaldehyde 1-Ha), 2.81 (1H, d, J 17.7, 
acetaldehyde 1-Hb), 2.10-1.97 (1H, m, propyl 2-H), 0.91 (3H, d, J 6.9, propyl 1-H3), 0.86 
(3H, d, J 6.8, propyl 3-H3); δC (126 MHz, CDCl3) 197.9 (acetaldehyde C-2), 175.3 (C-5), 
157.3 (C-2), 68.7 (methoxyethyl C-2), 64.6 (C-4), 58.5 (methoxyethyl C-4), 47.5 
(methoxyethyl C-1), 38.0 (acetaldehyde C-1), 34.2 (propyl C-2), 16.4 (propyl C-1) and 16.3 
(propyl C-3); HRMS found MH+, 243.1337.  C11H18N2O4 requires MH, 243.1345. 
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3-(2-Methoxyethyl)-5-{2-[(2-methoxyethyl)amino]ethyl}-5-(propan-2-yl) 
imidazolidine-2,4-dione, 201 
 
By general procedure M, 2-methoxyethyl amine (50.0 µL, 0.560 mmol) and 
aldehyde 200 (34.6 mg, 0.140 mmol) gave the decorated hydantoin 201 (41.2 mg, 100%) 
as a yellow oil which did not require further purification, Rf = 0.17 (10:90  MeOH–DCM); 
νmax/ cm-1 (ATR) 2918 (br), 1770, 1708, 1447 and 1117; δH (500 MHz, CDCl3) 3.61 (2H, t, J 
5.6, 3-methoxyethyl 2-H2), 3.51-3.46 (2H, m, 3-methoxyethyl 1-H2), 3.40 (2H, t, J 4.8, 5-
methoxyethyl 2-H2), 3.27 (3H, s, 3-methoxyethyl 4-H3), 3.25 (3H, s, 5-methoxyethyl 4-H3), 
2.74-2.69 (2H, m, 5-methoxyethyl 1-H2), 2.67-2.55 (2H, m, aminoethyl 2-H2), 2.01-1.87 
(3H, m, aminoethyl 1-H2 and propyl 2-H), 0.89 (3H, d, J 6.9, propyl 1-H3) and 0.84 (3H, d, J 
6.7, propyl 3-H3); δC (126 MHz, CDCl3) 176.22 (C-4), 157.4 (C-2), 70.8 (3-methoxyethyl C-
2), 68.8 (3-methoxyethyl C-1), 67.2 (C-5), 58.8 (5-methoxyethyl C-4), 58.4 (3-
methoxyethyl C-4), 48.7 (5-methoxyethyl C-2), 44.1 (5-methoxyethyl C-1), 37.7 
(aminoethyl C-2), 34.1 (propyl C-2), 33.4 (aminoethyl C-1), 16.5 (propyl C-1) and 16.4 
(propyl C-3); HRMS found MH+, 302.2105.  C14H27N3O4 requires MH, 302.2080. 
2-[1-Cyclopropyl-4(oxetane-3-yl)-2,5-dioxoimidazolidin-4-yl] acetaldehyde, 202 
 
By general procedure U, the hydantoin 197 (61.0 mg, 0.258 mmol) gave aldehyde 
202 (53.9 mg, 88%) as a colourless oil which was used without further purification, Rf = 
0.54 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 3277 (br), 2921, 1773, 1710 and 1434; δH 
(500 MHz, CDCl3) 9.57 (1H, s, acetaldehyde 2-H), 6.35 (1H, s, NH), 4.72-4.67 (1H, m, 
oxetanyl 2-Ha), 4.58-4.53 (1H, m, oxetanyl 4-Ha), 4.42 (1H, t, J 6.8, oxetanyl 2-Hb), 4.37 (1H, 
t, J 6.8, oxetanyl 4-Hb), 3.42-3.31 (1H, m, cyclopropyl 1-H), 2.95-2.83 (1H, m, oxetanyl 1-
H), 2.78 (1H, d, J 18.5, acetaldehyde 1-Ha), 2.60-2.56 (1H, m, acetaldehyde 1-Hb) and 0.96-
0.89 (4H, m, cyclopropyl 2-H2 and cyclopropyl 3-H2); δC (126 MHz, CDCl3) 196.7 
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(acetaldehyde C-2), 174.0 (C-5), 156.8 (C-2), 71.9 (oxetanyl C-2), 70.6 (oxetanyl C-4), 60.1 
(C-4), 47.2 (acetaldehyde C-1), 40.7 (cyclopropyl C-1), 22.0 (oxetanyl C-1), 4.94 
(cyclopropyl C-2) and 4.88 (cyclopropyl C-3); HRMS found MH+, 239.1022.  C11H14N2O4 
requires MH, 239.1032. 
5-[2-(Cyclobutylamino)ethyl]-3-cyclopropyl-5-(oxetan-3-yl)imidazolidino-2,4-
dione, 203 
 
By general procedure M, cyclobutylamine (77.0 µL, 0.904 mmol) and aldehyde 
202 (53.9 mg, 0.226 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 5:95 MeOH–DCM) to yield the decorated hydantoin 203 (45.5. mg, 
69%) as a yellow oil, Rf = 0.63 (20:80  MeOH–DCM); νmax/ cm-1 (ATR) 3319 (br), 2943, 
2832, 1448 and 1023; δH (500 MHz, MeOD) 3.39-3.35 (1H, m, oxetanyl 2-Ha), 3.27 (1H, dd, 
J 10.9 and 8.8, oxetanyl 4-Ha), 3.12-3.03 (2H, m, ethyl 2-H2), 3.01 (1H, dd, J 12.2 and 3.5, 
oxetanyl 2-Hb), 2.52 (1H, ddd, J 11.0, 6.9 and 4.4, cyclopropyl 1-H), 2.41 (1H, ddd, J 12.6, 
9.9 and 5.8, oxetanyl 1-H), 2.26-2.18 (1H, m, ethyl 1-Ha), 2.18-2.12 (2H, m, cyclobutyl 1-H 
and cyclobutyl 2-Ha), 2.09 (1H, dd, J 13.8 and 4.3, cyclobutyl 2-Hb), 2.06-1.99 (2H, m, 
cyclobutyl 4-H2), 1.89 (1H, t, J 12.4, oxetanyl 4-Hb), 1.83-1.74 (2H, m, cyclobutyl 3-H2), 1.71 
(1H, dt, J 13.9 and 2.0, ethyl 1-Hb) and 0.97-0.81 (4H, m, cyclopropyl 2-H2 and cyclopropyl 
3-H2); δC (126 MHz, MeOD) 178.7 (C-2), 159.3 (C-4), 69.1 (C-5), 61.30 (oxetanyl C-2), 
61.25 (cyclobutyl C-1), 48.5 (oxetanyl C-4), 46.2 (ethyl C-2), 43.5 (oxetanyl C-1), 34.7 
(ethyl C-1), 27.5 (cyclobutyl C-2 and cyclobutyl C-4), 22.1 (cyclopropyl C-1), 14.8 
(cyclobutyl C-3), 5.7 (cyclopropyl C-2) and 5.3 (cyclopropyl C-3); HRMS found MH+, 
294.1829.  C15H23N3O3 requires MH, 294.1817. 
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2-{4-[(4-Fluorophenyl)methyl]-1-(2-methoxyethyl)-2,5-dioxoimidazolidin-4-yl} 
acetaldehyde, 204 
 
By general procedure U, the hydantoin 196 (76.6 mg, 0.250 mmol) gave the 
aldehyde 204 (37.7 mg, 49%) as a yellow oil which was used without further purification, 
Rf = 0.29 (5:95 MeOH–DCM); νmax/ cm-1 (ATR) 3274 (br), 2929, 1701, 1450, 1222 and 1114; 
δH (500 MHz, CDCl3) 9.65 (1H, s, acetaldehyde 2-H), 7.09-7.01 (2H, m, fluorophenyl 3-H 
and fluorophenyl 6-H), 6.96-6.84 (2H, m, fluorophenyl 4-H and fluorophenyl 5-H), 6.30 
(1H, s, NH), 3.43 (2H, t, J 5.9, methoxyethyl 2-H2), 3.26-3.18 (2H, m, methoxyethyl 1-H2), 
3.17 (3H, s, methoxyethyl 4-H3), 3.05 (1H, d, J 18.6, 4-methyl-Ha), 3.00 (1H, d, J 13.7, 
acetaldehyde 1-Ha), 2.95 (1H, d, J 13.7, acetaldehyde 1-Hb) and 2.88 (1H, d, J 18.6, 4-
methyl-Hb); δC (126 MHz, CDCl3) 198.0 (acetaldehyde C-2), 174.5 (C-5), 162.4 (d, J 246.5, 
fluorophenyl C-4), 156.4 (C-2), 131.8 (d, J 8.0, fluorophenyl C-2 and fluorophenyl C-6), 
129.1 (d, J 3.3, fluorophenyl C-1), 115.4 (d, J 21.4, fluorophenyl C-3 and fluorophenyl C-5), 
68.6 (methoxyethyl C-2), 62.4 (C-4), 58.6 (methoxyethyl C-4), 48.8 (methoxyethyl C-1), 
41.2 (4-methyl) and 37.9 (acetaldehyde C-1); HRMS found MH+, 309.1310.  C15H17FN2O4 
requires MH, 309.1250. 
5-[(4-Fluorophenyl)methyl]-5-(2-hydroxyethyl)-3-(2-methoxyethyl)imidazolidine 
-2,4-dione, 205 
 
NaBH4 (9.23 mg, 0.244 mmol) was added to a solution of the aldehyde 204 
(37.7 mg, 0.122 mmol) in MeOH (1.22 mL, 0.1 M) at 0 °C.  The reaction mixture was stirred 
at room temperature overnight before the solvent was removed in vacuo and the residue 
was treated with water (2 mL).  The aqueous layer was extracted with EtOAc (3 × 2 mL) 
and the combined organic phases were dried (MgSO4) and concentrated in vacuo.  The 
crude residue was purified by flash chromatography (SiO2, 5:95 MeOH–DCM) to yield the 
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alcohol 205 (25.9 mg, 68%) as a yellow oil, Rf = 0.57 (10:90 MeOH–DCM); νmax/ cm-1 (ATR) 
3288 (br), 2927, 1697, 1509, 1449, 1221, 1115 and 1051; δH (500 MHz, CDCl3) 7.07 (2H, 
dd, J 8.4 and 5.5, fluorophenyl 2-H and fluorophenyl 6-H), 6.89 (2H, app t, J 8.4, 
fluorophenyl 3-H and fluorophenyl 5-H), 6.17 (1H, s, NH), 3.83-3.64 (2H, m, hydroxyethyl 
2-H2), 3.48-3.36 (2H, m, methoxyethyl 2-H2), 3.32-3.20 (2H, m, methoxyethyl 1-H2), 3.17 
(3H, s, methoxyethyl 4-H3), 2.99 (1H, d, J 13.7, 5-methyl-Ha), 2.89 (1H, d, J 13.7, 5-methyl-
Hb), 2.16 (1H, ddd, J 14.7, 9.1 and 5.0, hydroxyethyl 1-Ha), 1.88 (1H, dt, J 14.7 and 4.3, 
hydroxyethyl 1-Hb) and 1.66 (1H, s, OH); δC (126 MHz, CDCl3) 175.9 (C-4), 162.2 (d, J 246.0, 
fluorophenyl C-4), 156.8 (C-2), 131.9 (d, J 8.0, fluorophenyl C-2 and fluorophenyl C-6), 
129.7 (d, J 3.4, fluorophenyl C-1), 115.3 (d, J 21.3 fluorophenyl C-3 and fluorophenyl C-5), 
68.6 (hydroxyethyl C-2), 64.8 (C-5), 58.6 (methoxyethyl C-4), 58.1 (methoxyethyl C-2), 
41.6 (methoxyethyl C-1), 38.5 (5-methyl) and 37.6 (hydroxyethyl C-1); δF (282 MHz, CDCl3) 
-115.2; HRMS found MH+, 311.1417.  C15H19FN2O4 requires MH, 311.1407. 
N-Cyclopropyl-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxamide, 211 
 
By general procedure V, the amino ester 199 (394 mg, 1.52 mmol) and 
cyclopropylamine (1.05 mL, 15.2 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the amide 211 (200 mg, 46%) as a 
yellow oil, Rf = 0.47 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3336 (br), 2963, 2929, 1660, 
1504, 1455 and 773; δH (500 MHz, CDCl3) 7.54-7.46 (2H, m, 9-H and NH), 7.21 (2H, app 
dt, J 19.1 and 7.3, 7-H and 8-H), 7.05 (1H, d, J 7.3, 6-H), 5.47 (1H, s, alkene-Ha), 5.14 (1H, s, 
alkene-Hb), 4.12 (1H, d, J 16.5, 1-Ha), 3.94 (1H, d, J 16.5, 1-Hb), 3.05-2.94 (2H, m, 4-H2), 
2.76-2.65 (1H, m, cyclopropyl 1-H), 2.11 (1H, hept, 6.9, isopropyl 2-H), 1.76 (1H, s, NH), 
1.08 (3H, d, J 6.9, isopropyl-MeA), 0.99 (3H, d, J 6.9, isopropyl-MeB), 0.83-0.68 (2H, m, 
cyclopropyl 2-H2) and 0.49-0.37 (2H, m, cyclopropyl 3-H2); δC (126 MHz, CDCl3) 175.4 
(CO), 144.2 (C-5a), 140.0 (C-9a and C-5), 128.0 (C-9), 127.7 (C-7), 127.3 (C-8), 127.1 (C-
6), 116.2 (alkene), 67.3 (C-3), 49.2 (C-1), 39.6 (C-4), 33.9 (cyclopropyl C-1), 22.1 
(isopropyl C-2), 18.5 (isopropyl-MeA), 17.3 (isopropyl-MeB), 6.6 (cyclopropyl C-2) and 6.4 
(cyclopropyl C-3); HRMS found MH+, 285.1978.  C18H24N2O requires MH, 285.1967. 
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N-Cyclopropyl-7-methyl-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxamide, 288 
 
By general procedure V, the amino ester 279 (370 mg, 1.35 mmol) and 
cyclopropylamine (0.94 mL, 13.5 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 50:50 Petrol–EtOAc) to yield the amide 288 (80.0 mg, 20%) as a 
colourless oil, Rf = 0.35 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3331 (br), 3086, 3010, 
2963, 1661, 1496, 1457, 890 and 813; δH (400 MHz, CDCl3) 7.41 (1H, br s, NH), 7.21 (1H, 
s, 6-H), 6.93-6.88 (1H, m, 8-H), 6.84 (1H, d, J 7.7, 9-H), 5.37 (1H, d, J 1.2, alkene-Ha), 5.02 
(1H, app s, alkene-Hb), 3.97 (1H, d, J 16.4, 1-Ha), 3.79 (1H, d, J 16.4, 1-Hb), 2.90 (1H, d, J 
14.0, 4-Ha), 2.86 (1H, d, J 14.0, 4-Hb), 2.65-2.55 (1H, m, cyclopropyl 1-H), 2.25 (3H, s, tolyl), 
2.04-1.95 (1H, m, isopropyl 2-H), 1.54 (1H, br s, NH), 0.97 (3H, d, J 6.9, isopropyl-MeA), 
0.88 (3H, d, J 6.9, isopropyl-MeB), 0.72-0.60 (2H, m, cyclopropyl 2-H2) and 0.38-0.29 (2H, 
m, cyclopropyl 3-H2); δC (101 MHz, CDCl3) 175.5 (CO), 144.3 (C-5), 139.8 (C-9a), 136.6 (C-
5a), 136.5 (C-7), 128.2 (C-6), 128.0 (C-9), 127.9 (C-8), 115.8 (alkene), 67.1 (C-3), 48.8 (C-
1), 39.6 (C-4), 33.9 (isopropyl C-2), 22.0 (tolyl), 21.0 (cyclopropyl C-1), 18.5 (isopropyl-
MeA), 17.2 (isopropyl-MeB), 6.6 (cyclopropyl C-2) and 6.3 (cyclopropyl C-3); HRMS found 
MH+, 299.2137.  C19H26N2O requires MH, 299.2123. 
N-Cyclobutyl-8-methyl-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxamide, 289  
 
By general procedure V, the amino ester 280 (480 mg, 1.76 mmol) and 
cyclobutylamine (1.50 mL, 17.6 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 60:40 Petrol–EtOAc) to yield the amide 289 (210 mg, 38%) as an 
amorphous orange solid, Rf = 0.72 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3331 (br), 2966, 
2939, 2873, 1656, 1498, 896 and 728; δH (400 MHz, CDCl3) 7.61 (1H, d, J 8.5, NH), 7.38 
(1H, d, J 7.9, 6-H), 7.03 (1H, d, J 7.9, 7-H), 6.88 (1H, s, 9-H), 5.43 (1H, d, J 1.5, alkene-Ha), 
5.05 (1H, d, J 1.5, alkene-Hb), 4.37 (1H, h, J 8.2, cyclobutyl 1-H), 4.08 (1H, d, J 16.6, 1-Ha), 
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3.92 (1H, d, J 16.6, 1-Hb), 3.00 (1H, d, J 14.0, 4-Ha), 2.91 (1H, d, J 14.0, 4-Hb), 2.41-2.26 (5H, 
m, tolyl and cyclobutyl 2-H2), 2.08 (1H, hept, J 6.9, isopropyl 2-H), 1.92-1.76 (2H, m, 
cyclobutyl 4-H2), 1.75-1.62 (3H, m, cyclobutyl 3-H2 and NH), 1.06 (3H, d, J 6.9, isopropyl 
MeA) and 1.00 (3H, d, J 6.9, isopropyl-MeB); δC (101 MHz, CDCl3) 172.9 (CO), 144.0 (C-5), 
139.5 (C-9a), 137.1 (C-8), 137.0 (C-5a), 128.6 (C-6), 127.7 (C-7), 127.6 (C-9), 115.3 
(alkene), 67.0 (C-3), 49.1 (C-1), 44.2 (cyclobutyl C-1), 39.7 (C-4), 33.7 (isopropyl C-2), 
31.37 (cyclobutyl C-2), 31.35 (cyclobutyl C-4), 20.9 (tolyl), 18.6 (isopropyl-MeA), 17.3 
(isopropyl-MeB) and 15.2 (cyclobutyl C-3); HRMS found MH+, 313.2279.  C20H28N2O 
requires MH, 313.2280. 
N-Tetrahydropyran-8-fluoro-5-methylidene-3-(propan-2-yl)-2,3,4,5-tetrahydro-
1H-2-benzazepine-3-carboxamide, 290 
 
By general procedure V, the amino ester 281 (470 mg, 1.69 mmol) and 4-
aminotetrahydropyran (1.75 mL, 16.9 mmol) gave a crude residue which was purified by 
flash chromatography (SiO2, 40:60 Petrol–EtOAc) to yield the amide 290 (420 mg, 72%) 
as a colourless oil, Rf = 0.23 (50:50 Petrol–EtOAc); νmax/ cm-1 (ATR) 3326 (br), 3083, 2958, 
2846, 1656, 1493, 1142 and 731; δH (400 MHz, CDCl3) 7.43 (1H, dd, J 8.6 and 5.8, 9-H), 
7.39 (1H, d, J 8.4, NH), 6.91 (1H, td, J 8.6 and 2.6, 7-H), 6.76 (1H, dd, J 8.6 and 2.6, 6-H), 
5.40 (1H, d, J 1.0, alkene-Ha), 5.09 (1H, app s, alkene-Hb), 4.08 (1H, d, J 16.6, 1-Ha), 4.02-
3.87 (4H, m, 1-Hb, THP 1-H and THP 3-H2), 3.56-3.44 (2H, m, THP 5-H2), 2.99 (1H, d, J 14.1, 
4-Ha), 2.94 (1H, d, J 14.1, 4-Hb), 2.14-2.07 (1H, m, isopropyl 2-H), 1.92-1.85 (1H, m, THP 2-
Ha), 1.84-1.76 (1H, m, THP 2-Hb), 1.69 (1H, br s, NH), 1.55-1.39 (2H, m, THP 6-H2), 1.06 
(3H, d, J 6.9, isopropyl-MeA) and 1.00 (3H, d, J 6.9, isopropyl-MeB); δC (101 MHz, CDCl3) 
172.8 (CO), 160.6 (C-8), 143.3 (C-5), 141.5 (d, J 6.2, C-9a), 136.1 (d, J 3.3, C-5a), 129.4 (d, J 
7.9, C-6), 116.0 (alkene), 114.4 (d, J 21.2, C-7), 113.8 (d, J 21.1, C-9), 67.1 (C-3), 66.8 (THP 
C-3), 60.4 (THP C-5), 48.9 (C-1), 45.1 (THP C-1), 39.6 (C-4), 33.8 (isopropyl C-2), 33.5 
(THP C-2), 33.2 (THP C-6), 18.5 (isopropyl-MeA) and 17.2 (isopropyl-MeB); δF (376 MHz, 
CDCl3) -115.8; HRMS found MH+, 347.2150.  C20H27FN2O2 requires MH, 347.2135. 
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7-Fluoro-5-methylidene-N-(oxetan-3-yl)-3-(propan-2-yl)-2,3,4,5-tetrahydro-1H-2-
benzazepine-3-carboxamide, 291 
 
By general procedure V, the amino ester 282 (500 mg, 1.80 mmol) and 4-
aminooxetane (1.26 mL, 18.0 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 50:50 Petrol–EtOAc), then again (SiO2, 20:80 Petrol–EtOAc) to 
yield the amide 291 (210 mg, 37%) as a colourless oil, Rf = 0.24 (40:60 Petrol–EtOAc); 
νmax/ cm-1 (ATR) 3323 (br), 2962, 2876, 1659, 1491, 1206, 974 and 875; δH (400 MHz, 
CDCl3) 8.05 (1H, d, J 7.7, NH), 7.17 (1H, dd, J 9.2 and 2.7, 9-H), 7.03 (1H, dd, J 9.2 and 5.8, 
6-H), 6.89 (1H, td, J 9.2 and 2.7, 8-H), 5.46 (1H, d, J 1.2, alkene-Ha), 5.15-5.11 (1H, m, 
alkene-Hb), 5.07-4.97 (1H, m, oxetanyl 3-H), 4.95 (1H, t, J 6.9, oxetanyl 2-Ha), 4.91 (1H, t, J 
6.9, oxetanyl 2-Hb), 4.50 (1H, t, J 6.2, oxetanyl 4-Ha), 4.41 (1H, t, J 6.2, oxetanyl 4-Hb), 4.19-
4.11 (1H, m, 1-Ha), 3.93 (1H, d, J 16.3, 1-Hb), 3.00 (1H, dd, J 14.1 and 0.9, 4-Ha), 2.93 (1H, 
dd, J 14.1 and 0.8, 4-Hb), 2.18-2.09 (1H, m, isopropyl 2-H) and 1.03 (6H, t, J 6.9, isopropyl-
MeA and isopropyl-MeB); δC (101 MHz, CDCl3) 173.8 (CO), 163.1 (C-7), 143.3 (d, J 2.2, C-
5a), 141.8 (C-5), 134.9 (d, J 3.0, C-9a), 129.6 (d, J 8.1, C-9), 117.1 (alkene), 114.2 (d, J 8.2, 
C-6), 113.9 (d, J 7.5, C-8), 78.80 (oxetanyl C-7), 78.75 (oxetanyl C-4), 67.3 (C-3), 48.5 (C-
1), 44.3 (oxetanyl C-3), 39.3 (C-4), 34.0 (isopropyl C-2), 18.4 (isopropyl-MeA) and 17.2 
(isopropyl-MeB); δF (376 MHz, CDCl3) -116.2; HRMS found MH+, 319.1836.  C18H23FN2O2 
requires MH, 319.1822. 
N-Cyclopropyl-5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3-
carboxamide, 292  
 
By general procedure V, the amino ester 284 (140 mg, 0.640 mmol) and 
cyclopropylamine (0.44 mL, 6.40 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 100% EtOAc) to yield the amide 292 (60.0 mg, 39%) as a red oil, 
Rf = 0.50 (10:90 MeOH–EtOAc); νmax/ cm-1 (ATR) 3286 (br), 3065, 3011, 2926, 2852, 1651, 
1509, 904, 773 and 729; δH (400 MHz, CDCl3) 7.32 (1H, dd, J 7.3 and 1.6, 9-H), 7.27 (1H, br 
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s, NH), 7.18-7.08 (2H, m, 7-H and 8-H), 6.99 (1H, dd, J 7.5 and 1.3, 6-H), 5.22 (1H, d, J 1.5, 
alkene-Ha), 5.10 (1H, d, J 0.7, alkene-Hb), 3.90 (2H, s, 1-H2), 3.49 (1H, dd, J 9.5 and 4.8, 3-
H), 3.10 (1H, dd, J 13.9 and 4.8, 4-Ha), 2.70-2.61 (1H, m, cyclopropyl 1-H), 2.56 (1H, dd, J 
13.9 and 9.5, 4-Hb), 1.74 (1H, br s, NH), 0.72-0.66 (2H, m, cyclopropyl 2-H2) and 0.44-0.38 
(2H, m, cyclopropyl 3-H2); δC (101 MHz, CDCl3) 174.4 (CO), 146.6 (C-5), 141.3 (C-9a), 
138.8 (C-5a), 128.2 (C-9), 128.0 (C-8), 127.4 (C-7), 127.3 (C-6), 115.7 (alkene), 62.7 (C-3), 
51.1 (C-1), 38.8 (C-4), 22.2 (cyclopropyl C-1), 6.5 (cyclopropyl C-2) and 6.3 (cyclopropyl 
C-3); HRMS found MH+, 243.1507.  C15H18N2O requires MH, 243.1497. 
8-Fluoro-5-methylene-N-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-
benzo[c]azepine-3-carboxamide, 294 
 
By general procedure V, the amino ester 286 (300 mg, 1.28 mmol) and 4-
aminotetrahydropyran (1.00 g, 9.89 mmol) gave a crude residue which was purified by 
flash chromatography (SiO2, 10:90 to 20:80 MeOH–EtOAc) to yield the amide 294 
(70.9 mg, 18%) as a yellow oil, Rf = 0.18 (10:90 MeOH–EtOAc); νmax/ cm-1 (ATR) 3307 (br), 
2927, 2847, 1655, 1513, 1493 and 1140; δH (400 MHz, CDCl3) 7.34 (1 H, dd, J 8.8 and 5.7, 
9-H), 7.23 (1 H, br s, NH), 6.89 (1 H, td, J 8.8 and 2.7, 7-H), 6.77 (1 H, dd, J 8.8 and 2.7, 6-
H), 5.24 (1 H, d, J 1.5, alkene-Ha), 5.14 (1 H, app s, alkene-Hb), 4.01-3.86 (5 H, m, 1-H2, THP 
1-H and THP 2-H2), 3.57 (1 H, dd, J 9.2 and 4.9, 3-H), 3.52-3.39 (2 H, m, THP 6-H2), 3.14 (1 
H, dd, J 13.9 and 4.9, 4-Ha), 2.60 (1 H, dd, J 13.9 and 9.2, 4-Hb), 1.95 (1 H, br s, NH), 1.91-
1.77 (2 H, m, THP 3-H2) and 1.57-1.35 (2 H, m, THP 5-H2); δC (101 MHz, CDCl3) 172.0 (CO), 
161.9 (d, J 246.8, C-8), 145.5 (C-5), 141.0 (d, J 6.5, C-9a), 137.1 (d, J 3.2, C-5a), 130.0 (d, J 
7.6, C-9), 115.7 (alkene), 114.6 (d, J 21.7, C-7), 113.9 (d, J 20.7, C-6), 66.8 (THP C-2 and 
THP C-6), 62.4 (THP C-4), 50.7 (C-1), 45.2 (C-3), 38.8 (C-4), 33.2 (THP C-3) and 33.1 (THP 
C-5); HRMS found MH+, 305.1683.  C17H21FN2O2 requires MH, 305.1665. 
 238 
 
2-Cyclopropyl-1-hydroxy-4-isopropyl-1,2,5,6-tetrahydro-1,4-methanobenzo[f] 
[1,4]diazocin-3(4H)-one , 214 
 
By general procedure X, alkene 211 (200 mg, 0.700 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 100% EtOAc) to give the hemiaminal 
214 (97.5 mg, 49%, ≥ 98% closed form) as a brown oil, Rf = 0.66 (100% EtOAc); νmax/ 
cm-1 (ATR) 2926, 1721, 1676, 1264, 742 and 697; δH (501 MHz, MeOD) 7.69 (1H, dd, J 7.8 
and 1.3, 7-H), 7.21-7.17 (1H, m, 9-H), 7.13 (1H, td, J 7.4 and 1.4, 8-H), 7.07 (1H, dd, J 7.2 
and 0.6, 10-H), 3.79 (1H, d, J 15.4, 6-Ha), 3.71 (1H, d, J 15.4, 6-Hb), 2.31-2.24 (1H, m, 
cyclopropyl 1-H), 2.21 (1H, d, J 12.6, 11-Ha), 2.02 (1H, hept, J 6.9, isopropyl 2-H), 1.85 (1H, 
d, J 12.6, 11-Hb), 0.94-0.88 (1H, m, cyclopropyl 2-Ha), 0.86 (3H, d, J 6.7, isopropyl-MeA), 
0.83 (3H, d, J 6.9, isopropyl-MeB), 0.49-0.38 (2H, m, cyclopropyl 2-Hb and cyclopropyl 4-
Ha) and 0.37-0.29 (1H, m, cyclopropyl 4-Hb); δC (126 MHz, MeOD) 176.1 (C-3), 142.8 (C-
10a), 135.2 (C-6a), 129.8 (C-7), 127.5 (C-9), 126.9 (C-8), 125.0 (C-10), 89.7 (C-1), 68.0 (C-
4), 50.2 (C-6), 44.2 (C-11), 31.6 (cyclopropyl C-1), 22.2 (isopropyl C-2), 17.5 (isopropyl-
MeA), 15.2 (isopropyl-MeB), 3.0 (cyclopropyl C-2) and 2.8 (cyclopropyl C-3); HRMS found 
MH+, 287.1754.  C17H22N2O2 requires MH, 287.1759. 
2-Cyclopropyl-1-hydroxy-4-isopropyl-9-methyl-1,2,5,6-tetrahydro-1,4-
methanobenzo[f] [1,4]diazocin-3(4H)-one, 214a 
 
By general procedure X, alkene 288 (80.0 mg, 0.270 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 20:80 Petrol–EtOAc) to give the 
hemiaminal 214a (29.2 mg, 36%, ≥ 98% closed form) as a brown oil, Rf = 0.21 (20:80 
Petrol–EtOAc); νmax/ cm-1 (ATR) 3326 (br), 2962, 2927, 2874, 1673, 1498, 1458 and 731; 
δH (400 MHz, CDCl3) 7.50 (1H, s, 10-H), 7.07-6.97 (2H, m, 7-H and 8-H), 3.95 (1H, d, J 15.1, 
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6-Ha), 3.77 (1H, d, J 15.1, 6-Hb), 2.37 (3H, s, tolyl), 2.35-2.29 (1H, m, OH), 2.19-2.10 (2H, m, 
11-H2), 2.10-2.05 (1H, m, isopropyl 2-H), 1.06-0.99 (1H, m, cyclopropyl 1-H), 0.98-0.93 
(6H, m, isopropyl-MeA and isopropyl-MeB) and 0.70-0.46 (4H, m, cyclopropyl 2-H2 and 
cyclopropyl 3-H2); δC (101 MHz, CDCl3) 199.0 (C-1 open), 176.3 (C-3), 141.9 (C-10a), 137.1 
(C-6a), 132.54 (C-9), 130.6 (C-7), 128.6 (C-8), 125.4 (C-10), 90.0 (C-1 closed), 68.1 (C-4), 
50.7 (C-6), 45.6 (C-11), 32.4 (isopropyl C-2), 22.0 (tolyl), 21.3 (cyclopropyl C-1), 18.7 
(isopropyl-MeA), 16.5 (isopropyl-MeB), 4.3 (cyclopropyl C-2) and 3.7 (cyclopropyl C-3); 
HRMS found MH+, 301.1926.  C18H24N2O2 requires MH, 301.1916. 
N-Cyclobutyl-3-isopropyl-8-methyl-5-oxo-2,3,4,5-tetrahydro-1H-benzo[c]azepine-
3-carboxamide, 214ba 
 
By general procedure X, alkene 289 (210 mg, 0.670 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to give the ketone 
214ba (140 mg, 66%, ≥ 98% open form) as an amorphous orange solid, Rf = 0.54 (30:70 
Petrol–EtOAc); νmax/ cm-1 (ATR) 3332 (br), 2967, 2874, 1671, 1606, 1508 and 1298; δH 
(400 MHz, CDCl3) 7.88 (1H, d, J 7.9, 6-H), 7.61 (1H, d, J 8.6, NH), 7.18 (1H, d, J 7.9, 7-H), 
7.08-7.03 (1H, m, 9-H), 4.29-4.16 (2H, m, alkene-Ha and cyclobutyl 1-H), 4.09 (1H, d, J 15.8, 
alkene-Hb), 3.38 (1H, d, J 14.5, 1-Ha), 3.18 (1H, d, J 14.5, 1-Hb), 2.40 (3H, s, tolyl), 2.35-2.23 
(1H, m, cyclobutyl 2-Ha), 2.22-2.13 (1H, m, cyclobutyl 2-Hb), 2.00-1.89 (1H, m, isopropyl 
2-H), 1.84-1.75 (1H, m, cyclobutyl 3-Ha), 1.73-1.60 (3H, m, cyclobutyl 3-Hb and cyclobutyl 
4-H2), 1.04 (3H, d, J 6.9, isopropyl-MeA) and 0.96 (3H, d, J 6.9, isopropyl-MeB); δC (101 MHz, 
CDCl3) 199.3 (C-5), 172.4 (CO), 143.4 (C-9a), 143.3 (C-8), 134.6 (C-5a), 129.6 (C-6), 129.4 
(C-7), 128.5 (C-9), 64.9 (C-3), 49.6 (C-1), 47.8 (C-4), 44.2 (cyclobutyl C-1), 36.1 (isopropyl 
C-2), 31.2 (cyclobutyl C-2), 31.1 (cyclobutyl C-4), 21.5 (tolyl), 18.3 (isopropyl-MeA), 17.2 
(isopropyl-MeB) and 15.1 (cyclobutyl C-3); HRMS found MH+, 315.2089.  C19H26N2O2 
requires MH, 315.2072. 
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8-Fluoro-3-isopropyl-5-oxo-N-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-
benzo[c]azepine-3-carboxamide, 214ca 
 
By general procedure X, alkene 290 (420 mg, 1.21 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 40:60 Petrol–EtOAc) to give the ketone 
214ca (350 mg, 83%, ≥ 98% open form) as a brown oil, Rf = 0.35 (20:80 Petrol–EtOAc); 
νmax/ cm-1 (ATR) 3330 (br), 2960, 2848, 1672, 1509, 1250, 1089 and 729; δH (400 MHz, 
CDCl3) 7.96 (1H, dd, J 8.7 and 5.9, 6-H), 7.37 (1H, d, J 8.2, NH), 7.02 (1H, td, J 8.7 and 2.5, 
7-H), 6.91 (1H, dd, J 8.7 and 2.4, 9-H), 4.22 (1H, d, J 15.7, 1-Ha), 4.05 (1H, d, J 15.7, 1-Hb), 
3.92-3.73 (3H, m, THP 1-H and THP 3-H2), 3.44-3.35 (2H, m, THP 5-H2), 3.33 (1H, d, J 14.7, 
4-Ha), 3.17 (1H, d, J 14.7, 4-Hb), 2.01-1.93 (1H, m, isopropyl 2-H), 1.81-1.73 (1H, m, THP 2-
Ha), 1.57-1.48 (1H, m, THP 2-Hb), 1.37 (1H, ddd, J 23.8, 11.3 and 4.5, THP 6-Ha), 1.00 (3H, 
d, J 6.9, isopropyl-MeA), 0.95 (3H, d, J 6.9, isopropyl-MeB) and 0.91-0.85 (1H, m, THP 6-Hb); 
δC (101 MHz, CDCl3) 197.8 (C-5), 172.6 (CO), 163.6 (C-8), 145.9 (C-9a), 133.5 (d, J 2.9, C-
5a), 132.5 (d, J 9.4, C-6), 115.5 (d, J 21.8, C-7), 115.0 (d, J 21.3, C-9), 66.7 (THP C-3), 64.9 
(C-3), 60.4 (THP C-5), 49.3 (C-1), 47.6 (C-4), 45.1 (THP C-1), 36.0 (isopropyl C-2), 33.2 
(THP C-2), 32.9 (THP C-6), 18.1 (isopropyl-MeA) and 17.0 (isopropyl-MeB); δF (376 MHz, 
CDCl3) -106.0; HRMS found MH+, 349.1934.  C19H25FN2O3 requires MH, 349.1927. 
9-Fluoro-1-hydroxy-4-isopropyl-2-(oxetan-3-yl)-1,2,5,6-tetrahydro-1,4-
methanobenzo[f] [1,4]diazocin-3(4H)-one, 214f 
 
By general procedure X, alkene 291 (210 mg, 0.660 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 50:50 to 10:90 Petrol–EtOAc) to yield 
the crude imine which was used as a mixture of ketone and hemiaminal.  NaBH(OAc)3 
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(560 mg, 2.64 mmol) was added to a solution of the crude imine in DCM (6.60 mL, 0.1 M) 
and the reaction was stirred at room temperature overnight.  Water (10 mL) was added 
and the aqueous layer was extracted with DCM (3 × 10 mL).  The combined organic layers 
were washed with water (10 mL), brine (10 mL), dried (MgSO4) and concentrated in vacuo.  
The residue was purified by flash chromatography (SiO2, 10:90 Petrol–EtOAc to 10:90 
MeOH–EtOAc) to give the tetrahydrobenzazepine 214f (34.5 mg, 16% over two steps, 
70:30  closed : open forms) as a yellow oil, Rf = 0.22 (100% EtOAc); νmax/ cm-1 (ATR) 3322 
(br), 2963, 2877, 1680, 1491, 1305, 1274 and 974; δH (400 MHz, CDCl3) 8.00 (1H, d, J 6.9, 
NH), 7.55 (1H, dd, J 8.6, 2.8, 7-H open), 7.42 (1H, dd, J 9.1 and 2.8, 7-H closed), 7.21-7.16 (1H, 
m, 10-H open), 7.11 (1H, dd, J 8.6 and 2.8, 8-H open), 7.06 (1H, dd, J 9.1 and 5.6, 10-H closed), 
6.85 (1H, td, J 9.1 and 2.8, 8-H closed), 5.06 (1H, dd, J 7.5 and 6.1, oxetanyl 2-Ha), 4.99 (1H, 
dd, J 7.5 and 6.2, oxetanyl 2-Hb), 4.85-4.76 (2H, m, oxetanyl 3-H open), 4.69-4.59 (1H, m, 
oxetanyl 3-H closed), 4.56-4.40 (2H, m, oxetanyl 4-H2 closed), 4.15-3.98 (2 H, m, oxetanyl 4-H2 
open), 3.88 (1H, d, J 15.4, 6-Ha closed), 3.77 (1H, d, J 15.4, 6-Hb closed), 3.28 (1H, d, J 14.7, 6-Ha 
open), 3.12 (1H, d, J 14.7, 6-Hb open), 2.12 (2H, s, 11-H2 closed), 2.07-2.00 (1H, m, isopropyl 2-H 
closed), 1.98 (2H, s, 11-H2 open), 1.95-1.85 (1H, m, isopropyl 2-H open), 0.94 (3H, d, J 6.9, 
isopropyl-MeA open), 0.93-0.88 (6 H, m, isopropyl-MeA closed and isopropyl-MeB closed) and 
0.87-0.72 (3H, m, isopropyl-MeB open); δC (101 MHz, CDCl3) 175.3 (C-3), 160.3 (d, J 107.8, 
C-9), 143.7 (d, J 6.6, C-10a), 132.2 (d, J 7.6, C-7 closed), 131.3 (d, J 3.4, C-7 open), 130.8 (d, J 7.4, 
C-6a), 119.6 (d, J 21.8, C-10 open), 115.8 (d, J 22.6, C-8 open), 114.7 (d, J 21.0, C-10 closed), 113.0 
(d, J 24.2, C-8 closed), 78.6 (oxetanyl C-2 open), 78.4 (oxetanyl C-4 open), 75.6 (oxetanyl C-2 
closed), 75.2 (oxetanyl C-4 closed), 68.6 (C-4 closed), 65.0 (C-4 open), 50.3 (C-6 closed), 48.7 (C-6 
open), 47.3 (C-11 open), 46.4 (C-11 closed), 46.1 (oxetanyl C-1 closed), 44.3 (oxetanyl C-1 open), 
36.1 (isopropyl C-2 open), 32.3 (isopropyl C-2 closed), 18.7 (isopropyl-MeA closed), 18.1 
(isopropyl-MeA open), 17.1 (isopropyl-MeB open) and 16.5 (isopropyl-MeB closed); numbering 
of the compound has been completed using the closed major form; δF (282 MHz, CDCl3) -
113.5 and -113.8; HRMS found MH+, 321.1622.  C17H21FN2O3 requires MH, 321.1614. 
tert-Butyl 3-(cyclopropylcarbamoyl)-5-methylidene-2,3,4,5-tetrahydro-1H-2-
benzazepine-2-carboxylate, 295 
 
Boc2O (28.4 mg, 0.130 mmol) was added to a solution of amine 292 (30.0 mg, 
0.124 mmol) in DCM (1.24 mL, 0.1 M), and the resulting solution was stirred at room 
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temperature overnight before being concentrated in vacuo.  The residue was purified by 
flash chromatography (SiO2, 30:70 Petrol–EtOAc) to give the protected 
tetrahydrobenzazepine 295 (29.7 mg, 70%) as a colourless oil, Rf = 0.62 (30:70 Petrol–
EtOAc); νmax/ cm-1 (ATR) 3305 (br), 3066, 3007, 2976, 2929, 1692, 1659, 1538, 1411 and 
1162; δH (400 MHz, CDCl3, 333 K) 7.44 (1H, d, J 6.8, 9-H), 7.25-7.15 (2H, m, 7-H and 8-H), 
7.09 (1H, d, J 6.5, 6-H), 6.45 (1H, br s, NH), 5.36 (1H, s, alkene-Ha), 5.18 (1H, s, alkene-Hb), 
4.68 (1H, dd, J 10.9 and 6.0, 3-H), 4.55 (1H, d, J 16.5, 1-Ha), 4.40 (1H, d, J 16.5, 1-Hb), 3.15-
2.84 (2H, m, 4-H2), 2.78-2.65 (1H, m, cyclopropyl 1-H), 1.38 (2H, s, Boc, rotamer A), 1.26 
(7H, s, Boc, rotamer B), 0.78 (2H, d, J 6.8, cyclopropyl 2-H2) and 0.59-0.38 (2H, m, 
cyclopropyl 3-H2); δC (101 MHz, CDCl3) 188.4 (Boc), 172.3 (CO), 144.5 (C-5), 139.1 (C-9a), 
136.5 (C-5a), 128.0 (C-9), 127.8 (C-8), 127.4 (C-7), 127.3 (C-6), 116.5 (alkene), 80.8 (Boc), 
59.7 (C-3), 48.3 (C-1), 35.7, (C-4) 28.1 (Boc), 22.5 (cyclopropyl C-1) and 6.6 (cyclopropyl 
C-2 and cyclopropyl C-3); HRMS found MH+, 343.2009.  C20H26N2O3 requires MH, 343.2021. 
tert-Butyl 3-(cyclopropylcarbamoyl)-5-oxo-4,5-dihydro-1H-benzo[c]azepine-
2(3H)-carboxylate, 214ka 
 
By general procedure U, alkene 295 (161 mg, 0.47 mmol) gave a crude residue 
which was purified by flash chromatography (SiO2, 30:70 Petrol–EtOAc) then again (SiO2, 
50:50 Petrol–EtOAc) to give the ketone 214ka (110 mg, 68%) as a yellow oil, Rf = 0.47 
(30:70 Petrol–EtOAc); νmax/ cm-1 (ATR) 3305 (br), 2976, 2932, 1662, 1392, 1366, 1156 
and 730; δH (501 MHz, CDCl3) 7.97 (1H, d, J 7.6, 9-H), 7.47 (1H, td, J 7.6 and 1.4, 8-H), 7.38 
(1H, t, J 7.6, 7-H), 7.34-7.28 (1H, m, 6-H), 4.91-4.69 (2H, m, 1-Ha and 3-H), 4.62 (1H, d, J 
10.2, 1-Hb), 3.59 (1H, t, J 13.5, 4-Ha), 3.01 (1H, dd, J 13.5 and 4.6, 4-Hb), 2.80-2.69 (1H, m, 
cyclopropyl 1-H), 1.35 (9H, s, Boc), 0.83-0.71 (2H, m, cyclopropyl 2-H2) and 0.58-0.39 (2H, 
m, cyclopropyl 3-H2); δC (101 MHz, CDCl3) 198.6 (C-5), 171.3 (CO), 155.4 (Boc), 141.6 (C-
5a), 132.5 (C-9a), 129.4 (C-9), 129.3 (C-8), 128.6 (C-7), 127.9 (C-6), 81.5 (Boc), 53.6 (C-3), 
48.1 (C-1), 28.1 (C-4), 23.8 (Boc), 22.6 (cyclopropyl C-1) and 6.7 (cyclopropyl C-2 and 
cyclopropyl C-3); HRMS found MH+, 345.1802.  C19H24N2O4 requires MH, 345.1814. 
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N-Cyclopropyl-5-oxo-2,3,4,5-tetrahydro-1H-benzo[c]azepine-3-carboxamide, 
214ga 
 
By general procedure Y, the protected hemiaminal 214ka (50.0 mg, 0.150 mmol) 
gave a crude residue which was purified by flash chromatography (SiO2, 5:95 MeOH–
EtOAc) to give the ketone 214ga (22.1 mg, 60%, ≥ 98% open form) as a yellow oil, Rf = 
0.73 (20:80 MeOH–EtOAc); νmax/ cm-1 (ATR) 3315 (br), 3009, 2925, 2854, 1673, 1513, 
1284 and 770; δH (400 MHz, CDCl3) 7.82-7.78 (1H, m, 9-H), 7.39 (1H, t, J 7.5, 8-H), 7.35 
(1H, br s, NH), 7.31 (1H, td, J 7.5 and 0.9, 7-H), 7.15 (1H, d, J 7.5, 6-H), 4.09 (1H, d, J 16.1, 
1-Ha), 4.04 (1H, d, J 16.1, 1-Hb), 3.67 (1H, dd, J 9.9 and 4.4, 3-H), 3.25 (1H, dd, J 14.7 and 
4.4, 4-Ha), 3.09 (1H, dd, J 14.7 and 9.9, 4-Hb), 2.61 (1H, tq, J 7.4 and 3.8, cyclopropyl 1-H), 
1.89 (1H, br s, NH), 0.73-0.63 (2H, m, cyclopropyl 2-H2) and 0.43-0.26 (2H, m, cyclopropyl 
3-H2); δC (101 MHz, CDCl3) 200.5 (C-5), 173.7 (CO), 142.2 (C-5a), 137.7 (C-9a), 132.5 (C-
9), 129.2 (C-8), 128.5 (C-7), 127.9 (C-6), 55.7 (C-3), 49.2 (C-1), 44.5 (C-4), 22.3 
(cyclopropyl C-1), 6.5 (cyclopropyl C-2) and 6.4 (cyclopropyl C-3); HRMS found MH+, 
245.1283.  C14H16N2O2 requires MH, 245.1290. 
tert-Butyl 3-(cyclobutylcarbamoyl)-7-fluoro-5-methylene-4,5-dihydro-1H- 
benzo[c]azepine-2(3H)-carboxylate, 296 
 
By general procedure V, the amino ester 285 (170 mg, 0.720 mmol) and 
cyclobutylamine (0.610 mL, 7.20 mmol) gave a crude residue which was purified by flash 
chromatography (SiO2, 5:95 MeOH–EtOAc) and then again (SiO2, 5:95 MeOH–EtOAc) to 
yield the crude amide.  Boc2O (50.4 mg, 0.231 mmol) was added to a solution of crude 
amide (59.2 mg, 0.22mmol) in DCM (2.20 mL, 0.1 M), and the resulting mixture was 
stirred at room temperature overnight before being concentrated in vacuo.  The residue 
was purified by flash chromatography (SiO2, 20:80 Petrol–EtOAc) to give the protected 
tetrahydrobenzazepine 296 (82.0 mg, 31% over two steps) as a colourless oil, Rf = 0.79 
(10:90 Petrol–EtOAc); νmax/ cm-1 (ATR) 3312 (br), 2978, 2939, 1657, 1368, 1212, 1161, 
1118 and 1070; δH (400 MHz, CDCl3, 333K) 7.05 (1H, dd, J 9.2 and 2.5, 9-H), 6.99 (1H, br 
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s, 6-H), 6.80 (1H, td, J 9.2 and 2.6, 8-H), 6.30 (1H, br s, NH), 5.29 (1H, s, alkene-Ha), 5.15 
(1H, s, alkene-Hb), 4.55 (2H, s, 1-H2), 4.38-4.19 (2H, m, cyclobutyl 1-H and 3-H), 3.03-2.65 
(2H, m, 4-H2), 2.39-2.20 (2H, m, cyclobutyl 2-H2), 1.88-1.71 (2H, m, cyclobutyl 4-H2), 1.70-
1.59 (2H, m, cyclobutyl 3-H2), 1.45 (7H, s, Boc, rotamer A) and 1.39 (2H, s, Boc, rotamer 
B); δC (101 MHz, CDCl3) 177.24 (CO), 169.7 (Boc), 162.0 (d, J 245.0, C-7), 146.8 (C-5), 144.0 
(C-9a), 141.4 (C-5a), 129.6 (C-9), 119.7 (C-6), 117.1 (alkene), 114.3 (d, J 22.2, C-8), 85.0 
(Boc), 47.4 (C-1), 44.8 (C-3 and cyclobutyl C-1), 35.6 (C-4), 31.2 (cyclobutyl C-2), 31.1 
(cyclobutyl C-4), 28.2 (Boc), 27.4 (Boc) and 15.1 (cyclobutyl C-3); HRMS found MH+, 
375.2075.  C21H27FN2O3 requires MH, 375.2084. 
N-Cyclobutyl-7-fluoro-5-oxo-2,3,4,5-tetrahydro-1H-benzo[c]azepine-3-
carboxamide, 214ia 
 
By general procedure U, alkene 296 (82.0 mg, 0.22 mmol) gave a crude ketone 
which by general procedure Y, gave a crude residue which was purified by flash 
chromatography (SiO2, 5:95 MeOH–EtOAc) to give the ketone 214ia (60.8 mg, 100% over 
two steps, ≥ 98% open form) as a dark brown oil, Rf = 0.59 (10:90 MeOH–EtOAc); νmax/ 
cm-1 (ATR) 3077 (br), 2953, 1671, 1447, 1201 and 1137; δH (400 MHz, MeOD) 7.60-7.55 
(2H, m, 6-H and 9-H), 7.43 (1H, td, J 8.2 and 2.8, 8-H), 4.65 (1H, d, J 14.8, 1-Ha), 4.56 (1H, 
d, J 14.8, 1-Hb), 4.28-4.16 (2H, m, 3-H and cyclobutyl 1-H), 3.48 (1H, dd, J 18.3 and 9.9, 4-
Ha), 3.33-3.28 (1H, m, 4-Hb), 2.31-2.19 (2H, m, cyclobutyl 2-H2), 1.98-1.87 (2H, m, 
cyclobutyl 4-H2) and 1.80-1.69 (3H, m, cyclobutyl 3-H2 and NH); δC (101 MHz, MeOD) 
195.5 (C-5), 164.0 (d, J 355.6, C-7), 139.4 (C-9a), 133.5 (d, J 8.1, C-9), 127.6 (d, J 3.4, C-5a), 
120.2 (d, J 22.0, C-6), 115.3 (d, J 23.5, C-8), 53.2 (cyclobutyl C-1), 45.04 (C-3), 45.03 (C-1), 
41.4 (C-4), 29.7 (cyclobutyl C-2 and cyclobutyl C-4) and 14.6 (cyclobutyl C-3); δF (282 MHz, 
CDCl3) -72.9 and -73.1; HRMS found MH+, 277.1346.  C15H17FN2O2 requires MH, 277.1352. 
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8-Fluoro-5-oxo-N-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-
benzo[c]azepine-3-carboxamide, 214ha 
 
Boc2O (52.7 mg, 0.240 mmol) was added to a solution of amine 294 (70.9 mg, 
0.230 mmol) in DCM (2.30 mL, 0.1 M), and the resulting solution was stirred at room 
temperature overnight before being concentrated in vacuo.  The residue was purified by 
flash chromatography (SiO2, 10:90 Petrol–EtOAc) to give the crude 
tetrahydrobenzazepine which was subjected to general procedures U followed by Y.  This 
gave a crude residue which was purified by flash chromatography (SiO2, 5:95 to 20:80 
MeOH–EtOAc) to give the ketone 214ha (70.4 mg, 100% over three steps, ≥ 98% open 
form) as a dark brown oil, Rf = 0.60 (20:80 MeOH–EtOAc); νmax/ cm-1 (ATR) 3415 (br), 
2959, 2858, 2400, 1671, 1441, 1203, 1182 and 1133; δH (400 MHz, MeOD) 7.89-7.82 (1H, 
m, 9-H), 7.26-7.17 (2H, m, 6-H and 7-H), 4.53 (1H, d, J 14.9, 1-Ha), 4.46 (1H, d, J 14.9, 1-Hb), 
4.16-4.06 (1H, m, THP 4-H), 3.88-3.64 (4H, m, THP 2-H2 and THP 6-H2), 3.41-3.28 (3H, m, 
3-H and 4-H2), 1.74-1.60 (2H, m, THP 3-H2) and 1.47-1.31 (2H, m, THP 5-H2); δC (101 MHz, 
MeOD) 195.3 (C-5), 166.7 (CO), 165.3 (d, J 216.7, C-8), 132.1 (d, J 9.6, C-6), 117.8 (d, J 23.4, 
C-7), 116.8 (d, J 22.0, C-9), 66.1 (THP C-2 and THP C-6), 53.5 (THP C-4), 46.3 (C-3), 45.5 
(C-1), 41.7 (C-4), 31.9 (THP C-3) and 31.9 (THP C-5), aromatic quaternary carbons not 
observed; δF (376 MHz, MeOD) -77.0; HRMS found MH+, 307.1457.  C16H19FN2O3 requires 
MH, 307.1458. 
tert-Butyl 3-({2-[(2-fluorophenyl)-3,6-dioxopiperazin-2-yl]ethyl}amino)azetidine-
1-carboxylate, 207 
 
By general procedure W, alkene 198 (125 mg, 0.500 mmol) gave the crude 
aldehyde which was combined with 1-Boc-3-(amino)azetidine (344 mg, 2.00 mmol) and 
by general procedure M, gave a crude residue which was purified by flash 
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chromatography (SiO2, 10:90 MeOH–DCM) to give the decorated piperazine 207 (46.0 mg, 
23% over two steps) as a yellow oil, Rf = 0.44 (30:70 MeOH–DCM); νmax/ cm-1 (ATR) 3364 
(br), 2483, 2071, 1677, 1414, 1119 and 972; δH (501 MHz, MeOD) 7.31-7.24 (1H, m, 
fluorophenyl 4-H), 7.13 (1H, td, J 8.0 and 1.7, fluorophenyl 3-H), 7.07 (1H, ddd, J 11.9, 8.0 
and 1.0, fluorophenyl 5-H), 7.02 (1H, td, J 8.0 and 1.2, fluorophenyl 6-H), 4.78-4.70 (1H, m, 
azetidine 1-H), 4.10-4.01 (3H, m, azetidine 2-H2 and azetidine  4-Ha), 4.00-3.89 (1H, m, 
azetidine 4-Hb), 3.57 (1H, td, J 9.4 and 2.3, ethyl 2-Ha), 3.36 (2H, s, 5-H2), 3.25 (1H, dt, J 9.4 
and 7.6, ethyl 2-Hb), 2.89 (1H, dt, J 13.0 and 9.0, ethyl 1-Ha), 2.44 (1H, ddt, J 13.0, 7.6 and 
2.3, ethyl 1-Hb) and 1.29 (9H, s, Boc); δC (126 MHz, MeOD) 173.8 (C-3), 170.5 (Boc), 162.4 
(d, J 248.2, fluorophenyl C-2), 157.9 (C-6), 131.9 (d, J 8.8, fluorophenyl C-4), 129.2 (d, J 3.3, 
fluorophenyl C-3), 127.2 (d, J 12.0, fluorophenyl C-1), 125.4 (d, J 3.4, fluorophenyl C-5), 
117.9 (d, J 22.2, fluorophenyl C-6), 81.3 (Boc), 65.1 (C-3), 53.7 (azetidine C-2 and azetidine 
C-4), 44.0 (azetidine C-1), 43.0 (C-5), 41.7 (ethyl C-2), 32.9 (1H, d, J 2.7, ethyl C-1) and 28.5 
(Boc); HRMS found MH+, 407.2092.  C20H27FN4O4 requires MH, 407.2094. 
3-{2-[(Azetidin-3-yl)amino]ethyl}-3-(2-fluorophenyl)piperazine-2,5-dione, 208 
 
By general procedure Y, the protected amine 207 (46.0 mg, 0.110 mmol) gave the 
piperazine 208 (20.3 mg, 60%) as a yellow oil, νmax/ cm-1 (ATR) 3269 (br), 2951, 2934, 
1711, 1553 and 1438; δH (500 MHz, MeOD) 7.51-7.40 (1H, m, fluorophenyl 4-H), 7.30 (1H, 
td, J 8.1 and 1.6, fluorophenyl 3-H), 7.25 (1H, ddd, J 11.9, 8.1 and 0.9, fluorophenyl 5-H), 
7.22-7.18 (1H, m, fluorophenyl 6-H), 5.12-5.03 (1H, m, azetidine 3-H), 4.02 (1H, t, J 7.7, 
azetidine 2-Ha), 3.91 (1H, t, J 7.7, azetidine 2-Hb), 3.84-3.70 (3H, m, azetidine 4-H2 and 
ethyl 2-Ha), 3.44 (1H, dd, J 17.4 and 7.9, ethyl 2-Hb), 3.34-3.26 (2H, m, 6-H2), 3.07 (1H, dt, 
J 13.1 and 8.9, ethyl 1-Ha) and 2.66-2.56 (1H, m, ethyl 1-Hb); δC (126 MHz, MeOD) 174.9 
(C-2), 173.5 (C-5), 162.5 (d, J 248.1, fluorophenyl C-2), 131.8 (d, J 8.8, fluorophenyl C-4), 
129.3 (d, J 3.4, fluorophenyl C-3), 127.6 (d, J 12.0, fluorophenyl C-1), 125.4 (d, J 3.3, 
fluorophenyl C-5), 117.9 (d, J 22.3, fluorophenyl C-6), 65.0 (C-3), 51.2 (azetidine C-2 and 
azetidine C-4), 48.3 (azetidine C-3), 45.1 (C-6), 41.8 (ethyl C-2) and 32.9 (ethyl C-1); HRMS 
found MH+, 307.1567.  C15H19FN4O2 requires MH, 307.1570. 
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(2R, 5S)-5-Cyclopropyl-1-(2-nitrobenzenesulfonyl)piperazine-2-carboxamide, 236 
 
A solution of the protected piperazine 235 (14.6 mg, 250 µmol) and CAN (54.8 mg, 
0.100 mmol) in MeCN (0.250 mL, 0.1 M) and water (80.0 µL, 0.3 M) was stirred at room 
temperature overnight before more CAN (54.8 mg, 0.100 mmol) was added.  The reaction 
mixture was concentrated in vacuo before being purified by mass-directed preparative 
HPLC to yield the deprotected piperazine 236 (6.10 mg, 69%) as a yellow oil, Rf = 0.72 
(30:70 MeOH–DCM); νmax/ cm-1 (ATR) 3327 (br), 3195 (br), 2928, 1677, 1543, 1369 and 
1170; [α]D25 158 (c = 0.15, CHCl3); δH (501 MHz, MeOD) 8.12-8.07 (1H, m, nitrophenyl 3-
H), 7.78-7.70 (3H, m, nitrophenyl 4-H, nitrophenyl 5-H and nitrophenyl 6-H), 4.52 (1H, 
app s, 2-H), 3.76-3.69 (1H, m, 6-Ha), 3.61 (1H, d, J 13.2, 6-Hb), 3.54-3.46 (1H, m, 3-Ha), 3.39-
3.29 (1H, m, 3-Hb), 2.17 (1H, d, J 7.8, NH), 1.27-1.12 (1H, m, 5-H), 0.96-0.89 (1H, m, 
cyclopropyl 1-H), 0.47-0.39 (1H, m, cyclopropyl 2-Ha), 0.31-0.19 (1H, m, cyclopropyl 2-Hb) 
and 0.13-0.04 (2H, m, cyclopropyl 4-H2); δC (126 MHz, MeOD) 147.1 (nitrophenyl C-2), 
135.7 (nitrophenyl C-5), 133.33 (nitrophenyl C-1), 133.29 (nitrophenyl C-4), 132.5 
(nitrophenyl C-6), 125.7 (nitrophenyl C-3), 58.5 (C-5), 55.6 (C-2), 46.9 (C-6), 42.2 (C-3), 
12.4 (cyclopropyl C-1), 4.8 (cyclopropyl C-2) and 4.2 (cyclopropyl C-4); HRMS found MH+, 
355.1079.  C14H18N4O5S requires MH, 355.1076.
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Appendix 
Table 31 Methodologies for the formation, and available yields of exemplified scaffolds formed using 
previously established chemistry in Leeds.  This information was gathered in order to identify a range of 
scaffolds which could be formed in reasonable yields, as well as reliable methodology for their synthesis.  A 
full description can be found in Section 2.2.1.  
Iridium Chemistry41 
Starting Material: 
 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Iodine-
mediated 
morpholine 
formation 
ii) CDI-urea 
formation 
 
40% 
 
i) Amino-
arylation 
ii) Lactamisation 
 
77% 
 
i) Iodine-
mediated 
morpholine 
formation 
ii) Sulfurea 
formation  
i) CDI-carbamate 
formation 
ii) Amino-
arylation 
 
66-90%  
i) Aminoarylation 
ii) Lactamisation 
 
38% 
 
i) Keto-
morpholine 
formation 
ii) Amino-
arylation × 2 
 
83% 
 
i) Iodine-
mediated 
morpholine 
formation 
ii) Keto-
piperazine 
formation 
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Iridium Chemistry 
Starting Material:  
n = 1, 2 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Ketopiperazine 
formation 
ii) Amino-
arylation × 2 
(Not compatible 
with Ns) 
 
CDI-urea 
formation 
 
49%  
Ketopiperazine 
formation 
 
95%  
CDI-urea 
formation 
 
57%  
Iridium Chemistry 
Starting Material:  
m, n = 1, 2 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
RCM 
m=1, n=1, 72% 
m=1, n=2, 54% 
m=2, n=1, 54% 
m=2, n=2, 72% 
 
i) CDI-urea 
formation 
ii) RCM 
m=1, n=1, 51% 
m=1, n=2 
m=2, n=1, 67% 
m=2, n=2, 50% 
 
i) Ketopiperazine 
formation 
ii) RCM 
m=1, n=1 
m=1, n=2, 67% 
m=2, n=1 
m=2, n=2, 72% 
 
  
Iridium Chemistry 
Starting Material: 
 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Allylic 
amination 
ii) Amino-
arylation 
 
53-83% 
 
i) Allylic 
amination 
ii) Amino-
arylation 
iii) Lactam-
isation 
 
68% 
 
i) Allylic 
amination 
ii) Amino-
arylation 
 
74-80% 
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Amino Acid Chemistry43 
Starting Material:  
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
Iodine-mediated 
carbamate 
formation 
 
53%  
i) Urea 
formation 
ii) Hydantoin 
formation 
 
86%  
i) N-allylation 
ii) RCM 
 
77%  
i) Reductive 
amination 
ii) Keto-
piperazine 
formation 
 
63% 
 
i) Reductive 
amination 
ii) Heck 
 
54%  
  
Amino Acid Chemistry Starting Material:   
R, R’ = Bn, Me 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Amide 
formation 
ii) Diketo-
piperazine 
formation 
 
93% 
 
i) Boc-protection 
ii) Iodine-
mediated 
carbamate 
formation 
 
88% 
 
i) Urea formation 
ii) Iodine-
mediated 
cyclisation 
 
86%  
i) N-allylation 
ii) RCM 
 
68%   
i) Urea formation 
ii) Hydantoin 
formation 
 
86%  
i) Reductive 
amination 
ii) Heck  
 
97%  
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Amino Acid Chemistry 
Starting Material: 
 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Boc-protection 
ii) Iodine-
mediated 
carbamate 
formation 
 
80% 
 
i) Urea 
formation 
ii) Iodine-
mediated 
cyclisation 
 
67% 
 
Amino Acid Chemistry  
Starting Material:  
Urea Chemistry43 
Starting Material: 
 
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Boc-protection 
ii) Iodine-
mediated 
cyclisation 
iii) Nucleophilic 
displacement 
  
78-80% 
 
Iodine-mediated 
cyclisation 
 
64-80% 
 
Ugi Chemistry44 Starting Material:   
R = H, Et 
Method / Yield 
Exemplified 
Scaffoldviii 
Method / Yield Exemplified Scaffold 
i) Cyclic 
sulfamidate ring 
opening 
ii) Alkyne 
hydration 
iii) Ugi reaction 
 
71% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Au-mediated 
hydroamination 
iii) Ugi reaction 
 
70% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Au-mediated 
hydroamination 
iii) Ugi reaction 
 
28% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Au-mediated 
hydroamination 
iii) Ugi reaction 
 
65%  
                                                             
viii  o-Ns refers to 2-nitrobenzenesulfonamide whereas Ns refers to 4-nitrobenzenesulfonamide from here 
onwards. 
 252 
 
Mitsunobu Chemistry42 
Starting Material:  
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
87% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
44% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
55% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
80%  
Mitsunobu Chemistry 
Starting Material:  
Method / Yield Exemplified Scaffold Method / Yield Exemplified Scaffold 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
38% 
 
i) Cyclic 
sulfamidate ring 
opening 
ii) Mitsunobu 
reaction 
 
28%  
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Table 32 Alternative building blocks used and functional group interconversions applied for each exemplified 
scaffold, in the enumeration of the virtual library.  This shows the range of transformations applied to each 
exemplified scaffold in the generation of a library of virtual scaffolds.  A full description can be found in Section 
2.2.2. 
Iridium Chemistry 
Starting Material:  
Exemplified Scaffold Alternative Building Blocks 
 
 
 
 
Iridium Chemistry 
Starting Material: 
n=1,2 
Exemplified Scaffold 
Alternative Building Blocks and 
Functional Group Interconversions 
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Iridium Chemistry 
Starting Material:  
m, n=1,2 
Exemplified Scaffold Functional Group Interconversions 
 
 
Iridium Chemistry Starting Material:  
Exemplified Scaffold Alternatives Building Blocks 
 
 
Amino Acid Chemistry 
Starting Material:  
Exemplified Scaffold 
Alternative Building Blocks and 
Functional Group Interconversions 
 
 
 
 
      
 
Amino Acid Chemistry 
Starting Material:  
Exemplified Scaffold 
Alternative Building Blocks and 
Functional Group Interconversions 
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Amino Acid Chemistry 
Starting Material:  
Exemplified Scaffold Alternative Building Blocks 
 
 
Amino Acid Chemistry 
Starting Material:  
Exemplified Scaffold 
Alternative Building Blocks and 
Functional Group Interconversions 
 
 
 
Amino Acid Chemistry 
Starting Material:  
Exemplified Scaffold Alternative Building Blocks 
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Ugi Chemistry Starting Material:  
R = H, Et 
Exemplified Scaffold Alternative Building Blocks 
 
 
Mitsunobu Chemistry 
Starting Material:  
Exemplified Scaffold Alternative Building Blocks 
 
 
Mitsunobu Chemistry 
Starting Material:  
Exemplified Scaffold Alternative Building Blocks 
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Table 33 Derivatisations applied to virtual scaffolds in the enumeration of the virtual fragment library.  Derivatisation adds complexity and shape diversity to the virtual scaffolds and 
removes any reactive functionality by reacting them with capping groups, improving fragment properties.  A full description can be found in Section 2.2.3. 
Secondary Amine Decorations 
Amide Formation Reductive Amination 
 
 
 
Carbamate Formation 
 
Sulfonamide Formation Urea Formation 
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N-Alkylation 
 
 
Alcohol Decorations Aldehyde Decorations 
O-Alkylation Reductive Amination 
  
Carboxylic Acid Decorations Amide Formation 
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Table 34  Percentage of molecules belonging to HA (heavy atom) ranges 16-20, 18-22 and 20-24, of the total number of fragments derivatised from each scaffold (identified by the 
chemistry used in a key step, with some differentiated by the ring size of the product e.g. “Mitsunobu 6” refers to a scaffold formed using Mitsunobu chemistry in a key step to form a 
product with a 6-membered ring), shown using an exemplar fragment (hydrogens omitted by PLP).  Maximum scaffold coverage is desired in order to incorporate the most diverse 
range of virtual fragments, thus, “0% coverage” of a scaffold by each of the three HA ranges has been highlighted and noted.  It was on this basis that the heavy atom range 18-22 was 
chosen for fragment identification, as it contained the least number of scaffolds with “0% coverage,” i.e. covered the highest number of scaffolds.  A full description can be found in 
Section 2.3. 
Scaffold ID Exemplar fragment 
No. 
fragments 
based on 
scaffold 
16-20 
HA 
Percentage 
of total 
fragments  
18-22 HA 
Percentage 
of total 
fragments 
20-24 
HA 
Percentage 
of total 
fragments 
amino acid scaffold-1 
 
128 6 4.7% 50 39.1% 122 95.3% 
amino acid scaffold-11 
 
530 16 3.0% 192 36.2% 520 98.1% 
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amino acid scaffold-12 
 
2604 808 31.0% 1516 58.2% 2088 80.2% 
amino acid scaffold-13 
 
74 4 5.4% 30 40.5% 71 95.9% 
amino acid scaffold-14 
 
128 6 4.7% 50 39.1% 122 95.3% 
amino acid scaffold-15 
 
56 56 100% 10 17.9% 0 0% 
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amino acid scaffold-16 
 
66 66 100% 56 84.8% 10 15.2% 
amino acid scaffold-17 
 
56 56 100% 10 17.9% 0 0% 
amino acid scaffold-18 
 
66 66 100% 56 84.8% 10 15.2% 
amino acid scaffold-19 
 
62 14 22.6% 60 96.8% 60 96.8% 
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amino acid scaffold-2 
 
64 64 100% 32 50% 0 0% 
amino acid scaffold-20 
 
62 2 3.2% 14 22.6% 60 96.8% 
amino acid scaffold-21 
 
12 12 100% 5 41.7% 0 0% 
amino acid scaffold-22 
 
12 12 100% 12 100% 5 41.7% 
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amino acid scaffold-3 
 
64 64 100% 32 50% 0 0% 
amino acid scaffold-4 
 
62 2 3.2% 44 71.0% 60 96.8% 
amino acid scaffold-5 
 
12 12 100% 10 83.3% 0 0% 
amino acid scaffold-6 
 
20 1 5.0% 9 45.0% 19 95.0% 
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amino acid scaffold-7 
 
1782 284 15.9% 814 45.7% 1672 93.8% 
amino acid scaffold-8 
 
614 244 39.7% 388 63.2% 434 70.7% 
amino acid scaffold-9 
 
6 0 0% 0 0% 6 100% 
Ir scaffold-1 
 
106 4 3.8% 22 20.8% 105 99.1% 
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Ir scaffold-10 
 
176 165 93.8% 106 60.2% 31 17.6% 
Ir scaffold-11 
 
779 579 74.3% 464 59.6% 300 38.5% 
Ir scaffold-12 
 
26 5 19.2% 10 38.5% 23 88.5% 
Ir scaffold-14 
 
72 69 95.8% 42 58.3% 8 11.1% 
 266 
 
Ir scaffold-16 
 
77 54 70.1% 69 89.6% 42 54.5% 
Ir scaffold-18 
 
76 68 89.5% 59 77.6% 23 30.3% 
Ir scaffold-19 
 
76 68 89.5% 59 77.6% 23 30.3% 
Ir scaffold-2 
 
416 15 3.6% 84 20.2% 411 98.8% 
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Ir scaffold-21 
 
213 11 5.2% 46 21.6% 209 98.1% 
Ir scaffold-22 
 
46 46 100% 6 13.0% 0 0% 
Ir scaffold-23 
 
122 118 96.7% 46 37.7% 6 4.9% 
Ir scaffold-24 
 
84 84 100% 16 19.0% 4 4.8% 
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Ir scaffold-25 
 
84 84 100% 16 19.0% 4 4.8% 
Ir scaffold-3 
 
500 75 15.0% 231 46.2% 466 93.2% 
Ir scaffold-4 
 
8 1 12.5% 7 87.5% 8 100% 
Ir scaffold-5 
 
8 0 0% 3 37.5% 8 100% 
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Ir scaffold-6 
 
22 0 0% 4 18.2% 22 100% 
Ir scaffold-7 
 
399 20 5.0% 94 23.6% 389 97.5% 
Ir scaffold-8 
 
420 20 4.8% 104 24.8% 410 97.6% 
Ir scaffold-9 
 
824 548 66.5% 543 65.9% 382 46.4% 
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Mitsunobu 6 scaffold-1 
 
1315 783 59.5% 751 57.1% 660 50.2% 
Mitsunobu 6 scaffold-2 
 
1315 783 59.5% 751 57.1% 660 50.2% 
Mitsunobu 6 scaffold-3 
 
414 80 19.3% 251 60.6% 379 91.5% 
Mitsunobu 6 scaffold-4 
 
414 80 19.3% 251 60.6% 379 91.5% 
 271 
 
Mitsunobu 7 scaffold-1 
 
77 54 70.1% 69 89.6% 42 54.5% 
Mitsunobu 7 scaffold-2 
 
896 476 53.1% 541 60.4% 515 57.5% 
Mitsunobu 7 scaffold-4 
 
220 28 12.7% 113 51.4% 208 94.5% 
Ugi scaffold-1 
 
334 13 3.9% 71 21.3% 329 98.5% 
 272 
 
Ugi scaffold-2 
 
959 329 34.3% 661 68.9% 793 82.7% 
Ugi scaffold-3 
 
1257 661 52.6% 793 63.1% 763 60.7% 
Ugi scaffold-4 
 
171 5 2.9% 29 17.0% 170 99.4% 
Ugi scaffold-5 
 
1064 387 36.4% 727 68.3% 860 80.8% 
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Ugi scaffold-6 
 
1107 510 46.1% 757 68.4% 786 71.0% 
Ugi scaffold-7 
 
959 329 34.3% 661 68.9% 793 82.7% 
Ugi scaffold-8 
 
 
1064 387 36.4% 727 68.3% 860 80.8% 
urea scaffold-1 
 
395 37 9.4% 141 35.7% 373 94.4% 
Total 22975 8771 38.2% 12715 55.3% 16703 72.7% 
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Table 35 Retrosynthetic analysis of compounds from two selected libraries after applying a simulated annealing PLP protocol for the generation of a shape-diverse fragment library.  
The fragment as well as key intermediates and building blocks can be seen; the key reactions which take place are also summarised.  Molecules produced by run 1 were taken forward 
for synthesis due to their chemistry being more developed than molecules from run 2.  A full description can be found in Section 2.6.2. 
Virtual Fragment (Run 1) Key Intermediate Key Intermediate Building Blocks Reactions Occurred 
 
 
 
 
 
Allylic amination 
 
CDI-urea formation 
   
  
N-allylation 
 
RCM 
 
 
 
 
 
Cyclic sulfamidate ring 
opening 
 
Alkyne hydration 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Alkyne hydration 
 
Ugi reaction 
 
 
 
 
Cyclic sulfamidate ring 
opening 
 
Alkyne hydration 
 
Ugi reaction 
 
   
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
  
 
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
    
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
 
 
 
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
  
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
   
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
  
 
 
Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
 
  
 
 
Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
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Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
Virtual Fragment (Run 2) Key Intermediate Key Intermediate Building Blocks Reactions Occurred 
  
 
 
Allylic amination 
 
CDI-urea formation 
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Allylic amination 
 
CDI-urea formation 
 
 
 
 
 
Allylic amination 
 
CDI-urea formation 
 
  
 
 
 
Urea formation 
 
Hydantoin formation 
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Urea formation 
 
Hydantoin formation 
 
 
 
  
Urea formation 
 
Hydantoin formation 
 
 
 
 
 
Cyclic sulfamidate ring 
opening 
 
Alkyne hydration 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
     
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
      
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
    
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
     
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
   
  
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Au-mediated 
hydroamination 
 
Ugi reaction 
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Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
   
 
 
Cyclic sulfamidate ring 
opening 
 
Mitsunobu reaction 
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Table 36 For each framework type in the random library of 80 fragments, the frequency of compounds containing the framework has been summarised, as well as the corresponding 
frequency of compounds containing the same framework in the combined library of 73,031 fragments.  The frameworks were ordered in decreasing frequency of compounds present 
in the random library of 80, and those frequencies were then normalised in order to make them independent of the library size.  This was done in order to compare the relationship 
between frequencies of frameworks in a random library of 80 fragments and the combined library.  A full description can be found in Section 2.7.2. 
Framework (Smiles) 
Frequency in Random 
Library of 80 
Normalised Frequency 
Frequency in 
Combined Library of  
73,031 
Normalised Frequency 
C1CCCCC1 8 0.1000 6714 0.0919 
C(CC1CCCCC1)C2CCCCC2 6 0.0750 3156 0.0432 
C1CCC(CC1)C2CCCCC2 3 0.0375 2331 0.0319 
C(C1CCCC1)C2CCCCC2 3 0.0375 2209 0.0302 
C(C1CCCCC1)C2CCCCC2 3 0.0375 2498 0.0342 
C(CC1CCCCC1)CC2CCCCC2 3 0.0375 2809 0.0385 
C1CCCCCC1 2 0.0250 328 0.0045 
C(CCC1CCCC1)CC2CCCC2 1 0.0125 338 0.0046 
C(CCC1CCCCC1)CC2CC2 1 0.0125 117 0.0016 
C(CC1CCC2CCCCC2C1)C3CC3 1 0.0125 19 0.0003 
C(CC1CC1)CC2CCCCC2 1 0.0125 131 0.0018 
C(CCC1CCCC1)CCC2CCCCC2 1 0.0125 1589 0.0218 
C1CCC(CC1)C2CC3C4CCC(C4)C3C2 1 0.0125 65 0.0009 
C(CC1CCC(C1)C2CC2)C3CCCC3 1 0.0125 17 0.0002 
C(CC1CCCCC1)CC2CCC3CCCC23 1 0.0125 58 0.0008 
C(C1CCCCC1)C2CCCC3CCCC23 1 0.0125 95 0.0013 
C(CCCC1CCCCC1)CCC2CC2 1 0.0125 92 0.0013 
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C(C1CCCC1)C2CCC(CC2)C3CCCCC3 1 0.0125 128 0.0018 
C(CC1CCCC1)CC2CC3CCC2C3 1 0.0125 7 0.0001 
C(CC(C1CCCC1)C2CCCC2)CC3CCCC3 1 0.0125 21 0.0003 
C(C1CCCC1)C2CCCC3CCCCC23 1 0.0125 104 0.0014 
C(C1CCCC1)C2CCCC3CCCC23 1 0.0125 18 0.0002 
C(C1CCCC1)C2CCCC3C4CCCCC4CC23 1 0.0125 1 0 
C(CC1CCCC1)CC2CCCCC2 1 0.0125 2307 0.0316 
C(CC1CC2CCCCC2C1)C3CCCC3 1 0.0125 174 0.0024 
C(C1CCCC1)C2CCCC(C2)C3CCCCC3 1 0.0125 108 0.0015 
C(CC1CCCC1C2CC2)C3CCCCC3 1 0.0125 7 0.0001 
C(C1CCCCC1)C2CCC(C2)C3CCCCC3 1 0.0125 286 0.0039 
C(C1CCCC1)C2CCCC2C3CCCC3 1 0.0125 95 0.0013 
C(CCCC1CCCCC1)CCC2CCCCC2 1 0.0125 593 0.0081 
C(CC1CCC(C1)C2CCCCC2)C3CC3 1 0.0125 20 0.0003 
C(CC1CCC2CCCC2C1)C3CCCC3 1 0.0125 161 0.0022 
C(C1CCCCC1)C2CCC(C2)C3CCCC3 1 0.0125 102 0.0014 
C(CC1CCC1)CC2CCCC2 1 0.0125 34 0.0005 
C(CC1CCC1)CC2CC3CCCCC3CC4CCCC24 1 0.0125 2 0 
C(CC1CCCCC1CC2CC2)C3CC3 1 0.0125 20 0.0003 
C(C1CCCC1)C2CCC3CCCC3CC2 1 0.0125 8 0.0001 
C1CCC(CC1)C2CCCCC2C3CCCC3 1 0.0125 54 0.0007 
C1CCCC(CC1)C2CC2 1 0.0125 6 0.0001 
C(CC1CCCCCC1C2CCCC2)C3CC3 1 0.0125 5 0.0001 
C1CCC2CCCCC2CC1 1 0.0125 139 0.0019 
C(C1CCC1)C2CCCCCC2 1 0.0125 38 0.0005 
C1CCCC(CC1)C2CCC2 1 0.0125 24 0.0003 
C(CC1CCCCC1)C2CC2 1 0.0125 426 0.0058 
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C(CC1CCCCC1)CC2CCC3CCCC3C2 1 0.0125 213 0.0029 
C1CCC(CC1)C2CCC3CCCCC3C2 1 0.0125 323 0.0044 
C(CC1CCC2CCCCC12)C3CCCCC3 1 0.0125 240 0.0033 
C1CCCCCCC2CCCCC2CCCCCC1 1 0.0125 4 0.0001 
C1CCCC(CC1)C2CCCC2 1 0.0125 61 0.0008 
C(CCC1CC2CCCCC2C1)CC3CCCC3 1 0.0125 114 0.0016 
C(CCC1CCCCC1)CC2CCCCC2 1 0.0125 2299 0.0315 
C(CC1CCCC1)CC2CCC3CCCCC3C2 1 0.0125 209 0.0029 
C1CCC(CC1)C2CCC(C2)C3CCCC3 1 0.0125 140 0.0019 
C1CCC2CCCCC2C1 1 0.0125 1437 0.0197 
C(CC(C1CCCC1)C2CCCCC2)CC3CCCC3 1 0.0125 21 0.0003 
C(CC1CCCCC1)C2CCCC2 1 0.0125 2343 0.0321 
C1CCC(C1)C2CC3CCC(C4CCCC4)C3C2 1 0.0125 11 0.0002 
C(CC1CCCC1)CC2CCCC(CC3CC3)C2 1 0.0125 1 0 
C1CCC2CC3CCCC3CC2C1 1 0.0125 99 0.0014 
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Table 37 A: Library A, the original library of 20 fragments selected from the Leeds virtual fragment library; B: Library B, the second library of 20 fragments selected from the Leeds 
virtual fragment library.  Fragments in blue are from Library A and fragments in pink are new; C: Library C, the third library of 20 fragments selected from the Leeds virtual fragment 
library.  Fragments in blue are from Libraries A and B and fragments in pink are new; D: Library D, the final library of 20 fragments selected from the Leeds virtual fragment library 
which was eventually synthesised.  Fragments in blue are from Libraries A, B and C and fragments in pink are new.  Each fragment has been labelled with the scaffold from which they 
originate as well as the chemistry used for their key stage for formation.  A full description can be found in Section 3.2 
Library A 
 
scaffold 1 (Amino acid) 
 
scaffold 2 (Iridium) 
 
scaffold 3 (Ugi) 
 
scaffold 4 (Ugi) 
 
scaffold 5 (Ugi) 
 
scaffold 6 (Ugi) 
 
scaffold 6 (Ugi) 
 
scaffold 7 (Ugi) 
 
scaffold 7 (Ugi) 
 
scaffold 8 (Ugi) 
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scaffold 9 (Ugi)  
scaffold 10 (Ugi) 
 
scaffold 11 (Ugi) 
 
scaffold 11 (Ugi) 
 
scaffold 12 (Ugi) 
 
scaffold 13 (Ugi) 
 
scaffold 14 (Mitsunobu) 
 
scaffold 15 (Mitsunobu) 
 
scaffold 16 (Mitsunobu) 
 
scaffold 17 (Mitsunobu) 
Library B 
 
scaffold 1 (Amino acid) 
 
scaffold 2 (Amino acid) 
 
scaffold 3 (Amino acid)  
scaffold 4 (Amino acid) 
 
scaffold 5 (Amino acid) 
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scaffold 6 (Iridium) 
 
scaffold 7 (Ugi) 
 
scaffold 7 (Ugi)  
scaffold 8 (Ugi) 
 
scaffold 9 (Ugi) 
 
scaffold 9 (Ugi) 
 
scaffold 10 (Ugi) 
 
scaffold 10 (Ugi) 
 
scaffold 11 (Ugi) 
 
scaffold 12 (Ugi) 
 
scaffold 13 (Ugi) 
 
scaffold 13 (Ugi) 
 
scaffold 14 (Mitsunobu) 
 
scaffold 15 (Mitsunobu)  
scaffold 16 (Mitsunobu) 
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Library C 
 
scaffold 1 (Amino acid) 
 
scaffold 2 (Amino acid) 
 
scaffold 3 (Amino acid)  
scaffold 4 (Amino acid) 
 
scaffold 5 (Amino acid) 
 
scaffold 6 (Iridium) 
 
 
scaffold 7 (Iridium) 
 
scaffold 8 (Ugi) 
 
scaffold 8 (Ugi) 
 
scaffold 9 (Ugi) 
 
scaffold 10 (Ugi) 
 
scaffold 10 (Ugi) 
 
scaffold 10 (Ugi)  
scaffold 11 (Ugi) 
 
scaffold 11 (Ugi) 
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scaffold 12 (Ugi) 
 
 
scaffold 13 (Ugi) 
 
scaffold 14 (Ugi) 
 
scaffold 14 (Ugi) 
 
scaffold 15 (Ugi) 
Library D 
 
scaffold 1 (Amino acid) 
 
scaffold 2 (Amino acid) 
 
scaffold 3 (Amino acid) 
 
scaffold 4 (Amino acid) 
 
scaffold 5 (Amino acid) 
 
scaffold 6 (Ugi) 
 
scaffold 6 (Ugi)  
scaffold 7 (Ugi) 
 
scaffold 8 (Ugi) 
 
scaffold 8 (Ugi) 
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scaffold 8 (Ugi) 
 
scaffold 9 (Ugi) 
 
scaffold 9 (Ugi)  
scaffold 10 (Ugi) 
 
scaffold 11 (Ugi) 
 
scaffold 12 (Ugi) 
 
scaffold 12 (Ugi) 
 
scaffold 13 (Ugi) 
 
scaffold 13 (Ugi) 
 
scaffold 14 (Ugi) 
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Table 38 Other hits identified from the screen of 60 commercial molecules and 10 Leeds analogues against 
Aurora A.  The sites targeted by each fragment has been described along with quality of their observed crystal 
densities.  A full description can be found in Section 4.3.2. 
Structure Site of Target Comment 
ZINC Commercial Library 
 
1 
Weak crystal density and orientation 
unclear. 
 
1 
Reasonable crystal density and exists 
in two conformations. 
 
2 
Reasonable crystal density but tail of 
fragment unclear. 
 
2  Weak crystal density. 
Leeds Library 
 
1 
Weak crystal density, fragment 
orientation unclear. 
 
1 
Weak crystal density, fragment 
orientation unclear. 
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